


**CUMULATIVE  
SUPPLEMENT 9  
SEPTEMBER 2017**



**APPROVED  
DRUG PRODUCTS**

**WITH  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**37th EDITION**

**Department of Health and Human Services**

**Food and Drug Administration  
Office of Medical Products and Tobacco  
Center for Drug Evaluation and Research  
Office of Generic Drugs  
Office of Generic Drug Policy**

**2017**

Prepared By  
Food and Drug Administration  
Office of Medical Products and Tobacco  
Center for Drug Evaluation and Research  
Office of Generic Drugs  
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS  
with  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**37<sup>th</sup> EDITION**

**Cumulative Supplement 9  
September 2017**

**CONTENTS**

	<i>PAGE</i>
1.0 INTRODUCTION.....	v
1.1 How to use the Cumulative Supplement.....	v
1.2 Cumulative Supplement Content .....	vi
1.3 Applicant Name Changes .....	vii
1.4 Levothyroxine Sodium.....	vii
1.5 Availability of the Edition .....	viii
1.6 Report of Counts for the Prescription Drug Product List.....	ix
1.7 Cumulative Supplement Legend.....	x
DRUG PRODUCT LISTS	
Prescription Drug Product List .....	1-1
OTC Drug Product List .....	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List .....	3-1
Orphan Product Designations and Approvals List .....	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution .....	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists .....	A-1
B. Patent and Exclusivity Terms .....	B-1

**APPROVED DRUG PRODUCTS**  
**with**  
**THERAPEUTIC EQUIVALENCE EVALUATIONS**

**37<sup>th</sup> EDITION**

**CUMULATIVE SUPPLEMENT 9**  
**September 2017**

**1.0 INTRODUCTION**

**1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT**

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 37th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the

next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

## 1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
  - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
  - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at [orangebook@fda.hhs.gov](mailto:orangebook@fda.hhs.gov).

mail to:                     FDA/CDER Orange Book Staff  
                                   Office of Generic Drugs  
                                   7620 Standish Place  
                                   Rockville, MD 20855-2773

### 1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
JAI PHARMA LTD (JAI PHARMA LTD)	MYLAN LABORATORIES LTD (MYLAN LABS LTD)

### 1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 076187), Levoxyl (King Pharms NDA 021301), Synthroid (Abbvie NDA 021402), and Levo-T (Alara NDA 021342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 076187), and Unithroid (Jerome Stevens NDA 021210) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbvie NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products in the active section of the Orange Book. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Strength	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	076187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	021301	001
SYNTHROID	ABBVIE	0.025MG	AB1	021402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	021342	001
SYNTHROID	ABBVIE	0.025MG	AB2	021402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	076187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	021342	001
UNITHROID	STEVENS J	0.025MG	AB2	021210	001
LEVOXYL	KING PHARMS	0.025MG	AB3	021301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	021342	001
UNITHROID	STEVENS J	0.025MG	AB3	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	076187	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	076187	001

## 1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket \*95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

## 1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

### DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

### DEFINITIONS

#### Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.



## New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

### REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2016</u>	<u>MAR 2017</u>	<u>JUN 2017</u>	<u>SEP 2017</u>	<u>DEC 2017</u>
DRUG PRODUCTS LISTED SINGLE SOURCE	18130 2646 (14.6%)	18391 2688 (14.6%)	18711 2708 (14.5%)	19012 2721 (14.3%)	
MULTISOURCE	15484 (85.4%)	15703 (85.4%)	16003 (85.5%)	16291 (85.7%)	
THERAPEUTICALLY EQUIVALENT	15335 (84.7%)	15581 (84.7%)	15882 (84.9%)	16180 (85.1%)	
NOT THERAPEUTICALLY EQUIVALENT	129 (0.7%)	122 (0.7%)	121 (0.6%)	111 (0.6%)	
EXCEPTIONS <sup>1</sup>	73 (0.4%)	73 (0.4%)	73 (0.4%)	73 (0.4%)	
NEW MOLECULAR ENTITIES APPROVED	7	14	17	14	
NUMBER OF APPLICANTS	1051	1053	1050	1054	

<sup>1</sup>Amino acid-containing products of varying composition (see Introduction, page xx of the List).

## 1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug

Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >D>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN**	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CHRS	Change. Reference Standard.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

**\*\*Note:**

The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 240 character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ABACAVIR SULFATE; LAMIVUDINE

TABLET;ORAL		ABACAVIR SULFATE AND LAMIVUDINE					
AB	AUROBINDO PHARMA LTD	EQ 600MG BASE;300MG		A206151	001	Mar 28, 2017	Mar NEWA
AB	CIPLA LTD	EQ 600MG BASE;300MG		A091144	001	Mar 28, 2017	Mar NEWA
AB	LUPIN LTD	EQ 600MG BASE;300MG		A204990	001	Mar 28, 2017	Mar NEWA

ABALOPARATIDE

SOLUTION;SUBCUTANEOUS		TYMLOS					
+!	RADIUS HEALTH INC	3.12MG/1.56ML (2MG/ML)		N208743	001	Apr 28, 2017	Apr NEWA

ABEMACICLIB

>A>		TABLET;ORAL					
>A>		VERZENIO					
>A>	+	ELI LILLY AND CO	50MG	N208716	001	Sep 28, 2017	Sep NEWA
>A>	+		100MG	N208716	002	Sep 28, 2017	Sep NEWA
>A>	+		150MG	N208716	003	Sep 28, 2017	Sep NEWA
>A>	+!		200MG	N208716	004	Sep 28, 2017	Sep NEWA

ABIRATERONE ACETATE

TABLET;ORAL		ZYTIGA					
+	JANSSEN BIOTECH	500MG		N202379	002	Apr 14, 2017	May NEWA

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE;ORAL		ACAMPROSATE CALCIUM					
AB	ZYDUS PHARMS USA INC	333MG		A205995	001	May 26, 2017	May NEWA

ACETAMINOPHEN

SOLUTION;IV (INFUSION)		ACETAMINOPHEN					
AP	CUSTOPHARM INC	1GM/100ML (10MG/ML)		A202605	001	Jun 13, 2016	Jan CAHN

ACETAMINOPHEN; BUTALBITAL

TABLET;ORAL		BUTALBITAL AND ACETAMINOPHEN					
AA	TEDOR PHARMA INC	300MG;50MG		A207635	001	Jun 05, 2017	May NEWA

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL		BUTALBITAL, ACETAMINOPHEN AND CAFFEINE					
AB	TEDOR PHARMA INC	300MG;50MG;40MG		A206615	001	Aug 04, 2017	Jul NEWA
TABLET;ORAL		BUTALBITAL, ACETAMINOPHEN AND CAFFEINE					
AA	ACTAVIS LABS UT INC	325MG;50MG;40MG		A088616	001	Nov 09, 1984	Apr CTNA
>D>	@	INGENUS PHARMS NJ	325MG;50MG;40MG	A040864	001	Dec 01, 2008	Sep CAHN
AA	@	MALLINCKRODT INC	325MG;50MG;40MG	A087804	001	Jan 24, 1985	Mar CAHN
>A>	@	NOVAST LABS LTD	325MG;50MG;40MG	A040864	001	Dec 01, 2008	Sep CAHN

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION;ORAL		ACETAMINOPHEN AND CODEINE PHOSPHATE					
@	ALLIED PHARMA INC	120MG/5ML;12MG/5ML		A086366	001		Jul CAHN
SUSPENSION;ORAL		CAPITAL AND CODEINE					
@	VALEANT PHARMS LLC	120MG/5ML;12MG/5ML		A086024	001		Aug DISC
TABLET;ORAL		ACETAMINOPHEN AND CODEINE PHOSPHATE					
>A>	@	ANDA REPOSITORY	300MG;15MG	A089671	001	Feb 10, 1988	Sep CAHN
>A>	@		300MG;30MG	A089672	001	Feb 10, 1988	Sep CAHN
>A>	@		300MG;60MG	A089673	001	Feb 10, 1988	Sep CAHN
>D>	@	FRONTIDA BIOPHARM	300MG;15MG	A089671	001	Feb 10, 1988	Sep CAHN
>D>	@		300MG;30MG	A089672	001	Feb 10, 1988	Sep CAHN
>D>	@		300MG;60MG	A089673	001	Feb 10, 1988	Sep CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	ABHAI LLC	300MG; 5MG	A209036	001	Jun 21, 2017	Jun	NEWA
AA		300MG; 7.5MG	A209036	002	Jun 21, 2017	Jun	NEWA
AA		300MG; 10MG	A209036	003	Jun 21, 2017	Jun	NEWA
AA		325MG; 5MG	A209037	001	Jun 21, 2017	Jun	NEWA
AA		325MG; 7.5MG	A209037	002	Jun 21, 2017	Jun	NEWA
AA		325MG; 10MG	A209037	003	Jun 21, 2017	Jun	NEWA
AA	AMNEAL PHARMS NY	300MG; 5MG	A206869	001	Jun 23, 2017	Jun	NEWA
AA	LANNETT HOLDINGS INC	300MG; 5MG	A207171	001	Jun 20, 2017	Jun	NEWA
AA		300MG; 7.5MG	A207171	002	Jun 20, 2017	Jun	NEWA
AA		300MG; 10MG	A207171	003	Jun 20, 2017	Jun	NEWA
AA		325MG; 5MG	A207172	001	Jun 22, 2017	Jun	NEWA
AA		325MG; 7.5MG	A207172	002	Jun 22, 2017	Jun	NEWA
AA		325MG; 10MG	A207172	003	Jun 22, 2017	Jun	NEWA
AA	MALLINCKRODT INC	300MG; 5MG	A206718	001	Mar 31, 2017	Mar	NEWA
AA		300MG; 7.5MG	A206718	002	Mar 31, 2017	Mar	NEWA
AA		300MG; 10MG	A206718	003	Mar 31, 2017	Mar	NEWA
AA	! MIKART	300MG; 7.5MG	A040658	002	Mar 24, 2006	May	CHRS
AA		300MG; 7.5MG	A040658	002	Mar 24, 2006	Apr	CMS1
AA	!	300MG; 10MG	A040658	003	Jun 23, 2004	May	CHRS
AA		300MG; 10MG	A040658	003	Jun 23, 2004	Apr	CMS1
AA	UPSHER-SMITH LABS	325MG; 5MG	A206484	001	Mar 24, 2017	Jun	CAHN
AA		325MG; 5MG	A206484	001	Mar 24, 2017	Mar	NEWA
AA		325MG; 7.5MG	A206484	002	Mar 24, 2017	Jun	CAHN
AA		325MG; 7.5MG	A206484	002	Mar 24, 2017	Mar	NEWA
AA		325MG; 10MG	A206484	003	Mar 24, 2017	Jun	CAHN
AA		325MG; 10MG	A206484	003	Mar 24, 2017	Mar	NEWA

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

AA	AMNEAL PHARMS	325MG; 5MG	A040777	001	Nov 27, 2007	May	CAHN
AA	ASCENT PHARMS INC	325MG; 2.5MG	A207419	001	Mar 22, 2017	Mar	NEWA
AA		325MG; 5MG	A207419	002	Mar 22, 2017	Mar	NEWA
AA		325MG; 7.5MG	A207419	003	Mar 22, 2017	Mar	NEWA
AA		325MG; 10MG	A207419	004	Mar 22, 2017	Mar	NEWA
>A>	AA	LANNETT HOLDINGS INC	A207333	001	Sep 25, 2017	Sep	NEWA
>A>	AA		A207333	002	Sep 25, 2017	Sep	NEWA
AA	NOVEL LABS INC	325MG; 2.5MG	A204407	001	Feb 24, 2017	Feb	NEWA
AA		325MG; 5MG	A204407	002	Feb 24, 2017	Feb	NEWA
AA		325MG; 7.5MG	A204407	003	Feb 24, 2017	Feb	NEWA
AA		325MG; 10MG	A204407	004	Feb 24, 2017	Feb	NEWA
	PERCOCET						
AA	! VINTAGE PHARMS LLC	325MG; 7.5MG	A040330	003	Nov 23, 2001	Jan	CMS1
AA	!	325MG; 10MG	A040330	004	Nov 23, 2001	Jan	CMS1

TABLET, EXTENDED RELEASE; ORAL

XARTEMIS XR

+	@	MALLINCKRODT INC	325MG; 7.5MG	N204031	001	Mar 11, 2014	Aug	DISC
---	---	------------------	--------------	---------	-----	--------------	-----	------

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

>A>	AB	APOGEE PHARMA	325MG; 37.5MG	A202076	001	Mar 30, 2012	Sep	CAHN
>D>	AB	ATLAS PHARMS LLC	325MG; 37.5MG	A202076	001	Mar 30, 2012	Sep	CAHN
AB		AUROBINDO PHARMA LTD	325MG; 37.5MG	A207152	001	Mar 22, 2017	Mar	NEWA
AB		MACLEODS PHARMS LTD	325MG; 37.5MG	A206885	001	May 02, 2017	Apr	NEWA

ACETAZOLAMIDE

TABLET; ORAL

ACETAZOLAMIDE

AB	SUN PHARM INDS	125MG	A089753	002	Jun 22, 1988	Jul	CMS1
----	----------------	-------	---------	-----	--------------	-----	------

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

ACETAZOLAMIDE SODIUM

AP	PAR STERILE PRODUCTS	EQ 500MG BASE/VIAL	A205358	001	Jun 20, 2017	Jun	NEWA
----	----------------------	--------------------	---------	-----	--------------	-----	------

ACETIC ACID, GLACIAL

SOLUTION;IRRIGATION, URETHRAL  
ACETIC ACID 0.25% IN PLASTIC CONTAINER

AT ICU MEDICAL INC 250MG/100ML N017656 001 Feb CAHN

ACETOHEXAMIDE

TABLET;ORAL  
ACETOHEXAMIDE

@ WATSON LABS TEVA 250MG A071893 001 Nov 25, 1987 May CAHN  
@ 500MG A071894 001 Nov 25, 1987 May CAHN

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE;ORAL  
SEMPREX-D

+! AUXILIUM PHARMS LLC 8MG;60MG N019806 001 Mar 25, 1994 May CAHN

ACYCLOVIR

CAPSULE;ORAL  
ACYCLOVIR

AB BOSCOGEN 200MG A075090 001 Jan 26, 1999 May CAHN  
AB CARLSBAD TECHNOLOGY 200MG A206261 001 Aug 16, 2017 Aug NEWA  
@ CHARTWELL MOLECULES 200MG A074872 001 Apr 22, 1997 Jan CAHN  
@ MYLAN 200MG A074727 001 Apr 22, 1997 Jun DISC  
ZOVIRAX

AB +! MYLAN PHARMS INC 200MG N018828 001 Jan 25, 1985 Jan CAHN

OINTMENT;TOPICAL  
ACYCLOVIR

AB GLENMARK PHARMS LTD 5% A205510 001 Jul 31, 2017 Jul NEWA  
AB TOLMAR 5% A206437 001 Jul 31, 2017 Jul NEWA

SUSPENSION;ORAL  
ZOVIRAX

AB +! MYLAN PHARMS INC 200MG/5ML N019909 001 Dec 22, 1989 Jan CAHN

TABLET;BUCCAL  
SITAVIG

+! EPI HLTH 50MG N203791 001 Apr 12, 2013 Jun CAHN

TABLET;ORAL  
ACYCLOVIR

@ CHARTWELL MOLECULES 400MG A074834 001 Apr 24, 1997 Jan CAHN  
@ 800MG A074834 002 Apr 24, 1997 Jan CAHN  
AB HERITAGE PHARMS INC 400MG A074891 001 Oct 31, 1997 Apr CMFD  
AB 800MG A074891 002 Oct 31, 1997 Apr CMFD  
AB MYLAN PHARMS INC 400MG A075211 001 Sep 28, 1998 Mar CAHN  
AB 800MG A075211 002 Sep 28, 1998 Mar CAHN  
ZOVIRAX

AB + MYLAN PHARMS INC 400MG N020089 001 Apr 30, 1991 Jan CAHN

AB +! 800MG N020089 002 Apr 30, 1991 Jan CAHN

ACYCLOVIR SODIUM

INJECTABLE;INJECTION  
ACYCLOVIR SODIUM

@ ATHENEX INC EQ 500MG BASE/VIAL A074596 002 Apr 22, 1997 Mar CAHN  
@ EQ 1GM BASE/VIAL A074596 001 Apr 22, 1997 Mar CAHN  
AP ! HIKMA PHARMS EQ 1GM BASE/VIAL A205771 002 Feb 29, 2016 Mar CTEC  
AP MYLAN LABS LTD EQ 500MG BASE/VIAL A203927 001 Mar 29, 2017 Mar NEWA  
AP EQ 1GM BASE/VIAL A203927 002 Mar 29, 2017 Mar NEWA  
AP ZYDUS PHARMS USA INC EQ 500MG BASE/VIAL A206606 001 Jun 13, 2017 May NEWA  
AP EQ 1GM BASE/VIAL A206606 002 Jun 13, 2017 May NEWA

ADENOSINE

INJECTABLE;INJECTION  
ADENOSINE

AP WEST-WARD PHARMS INT 3MG/ML A076404 001 Jun 16, 2004 Jan CAHN  
AP 3MG/ML A076500 001 Jun 16, 2004 Jan CAHN  
@ 3MG/ML A076501 001 Jun 16, 2004 Jan CAHN

ALBENDAZOLETABLET; ORAL  
ALBENZA

+! IMPAX LABS INC 200MG N020666 001 Jun 11, 1996 Jun CAHN

ALBUTEROL SULFATEAEROSOL, METERED; INHALATION  
PROVENTIL-HFA

BX +! 3M DRUG DELIVERY EQ 0.09MG BASE/INH N020503 001 Aug 15, 1996 May CAHN

SOLUTION; INHALATION  
ALBUTEROL SULFATE

AN SUN PHARMA GLOBAL EQ 0.083% BASE A207857 001 Jul 21, 2017 Jul NEWA

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION; INHALATION

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

AN SUN PHARMA GLOBAL EQ 0.083% BASE; 0.17% A207875 001 Aug 07, 2017 Jul NEWA

AN WATSON LABS TEVA EQ 0.083% BASE; 0.017% A077063 001 Dec 31, 2007 Feb CAHN

ALENDRONATE SODIUM

SOLUTION; ORAL

FOSAMAX

&gt;D&gt; @ MERCK EQ 70MG BASE/75ML N021575 001 Sep 17, 2003 Sep CRLD

&gt;A&gt; + @ EQ 70MG BASE/75ML N021575 001 Sep 17, 2003 Sep CRLD

TABLET; ORAL

ALENDRONATE SODIUM

@ UPSHER-SMITH LABS EQ 5MG BASE A075871 001 Apr 22, 2009 Jun CAHN

@ EQ 10MG BASE A075871 002 Apr 22, 2009 Jun CAHN

@ EQ 35MG BASE A075871 004 Apr 22, 2009 Jun CAHN

@ EQ 40MG BASE A075871 003 Apr 22, 2009 Jun CAHN

@ EQ 70MG BASE A075871 005 Apr 22, 2009 Jun CAHN

ALLOPURINOL

TABLET; ORAL

ZYLOPRIM

AB + CASPER PHARMA LLC 100MG N016084 001 Jul CAHN

AB +! 300MG N016084 002 Jul CAHN

ALLOPURINOL; LESINURAD

TABLET; ORAL

DUZALLO

&gt;D&gt; + ARDEA BIOSCIENCES 200MG; 200MG N209203 001 Aug 18, 2017 Sep CAHN

+ 200MG; 200MG N209203 001 Aug 18, 2017 Aug NEWA

&gt;D&gt; +! 300MG; 200MG N209203 002 Aug 18, 2017 Sep CAHN

+! 300MG; 200MG N209203 002 Aug 18, 2017 Aug NEWA

&gt;A&gt; + IRONWOOD PHARMS INC 200MG; 200MG N209203 001 Aug 18, 2017 Sep CAHN

&gt;A&gt; +! 300MG; 200MG N209203 002 Aug 18, 2017 Sep CAHN

ALOSETRON HYDROCHLORIDE

TABLET; ORAL

ALOSETRON HYDROCHLORIDE

AB AMNEAL PHARMS EQ 0.5MG BASE A206647 001 Dec 22, 2016 May CAHN

AB EQ 1MG BASE A206647 002 Dec 22, 2016 May CAHN

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

INJECTABLE; INJECTION

INFUVITE ADULT

+! SANDOZ INC 2 IU/ML; 40MG/ML; 12MCG/ML; 40 IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML; 8MG/ML; 1.2MG/ML; 0.72MG/ML; 1.2MG/ML; 660 IU/ML; 0.03MG/ML N021163 001 May 18, 2000 May CAHN

INJECTABLE; IV (INFUSION)

INFUVITE ADULT

+! SANDOZ INC 2 IU/ML; 40MG/ML; 12MCG/ML; 40 IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML; 8MG/ML; 1.2MG/ML; 0.72MG/ML; 1.2MG/ML; 660 IU/ML; 30MCG/ML N021559 001 Jun 16, 2003 May CAHN

ALPRAZOLAM

## TABLET; ORAL

## ALPRAZOLAM

AB	ACTAVIS ELIZABETH	0.25MG	A074342	001	Oct 31, 1993	Apr	CAHN
AB		0.5MG	A074342	002	Oct 31, 1993	Apr	CAHN
AB		1MG	A074342	003	Oct 31, 1993	Apr	CAHN
AB		2MG	A074342	004	Oct 31, 1993	Apr	CAHN

## TABLET, EXTENDED RELEASE; ORAL

## ALPRAZOLAM

AB	AUROBINDO PHARMA LTD	0.5MG	A090871	001	Jun 07, 2011	Jan	CAHN
AB		1MG	A090871	002	Jun 07, 2011	Jan	CAHN
AB		2MG	A090871	003	Jun 07, 2011	Jan	CAHN
AB		3MG	A090871	004	Jun 07, 2011	Jan	CAHN

## TABLET, ORALLY DISINTEGRATING; ORAL

## ALPRAZOLAM

>D>	AB	ACTAVIS ELIZABETH	0.25MG	A078561	001	Mar 16, 2010	Sep	CAHN
>A>	AB		0.25MG	A078561	001	Mar 16, 2010	Sep	CAHN
>D>	AB		0.5MG	A078561	002	Mar 16, 2010	Sep	CAHN
>A>	AB		0.5MG	A078561	002	Mar 16, 2010	Sep	CAHN
>D>	AB		1MG	A078561	003	Mar 16, 2010	Sep	CAHN
>A>	AB		1MG	A078561	003	Mar 16, 2010	Sep	CAHN
>D>	AB		2MG	A078561	004	Mar 16, 2010	Sep	CAHN
>A>	AB		2MG	A078561	004	Mar 16, 2010	Sep	CAHN

ALPROSTADIL

## INJECTABLE; INJECTION

## EDEX

	@	AUXILIUM PHARMS LLC	0.005MG/VIAL	N020649	001	Jun 12, 1997	May	CAHN
AP	+		0.01MG/VIAL	N020649	002	Jun 12, 1997	May	CAHN
	+	!	0.01MG/VIAL	N020649	005	Jul 30, 1998	May	CAHN
AP	+		0.02MG/VIAL	N020649	003	Jun 12, 1997	May	CAHN
	+	!	0.02MG/VIAL	N020649	006	Jul 30, 1998	May	CAHN
AP	+	!	0.04MG/VIAL	N020649	004	Jun 12, 1997	May	CAHN
	+	!	0.04MG/VIAL	N020649	007	Jul 30, 1998	May	CAHN

## SUPPOSITORY; URETHRAL

## MUSE

	+	!	MYLAN SPECIALITY LP	0.125MG	N020700	001	Nov 19, 1996	Mar	CAHN
	+	!		0.25MG	N020700	002	Nov 19, 1996	Mar	CAHN
	+	!		0.5MG	N020700	003	Nov 19, 1996	Mar	CAHN
	+	!		1MG	N020700	004	Nov 19, 1996	Mar	CAHN

AMANTADINE HYDROCHLORIDE

## CAPSULE; ORAL

## AMANTADINE HYDROCHLORIDE

AB	ALEMBIC PHARMS LTD	100MG	A208966	001	Jun 21, 2017	Jun	NEWA
AB	HERITAGE PHARMA	100MG	A209171	001	Jun 12, 2017	May	NEWA
AB	LANNETT HOLDINGS INC	100MG	A209221	001	Jun 15, 2017	May	NEWA
AB	STRIDES PHARMA	100MG	A209047	001	Jun 07, 2017	May	NEWA
AB	USL PHARMA	100MG	A070589	001	Aug 05, 1986	Jun	CAHN

## CAPSULE, EXTENDED RELEASE; ORAL

## GOCOVRI

	+	ADAMAS PHARMA	EQ 68.5MG BASE	N208944	001	Aug 24, 2017	Aug	NEWA
	+	!	EQ 137MG BASE	N208944	002	Aug 24, 2017	Aug	NEWA

## SYRUP; ORAL

## AMANTADINE HYDROCHLORIDE

AA	!	CMP PHARMA INC	50MG/5ML	A075819	001	Sep 11, 2002	Apr	CAHN
AA	!	PHARM ASSOC	50MG/5ML	A074509	001	Jul 17, 1995	May	CAHN

## SYMMETREL

	+	@	ENDO PHARMS	50MG/5ML	N016023	002		Jan	CRLD
--	---	---	-------------	----------	---------	-----	--	-----	------

## TABLET; ORAL

## AMANTADINE HYDROCHLORIDE

AB	NEWGEN PHARMS LLC	100MG	A207571	001	Jan 31, 2017	Jan	NEWA	
AB	STRIDES PHARMA	100MG	A209035	001	Jun 09, 2017	May	NEWA	
AB	!	USL PHARMA	100MG	A076186	001	Dec 16, 2002	Jun	CAHN

AMCINONIDE

## CREAM; TOPICAL

## CYCLOCORT

	+	@	ASTELLAS	0.025%	N018116	001		Jun	CRLD
	+	@		0.1%	N018116	002		Jun	CRLD

	LOTION; TOPICAL						
	CYCLOCORT						
	+ @ ASTELLAS	0.1%	N019729	001	Jun 13, 1988	Jun	CRLD
	OINTMENT; TOPICAL						
	CYCLOCORT						
	+ @ ASTELLAS	0.1%	N018498	001		Jun	CRLD
<u>AMIFOSTINE</u>							
	INJECTABLE; INJECTION						
	AMIFOSTINE						
AP	MYLAN LABS LTD	500MG/VIAL	A204363	001	Jul 17, 2017	Jul	NEWA
AP	SUN PHARMA GLOBAL	500MG/VIAL	A077126	001	Mar 14, 2008	Apr	CAHN
<u>AMILORIDE HYDROCHLORIDE</u>							
	TABLET; ORAL						
	AMILORIDE HYDROCHLORIDE						
AB	WINDLAS HLTHCARE	5MG	A204180	001	Aug 07, 2015	Jul	CAHN
<u>AMINO ACIDS</u>							
	INJECTABLE; INJECTION						
	AMINOSYN 10%						
	ICU MEDICAL INC	10% (10GM/100ML)	N017673	003		Feb	CAHN
	AMINOSYN 10% (PH6)						
	ICU MEDICAL INC	10% (10GM/100ML)	N017673	008	Nov 18, 1985	Feb	CAHN
	AMINOSYN 3.5%						
	ICU MEDICAL INC	3.5% (3.5GM/100ML)	N017789	004		Feb	CAHN
	AMINOSYN 5%						
	ICU MEDICAL INC	5% (5GM/100ML)	N017673	001		Feb	CAHN
	AMINOSYN 7%						
	ICU MEDICAL INC	7% (7GM/100ML)	N017673	002		Feb	CAHN
	AMINOSYN 7% (PH6)						
	ICU MEDICAL INC	7% (7GM/100ML)	N017673	006	Nov 18, 1985	Feb	CAHN
	AMINOSYN 8.5%						
	ICU MEDICAL INC	8.5% (8.5GM/100ML)	N017673	004		Feb	CAHN
	AMINOSYN 8.5% (PH6)						
	ICU MEDICAL INC	8.5% (8.5GM/100ML)	N017673	007	Nov 18, 1985	Feb	CAHN
	AMINOSYN II 10%						
	ICU MEDICAL INC	10% (10GM/100ML)	N019438	005	Apr 03, 1986	Feb	CAHN
	AMINOSYN II 10% IN PLASTIC CONTAINER						
	ICU MEDICAL INC	10% (10GM/100ML)	N020015	001	Dec 19, 1991	Feb	CAHN
	AMINOSYN II 15% IN PLASTIC CONTAINER						
	ICU MEDICAL INC	15% (15GM/100ML)	N020041	001	Dec 19, 1991	Feb	CAHN
	AMINOSYN II 3.5%						
	@ ICU MEDICAL INC	3.5% (3.5GM/100ML)	N019438	001	Apr 03, 1986	Feb	CAHN
	AMINOSYN II 5%						
	@ ICU MEDICAL INC	5% (5GM/100ML)	N019438	002	Apr 03, 1986	Feb	CAHN
	AMINOSYN II 7%						
	ICU MEDICAL INC	7% (7GM/100ML)	N019438	003	Apr 03, 1986	Feb	CAHN
	AMINOSYN II 8.5%						
	ICU MEDICAL INC	8.5% (8.5GM/100ML)	N019438	004	Apr 03, 1986	Feb	CAHN
	AMINOSYN-HBC 7%						
	ICU MEDICAL INC	7% (7GM/100ML)	N019374	001	Jul 12, 1985	Feb	CAHN
	AMINOSYN-HF 8%						
	ICU MEDICAL INC	8% (8GM/100ML)	A020345	001	Apr 04, 1996	Jun	CAHN
	AMINOSYN-PF 10%						
	ICU MEDICAL INC	10% (10GM/100ML)	N019492	002	Oct 17, 1986	Feb	CAHN
	AMINOSYN-PF 7%						
	ICU MEDICAL INC	7% (7GM/100ML)	N019398	001	Sep 06, 1985	Feb	CAHN
	AMINOSYN-RF 5.2%						
	ICU MEDICAL INC	5.2% (5.2GM/100ML)	N018429	001		Apr	CAHN
<u>AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE</u>							
	INJECTABLE; INJECTION						
	AMINOSYN 3.5% M						
	ICU MEDICAL INC	3.5%;21MG/100ML;40MG/100ML;128MG/100ML;234MG/100ML	N017789	003		Feb	CAHN



AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 3.5% M

@ ICU MEDICAL INC 3.5%; 21MG/100ML; 128MG/100ML; 234MG/100ML N017789 005 Feb CAHN

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 10% W/ ELECTROLYTES

ICU MEDICAL INC 10%; 102MG/100ML; 45MG/100ML; 522MG/100ML; 410MG/100ML N019437 004 Apr 03, 1986 Apr CAHN

AMINOSYN II 7% W/ ELECTROLYTES

@ ICU MEDICAL INC 7%; 102MG/100ML; 45MG/100ML; 522MG/100ML; 410MG/100ML N019437 006 Apr 03, 1986 Apr CAHN

AMINOSYN II 8.5% W/ ELECTROLYTES

ICU MEDICAL INC 8.5%; 102MG/100ML; 45MG/100ML; 522MG/100ML; 410MG/100ML N019437 005 Apr 03, 1986 Apr CAHN

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

AMINOSYN II 3.5% M

@ ICU MEDICAL INC 3.5%; 30MG/100ML; 97MG/100ML; 120MG/100ML; 49MG/100ML N019437 007 Apr 03, 1986 Apr CAHN

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 7% W/ ELECTROLYTES

ICU MEDICAL INC 7%; 102MG/100ML; 522MG/100ML; 410MG/100ML N017789 002 Feb CAHN

AMINOSYN 8.5% W/ ELECTROLYTES

ICU MEDICAL INC 8.5%; 102MG/100ML; 522MG/100ML; 410MG/100ML N017673 005 Feb CAHN

AMINOLEVULINIC ACID HYDROCHLORIDE

FOR SOLUTION; ORAL

GLEOLAN

+! NXDC 1.5GM/VIAL N208630 001 Jun 06, 2017 Jun NEWA

AMIODARONE HYDROCHLORIDE

TABLET; ORAL

AMIODARONE HYDROCHLORIDE

AB	MAYNE PHARMA INC	200MG	A075389	001	Jan 25, 2001	Jan	CAHN
	@ MYLAN	200MG	A075188	001	Feb 24, 1999	Mar	DISC
AB	! SANDOZ	200MG	A075315	001	Dec 23, 1998	Mar	CHRS
AB	TARO PHARM	100MG	A075424	002	Dec 18, 2002	Mar	CAHN
AB		200MG	A075424	001	Mar 30, 2001	Mar	CAHN
		300MG	A076362	002	Dec 02, 2003	Mar	CAHN
AB		400MG	A076362	001	Nov 29, 2002	Mar	CAHN
	PACERONE						
AB	UPSHER-SMITH LABS	100MG	A075135	002	Apr 12, 2005	Jun	CAHN
AB		200MG	A075135	001	Apr 30, 1998	Jun	CAHN

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

>A>	AB	ZYDUS PHARMS USA INC	10MG	A210086	001	Oct 06, 2017	Sep	NEWA
>A>	AB		25MG	A210086	002	Oct 06, 2017	Sep	NEWA
>A>	AB		50MG	A210086	003	Oct 06, 2017	Sep	NEWA
>A>	AB		75MG	A210086	004	Oct 06, 2017	Sep	NEWA
>A>	AB		100MG	A210086	005	Oct 06, 2017	Sep	NEWA
>A>	AB		150MG	A210086	006	Oct 06, 2017	Sep	NEWA

ELAVIL

+	@	ASTRAZENECA	10MG	N012703	001		Mar	CRLD
+	@		25MG	N012703	003		Mar	CRLD
+	@		50MG	N012703	004		Mar	CRLD
+	@		75MG	N012703	005		Mar	CRLD
+	@		100MG	N012703	006		Mar	CRLD
+	@		150MG	N012703	007		Mar	CRLD

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

>A>	@	ANDA REPOSITORY	EQ 12.5MG BASE;5MG	A 070765	001	Dec 10, 1986	Sep CAHN
>A>	@		EQ 25MG BASE;10MG	A 070766	001	Dec 10, 1986	Sep CAHN
>D>	@	FRONTIDA BIOPHARM	EQ 12.5MG BASE;5MG	A 070765	001	Dec 10, 1986	Sep CAHN
>D>	@		EQ 25MG BASE;10MG	A 070766	001	Dec 10, 1986	Sep CAHN
	@	WATSON LABS TEVA	EQ 12.5MG BASE;5MG	A 072052	001	Dec 16, 1988	May CAHN

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

AB		MYLAN PHARMS INC	EQ 2.5MG BASE	A 076418	001	Oct 03, 2005	Mar CAHN
	@		EQ 2.5MG BASE	A 078224	001	Feb 27, 2008	May DISC
AB			EQ 5MG BASE	A 076418	002	Oct 03, 2005	Mar CAHN
	@		EQ 5MG BASE	A 078224	002	Feb 27, 2008	May DISC
AB			EQ 10MG BASE	A 076418	003	Oct 03, 2005	Mar CAHN
	@		EQ 10MG BASE	A 078224	003	Feb 27, 2008	May DISC
>D>	AB	SOVEREIGN PHARMS	EQ 2.5MG BASE	A 204900	001	Jul 23, 2015	Sep DISC
>A>	@		EQ 2.5MG BASE	A 204900	001	Jul 23, 2015	Sep DISC
>D>	AB		EQ 5MG BASE	A 204900	002	Jul 23, 2015	Sep DISC
>A>	@		EQ 5MG BASE	A 204900	002	Jul 23, 2015	Sep DISC
>D>	AB		EQ 10MG BASE	A 204900	003	Jul 23, 2015	Sep DISC
>A>	@		EQ 10MG BASE	A 204900	003	Jul 23, 2015	Sep DISC
AB		UPSHER-SMITH LABS	EQ 2.5MG BASE	A 077759	001	Jul 09, 2007	Jun CAHN
AB			EQ 5MG BASE	A 077759	002	Jul 09, 2007	Jun CAHN
AB			EQ 10MG BASE	A 077759	003	Jul 09, 2007	Jun CAHN
AB		VIVIMED GLOBAL	EQ 2.5MG BASE	A 077516	001	Jul 11, 2007	Aug CAHN
AB			EQ 5MG BASE	A 077516	002	Jul 11, 2007	Aug CAHN
AB			EQ 10MG BASE	A 077516	003	Jul 11, 2007	Aug CAHN

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

AB		ALEMBIC PHARMS LTD	EQ 5MG BASE;20MG	A 207073	001	Jul 17, 2017	Jul NEWA
AB			EQ 5MG BASE;40MG	A 207073	002	Jul 17, 2017	Jul NEWA
AB			EQ 10MG BASE;20MG	A 207073	003	Jul 17, 2017	Jul NEWA
AB			EQ 10MG BASE;40MG	A 207073	004	Jul 17, 2017	Jul NEWA
AB		ALKEM LABS LTD	EQ 5MG BASE;20MG	A 209042	001	Aug 14, 2017	Jul NEWA
AB			EQ 5MG BASE;40MG	A 209042	002	Aug 14, 2017	Jul NEWA
AB			EQ 10MG BASE;20MG	A 209042	003	Aug 14, 2017	Jul NEWA
AB			EQ 10MG BASE;40MG	A 209042	004	Aug 14, 2017	Jul NEWA
AB		AUROBINDO PHARMA LTD	EQ 5MG BASE;20MG	A 206906	001	May 15, 2017	May NEWA
AB			EQ 5MG BASE;40MG	A 206906	002	May 15, 2017	May NEWA
AB			EQ 10MG BASE;20MG	A 206906	003	May 15, 2017	May NEWA
AB			EQ 10MG BASE;40MG	A 206906	004	May 15, 2017	May NEWA
AB		GLENMARK PHARMS LTD	EQ 5MG BASE;20MG	A 207807	001	Jul 05, 2017	Jun NEWA
AB			EQ 5MG BASE;40MG	A 207807	002	Jul 05, 2017	Jun NEWA
AB			EQ 10MG BASE;20MG	A 207807	003	Jul 05, 2017	Jun NEWA
AB			EQ 10MG BASE;40MG	A 207807	004	Jul 05, 2017	Jun NEWA
AB		JUBILANT GENERICS	EQ 5MG BASE;20MG	A 207450	001	May 15, 2017	May NEWA
AB			EQ 5MG BASE;40MG	A 207450	002	May 15, 2017	May NEWA
AB			EQ 10MG BASE;20MG	A 207450	003	May 15, 2017	May NEWA
AB			EQ 10MG BASE;40MG	A 207450	004	May 15, 2017	May NEWA
AB		TORRENT PHARMS LTD	EQ 5MG BASE;20MG	A 202933	001	Nov 25, 2016	Apr CAHN
AB			EQ 5MG BASE;40MG	A 202933	002	Nov 25, 2016	Apr CAHN
AB			EQ 10MG BASE;20MG	A 202933	003	Nov 25, 2016	Apr CAHN
AB			EQ 10MG BASE;40MG	A 202933	004	Nov 25, 2016	Apr CAHN
>A>	AB	ZYDUS PHARMS USA INC	EQ 5MG BASE;20MG	A 207771	001	Sep 22, 2017	Sep NEWA
>A>	AB		EQ 5MG BASE;40MG	A 207771	002	Sep 22, 2017	Sep NEWA
>A>	AB		EQ 10MG BASE;20MG	A 207771	003	Sep 22, 2017	Sep NEWA
>A>	AB		EQ 10MG BASE;40MG	A 207771	004	Sep 22, 2017	Sep NEWA

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

AP		GEN HOSP	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A 207025	001	Feb 03, 2016	May CAHN
----	--	----------	------------------------------------	----------	-----	--------------	----------

AMMONIUM LACTATE

LOTION;TOPICAL  
LAC-HYDRIN

+ @ RANBAXY EQ 12% BASE N019155 001 Apr 24, 1985 Jan CRLD

AMOXAPINE

TABLET;ORAL  
AMOXAPINE

@ UPSHER-SMITH LABS 25MG A072943 001 Jun 28, 1991 Jun CAHN  
 @ 50MG A072944 001 Jun 28, 1991 Jun CAHN  
 @ 100MG A072878 001 Jun 28, 1991 Jun CAHN  
 @ 150MG A072879 001 Jun 28, 1991 Jun CAHN  
 @ WATSON PHARMS TEVA 25MG A072418 001 May 11, 1989 Feb CAHN  
 @ 50MG A072419 001 May 11, 1989 Feb CAHN  
 @ 100MG A072420 001 May 11, 1989 Feb CAHN  
 @ 150MG A072421 001 May 11, 1989 Feb CAHN

AMOXICILLIN

FOR SUSPENSION;ORAL  
AMOXIL

>D> @ DR REDDYS LABS INC 200MG/5ML N050760 001 Apr 15, 1999 Sep CRLD  
 >A> + @ 200MG/5ML N050760 001 Apr 15, 1999 Sep CRLD  
 @ 200MG/5ML N050760 001 Apr 15, 1999 Feb DISC  
 >D> @ 400MG/5ML N050760 002 Apr 15, 1999 Sep CRLD  
 >A> + @ 400MG/5ML N050760 002 Apr 15, 1999 Sep CRLD  
 @ 400MG/5ML N050760 002 Apr 15, 1999 Feb DISC

TABLET, CHEWABLE;ORAL  
AMOXICILLIN

TEVA 125MG A064013 002 Sep 11, 1995 Feb CTEC  
 ! 250MG A064013 001 Dec 22, 1992 Feb CTEC

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION;ORAL  
AUGMENTIN '200'

+ @ DR REDDYS LABS INC 200MG/5ML;EQ 28.5MG BASE/5ML N050725 001 May 31, 1996 Feb DISC  
 AUGMENTIN '400'  
 + @ DR REDDYS LABS INC 400MG/5ML;EQ 57MG BASE/5ML N050725 002 May 31, 1996 Feb DISC  
 AUGMENTIN ES-600  
 + @ DR REDDYS LABS INC 600MG/5ML;EQ 42.9MG BASE/5ML N050755 001 Jun 22, 2001 Feb DISC

TABLET;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB ! SANDOZ 250MG;EQ 125MG BASE A065189 001 Aug 23, 2005 Feb CHRS  
 AB ! SANDOZ INC 500MG;EQ 125MG BASE A065117 001 Nov 27, 2002 Feb CHRS

TABLET, CHEWABLE;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

TEVA 200MG;EQ 28.5MG BASE A065205 001 Feb 09, 2005 Feb CTEC  
 ! 400MG;EQ 57MG BASE A065205 002 Feb 09, 2005 Feb CTEC

AUGMENTIN '200'

+ @ DR REDDYS LABS INC 200MG;EQ 28.5MG BASE N050726 001 May 31, 1996 Feb DISC  
 AUGMENTIN '400'  
 + @ DR REDDYS LABS INC 400MG;EQ 57MG BASE N050726 002 May 31, 1996 Feb DISC

AMPHETAMINE

SUSPENSION, EXTENDED RELEASE;ORAL

>A> ADZENYS ER  
 >A> +! NEOS THERAPS INC EQ 1.25MG BASE/ML N204325 001 Sep 15, 2017 Sep NEWA

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

MYDAYIS

+ SHIRE DEV LLC 3.125MG;3.125MG;3.125MG;3.125MG N022063 001 Jun 20, 2017 Jun NEWA  
 + 6.25MG;6.25MG;6.25MG;6.25MG N022063 002 Jun 20, 2017 Jun NEWA  
 + 9.375MG;9.375MG;9.375MG;9.375MG N022063 003 Jun 20, 2017 Jun NEWA  
 + 12.5MG;12.5MG;12.5MG;12.5MG N022063 004 Jun 20, 2017 Jun NEWA

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB ALVOGEN MALTA 1.25MG;1.25MG;1.25MG;1.25MG A207388 001 Jul 28, 2017 Jul NEWA  
 AB 1.875MG;1.875MG;1.875MG;1.875MG A207388 002 Jul 28, 2017 Jul NEWA  
 AB 2.5MG;2.5MG;2.5MG;2.5MG A207388 003 Jul 28, 2017 Jul NEWA  
 AB 3.125MG;3.125MG;3.125MG;3.125MG A207388 004 Jul 28, 2017 Jul NEWA  
 AB 3.75MG;3.75MG;3.75MG;3.75MG A207388 005 Jul 28, 2017 Jul NEWA

## TABLET; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE							
AB		5MG; 5MG; 5MG; 5MG	A 207388	006	Jul 28, 2017	Jul	NEWA
AB		7.5MG; 7.5MG; 7.5MG; 7.5MG	A 207388	007	Jul 28, 2017	Jul	NEWA
AB	EPIC PHARMA LLC	1.25MG; 1.25MG; 1.25MG; 1.25MG	A 040444	001	Jun 19, 2002	May	CAHN
AB		1.875MG; 1.875MG; 1.875MG; 1.875MG	A 040444	005	Nov 03, 2014	May	CAHN
AB		2.5MG; 2.5MG; 2.5MG; 2.5MG	A 040444	002	Jun 19, 2002	May	CAHN
AB		3.125MG; 3.125MG; 3.125MG; 3.125MG	A 040444	006	Nov 03, 2014	May	CAHN
AB		3.75MG; 3.75MG; 3.75MG; 3.75MG	A 040444	007	Nov 03, 2014	May	CAHN
AB		5MG; 5MG; 5MG; 5MG	A 040444	003	Jun 19, 2002	May	CAHN
AB		7.5MG; 7.5MG; 7.5MG; 7.5MG	A 040444	004	Jun 19, 2002	May	CAHN

AMPICILLIN SODIUM

## INJECTABLE; INJECTION

## AMPICILLIN SODIUM

	@ WEST-WARD PHARMS INT	EQ 125MG BASE/VIAL	A 062692	001	Jun 24, 1986	Jan	CAHN
	@	EQ 250MG BASE/VIAL	A 062692	002	Jun 24, 1986	Jan	CAHN
	@	EQ 500MG BASE/VIAL	A 062692	003	Jun 24, 1986	Jan	CAHN
	@	EQ 1GM BASE/VIAL	A 062692	004	Jun 24, 1986	Jan	CAHN
	@	EQ 2GM BASE/VIAL	A 062692	005	Jun 24, 1986	Jan	CAHN
	@	EQ 10GM BASE/VIAL	A 062692	006	Jun 24, 1986	Jan	CAHN
	PENBRITIN-S						
+	@ WYETH AYERST	EQ 125MG BASE/VIAL	N 050072	001		Jun	CRLD
+	@	EQ 250MG BASE/VIAL	N 050072	002		Jun	CRLD
+	@	EQ 500MG BASE/VIAL	N 050072	003		Jun	CRLD
+	@	EQ 1GM BASE/VIAL	N 050072	004		Jun	CRLD
+	@	EQ 2GM BASE/VIAL	N 050072	005		Jun	CRLD
+	@	EQ 4GM BASE/VIAL	N 050072	006		Jun	CRLD

AMPICILLIN SODIUM; SULBACTAM SODIUM

## INJECTABLE; INJECTION

## AMPICILLIN AND SULBACTAM

AP	ANTIBIOTICE	EQ 1GM BASE/VIAL; EQ 500MG BASE/VIAL	A 201406	001	Dec 07, 2015	Jul	CAHN
AP		EQ 2GM BASE/VIAL; EQ 1GM BASE/VIAL	A 201406	002	Dec 07, 2015	Jul	CAHN
AP	WEST-WARD PHARMS INT	EQ 1GM BASE/VIAL; EQ 500MG BASE/VIAL	A 065074	001	Mar 19, 2002	Jan	CAHN
AP		EQ 2GM BASE/VIAL; EQ 1GM BASE/VIAL	A 065074	002	Mar 19, 2002	Jan	CAHN
AP		EQ 10GM BASE/VIAL; EQ 5GM BASE/VIAL	A 065076	001	Mar 19, 2002	Jan	CAHN

ANAGRELIDE HYDROCHLORIDE

## CAPSULE; ORAL

## ANAGRELIDE HYDROCHLORIDE

AB	@ MYLAN PHARMS INC	EQ 0.5MG BASE	A 076811	001	Apr 18, 2005	May	DISC
AB		EQ 0.5MG BASE	A 076811	001	Apr 18, 2005	Mar	CAHN
	@	EQ 0.5MG BASE	A 077613	001	Jun 27, 2006	May	DISC
	@	EQ 1MG BASE	A 076811	002	Apr 18, 2005	May	DISC
AB		EQ 1MG BASE	A 076811	002	Apr 18, 2005	Mar	CAHN
	@	EQ 1MG BASE	A 077613	002	Jun 27, 2006	May	DISC
AB	TORRENT PHARMS LTD	EQ 0.5MG BASE	A 209151	001	Jun 30, 2017	Jun	NEWA
AB		EQ 1MG BASE	A 209151	002	Jun 30, 2017	Jun	NEWA
	@ UPSHER-SMITH LABS	EQ 0.5MG BASE	A 076683	001	Apr 18, 2005	Jun	CAHN
	@	EQ 1MG BASE	A 076683	002	Apr 18, 2005	Jun	CAHN

ANASTROZOLE

## TABLET; ORAL

## ANASTROZOLE

>D>	AB	SUN PHARM INDS LTD	1MG	A 091177	001	Jul 15, 2011	Sep	DISC
>A>		@	1MG	A 091177	001	Jul 15, 2011	Sep	DISC
		@ WATSON LABS TEVA	1MG	A 078984	001	Jun 28, 2010	May	CAHN
		ARIMIDEX						
AB	+	ASTRAZENECA PHARMS	1MG	N 020541	001	Dec 27, 1995	May	CAHN

ARGATROBAN

## INJECTABLE; INJECTION

## ARGATROBAN

	+	HIKMA PHARM CO LTD	50MG/50ML (1MG/ML)	N 203049	002	Sep 30, 2016	Feb	NEWA
AP	+	NOVARTIS PHARMS CORP	250MG/2.5ML (100MG/ML)	N 020883	001	Jun 30, 2000	Jun	CAHN
		INJECTABLE; IV (INFUSION)						
		ARGATROBAN IN SODIUM CHLORIDE						
AP		GLAND PHARMA LTD	125MG/125ML (1MG/ML)	A 205570	001	May 22, 2017	May	NEWA
AP	+	SANDOZ	125MG/125ML (1MG/ML)	N 022485	001	May 09, 2011	May	CFTG

ARIPIPIRAZOLE

TABLET; ORAL

ARIPIPIRAZOLE

AB	ORCHID HLTHCARE	2MG	A202683	001	May 23, 2017	May	NEWA
AB		5MG	A202683	002	May 23, 2017	May	NEWA
AB		10MG	A202683	003	May 23, 2017	May	NEWA
AB		15MG	A202683	004	May 23, 2017	May	NEWA
AB		20MG	A202683	005	May 23, 2017	May	NEWA
AB		30MG	A202683	006	May 23, 2017	May	NEWA
AB	SANTOS BIOTECH	2MG	A091279	001	Jan 09, 2017	May	CAHN
AB		5MG	A091279	002	Jan 09, 2017	May	CAHN
AB		10MG	A091279	003	Jan 09, 2017	May	CAHN
AB		15MG	A091279	004	Jan 09, 2017	May	CAHN
AB		20MG	A091279	005	Jan 09, 2017	May	CAHN
AB		30MG	A091279	006	Jan 09, 2017	May	CAHN

ARIPIPIRAZOLE LAUROXIL

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

ARISTADA

+	ALKERMES INC	1064MG/3.9ML (272.82MG/ML)	N207533	004	Jun 05, 2017	Jun	NEWA
---	--------------	----------------------------	---------	-----	--------------	-----	------

ARMODAFINIL

TABLET; ORAL

ARMODAFINIL

>A>	NATCO PHARMA LTD	100MG	A202768	004	Sep 28, 2017	Sep	NEWA
>A> AB		200MG	A202768	005	Sep 28, 2017	Sep	NEWA

ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

SEPTOCAINE

AP	+! DEPROCO	4%;EQ 0.0085MG BASE/1.7ML (4%;EQ 0.005MG BASE/ML)	N022010	001	Mar 30, 2006	Jun	CFTG
AP	ULTACAN						
AP	HANSAMED INC	4%;EQ 0.0085MG BASE/1.7ML (4%; EQ 0.005MG BASE/ML)	A201751	001	Jul 11, 2017	Jun	NEWA
AP	ULTACAN FORTE						
AP	HANSAMED INC	4%;EQ 0.017MG BASE/1.7ML (4%; EQ 0.01MG BASE/ML)	A201750	001	Jul 11, 2017	Jun	NEWA

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE; IV (INFUSION)

INFUVITE PEDIATRIC

+	SANDOZ INC	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14 MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N021265	001	Feb 21, 2001	May	CAHN
+	SANDOZ INC	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14 MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N021646	001	Jan 29, 2004	May	CAHN

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12 (WITHOUT VITAMIN K)

+	@ HOSPIRA	20MG/ML;0.006MG/ML;0.05MCG/ML;1.5MG/ML;0.0005MG/ML;0.06MG/ML;4MG/ML;0.6MG/ML;0.36MG/ML;0.6MG/ML;0.1MG/ML;1MG/ML	N008809	006	Sep 09, 2004	Aug	DISC
---	-----------	---	---------	-----	--------------	-----	------

ASPIRIN; BUTALBITAL; CAFFEINE

TABLET; ORAL

FIORINAL

+	@ ALLERGAN SALES LLC	325MG;50MG;40MG	N017534	003	Apr 16, 1986	Jan	CRLD
---	----------------------	-----------------	---------	-----	--------------	-----	------

ASPIRIN; CARISOPRODOL

TABLET;ORAL

CARISOPRODOL AND ASPIRIN

>D>	AB	INGENUS PHARMS NJ	325MG;200MG	A 040832	001	Jan 07, 2010	Sep	CAHN
>A>	AB	NOVAST LABS LTD	325MG;200MG	A 040832	001	Jan 07, 2010	Sep	CAHN

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE;ORAL

ASPIRIN AND DIPYRIDAMOLE

AB	AMNEAL PHARMS	25MG;200MG	A 206392	001	Mar 08, 2016	May	CAHN
AB	IMPAX LABS INC	25MG;200MG	A 206964	001	Jan 18, 2017	Jan	NEWA
AB	PAR PHARM INC	25MG;200MG	A 207944	001	Jan 18, 2017	Jan	NEWA
AB	SANDOZ INC	25MG;200MG	A 206739	001	Jan 18, 2017	Jan	NEWA
AB	ZYDUS PHARMS USA INC	25MG;200MG	A 206753	001	Aug 29, 2017	Aug	NEWA

ATENOLOL

TABLET;ORAL

ATENOLOL

AB	UNIQUE PHARM LABS	25MG	A 077443	001	Sep 13, 2006	Aug	CAHN
AB		50MG	A 077443	002	Sep 13, 2006	Aug	CAHN
AB		100MG	A 077443	003	Sep 13, 2006	Aug	CAHN
	@ WATSON LABS TEVA	100MG	A 073353	001	Dec 27, 1991	May	CAHN

ATOMOXETINE HYDROCHLORIDE

CAPSULE;ORAL

ATOMOXETINE HYDROCHLORIDE

AB	APOTEX INC	10MG	A 078983	001	May 30, 2017	May	NEWA
AB		18MG	A 078983	002	May 30, 2017	May	NEWA
AB		25MG	A 078983	003	May 30, 2017	May	NEWA
AB		40MG	A 078983	004	May 30, 2017	May	NEWA
AB		60MG	A 078983	005	May 30, 2017	May	NEWA
AB		80MG	A 078983	006	May 30, 2017	May	NEWA
AB		100MG	A 078983	007	May 30, 2017	May	NEWA
AB	AUROBINDO PHARMA LTD	10MG	A 079016	001	May 30, 2017	May	NEWA
AB		18MG	A 079016	002	May 30, 2017	May	NEWA
AB		25MG	A 079016	003	May 30, 2017	May	NEWA
AB		40MG	A 079016	004	May 30, 2017	May	NEWA
AB		60MG	A 079016	005	May 30, 2017	May	NEWA
AB		80MG	A 079016	006	May 30, 2017	May	NEWA
AB		100MG	A 079016	007	May 30, 2017	May	NEWA
AB	GLENMARK PHARMS LTD	10MG	A 079019	001	May 30, 2017	May	NEWA
AB		18MG	A 079019	002	May 30, 2017	May	NEWA
AB		25MG	A 079019	003	May 30, 2017	May	NEWA
AB		40MG	A 079019	004	May 30, 2017	May	NEWA
AB		60MG	A 079019	005	May 30, 2017	May	NEWA
AB		80MG	A 079019	006	May 30, 2017	May	NEWA
AB		100MG	A 079019	007	May 30, 2017	May	NEWA
AB	TEVA PHARMS USA	10MG	A 079022	001	May 30, 2017	May	NEWA
AB		18MG	A 079022	002	May 30, 2017	May	NEWA
AB		25MG	A 079022	003	May 30, 2017	May	NEWA
AB		40MG	A 079022	004	May 30, 2017	May	NEWA
AB		60MG	A 079022	005	May 30, 2017	May	NEWA
AB		80MG	A 079022	006	May 30, 2017	May	NEWA
AB		100MG	A 079022	007	May 30, 2017	May	NEWA
	STRATTERA						
AB	+ LILLY	10MG	N 021411	002	Nov 26, 2002	May	CFTG
AB	+	18MG	N 021411	003	Nov 26, 2002	May	CFTG
AB	+	25MG	N 021411	004	Nov 26, 2002	May	CFTG
AB	+	40MG	N 021411	005	Nov 26, 2002	May	CFTG
AB	+	60MG	N 021411	006	Nov 26, 2002	May	CFTG
AB	+	80MG	N 021411	007	Feb 14, 2005	May	CFTG
AB	+	100MG	N 021411	008	Feb 14, 2005	May	CFTG

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

AB	TEVA PHARMS USA	EQ 10MG BASE	A 205300	001	Mar 27, 2017	Mar	NEWA
AB		EQ 20MG BASE	A 205300	002	Mar 27, 2017	Mar	NEWA
AB		EQ 40MG BASE	A 205300	003	Mar 27, 2017	Mar	NEWA
AB		EQ 80MG BASE	A 205300	004	Mar 27, 2017	Mar	NEWA

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET; ORAL

EZETIMIBE AND ATORVASTATIN CALCIUM

	WATSON LABS TEVA	EQ 10MG BASE;10MG	A206084	001	Apr 26, 2017	Apr	NEWA
		EQ 20MG BASE;10MG	A206084	002	Apr 26, 2017	Apr	NEWA
		EQ 40MG BASE;10MG	A206084	003	Apr 26, 2017	Apr	NEWA
!		EQ 80MG BASE;10MG	A206084	004	Apr 26, 2017	Apr	NEWA

ATOVAQUONE

SUSPENSION; ORAL

ATOVAQUONE

AB	PADDOCK LLC	750MG/5ML	A207833	001	Apr 28, 2017	Apr	NEWA
----	-------------	-----------	---------	-----	--------------	-----	------

ATACURIUM BESYLATE

INJECTABLE; INJECTION

ATACURIUM BESYLATE

AP	MYLAN LABS LTD	10MG/ML	A206096	001	Jun 22, 2017	Jun	NEWA
	@ WATSON PHARMS TEVA	10MG/ML	A074945	001	Jul 28, 1998	Feb	CAHN
	ATACURIUM BESYLATE PRESERVATIVE FREE						
AP	MYLAN LABS LTD	10MG/ML	A206001	001	Apr 07, 2017	Mar	NEWA
	TRACRIUM						
	+ @ HOSPIRA	10MG/ML	N018831	002	Jun 20, 1985	Apr	CMS1
	TRACRIUM PRESERVATIVE FREE						
	+ @ HOSPIRA	10MG/ML	N018831	001	Nov 23, 1983	Apr	CMS1

ATROPINE SULFATE

SOLUTION; INTRAVENOUS

ATROPINE SULFATE LIFESHIELD ABOJECT SYRINGE

+	!	HOSPIRA	0.5MG/5ML (0.1MG/ML)	N021146	004	Aug 17, 2017	Aug	NEWA
+	!		1MG/10ML (0.1MG/ML)	N021146	005	Aug 17, 2017	Aug	NEWA

SOLUTION; INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS, ENDOTRACHEAL

ATROPINE SULFATE ANSYR PLASTIC SYRINGE

+	!	HOSPIRA	0.25MG/5ML (0.05MG/ML)	N021146	002	Jul 09, 2001	Aug	CDFR
+	!		0.5MG/5ML (0.1MG/ML)	N021146	001	Jul 09, 2001	Aug	CDFR
+	!		1MG/10ML (0.1MG/ML)	N021146	003	Jul 09, 2001	Aug	NEWA

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

AA	ANI PHARMS INC	0.025MG;2.5MG	A086727	001		Jun	CMFD
----	----------------	---------------	---------	-----	--	-----	------

AVIBACTAM SODIUM; CEFTAZIDIME

POWDER; IV (INFUSION)

AVYCAZ

+	!	CEREXA	EQ 0.5GM BASE;2GM/VIAL	N206494	001	Feb 25, 2015	May	CAHN
---	---	--------	------------------------	---------	-----	--------------	-----	------

AZACITIDINE

POWDER; IV (INFUSION), SUBCUTANEOUS

AZACITIDINE

AP	ACTAVIS LLC	100MG/VIAL	N208216	001	Apr 29, 2016	Mar	CTEC	
AP	DR REDDYS LABS LTD	100MG/VIAL	A201537	001	Sep 16, 2013	Mar	CDFR	
AP	MYLAN INSTITUTIONAL	100MG/VIAL	A204949	001	Apr 28, 2016	Mar	CDFR	
AP	NATCO PHARMA LTD	100MG/VIAL	A207234	001	Jun 23, 2017	Jun	NEWA	
AP	SHILPA MEDICARE	100MG/VIAL	A207518	001	Sep 29, 2016	Mar	CDFR	
	VIDAZA							
AP	+!	CELGENE	100MG/VIAL	N050794	001	May 19, 2004	Mar	CDFR

AZATHIOPRINE SODIUM

INJECTABLE; INJECTION

IMURAN

+	@	CASPER PHARMA LLC	EQ 100MG BASE/VIAL	N017391	001		Jul	CAHN
---	---	-------------------	--------------------	---------	-----	--	-----	------

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AZELASTINE HYDROCHLORIDE

AT		SANDOZ INC	0.05%	A202305	001	May 31, 2012	Feb	CAHN	
		OPTIVAR							
AT	+	!	MYLAN SPECIALITY LP	0.05%	N021127	001	May 22, 2000	Mar	CAHN

## SPRAY, METERED;NASAL

## ASTELIN

AB	+	MYLAN SPECIALITY LP	EQ 0.125MG BASE/SPRAY	N020114	001	Nov 01, 1996	Mar CAHN
----	---	---------------------	-----------------------	---------	-----	--------------	----------

## ASTEPRO

AB	+	@ MYLAN SPECIALITY LP	EQ 0.125MG BASE/SPRAY	N022203	001	Oct 15, 2008	Mar CAHN
----	---	-----------------------	-----------------------	---------	-----	--------------	----------

## AZELASTINE HYDROCHLORIDE

AB		ALKEM LABS LTD	EQ 0.125MG BASE/SPRAY	A208156	001	Aug 18, 2017	Aug NEWA
----	--	----------------	-----------------------	---------	-----	--------------	----------

AB		AMNEAL PHARMS LLC	EQ 0.125MG BASE/SPRAY	A204660	001	Aug 28, 2017	Aug NEWA
----	--	-------------------	-----------------------	---------	-----	--------------	----------

AB		BRECKENRIDGE PHARM	EQ 0.125MG BASE/SPRAY	A090176	001	Jul 28, 2015	Feb CAHN
----	--	--------------------	-----------------------	---------	-----	--------------	----------

AB		UPSHER-SMITH LABS	EQ 0.125MG BASE/SPRAY	A202609	001	Mar 17, 2017	Jun CAHN
----	--	-------------------	-----------------------	---------	-----	--------------	----------

AB			EQ 0.125MG BASE/SPRAY	A202609	001	Mar 17, 2017	Mar NEWA
----	--	--	-----------------------	---------	-----	--------------	----------

>A>	AB	WEST-WARD PHARMS INT	EQ 0.1876MG BASE/SPRAY	A207243	001	Sep 22, 2017	Sep NEWA
-----	----	----------------------	------------------------	---------	-----	--------------	----------

AB		ZYDUS PHARMS USA INC	EQ 0.125MG BASE/SPRAY	A091409	001	Aug 14, 2017	Jul NEWA
----	--	----------------------	-----------------------	---------	-----	--------------	----------

AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE

## SPRAY, METERED;NASAL

## AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE

AB		APOTEX INC	EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY	A207712	001	Apr 28, 2017	Apr NEWA
----	--	------------	------------------------------------	---------	-----	--------------	----------

## DYMISTA

AB	+	MYLAN SPECIALITY LP	EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY	N202236	001	May 01, 2012	Apr CFTG
----	---	---------------------	------------------------------------	---------	-----	--------------	----------

	+		EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY	N202236	001	May 01, 2012	Mar CAHN
--	---	--	------------------------------------	---------	-----	--------------	----------

AZITHROMYCIN

## FOR SUSPENSION;ORAL

## AZITHROMYCIN

AB		LUPIN LTD	EQ 100MG BASE/5ML	A065488	001	May 15, 2015	Aug CTEC
----	--	-----------	-------------------	---------	-----	--------------	----------

AB			EQ 200MG BASE/5ML	A065488	002	May 15, 2015	Aug CTEC
----	--	--	-------------------	---------	-----	--------------	----------

## INJECTABLE;INJECTION

## AZITHROMYCIN

AP		MYLAN LABS LTD	EQ 500MG BASE/VIAL	A204732	001	Jan 26, 2017	Jan NEWA
----	--	----------------	--------------------	---------	-----	--------------	----------

## TABLET;ORAL

## AZITHROMYCIN

## @ MYLAN

## @

			EQ 250MG BASE	A065365	001	May 30, 2007	Jun DISC
--	--	--	---------------	---------	-----	--------------	----------

			EQ 500MG BASE	A065366	001	May 30, 2007	May DISC
--	--	--	---------------	---------	-----	--------------	----------

## ZITHROMAX

AB	+	PFIZER	EQ 250MG BASE	N050711	001	Jul 18, 1996	Apr CRLD
----	---	--------	---------------	---------	-----	--------------	----------

AB	+		EQ 500MG BASE	N050784	001	May 24, 2002	Apr CRLD
----	---	--	---------------	---------	-----	--------------	----------

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

## OINTMENT;TOPICAL

## CORTISPORIN

	+	MONARCH PHARMS	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;5,000 UNITS/GM	N050168	002	May 04, 1984	Feb CAHN
--	---	----------------	--	---------	-----	--------------	----------

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

## OINTMENT;OPHTHALMIC

## NEOSPORIN

AT	+	CASPER PHARMA LLC	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050417	001		Apr CMFD
----	---	-------------------	--	---------	-----	--	----------

BACLOFEN

## INJECTABLE;INTRATHECAL

## BACLOFEN

AP		EMERALD INTL LTD	0.05MG/ML	A091193	001	May 03, 2016	Mar CAHN
----	--	------------------	-----------	---------	-----	--------------	----------

AP			0.5MG/ML	A091193	002	May 03, 2016	Mar CAHN
----	--	--	----------	---------	-----	--------------	----------

AP			2MG/ML	A091193	003	May 03, 2016	Mar CAHN
----	--	--	--------	---------	-----	--------------	----------

## GABLOFEN

	+	MALLINCKRODT INC	1MG/ML	N022462	004	Jun 22, 2012	Mar CRLD
--	---	------------------	--------	---------	-----	--------------	----------

AP		PIRAMAL CRITICAL	0.05MG/ML	N022462	001	Nov 19, 2010	Apr CAHN
----	--	------------------	-----------	---------	-----	--------------	----------

AP			0.5MG/ML	N022462	002	Nov 19, 2010	Apr CAHN
----	--	--	----------	---------	-----	--------------	----------

	+		1MG/ML	N022462	004	Jun 22, 2012	Apr CAHN
--	---	--	--------	---------	-----	--------------	----------

AP			2MG/ML	N022462	003	Nov 19, 2010	Apr CAHN
----	--	--	--------	---------	-----	--------------	----------

## TABLET;ORAL

## BACLOFEN

## @ MYLAN

AB		OXFORD PHARMS	10MG	A077181	001	Jul 29, 2005	May DISC
----	--	---------------	------	---------	-----	--------------	----------

AB		USL PHARMA	10MG	A074584	001	Aug 19, 1996	Jun CAHN
----	--	------------	------	---------	-----	--------------	----------

AB			20MG	A074584	002	Aug 19, 1996	Jun CAHN
----	--	--	------	---------	-----	--------------	----------



BALSALAZIDE DISODIUM

	CAPSULE;ORAL						
	BALSALAZIDE DISODIUM						
AB	WEST-WARD PHARMS INT	750MG	A077806	001	Dec 28, 2007	Jul	CTEC
BX		750MG	A077806	001	Dec 28, 2007	Apr	CTEC

BARIUM SULFATE

	FOR SUSPENSION;ORAL						
	E-Z-CAT DRY						
+!	BRACCO	40% (9GM/POUCH)	N208036	003	Jan 03, 2017	Aug	NEWA
	E-Z-HD						
+!	BRACCO	98% (334GM/BOTTLE)	N208036	001	Jan 11, 2016	Apr	CPOT
	E-Z-PAQUE						
+!	BRACCO	96% (169GM/BOTTLE)	N208036	002	Apr 07, 2017	Apr	NEWA
	SUSPENSION;ORAL						
	LIQUID E-Z-PAQUE						
+!	BRACCO	60% (213GM/355ML)	N208143	003	Mar 01, 2017	Mar	NEWA
	TAGITOL V						
+!	BRACCO	40% (8GM/20ML)	N208143	005	Aug 04, 2017	Aug	NEWA
	VARIBAR NECTAR						
+!	BRACCO	40% (96GM/240ML)	N208143	004	Jul 07, 2017	Jul	NEWA

BECLOMETHASONE DIPROPIONATE

	AEROSOL, METERED; INHALATION						
	QVAR REDHALER						
+	NORTON WATERFORD	0.04MG/INH	N207921	001	Aug 03, 2017	Aug	NEWA
+!		0.08MG/INH	N207921	002	Aug 03, 2017	Aug	NEWA

BENAZEPRIL HYDROCHLORIDE

	TABLET;ORAL						
	BENAZEPRIL HYDROCHLORIDE						
AB	AMNEAL PHARMS	5MG	A076820	001	Feb 03, 2006	Apr	CAHN
AB		10MG	A076820	002	Feb 03, 2006	Apr	CAHN
AB		20MG	A076820	003	Feb 03, 2006	Apr	CAHN
AB		40MG	A076820	004	Feb 03, 2006	Apr	CAHN

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

	TABLET;ORAL						
	LOTENSIN HCT						
+	@ US PHARMS HOLDINGS I	5MG;6.25MG	N020033	001	May 19, 1992	May	DISC

BENDROFLUMETHIAZIDE; NADOLOL

	TABLET;ORAL							
	CORZIDE							
AB	+	KING PHARMS LLC	5MG;40MG	N018647	001	May 25, 1983	Mar	CAHN
AB	+!		5MG;80MG	N018647	002	May 25, 1983	Mar	CAHN

BENZNIDAZOLE

	TABLET;ORAL						
	BENZNIDAZOLE						
+	CHEMO RESEARCH SL	12.5MG	N209570	001	Aug 29, 2017	Aug	NEWA
+!		100MG	N209570	002	Aug 29, 2017	Aug	NEWA

BENZONATATE

	CAPSULE;ORAL							
	TESSALON							
AA	+	PFIZER	100MG	N011210	001		Apr	CRLD

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

	GEL;TOPICAL						
	CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE						
AB	TOLMAR	5%;EQ 1% BASE	A204087	001	Jun 27, 2017	Jun	NEWA

BENZPHETAMINE HYDROCHLORIDE

	TABLET;ORAL							
	BENZPHETAMINE HYDROCHLORIDE							
>A>	AA	ANDA REPOSITORY	50MG	A040578	001	Apr 17, 2006	Sep	CAHN
		@ EPIC PHARMA LLC	50MG	A040714	001	Oct 29, 2007	May	CAHN
>D>	AA	TWI PHARMS INC	50MG	A040578	001	Apr 17, 2006	Sep	CAHN
	AA		50MG	A040578	001	Apr 17, 2006	Mar	CAHN

BENZTROPINE MESYLATE

TABLET;ORAL

BENZTROPINE MESYLATE

>A>	@	ANDA REPOSITORY	1MG	A 081264	001	Jan 23, 1992	Sep	CAHN
>A>	@		2MG	A 081265	001	Jan 23, 1992	Sep	CAHN
AA		EPIC PHARMA LLC	0.5MG	A 072264	001	Feb 27, 1989	May	CAHN
AA			1MG	A 072265	001	Feb 27, 1989	May	CAHN
AA			2MG	A 072266	001	Feb 27, 1989	May	CAHN
>D>	@	FRONTIDA BIOPHARM	1MG	A 081264	001	Jan 23, 1992	Sep	CAHN
>D>	@		2MG	A 081265	001	Jan 23, 1992	Sep	CAHN
		OXFORD PHARMS	0.5MG	A 040706	002	Feb 14, 2008	May	CMS1
			1MG	A 040706	003	Feb 14, 2008	May	CMS1
AA	!	UPSHER-SMITH LABS	0.5MG	A 040103	001	Dec 12, 1996	Feb	CAHN
AA	!		1MG	A 040103	002	Dec 12, 1996	Feb	CAHN
AA	!		2MG	A 040103	003	Dec 12, 1996	Feb	CAHN
AA	!	USL PHARMA	0.5MG	A 040103	001	Dec 12, 1996	Jun	CAHN
AA	!		1MG	A 040103	002	Dec 12, 1996	Jun	CAHN
AA	!		2MG	A 040103	003	Dec 12, 1996	Jun	CAHN

BETAINE HYDROCHLORIDEFOR SOLUTION;ORAL  
CYSTADANE

+!	ORPHAN EUROPE	1GM/SCOOPFUL	N 020576	001	Oct 25, 1996	Jul	CAHN
----	---------------	--------------	----------	-----	--------------	-----	------

BETAMETHASONE DIPROPIONATE

LOTION;TOPICAL

BETAMETHASONE DIPROPIONATE

AB	!	FOUGERA PHARMS INC	EQ 0.05% BASE	A 070275	001	Aug 12, 1985	Jan	CAHN
	@	TARO	EQ 0.05% BASE	A 074272	001	Sep 30, 1994	Apr	CAHN
		DIPROSONE						
+	@	SCHERING	EQ 0.05% BASE	N 017781	001		Jan	CRLD

OINTMENT;TOPICAL

BETAMETHASONE DIPROPIONATE

AB	+!	FOUGERA PHARMS INC	EQ 0.05% BASE	N 019141	001	Sep 04, 1984	Aug	CAHN
AB		TARO	EQ 0.05% BASE	A 074271	001	Sep 15, 1994	Apr	CAHN

BETAMETHASONE VALERATE

AEROSOL, FOAM;TOPICAL

BETAMETHASONE VALERATE

AB		PERRIGO UK FINCO	0.12%	A 078337	001	Nov 26, 2012	Apr	CAHN
AB		RICONPHARMA LLC	0.12%	A 207144	001	May 24, 2017	May	NEWA
AB		TARO PHARM	0.12%	A 208204	001	May 24, 2017	May	NEWA

LUXIQ

AB	+!	MYLAN PHARMS INC	0.12%	N 020934	001	Feb 28, 1999	Jan	CAHN
----	----	------------------	-------	----------	-----	--------------	-----	------

CREAM;TOPICAL

BETAMETHASONE VALERATE

AB	+!	FOUGERA PHARMS INC	EQ 0.1% BASE	N 018861	001	Aug 31, 1983	Aug	CAHN
----	----	--------------------	--------------	----------	-----	--------------	-----	------

LOTION;TOPICAL

BETAMETHASONE VALERATE

AB	+!	FOUGERA PHARMS INC	EQ 0.1% BASE	N 018866	001	Aug 31, 1983	Aug	CAHN
----	----	--------------------	--------------	----------	-----	--------------	-----	------

OINTMENT;TOPICAL

BETAMETHASONE VALERATE

AB	+!	FOUGERA PHARMS INC	EQ 0.1% BASE	N 018865	001	Aug 31, 1983	Aug	CAHN
----	----	--------------------	--------------	----------	-----	--------------	-----	------

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

BETAXOLOL HYDROCHLORIDE

>A>	AT	MEDIMETRIKS PHARMS	EQ 0.5% BASE	A 075630	001	Apr 12, 2001	Sep	CAHN
>D>	AT	TELGENT	EQ 0.5% BASE	A 075630	001	Apr 12, 2001	Sep	CAHN
	AT		EQ 0.5% BASE	A 075630	001	Apr 12, 2001	Apr	CAHN

BETHANECHOL CHLORIDE

TABLET;ORAL

BETHANECHOL CHLORIDE

>A>	AA	ECI PHARMS LLC	5MG	A 040725	001	Oct 26, 2007	Sep	CAHN
>A>	AA		10MG	A 040726	001	Oct 26, 2007	Sep	CAHN
>A>	AA		25MG	A 040727	001	Oct 26, 2007	Sep	CAHN
>A>	AA		50MG	A 040728	001	Oct 26, 2007	Sep	CAHN
		@ IMPAX LABS	5MG	A 040721	001	Nov 01, 2006	Jan	CMS1
		@	10MG	A 040721	002	Nov 01, 2006	Jan	CMS1
		@	25MG	A 040721	003	Nov 01, 2016	Jan	CMS1

## TABLET;ORAL

## BETHANECHOL CHLORIDE

AA	LANNETT HOLDINGS INC	5MG	A 040677	002	Mar 27, 2008	May CMS1
AA		10MG	A 040677	003	Mar 27, 2008	May CMS1
AA		25MG	A 040677	004	Mar 27, 2008	May CMS1
>D>	PHARMAX	5MG	A 040725	001	Oct 26, 2007	Sep CAHN
>D>		10MG	A 040726	001	Oct 26, 2007	Sep CAHN
>D>		25MG	A 040727	001	Oct 26, 2007	Sep CAHN
>D>		50MG	A 040728	001	Oct 26, 2007	Sep CAHN
AA	UPSHER-SMITH LABS	5MG	A 040633	001	Jun 01, 2005	Jun CAHN
AA		10MG	A 040634	001	Jun 01, 2005	Jun CAHN
AA		25MG	A 040635	001	Jun 01, 2005	Jun CAHN
AA		50MG	A 040636	001	Jun 01, 2005	Jun CAHN

BETRIXABAN

## CAPSULE;ORAL

## BEVYXXA

+	PORTOLA PHARMS INC	40MG	N 208383	001	Jun 23, 2017	Jun NEWA
+	!	80MG	N 208383	002	Jun 23, 2017	Jun NEWA

BICALUTAMIDE

## TABLET;ORAL

## BICALUTAMIDE

AB	SANTOS BIOTECH	50MG	A 091011	001	Jun 10, 2015	May CAHN
AB	WATSON LABS TEVA	50MG	A 078634	001	Aug 28, 2009	May CAHN
AB	+!	CASODEX	N 020498	001	Oct 04, 1995	May CAHN

BIMATOPROST

## SOLUTION/DROPS;OPHTHALMIC

## BIMATOPROST

AT	SANDOZ INC	0.03%	A 202565	001	May 05, 2015	Mar CAHN
----	------------	-------	----------	-----	--------------	----------

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

## TABLET, CHEWABLE, TABLET, CAPSULE;ORAL

## HELIDAC

+	@	CASPER PHARMA LLC	262.4MG,N/A,N/A;N/A,250MG,N/A;N/A,N/A,500MG	N 050719	001	Aug 15, 1996	Jul CAHN
---	---	-------------------	---	----------	-----	--------------	----------

BISOPROLOL FUMARATE

## TABLET;ORAL

## BISOPROLOL FUMARATE

>A>	@	ANDA REPOSITORY	5MG	A 075474	001	Oct 25, 2002	Sep CAHN
>A>	@		10MG	A 075474	002	Oct 25, 2002	Sep CAHN
>D>	@	FRONTIDA BIOPHARM	5MG	A 075474	001	Oct 25, 2002	Sep CAHN
>D>	@		10MG	A 075474	002	Oct 25, 2002	Sep CAHN
AB		ORIT LABS LLC	5MG	A 204891	001	Jan 11, 2017	Jan NEWA
AB			10MG	A 204891	002	Jan 11, 2017	Jan NEWA

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

## TABLET;ORAL

## BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

	@	WATSON LABS TEVA	2.5MG;6.25MG	A 075469	001	Sep 25, 2000	May CAHN
	@		5MG;6.25MG	A 075469	002	Sep 25, 2000	May CAHN
	@		10MG;6.25MG	A 075469	003	Sep 25, 2000	May CAHN
		ZIAC					
AB	+	TEVA BRANDED PHARM	2.5MG;6.25MG	N 020186	003	Mar 26, 1993	Jan CAHN
AB	+		5MG;6.25MG	N 020186	001	Mar 26, 1993	Jan CAHN
AB	+	!	10MG;6.25MG	N 020186	002	Mar 26, 1993	Jan CAHN

BIVALIRUDIN

## INJECTABLE;INTRAVENOUS

## BIVALIRUDIN

AP	APOTEX INC	250MG/VIAL	A 204876	001	Jul 06, 2017	Jun NEWA
AP	DR REDDYS LABS LTD	250MG/VIAL	A 201577	001	May 26, 2017	May NEWA

BOSENTAN

## TABLET, FOR SUSPENSION;ORAL

## TRACLEER

>A>	+	!	ACTELION PHARMS	32MG	N 209279	001	Sep 05, 2017	Sep NEWA
-----	---	---	-----------------	------	----------	-----	--------------	----------

BRETYLIUM TOSYLATEINJECTABLE; INJECTION  
BRETYLIUM TOSYLATE

@ WEST-WARD PHARMS INT	50MG/ML	A070545	001	May 14, 1986	Jan	CAHN
------------------------	---------	---------	-----	--------------	-----	------

BREXPIPIRAZOLETABLET; ORAL  
REXULTI

+! OTSUKA PHARM CO LTD	2MG	N205422	004	Jul 10, 2015	Aug	CHRS
+	4MG	N205422	006	Jul 10, 2015	Aug	CHRS

BRIGATINIBTABLET; ORAL  
ALUNBRIG

+ ARIAD	30MG	N208772	001	Apr 28, 2017	Apr	NEWA
+!	90MG	N208772	002	Apr 28, 2017	Apr	NEWA

BRIMONIDINE TARTRATESOLUTION/DROPS; OPHTHALMIC  
BRIMONIDINE TARTRATE

AT	SANDOZ INC	0.2%	A076254	001	Sep 16, 2003	Feb	CAHN
AT		0.2%	A078075	001	Jan 30, 2008	Mar	CAHN
	QOLIANA						
AT	SANDOZ INC	0.15%	N021764	001	May 22, 2006	Mar	CAHN

BROMFENAC SODIUMSOLUTION/DROPS; OPHTHALMIC  
BROMFENAC SODIUM

AT1	AMRING PHARMS	EQ 0.09% ACID	A202030	001	Jan 09, 2013	Mar	CAHN
AT1	! APOTEX INC	EQ 0.09% ACID	A202435	001	Jun 19, 2014	Feb	CHRS
AT2	! HI-TECH PHARMACAL	EQ 0.09% ACID	A203395	001	Jan 22, 2014	Mar	CHRS

BROMPHENIRAMINE MALEATETABLET; ORAL  
BROMPHENIRAMINE MALEATE

@ UPSHER-SMITH LABS	4MG	A083215	001		Jun	CAHN
---------------------	-----	---------	-----	--	-----	------

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP; ORAL

BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

AA	TARO PHARM	2MG/5ML; 10MG/5ML; 30MG/5ML	A205112	001	Feb 27, 2017	Feb	NEWA
----	------------	-----------------------------	---------	-----	--------------	-----	------

BUDESONIDECAPSULE; ORAL  
BUDESONIDE

AB	AMNEAL PHARMS	3MG	A206200	001	Jul 31, 2017	Jul	NEWA
AB	APPCO PHARMA LLC	3MG	A207367	001	Apr 07, 2017	Mar	NEWA
>A> AB	SCIECURE PHARMA INC	3MG	A209041	001	Sep 28, 2017	Sep	NEWA
AB	ZYDUS PHARMS USA INC	3MG	A206134	001	May 04, 2017	Apr	NEWA

BUMETANIDEINJECTABLE; INJECTION  
BUMETANIDE

AP	! ATHENEX INC	0.25MG/ML	A074441	001	Jan 27, 1995	Mar	CAHN
AP	WEST-WARD PHARMS INT	0.25MG/ML	A079196	001	Apr 30, 2008	Jan	CAHN
	BUMEX						
	+ @ VALIDUS PHARMS	0.25MG/ML	N018226	001	Feb 28, 1983	Jun	CAHN
	TABLET; ORAL						
	BUMEX						
AB	+ VALIDUS PHARMS	0.5MG	N018225	002	Feb 28, 1983	Jun	CAHN
AB	+	1MG	N018225	001	Feb 28, 1983	Jun	CAHN
AB	+	2MG	N018225	003	Jun 14, 1985	Jun	CAHN

BUPIVACAINE HYDROCHLORIDEINJECTABLE; SPINAL  
BUPIVACAINE HYDROCHLORIDE

AP	BAXTER HLTHCARE CORP	0.75%	A207266	001	Jul 25, 2016	Aug	CAHN
----	----------------------	-------	---------	-----	--------------	-----	------

BUPRENORPHINE HYDROCHLORIDE

FILM;BUCCAL

BELBUCA

+	BDSI	EQ 0.075MG BASE	N207932	001	Oct 23, 2015	Jan CAHN
+		EQ 0.15MG BASE	N207932	002	Oct 23, 2015	Jan CAHN
+		EQ 0.3MG BASE	N207932	003	Oct 23, 2015	Jan CAHN
+		EQ 0.45MG BASE	N207932	004	Oct 23, 2015	Jan CAHN
+		EQ 0.6MG BASE	N207932	005	Oct 23, 2015	Jan CAHN
+		EQ 0.75MG BASE	N207932	006	Oct 23, 2015	Jan CAHN
+	!	EQ 0.9MG BASE	N207932	007	Oct 23, 2015	Jan CAHN

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

AB	RHODES PHARMS	EQ 2MG BASE	A207276	001	Mar 27, 2017	Mar NEWA
AB		EQ 8MG BASE	A207276	002	Mar 27, 2017	Mar NEWA

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB	AMNEAL PHARMS	EQ 8MG BASE;EQ 2MG BASE	A203136	002	Feb 22, 2013	May CAHN
AB	AMNEAL PHARMS	EQ 2MG BASE;EQ 0.5MG BASE	A203136	001	Feb 22, 2013	May CAHN
	ZUBSOLV					
+	OREXO US INC	EQ 5.7MG BASE;EQ 1.4MG BASE	N204242	002	Jul 03, 2013	Jan CHRS
+	!	EQ 11.4MG BASE;EQ 2.9MG BASE	N204242	004	Dec 11, 2014	Jan CHRS

BUPROPION HYDROCHLORIDE

TABLET;ORAL

BUPROPION HYDROCHLORIDE

>A>	AB	INVAGEN PHARMS	75MG	A207389	001	Sep 18, 2017	Sep NEWA
>A>	AB		100MG	A207389	002	Sep 18, 2017	Sep NEWA
		WELLBUTRIN					
>D>	@	GLAXOSMITHKLINE	50MG	N018644	001	Dec 30, 1985	Sep CRLD
>A>	+	@	50MG	N018644	001	Dec 30, 1985	Sep CRLD
>D>	@		75MG	N018644	002	Dec 30, 1985	Sep CRLD
>A>	+	@	75MG	N018644	002	Dec 30, 1985	Sep CRLD
>D>	@		100MG	N018644	003	Dec 30, 1985	Sep CRLD
>A>	+	@	100MG	N018644	003	Dec 30, 1985	Sep CRLD

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

AB3	ANBISON LAB CO LTD	150MG	A207224	001	Jun 30, 2017	Jun NEWA	
AB3		300MG	A207224	002	Jun 30, 2017	Jun NEWA	
AB3	JUBILANT GENERICS	150MG	A207459	001	Jun 30, 2017	Jun NEWA	
AB3		300MG	A207459	002	Jun 30, 2017	Jun NEWA	
AB3	LUPIN LTD	150MG	A090693	001	Apr 06, 2017	Mar NEWA	
AB3		300MG	A090693	002	Apr 06, 2017	Mar NEWA	
>D>	AB2	SCIEGEN PHARMS INC	150MG	A206122	001	Aug 17, 2016	Sep CAHN
AB3		150MG	A207479	001	Apr 12, 2017	Mar NEWA	
AB3		300MG	A207479	002	Apr 12, 2017	Mar NEWA	
AB3	SINOTHERAPEUTICS INC	150MG	A208652	001	Aug 21, 2017	Aug NEWA	
AB3		300MG	A208652	002	Aug 21, 2017	Aug NEWA	
>A>	AB2	TECH ORGANIZED	150MG	A206122	001	Aug 17, 2016	Sep CAHN
		FORFIVO XL					
+	!	ALVOGEN	450MG	N022497	001	Nov 10, 2011	Jan CAHN

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL

BUSPIRONE HYDROCHLORIDE

AB	AMNEAL PHARMS CO	5MG	A208829	001	May 24, 2017	May NEWA	
AB		7.5MG	A208829	002	May 24, 2017	May NEWA	
AB		10MG	A208829	003	May 24, 2017	May NEWA	
AB		15MG	A208829	004	May 24, 2017	May NEWA	
AB		30MG	A208829	005	May 24, 2017	May NEWA	
	@	MYLAN	5MG	A075467	001	Feb 28, 2002	Jun DISC
	@		10MG	A075467	003	Feb 28, 2002	Jun DISC
	@		15MG	A075467	004	Feb 28, 2002	Jun DISC
AB	STRIDES PHARMA	5MG	A202330	001	Aug 25, 2014	Apr CAHN	
>A>	AB	7.5MG	A202330	005	Feb 17, 2017	Sep NEWA	
AB		10MG	A202330	002	Aug 25, 2014	Apr CAHN	
AB		15MG	A202330	003	Aug 25, 2014	Apr CAHN	
AB		30MG	A202330	004	Aug 25, 2014	Apr CAHN	

BUSULFAN

INJECTABLE; INJECTION		BUSULFAN					
AP	PHARMASCIENCE INC	6MG/ML	A207050	001	Mar 24, 2017	Mar	NEWA
AP	SANDOZ INC	6MG/ML	A205106	001	Jul 07, 2017	Jun	NEWA

BUTABARBITAL SODIUM

TABLET; ORAL		BUTISOL SODIUM					
	@ MYLAN SPECIALITY LP	15MG	N000793	002		Mar	CAHN
	+!	30MG	N000793	004		Mar	CAHN
	@	50MG	N000793	003		Mar	CAHN
	@	100MG	N000793	005		Mar	CAHN

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION		BUTORPHANOL TARTRATE					
	@ BAXTER HLTHCARE CORP	2MG/ML	A075697	001	Oct 23, 2001	Aug	CAHN
	BUTORPHANOL TARTRATE PRESERVATIVE FREE						
	@ BAXTER HLTHCARE CORP	1MG/ML	A075695	001	Oct 23, 2001	Aug	CAHN
	@	2MG/ML	A075695	002	Oct 23, 2001	Aug	CAHN
AP	WEST-WARD PHARMS INT	1MG/ML	A075045	001	Aug 12, 1998	Jan	CAHN
AP		2MG/ML	A075045	002	Aug 12, 1998	Jan	CAHN

CALCIPOTRIENE

AEROSOL, FOAM; TOPICAL		SORILUX					
	+! MAYNE PHARMA	0.005%	N022563	001	Oct 06, 2010	Jan	CAHN
	OINTMENT; TOPICAL						
	CALCIPOTRIENE						
	! GLENMARK PHARMS INC	0.005%	A090633	001	Mar 24, 2010	May	CAHN

CALCITONIN SALMON

SPRAY, METERED; NASAL		CALCITONIN-SALMON					
AB	! APOTEX INC	200 IU/SPRAY	A076396	001	Nov 17, 2008	Apr	CHRS
	MIACALCIN						
	+ @ MYLAN IRELAND LTD	200 IU/SPRAY	N020313	002	Aug 17, 1995	Apr	DISC

CALCITONIN SALMON RECOMBINANT

SPRAY, METERED; NASAL		FORTICAL					
	@ UPSHER-SMITH LABS	200 IU/SPRAY	N021406	001	Aug 12, 2005	Jun	CAHN

CALCITRIOL

CAPSULE; ORAL		CALCITRIOL					
AB	AMNEAL PHARMS	0.25MCG	A203289	002	Jun 14, 2017	May	NEWA
AB		0.5MCG	A203289	001	Jun 14, 2017	May	NEWA
	INJECTABLE; INJECTION						
	CALCIJEX						
	+ @ ABBVIE	0.001MG/ML	N018874	001	Sep 25, 1986	May	CRLD
	+ @	0.002MG/ML	N018874	002	Sep 25, 1986	May	CRLD
	CALCITRIOL						
	! AKORN	0.001MG/ML	A078066	001	Jan 29, 2008	May	CHRS

CALCIUM ACETATE

CAPSULE; ORAL		CALCIUM ACETATE					
AB	CHARTWELL RX	667MG	A091312	001	Jun 01, 2012	Mar	CAHN
	TABLET; ORAL						
	CALCIUM ACETATE						
AB	! PADDOCK LLC	667MG	A091561	001	Apr 13, 2011	Apr	CHRS
	ELIPHOS						
AB	CYPRESS PHARM	667MG	A078502	001	Nov 25, 2008	Apr	CHRS

CALCIUM CHLORIDE

INJECTABLE; INJECTION		CALCIUM CHLORIDE 10%	
AP	LUITPOLD PHARMS INC	100MG/ML	A209088 001 Jul 27, 2017 Jul NEWA
CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER			
AP	+! HOSPIRA	100MG/ML	N021117 001 Jan 28, 2000 Jul CFTG

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION		DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER	
@ HOSPIRA		33MG/100ML; 5GM/100ML; 30MG/100ML; 860MG/100ML	N018254 001 Aug DISC
DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER			
B BRAUN		33MG/100ML; 5GM/100ML; 30MG/100ML; 860MG/100ML	N020000 001 Apr 17, 1992 Aug CTEC

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION		DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER	
AP	ICU MEDICAL INC	20MG/100ML; 5GM/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	N017608 001 Feb CAHN
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER			
@ ICU MEDICAL INC		20MG/100ML; 5GM/100ML; 104MG/100ML; 600MG/100ML; 310MG/100ML	N019685 005 Oct 17, 1988 Feb CAHN
@		20MG/100ML; 5GM/100ML; 179MG/100ML; 600MG/100ML; 310MG/100ML	N019685 006 Oct 17, 1988 Feb CAHN
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER			
@ ICU MEDICAL INC		20MG/100ML; 5GM/100ML; 254MG/100ML; 600MG/100ML; 310MG/100ML	N019685 007 Oct 17, 1988 Feb CAHN
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER			
AP	ICU MEDICAL INC	20MG/100ML; 5GM/100ML; 179MG/100ML; 600MG/100ML; 310MG/100ML	N019685 002 Oct 17, 1988 Feb CAHN
AP		20MG/100ML; 5GM/100ML; 328MG/100ML; 600MG/100ML; 310MG/100ML	N019685 008 Oct 17, 1988 Feb CAHN
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER			
@ ICU MEDICAL INC		20MG/100ML; 5GM/100ML; 254MG/100ML; 600MG/100ML; 310MG/100ML	N019685 003 Oct 17, 1988 Feb CAHN
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER			
AP	ICU MEDICAL INC	20MG/100ML; 5GM/100ML; 328MG/100ML; 600MG/100ML; 310MG/100ML	N019685 004 Oct 17, 1988 Feb CAHN
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER			
@ ICU MEDICAL INC		20MG/100ML; 5GM/100ML; 104MG/100ML; 600MG/100ML; 310MG/100ML	N019685 001 Oct 17, 1988 Feb CAHN

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION		RINGER'S IN PLASTIC CONTAINER	
AP	ICU MEDICAL INC	33MG/100ML; 30MG/100ML; 860MG/100ML	N018251 001 Feb CAHN
SOLUTION; IRRIGATION			
RINGER'S IN PLASTIC CONTAINER			
AT	ICU MEDICAL INC	33MG/100ML; 30MG/100ML; 860MG/100ML	N017635 001 Feb CAHN

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION		LACTATED RINGER'S IN PLASTIC CONTAINER	
AP	ICU MEDICAL INC	20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	N017641 001 Feb CAHN
SOLUTION; IRRIGATION			
LACTATED RINGER'S IN PLASTIC CONTAINER			
AT	+! ICU MEDICAL INC	20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	N019416 001 Jan 17, 1986 Feb CAHN

CALCIUM GLUCONATE

SOLUTION; IV (INFUSION)		CALCIUM GLUCONATE	
+!	FRESENIUS KABI USA	1GM/10ML (100MG/ML)	N208418 001 Jun 15, 2017 Jun NEWA
+!		5GM/50ML (100MG/ML)	N208418 002 Jun 15, 2017 Jun NEWA
+!		10GM/100ML (100MG/ML)	N208418 003 Jun 15, 2017 Jun NEWA

CANDESARTAN CILEXETIL

TABLET; ORAL

CANDESARTAN CILEXETIL

AB	ALEMBIC PHARMS LTD	32MG	A 209119	001	Jun 20, 2017	Jun	NEWA
AB	ZYDUS PHARMS USA INC	4MG	A 091390	001	Aug 23, 2017	Aug	NEWA
AB		8MG	A 091390	002	Aug 23, 2017	Aug	NEWA
AB		16MG	A 091390	003	Aug 23, 2017	Aug	NEWA
AB		32MG	A 091390	004	Aug 23, 2017	Aug	NEWA

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

AB	MYLAN PHARMS INC	16MG;12.5MG	A 090704	001	Dec 04, 2012	May	CAHN
AB		32MG;12.5MG	A 090704	002	Dec 04, 2012	May	CAHN
AB		32MG;25MG	A 090704	003	Dec 04, 2012	May	CAHN

CAPECITABINE

TABLET; ORAL

CAPECITABINE

AB	AMNEAL PHARMS	150MG	A 204741	001	Feb 28, 2017	Feb	NEWA
AB		500MG	A 204741	002	Feb 28, 2017	Feb	NEWA

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

	@ BOSCOGEN	12.5MG	A 074677	004	May 30, 1997	May	CAHN
	@	25MG	A 074677	002	May 30, 1997	May	CAHN
	@	50MG	A 074677	001	May 30, 1997	May	CAHN
	@	100MG	A 074677	003	May 30, 1997	May	CAHN
AB	MYLAN PHARMS INC	12.5MG	A 074434	001	Feb 13, 1996	Mar	CAHN
AB		25MG	A 074434	002	Feb 13, 1996	Mar	CAHN
AB		50MG	A 074434	003	Feb 13, 1996	Mar	CAHN
AB	!	100MG	A 074434	004	Feb 13, 1996	Mar	CAHN

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL

EQUETRO

+	VALIDUS PHARMS	100MG	N 021710	001	Dec 10, 2004	Jun	CAHN
+		200MG	N 021710	002	Dec 10, 2004	Jun	CAHN
+	!	300MG	N 021710	003	Dec 10, 2004	Jun	CAHN

SOLUTION; IV (INFUSION)

CARNEXIV

+	LUNDBECK PHARMS LLC	200MG/20ML (10MG/ML)	N 206030	001	Oct 07, 2016	Jan	CAHN
---	---------------------	----------------------	----------	-----	--------------	-----	------

SUSPENSION; ORAL

TERIL

AB	TARO PHARM	100MG/5ML	A 076729	001	Sep 20, 2004	Mar	CAHN
----	------------	-----------	----------	-----	--------------	-----	------

CARBIDOPA; LEVODOPA

TABLET; ORAL

CARBIDOPA AND LEVODOPA

	IDT AUSTRALIA LTD	10MG;100MG	A 073587	002	Jun 29, 1995	Jul	CMS1
		25MG;250MG	A 073587	003	Jun 29, 1995	Jul	CMS1

CARBOPLATIN

INJECTABLE; INJECTION

CARBOPLATIN

	@ WATSON LABS TEVA	50MG/VIAL	A 076162	001	Oct 14, 2004	May	CAHN
	@	150MG/VIAL	A 076162	002	Oct 14, 2004	May	CAHN
	@	450MG/VIAL	A 076162	003	Oct 14, 2004	May	CAHN

INJECTABLE; IV (INFUSION)

CARBOPLATIN

AP	ACCORD HLTHCARE	50MG/5ML (10MG/ML)	A 206775	001	Feb 09, 2017	Jan	NEWA
AP		150MG/15ML (10MG/ML)	A 206775	002	Feb 09, 2017	Jan	NEWA
AP		450MG/45ML (10MG/ML)	A 206775	003	Feb 09, 2017	Jan	NEWA
AP		600MG/60ML (10MG/ML)	A 206775	004	Feb 09, 2017	Jan	NEWA
AP	GLAND PHARMA LTD	50MG/5ML (10MG/ML)	A 207324	001	Feb 15, 2017	Jan	NEWA
AP		150MG/15ML (10MG/ML)	A 207324	002	Feb 15, 2017	Jan	NEWA
AP		450MG/45ML (10MG/ML)	A 207324	003	Feb 15, 2017	Jan	NEWA
AP		600MG/60ML (10MG/ML)	A 207324	004	Feb 15, 2017	Jan	NEWA
AP	INGENUS PHARMS LLC	50MG/5ML (10MG/ML)	A 208487	001	Apr 26, 2017	Apr	NEWA
AP		150MG/15ML (10MG/ML)	A 208487	002	Apr 26, 2017	Apr	NEWA



INJECTABLE; IV (INFUSION)  
CARBOPLATIN

AP		450MG/45ML (10MG/ML)		A208487	003	Apr 26, 2017	Apr	NEWA
AP		600MG/60ML (10MG/ML)		A208487	004	Apr 26, 2017	Apr	NEWA

CARISOPRODOL

CAPSULE; ORAL  
SOMA

	@ MYLAN SPECIALITY LP	250MG		N011792	003		Mar	CAHN
--	-----------------------	-------	--	---------	-----	--	-----	------

TABLET; ORAL  
CARISOPRODOL

	@ EPIC PHARMA LLC	350MG		A040397	001	Sep 21, 2000	May	CAHN
AA	HIKMA INTL PHARMS	350MG		A040124	001	Jan 24, 1996	Apr	CMFD
AB	NOSTRUM LABS INC	250MG		A207237	001	May 11, 2017	Apr	NEWA
>D> AA	SUN PHARM INDS LTD	350MG		A040755	001	Feb 27, 2007	Sep	DISC
>A>	@	350MG		A040755	001	Feb 27, 2007	Sep	DISC
	@ WATSON LABS TEVA	350MG		A086179	001		May	CAHN
	SOMA							
AB	+! MYLAN SPECIALITY LP	250MG		N011792	004	Sep 13, 2007	Mar	CAHN
AA	+	350MG		N011792	001		Mar	CAHN

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC  
CARTEOLOL HYDROCHLORIDE

AT	! SANDOZ INC	1%		A075476	001	Jan 03, 2000	May	CHRS
AT		1%		A075476	001	Jan 03, 2000	Mar	CAHN
	OCUPRESS							
	+ @ NOVARTIS	1%		N019972	001	May 23, 1990	May	DISC

CARVEDILOL

TABLET; ORAL  
CARVEDILOL

	@ PLIVA HRVATSKA DOO	3.125MG		A078240	001	Oct 30, 2007	Jul	DISC
	@	6.25MG		A078240	002	Oct 30, 2007	Jul	DISC
	@	12.5MG		A078240	003	Oct 30, 2007	Jul	DISC
	@	25MG		A078240	004	Oct 30, 2007	Jul	DISC

CASPOFUNGIN ACETATE

POWDER; IV (INFUSION)  
CANCIDAS

AP	+! MERCK	50MG/VIAL		N021227	001	Jan 26, 2001	Mar	CDFR
AP	+!	70MG/VIAL		N021227	002	Jan 26, 2001	Mar	CDFR
	CASPOFUNGIN ACETATE							
>A> AP	GLAND PHARMA LTD	50MG/VIAL		A207092	001	Sep 29, 2017	Sep	NEWA
>A> AP		70MG/VIAL		A207092	002	Sep 29, 2017	Sep	NEWA
>A> AP	MYLAN LABS LTD	50MG/VIAL		A207650	001	Sep 29, 2017	Sep	NEWA
>A> AP		70MG/VIAL		A207650	002	Sep 29, 2017	Sep	NEWA

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL  
CEFADROXIL

AB	CSPC OUYI PHARM CO	EQ 500MG BASE		A205072	001	Jul 28, 2017	Jul	NEWA
----	--------------------	---------------	--	---------	-----	--------------	-----	------

CEFDINIR

CAPSULE; ORAL  
OMNICEF

	+ @ ABBVIE	300MG		N050739	001	Dec 04, 1997	Jan	CRLD
	FOR SUSPENSION; ORAL OMNICEF							
	+ @ ABBVIE	125MG/5ML		N050749	001	Dec 04, 1997	Jan	CRLD
	+ @	250MG/5ML		N050749	002	Jul 29, 2004	Jan	CRLD

CEFIXIME

FOR SUSPENSION; ORAL  
CEFIXIME

AB	BELCHER PHARMS LLC	100MG/5ML		A206938	001	Feb 06, 2017	Jan	NEWA
AB		200MG/5ML		A206938	002	Feb 06, 2017	Jan	NEWA
AB		500MG/5ML		A206939	001	Feb 06, 2017	Jan	NEWA
	SUPRAX							
AB	+! LUPIN LTD	500MG/5ML		N202091	001	Feb 20, 2013	Jan	CFTG

CEFOTAXIME SODIUMINJECTABLE; INJECTION  
CLAFORAN

@	SANOFI AVENTIS US	EQ 1GM BASE/VIAL	A 062659	001	Jan 13, 1987	Aug	DISC
@		EQ 2GM BASE/VIAL	A 062659	002	Jan 13, 1987	Aug	DISC

CEFOTETAN DISODIUMINJECTABLE; INJECTION  
CEFOTAN

AP	+	TELIGENT	EQ 1GM BASE/VIAL	N 050588	001	Dec 27, 1985	Apr	CAHN
AP	+		EQ 2GM BASE/VIAL	N 050588	002	Dec 27, 1985	Apr	CAHN
	@		EQ 10GM BASE/VIAL	N 050588	003	Apr 25, 1988	Apr	CAHN
		CEFOTAN IN PLASTIC CONTAINER						
	@	TELIGENT	EQ 20MG BASE/ML	N 050694	002	Jul 30, 1993	Apr	CAHN
	@		EQ 40MG BASE/ML	N 050694	001	Jul 30, 1993	Apr	CAHN

CEFOXITIN SODIUMINJECTABLE; INJECTION  
CEFOXITIN

AP		WEST-WARD PHARMS INT	EQ 1GM BASE/VIAL	A 065051	001	Sep 11, 2000	Jan	CAHN
AP			EQ 2GM BASE/VIAL	A 065051	002	Sep 11, 2000	Jan	CAHN
AP			EQ 10GM BASE/VIAL	A 065050	001	Sep 11, 2000	Jan	CAHN
		MEFOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER						
>D>	@	MERCK	EQ 20MG BASE/ML	N 050581	003	Sep 20, 1984	Sep	CRLD
>A>	+	@	EQ 20MG BASE/ML	N 050581	003	Sep 20, 1984	Sep	CRLD
>D>	@		EQ 40MG BASE/ML	N 050581	004	Sep 20, 1984	Sep	CRLD
>A>	+	@	EQ 40MG BASE/ML	N 050581	004	Sep 20, 1984	Sep	CRLD
		MEFOXIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
>D>	@	MERCK	EQ 20MG BASE/ML	N 050581	002	Sep 20, 1984	Sep	CRLD
>A>	+	@	EQ 20MG BASE/ML	N 050581	002	Sep 20, 1984	Sep	CRLD
>D>	@		EQ 40MG BASE/ML	N 050581	001	Sep 20, 1984	Sep	CRLD
>A>	+	@	EQ 40MG BASE/ML	N 050581	001	Sep 20, 1984	Sep	CRLD

CEFPROZILTABLET; ORAL  
CEFPROZIL

AB		AUROBINDO PHARMA LTD	250MG	A 065340	001	May 24, 2007	Jan	CAHN
AB			500MG	A 065340	002	May 24, 2007	Jan	CAHN

CEFTAZIDIMEINJECTABLE; INJECTION  
FORTAZ

AP	+	TELIGENT	500MG/VIAL	N 050578	001	Jul 19, 1985	Apr	CAHN
AP	+		1GM/VIAL	N 050578	002	Jul 19, 1985	Apr	CAHN
AP	+		2GM/VIAL	N 050578	003	Jul 19, 1985	Apr	CAHN
AP	+		6GM/VIAL	N 050578	004	Jul 19, 1985	Apr	CAHN

CEFTAZIDIME SODIUMINJECTABLE; INJECTION  
FORTAZ IN PLASTIC CONTAINER

	@	TELIGENT	EQ 10MG BASE/ML	N 050634	001	Apr 28, 1989	May	CAHN
	+	!	EQ 20MG BASE/ML	N 050634	002	Apr 28, 1989	May	CAHN
	+	!	EQ 40MG BASE/ML	N 050634	003	Apr 28, 1989	May	CAHN

CEFTRIAXONE SODIUMINJECTABLE; INJECTION  
CEFTRIAXONE SODIUM

>A>	AP	HIKMA FARMACEUTICA	EQ 10GM BASE/VIAL	A 090701	001	Oct 04, 2017	Sep	NEWA	
	AP	SAGENT PHARMS	EQ 10GM BASE/VIAL	A 091117	001	Jan 20, 2017	Jan	NEWA	
		ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER							
	+	@	HOFFMANN LA ROCHE	EQ 10MG BASE/ML	N 050624	001	Feb 11, 1987	Jan	CRLD
	+	@		EQ 20MG BASE/ML	N 050624	002	Feb 11, 1987	Jan	CRLD
	+	@		EQ 40MG BASE/ML	N 050624	003	Feb 11, 1987	Jan	CRLD

CEFUROXIME AXETILTABLET; ORAL  
CEFUROXIME AXETIL

AB		AUROBINDO PHARMA LTD	EQ 125MG BASE	A 065308	001	Mar 29, 2006	Jan	CAHN
AB			EQ 250MG BASE	A 065308	002	Mar 29, 2006	Jan	CAHN
AB			EQ 500MG BASE	A 065308	003	Mar 29, 2006	Jan	CAHN

CEFUROXIME SODIUMINJECTABLE; INJECTION  
CEFUROXIME SODIUM

>A>	AP	ACS DOBFAR SPA	EQ 1.5GM BASE/VIAL	A064125	002	May 30, 1997	Sep	CAHN
>A>	AP		EQ 7.5GM BASE/VIAL	A064124	001	May 30, 1997	Sep	CAHN
>D>	AP	FACTA FARMA	EQ 1.5GM BASE/VIAL	A064125	002	May 30, 1997	Sep	CAHN
>D>	AP		EQ 7.5GM BASE/VIAL	A064124	001	May 30, 1997	Sep	CAHN
		ZINACEF						
	AP	+! TELIGENT	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	May	CAHN
	AP	+!	EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	May	CAHN
		ZINACEF IN PLASTIC CONTAINER						
		@ TELIGENT	EQ 15MG BASE/ML	N050643	001	Apr 28, 1989	May	CAHN
		+!	EQ 30MG BASE/ML	N050643	002	Apr 28, 1989	May	CAHN
		INJECTABLE; INTRAMUSCULAR, INTRAVENOUS						
		CEFUROXIME SODIUM						
>A>	AB	ACS DOBFAR SPA	EQ 750MG BASE/VIAL	A064125	001	May 30, 1997	Sep	CAHN
>D>	AB	FACTA FARMA	EQ 750MG BASE/VIAL	A064125	001	May 30, 1997	Sep	CAHN
		ZINACEF						
	AB	+! TELIGENT	EQ 750MG BASE/VIAL	N050558	002	Oct 19, 1983	May	CAHN

CELECOXIBCAPSULE; ORAL  
CELECOXIB

	AB	JUBILANT GENERICS	50MG	A207061	001	Apr 04, 2017	Mar	NEWA
	AB		100MG	A207061	002	Apr 04, 2017	Mar	NEWA
	AB		200MG	A207061	003	Apr 04, 2017	Mar	NEWA
	AB		400MG	A207061	004	Apr 04, 2017	Mar	NEWA

CEPHALEXINCAPSULE; ORAL  
CEPHALEXIN

	AB	AUROBINDO PHARMA LTD	EQ 250MG BASE	A065253	001	Nov 16, 2005	Jan	CAHN
	AB		EQ 500MG BASE	A065253	002	Nov 16, 2005	Jan	CAHN
		FOR SUSPENSION; ORAL						
		CEPHALEXIN						
	AB	YUNG SHIN PHARM	EQ 125MG BASE/5ML	A065336	001	Jul 25, 2007	Aug	CMFD
	AB		EQ 250MG BASE/5ML	A065336	002	Jul 25, 2007	Aug	CMFD

CEPHAPIRIN SODIUMINJECTABLE; INJECTION  
CEPHAPIRIN SODIUM

		@ WEST-WARD PHARMS INT	EQ 500MG BASE/VIAL	A062720	001	Jul 02, 1987	Jan	CAHN
		@	EQ 1GM BASE/VIAL	A062720	002	Jul 02, 1987	Jan	CAHN
		@	EQ 2GM BASE/VIAL	A062720	003	Jul 02, 1987	Jan	CAHN
		@	EQ 20GM BASE/VIAL	A062720	004	Jul 02, 1987	Jan	CAHN

CETIRIZINE HYDROCHLORIDESOLUTION/DROPS; OPHTHALMIC  
ZERVIAE

		+! NICOX OPHTHALMICS	EQ 0.24% BASE	N208694	001	May 30, 2017	May	NEWA
		SYRUP; ORAL						
		CETIRIZINE HYDROCHLORIDE						
AA		ALLIED PHARMA INC	5MG/5ML	A090191	001	Nov 12, 2009	Apr	CAHN

CEVIMELINE HYDROCHLORIDECAPSULE; ORAL  
CEVIMELINE HYDROCHLORIDE

	AB	RISING PHARMS INC	30MG	A203775	001	Jun 04, 2014	May	CAHN
--	----	-------------------	------	---------	-----	--------------	-----	------

CHENODIOLTABLET; ORAL  
CHENIX

		+ @ LEADIANT BIOSCI INC	250MG	N018513	002	Jul 28, 1983	Feb	CAHN
--	--	-------------------------	-------	---------	-----	--------------	-----	------

CHLORAMPHENICOL SODIUM SUCCINATEINJECTABLE; INJECTION  
CHLOROMYCETIN

		+ @ PARKEDALE	EQ 1GM BASE/VIAL	N050155	001		Mar	CRLD
--	--	---------------	------------------	---------	-----	--	-----	------

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE

@	UPSHER-SMITH LABS	5MG	A 084678	001		Jun	CAHN
@		5MG	A 084919	001		Aug	CAHN
@		10MG	A 084041	001		Jun	CAHN
@		10MG	A 084920	001		Aug	CAHN
@		25MG	A 084679	002		Jun	CAHN
@		25MG	A 084823	001		Aug	CAHN
@	USL PHARMA	10MG	A 084623	001		Apr	DISC

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL

PERIOGARD

AT	COLGATE PALMOLIVE CO	0.12%	A 073695	001	Jan 14, 1994	May	CAHN
----	----------------------	-------	----------	-----	--------------	-----	------

CHLOROPROCAINE HYDROCHLORIDE

SOLUTION; INTRATHECAL

>A>	CLOROTEKAL						
>A>	+ SINTETICA SA	50MG/5ML (10MG/ML)	N 208791	001	Sep 26, 2017	Sep	NEWA

CHLOROQUINE PHOSPHATE

TABLET; ORAL

>D>	ARALEN						
>D> AA	+! SANOFI AVENTIS US	EQ 300MG BASE	N 006002	001		Sep	DISC
>A>	+ @	EQ 300MG BASE	N 006002	001		Sep	DISC
	CHLOROQUINE PHOSPHATE						
>D> AA	NATCO PHARMA LTD	EQ 300MG BASE	A 090612	001	Jan 21, 2011	Sep	CHRS
>A> AA	!	EQ 300MG BASE	A 090612	001	Jan 21, 2011	Sep	CHRS

CHLOROTHIAZIDE

TABLET; ORAL

CHLOROTHIAZIDE

>A>	! MYLAN	250MG	A 084217	002		Sep	CMS1
-----	---------	-------	----------	-----	--	-----	------

CHLORPHENESIN CARBAMATE

TABLET; ORAL

MAOLATE

@	PAMLAB LLC	400MG	N 014217	002		Mar	CAHN
---	------------	-------	----------	-----	--	-----	------

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE

AA	ACELLA PHARMS LLC	4MG/5ML; 5MG/5ML	A 206891	001	Jun 09, 2017	May	NEWA
>D> AA	TRIS PHARMA INC	4MG/5ML; 5MG/5ML	A 206438	001	Jan 27, 2015	Sep	DISC
>A>	@	4MG/5ML; 5MG/5ML	A 206438	001	Jan 27, 2015	Sep	DISC

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

AA	BIO-PHARM INC	4MG/5ML; 5MG/5ML; 60MG/5ML	A 206660	001	May 15, 2017	May	NEWA
>D> AA	TRIS PHARMA INC	4MG/5ML; 5MG/5ML; 60MG/5ML	A 203838	001	Nov 26, 2014	Sep	DISC
>A>	@	4MG/5ML; 5MG/5ML; 60MG/5ML	A 203838	001	Nov 26, 2014	Sep	DISC

CHLORPROMAZINE HYDROCHLORIDE

TABLET; ORAL

CHLORPROMAZINE HYDROCHLORIDE

	USL PHARMA	10MG	A 083386	001		Jun	CAHN
		10MG	A 083386	001		May	CTEC
!		25MG	A 084112	001		Jun	CAHN
!		25MG	A 084112	001		May	CHRS
		50MG	A 084113	001		Jun	CAHN
		50MG	A 084113	001		May	CTEC
!		100MG	A 084114	001		Jun	CAHN
!		100MG	A 084114	001		May	CHRS
		200MG	A 084115	001		Jun	CAHN
		200MG	A 084115	001		May	CTEC

THORAZINE

@	GLAXOSMITHKLINE	10MG	N 009149	002		May	CRLD
@		25MG	N 009149	007		May	CRLD
@		50MG	N 009149	013		May	CRLD

	TABLET;ORAL								
	THORAZINE								
	@	100MG			N009149	018			May CRLD
	@	200MG			N009149	020			May CRLD
	<u>CHLORPROPAMIDE</u>								
	TABLET;ORAL								
	CHLORPROPAMIDE								
	@ ANI PHARMS INC	250MG			A087353	001			Jan CAHN
	@ WATSON LABS TEVA	100MG			A088852	001	Sep 26, 1984		May CAHN
	@	250MG			A088826	001	Sep 26, 1984		May CAHN
	GLUCAMIDE								
AB	ANI PHARMS INC	250MG			A088641	001	Oct 11, 1984		Jul CMFD
	<u>CHLORTHALIDONE</u>								
	TABLET;ORAL								
	CHLORTHALIDONE								
AB	RICONPHARMA LLC	25MG			A206904	001	Mar 30, 2017		Mar NEWA
AB		50MG			A206904	002	Mar 30, 2017		Mar NEWA
	<u>CHOLESTYRAMINE</u>								
	POWDER;ORAL								
	CHOLESTYRAMINE LIGHT								
AB	ZYDUS PHARMS USA INC	EQ 4GM RESIN/SCOOPFUL			A202902	001	Apr 25, 2017		Aug CTNA
AB		EQ 4GM RESIN/SCOOPFUL			A202902	001	Apr 25, 2017		Apr NEWA
	PREVALITE								
AB	UPSHER-SMITH LABS	EQ 4GM RESIN/PACKET			A073263	001	Feb 22, 1996		Jun CAHN
AB		EQ 4GM RESIN/SCOOPFUL			A073263	002	Oct 30, 1997		Jun CAHN
	<u>CHOLINE C-11</u>								
	INJECTABLE;INTRAVENOUS								
	CHOLINE C-11								
	UNIV TX MD ANDERSON	4-100mCi/ML			A205690	001	Oct 29, 2015		Jul CPOT
	<u>CHOLINE FENOFIBRATE</u>								
	CAPSULE, DELAYED RELEASE;ORAL								
	FENOFIBRIC ACID								
AB	ALEMBIC PHARMS LTD	EQ 45MG FENOFIBRIC ACID			A208705	001	May 12, 2017		May NEWA
AB		EQ 135MG FENOFIBRIC ACID			A208705	002	May 12, 2017		May NEWA
	<u>CICLESONIDE</u>								
	AEROSOL, METERED;INHALATION								
	ALVESCO								
	+! ASTRAZENECA PHARMS	0.08MG/INH			N021658	002	Jan 10, 2008		Jul CAHN
	+!	0.16MG/INH			N021658	003	Jan 10, 2008		Jul CAHN
	AEROSOL, METERED;NASAL								
	ZETONNA								
	+! ASTRAZENECA PHARMS	0.037MG/INH			N202129	001	Jan 20, 2012		Jul CAHN
	SPRAY, METERED;NASAL								
	OMNARIS								
	+! ASTRAZENECA PHARMS	0.05MG/INH			N022004	001	Oct 20, 2006		Jul CAHN
	<u>CICLOPIROX</u>								
	CREAM;TOPICAL								
	CICLOPIROX								
AB	PERRIGO NEW YORK	0.77%			A077364	001	Mar 03, 2006		Apr CAHN
	GEL;TOPICAL								
>A>	CICLOPIROX								
>A>	AB +!	CNTY LINE PHARMS	0.77%		N020519	001	Jul 21, 1997		Sep CTNA
>D>	LOPROX								
>D>	AB +!	CNTY LINE PHARMS	0.77%		N020519	001	Jul 21, 1997		Sep CTNA
	SHAMPOO;TOPICAL								
	CICLOPIROX								
AT	PERRIGO CO	1%			A078594	001	Feb 16, 2010		Apr CAHN
	<u>CILOSTAZOL</u>								
	TABLET;ORAL								
	CILOSTAZOL								
>D>	AB	BIOKEY	50MG		A077722	001	Sep 24, 2012		Sep CAHN
>D>	AB		100MG		A077831	001	Sep 24, 2012		Sep CAHN
>A>	AB	CHARTWELL RX	50MG		A077722	001	Sep 24, 2012		Sep CAHN

TABLET;ORAL  
CILOSTAZOL

>A> AB		100MG	A077831	001	Sep 24, 2012	Sep CAHN
	@ EPIC PHARMA LLC	50MG	A077150	001	Mar 11, 2005	May CAHN
	@	100MG	A077022	001	Nov 23, 2004	May CAHN
	@ MYLAN	50MG	A077323	002	Apr 20, 2006	May DISC
	@	100MG	A077323	001	Apr 20, 2006	May DISC
	@ MYLAN PHARMS INC	50MG	A077019	001	Nov 23, 2004	Mar DISC
	@	100MG	A077019	002	Nov 23, 2004	Mar DISC
	@ PLIVA HRVATSKA DOO	50MG	A077898	001	Oct 29, 2007	Mar DISC
	@	100MG	A077898	002	Oct 29, 2007	Mar DISC
	PLETAL					
	+ @ OTSUKA	50MG	N020863	001	Jan 15, 1999	Jan CRLD
	+ @	100MG	N020863	002	Jan 15, 1999	Jan CRLD

CIMETIDINE

TABLET;ORAL  
CIMETIDINE

	@ CHARTWELL MOLECULES	200MG	A074281	001	May 17, 1994	Jan CAHN
	@	300MG	A074281	002	May 17, 1994	Jan CAHN
	@	400MG	A074281	003	May 17, 1994	Jan CAHN
	@	800MG	A074329	001	May 17, 1994	Jan CAHN
	@ SANDOZ INC	200MG	A074250	001	Jun 29, 1995	Mar CAHN
	@	300MG	A074250	002	Jun 29, 1995	Mar CAHN
	@	400MG	A074250	003	Jun 29, 1995	Mar CAHN
	@	800MG	A074250	004	Jun 29, 1995	Mar CAHN
	@ UPSHER-SMITH LABS	200MG	A074506	001	Jan 24, 1996	Jun CAHN
	@	300MG	A074506	002	Jan 24, 1996	Jun CAHN
	@	400MG	A074506	003	Jan 24, 1996	Jun CAHN
	@	800MG	A074506	004	Jan 24, 1996	Jun CAHN

CIMETIDINE HYDROCHLORIDE

SOLUTION;ORAL  
CIMETIDINE HYDROCHLORIDE

AA	PHARM ASSOC	EQ 300MG BASE/5ML	A074553	001	Jan 27, 1997	May CAHN
----	-------------	-------------------	---------	-----	--------------	----------

CIPROFLOXACIN

INJECTABLE;INJECTION  
CIPRO

	+ @ BAYER HLTHCARE	400MG/40ML (10MG/ML)	N019847	001	Dec 26, 1990	Feb DISC
	+ @	200MG/20ML (10MG/ML)	N019847	002	Dec 26, 1990	Feb DISC
	CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER					
	+ @ BAYER HLTHCARE	200MG/100ML	N019857	001	Dec 26, 1990	Feb DISC
	+ @	400MG/200ML	N019857	002	Dec 26, 1990	Feb DISC

CIPROFLOXACIN

AP	!	BAXTER HLTHCARE CORP	200MG/20ML (10MG/ML)	A078062	001	Apr 29, 2008	Aug CAHN
AP	!		400MG/40ML (10MG/ML)	A078062	002	Apr 29, 2008	Aug CAHN
AP	!	CLARIS	200MG/20ML (10MG/ML)	A078062	001	Apr 29, 2008	Feb CHRS
AP	!		400MG/40ML (10MG/ML)	A078062	002	Apr 29, 2008	Feb CHRS
	CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER						
AP		BAXTER HLTHCARE CORP	200MG/100ML	A078024	001	Mar 18, 2008	Aug CAHN
AP			400MG/200ML	A078024	002	Mar 18, 2008	Aug CAHN
AP	!	HOSPIRA	200MG/100ML	A077753	001	Mar 18, 2008	Feb CHRS
AP	!		400MG/200ML	A077753	002	Mar 18, 2008	Feb CHRS

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC  
CIPROFLOXACIN HYDROCHLORIDE

AT		AMRING PHARMS	EQ 0.3% BASE	A078598	001	Jan 16, 2008	Mar CAHN
AT		TELLIGENT	EQ 0.3% BASE	A076754	001	Jun 09, 2004	Apr CAHN

TABLET;ORAL

CIPROFLOXACIN HYDROCHLORIDE

	@ MYLAN	EQ 250MG BASE	A075685	002	Jun 09, 2004	Aug DISC
	@	EQ 500MG BASE	A075685	003	Jun 09, 2004	Aug DISC
	@	EQ 750MG BASE	A075685	001	Jun 09, 2004	Aug DISC
AB	TARO PHARM	EQ 100MG BASE	A076912	001	Feb 18, 2005	Mar CAHN
AB		EQ 250MG BASE	A076912	002	Oct 06, 2004	Mar CAHN
AB		EQ 500MG BASE	A076912	003	Oct 06, 2004	Mar CAHN
AB		EQ 750MG BASE	A076912	004	Oct 06, 2004	Mar CAHN
AB	UNIQUE PHARM LABS	EQ 250MG BASE	A076639	001	Sep 10, 2004	Aug CAHN
AB		EQ 500MG BASE	A076639	002	Sep 10, 2004	Aug CAHN
AB		EQ 750MG BASE	A076639	003	Sep 10, 2004	Aug CAHN

CISATRACURIUM BESYLATE

INJECTABLE; INJECTION

CISATRACURIUM BESYLATE

AP	ACCORD HLTHCARE	EQ 2MG BASE/ML	A205873	001	Jun 16, 2017	Jun	NEWA
AP	JIANGSU HENGRUI MED	EQ 2MG BASE/ML	A209334	001	Aug 30, 2017	Aug	NEWA
	CISATRACURIUM BESYLATE	PRESERVATIVE FREE					
AP	ACCORD HLTHCARE	EQ 2MG BASE/ML	A205872	001	Jun 16, 2017	Jun	NEWA
AP		EQ 10MG BASE/ML	A205872	002	Jun 16, 2017	Jun	NEWA
AP	JIANGSU HENGRUI MED	EQ 2MG BASE/ML	A204960	001	Jan 27, 2017	Jan	NEWA

CISATRACURIUM BESYLATE PRESERVATIVE FREE

INJECTABLE; INJECTION

CISATRACURIUM BESYLATE PRESERVATIVE FREE

>A> AP	JIANGSU HENGRUI MED	EQ 10MG BASE/ML	A204960	002	Sep 19, 2017	Sep	NEWA
--------	---------------------	-----------------	---------	-----	--------------	-----	------

CISPLATIN

INJECTABLE; INJECTION

CISPLATIN

AP	GLAND PHARMA LTD	1MG/ML	A207323	001	Mar 17, 2017	Mar	NEWA
AP	+ HQ SPCLT PHARMA	1MG/ML	N018057	004	Nov 08, 1988	Mar	CRLD
	PLATINOL						
	+ @ HQ SPCLT PHARMA	10MG/VIAL	N018057	001		Mar	CRLD
	+ @	50MG/VIAL	N018057	002		Mar	CRLD
	PLATINOL-AQ						
	+ @ HQ SPCLT PHARMA	0.5MG/ML	N018057	003	Jul 18, 1984	Mar	CRLD

CITALOPRAM HYDROBROMIDE

CAPSULE; ORAL

CITALOPRAM HYDROBROMIDE

@ MYLAN PHARMS INC EQ 10MG BASE  
 @ EQ 20MG BASE  
 @ EQ 40MG BASE

A077668 001 Feb 28, 2007 Mar DISC  
 A077668 002 Feb 28, 2007 Mar DISC  
 A077668 003 Feb 28, 2007 Mar DISC

SOLUTION; ORAL

CITALOPRAM HYDROBROMIDE

AA	AUROBINDO PHARMA LTD	EQ 10MG BASE/5ML	A077812	001	Aug 28, 2006	Jan	CAHN
----	----------------------	------------------	---------	-----	--------------	-----	------

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

@ EPIC PHARMA LLC EQ 10MG BASE  
 @ EQ 20MG BASE  
 @ EQ 40MG BASE  
 @ MYLAN EQ 10MG BASE  
 @ EQ 20MG BASE  
 @ EQ 40MG BASE  
 @ MYLAN PHARMS INC EQ 10MG BASE  
 @ EQ 20MG BASE  
 @ EQ 40MG BASE

A077036 001 Oct 28, 2004 May CAHN  
 A077036 002 Oct 28, 2004 May CAHN  
 A077036 003 Oct 28, 2004 May CAHN  
 A077039 001 Feb 03, 2005 Jun DISC  
 A077039 002 Feb 03, 2005 Jun DISC  
 A077039 003 Feb 03, 2005 Jun DISC  
 A077037 001 Nov 05, 2004 May DISC  
 A077037 002 Nov 05, 2004 May DISC  
 A077037 003 Nov 05, 2004 May DISC

CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE

FOR SOLUTION; ORAL

PREPOPIK

+!	FERRING PHARMS INC	12GM/PACKET; 3.5GM/PACKET; 10MG/PACKET	N202535	001	Jul 16, 2012	Mar	CAHN
----	--------------------	--	---------	-----	--------------	-----	------

CLARITHROMYCIN

TABLET; ORAL

CLARITHROMYCIN

@ MYLAN 250MG  
 @ 500MG

A065195 001 Mar 11, 2005 May DISC  
 A065195 002 Mar 11, 2005 May DISC

CLEMASTINE FUMARATE

TABLET; ORAL

CLEMASTINE FUMARATE

@ SANDOZ 2.68MG  
 ! TEVA 2.68MG

A073459 001 Oct 31, 1993 Feb DISC  
 A073283 001 Jan 31, 1992 Feb CTEC

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLINDAMYCIN HYDROCHLORIDE

AB	EPIC PHARMA LLC	EQ 150MG BASE	A065194	001	Mar 22, 2004	May	CAHN
AB		EQ 300MG BASE	A065194	002	Mar 22, 2004	May	CAHN
AB	LANNETT	EQ 75MG BASE	A065243	002	Aug 12, 2005	Aug	CMS1

## CAPSULE;ORAL

## CLINDAMYCIN HYDROCHLORIDE

	@ MYLAN PHARMS INC	EQ 75MG BASE	A091225	001	May 31, 2011	May DISC
	@	EQ 150MG BASE	A091225	002	May 31, 2011	May DISC
	@	EQ 300MG BASE	A091225	003	May 31, 2011	May DISC
		CLINDAMYCIN HYDROCLHORIDE				
AB	LANNETT	EQ 150MG BASE	A065243	003	Aug 12, 2005	Aug CMS1

CLINDAMYCIN PALMITATE HYDROCHLORIDE

## FOR SOLUTION;ORAL

## CLINDAMYCIN PALMITATE HYDROCHLORIDE

AA	INVAGEN PHARMS	EQ 75MG BASE/5ML	A206958	001	May 05, 2017	Apr NEWA
AA	ORIT LABS LLC	EQ 75MG BASE/5ML	A206958	001	May 05, 2017	Jun CAHN
AA	PADDOCK LLC	EQ 75MG BASE/5ML	A090902	001	Jul 07, 2010	Apr CAHN

CLINDAMYCIN PHOSPHATE

## AEROSOL, FOAM;TOPICAL

## EVOCLIN

AT	+! MYLAN PHARMS INC	1%	N050801	001	Oct 22, 2004	Jan CAHN
----	---------------------	----	---------	-----	--------------	----------

## INJECTABLE;INJECTION

## CLINDAMYCIN PHOSPHATE

>A>	AP	MYLAN LABS LTD	EQ 150MG BASE/ML	A204748	001	Oct 10, 2017	Sep NEWA
>A>	AP		EQ 150MG BASE/ML	A204749	001	Oct 10, 2017	Sep NEWA
	AP	SAGENT PHARMS	EQ 150MG BASE/ML	A090109	001	Sep 30, 2011	Apr CAHN
	AP	WEST-WARD PHARMS INT	EQ 150MG BASE/ML	A065206	001	Sep 24, 2004	Jan CAHN
		CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER					
	AP	BAXTER HLTHCARE CORP	EQ 6MG BASE/ML	A208084	001	Jun 28, 2017	Jul CAHN
	AP		EQ 12MG BASE/ML	A208084	002	Jun 28, 2017	Jul CAHN
	AP		EQ 18MG BASE/ML	A208084	003	Jun 28, 2017	Jul CAHN
	AP	CELERITY PHARMS	EQ 6MG BASE/ML	A208084	001	Jun 28, 2017	Jun NEWA
	AP		EQ 12MG BASE/ML	A208084	002	Jun 28, 2017	Jun NEWA
	AP		EQ 18MG BASE/ML	A208084	003	Jun 28, 2017	Jun NEWA

## SOLUTION;IV (INFUSION)

## CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE

	+! BAXTER HLTHCARE CORP	EQ 300MG BASE/50ML (EQ 6MG BASE/ML)	N208083	001	Apr 20, 2017	May CAHN
	+!	EQ 600MG BASE/50ML (EQ 12MG BASE/ML)	N208083	002	Apr 20, 2017	May CAHN
	+!	EQ 900MG BASE/50ML (EQ 18MG BASE/ML)	N208083	003	Apr 20, 2017	May CAHN
	+! CELERITY PHARMS	EQ 300MG BASE/50ML (EQ 6MG BASE/ML)	N208083	001	Apr 20, 2017	Apr NEWA
	+!	EQ 600MG BASE/50ML (EQ 12MG BASE/ML)	N208083	002	Apr 20, 2017	Apr NEWA
	+!	EQ 900MG BASE/50ML (EQ 18MG BASE/ML)	N208083	003	Apr 20, 2017	Apr NEWA

## SOLUTION;TOPICAL

## CLINDAMYCIN PHOSPHATE

	AT	FOUGERA PHARMS INC	EQ 1% BASE	A064159	001	Jun 05, 1997	Jan CAHN
>D>	@	INGENUS PHARMS LLC	EQ 1% BASE	A064108	001	Sep 27, 1996	Sep CAHN
>A>	@	NOVAST LABS LTD	EQ 1% BASE	A064108	001	Sep 27, 1996	Sep CAHN

## SWAB;TOPICAL

## CLINDETS

AT	PERRIGO CO	EQ 1% BASE	A064136	001	Sep 30, 1996	Apr CAHN
----	------------	------------	---------	-----	--------------	----------

CLOBAZAM

## SUSPENSION;ORAL

## ONFI

	+! LUNDBECK PHARMS LLC	2.5MG/ML	N203993	001	Dec 14, 2012	Jan CAHN
--	------------------------	----------	---------	-----	--------------	----------

## TABLET;ORAL

## ONFI

	@ LUNDBECK PHARMS LLC	5MG	N202067	001	Oct 21, 2011	Jan CAHN
	+	10MG	N202067	002	Oct 21, 2011	Jan CAHN
	+!	20MG	N202067	003	Oct 21, 2011	Jan CAHN

CLOBETASOL PROPIONATE

## AEROSOL, FOAM;TOPICAL

## CLOBETASOL PROPIONATE

AB1	INGENUS PHARMS LLC	0.05%	A206805	001	Jul 31, 2017	Jul NEWA
		OLUX				
AB1	+! MYLAN PHARMS INC	0.05%	N021142	001	May 26, 2000	Jan CAHN



	AEROSOL, FOAM;TOPICAL						
	OLUX E						
AB2	+!	MYLAN PHARMS INC	0.05%	N022013	001	Jan 12, 2007	Jan CAHN
	CREAM;TOPICAL						
	CLOBETASOL PROPIONATE						
AB1		FOUGERA PHARMS INC	0.05%	A074392	001	Sep 30, 1996	Jan CAHN
AB1		MYLAN PHARMS INC	0.05%	A075338	001	Feb 09, 2001	May CMFD
	@		0.05%	A075338	001	Feb 09, 2001	Jan CAHN
AB1		TARO	0.05%	A074249	001	Jul 08, 1996	Apr CAHN
	CLOBETASOL PROPIONATE (EMOLLIENT)						
>D>	@	INGENUS PHARMS LLC	0.05%	A075733	001	Aug 22, 2001	Sep CAHN
>A>	@	NOVAST LABS LTD	0.05%	A075733	001	Aug 22, 2001	Sep CAHN
AB2		TELIGENT PHARMA INC	0.05%	A209411	001	Aug 21, 2017	Aug NEWA
	GEL;TOPICAL						
	CLOBETASOL PROPIONATE						
AB		PERRIGO CO	0.05%	A075027	001	Oct 31, 1997	Apr CAHN
AB		TARO	0.05%	A075279	001	May 28, 1999	Apr CAHN
AB		TELIGENT PHARMA INC	0.05%	A208881	001	Mar 06, 2017	Feb NEWA
	LOTION;TOPICAL						
	CLOBETASOL PROPIONATE						
>A>	AB	LUPIN LTD	0.05%	A209147	001	Sep 22, 2017	Sep NEWA
	OINTMENT;TOPICAL						
	CLOBETASOL PROPIONATE						
AB		GLENMARK PHARMS	0.05%	A208933	001	Mar 20, 2017	Mar NEWA
AB1		MYLAN PHARMS INC	0.05%	A075057	001	Aug 12, 1998	May CMFD
	@		0.05%	A075057	001	Aug 12, 1998	Jan CAHN
AB		TARO	0.05%	A074248	001	Jul 12, 1996	Apr CAHN
		TEMOVATE					
	+ @	FOUGERA PHARMS	0.05%	N019323	001	Dec 27, 1985	Jan CRLD
	SOLUTION;TOPICAL						
	CLOBETASOL PROPIONATE						
AT		TARO	0.05%	A075224	001	Nov 16, 1998	Apr CAHN
	SPRAY;TOPICAL						
	CLOBETASOL PROPIONATE						
AT		AKORN	0.05%	A207218	001	Apr 28, 2017	Apr NEWA
AT		ZYDUS PHARMS USA INC	0.05%	A206378	001	Feb 16, 2017	Feb NEWA
	<u>CLOFARABINE</u>						
	INJECTABLE;IV (INFUSION)						
	CLOFARABINE						
AP		ABON PHARMS LLC	20MG/20ML (1MG/ML)	A204029	001	May 09, 2017	Apr NEWA
	CLOLAR						
AP	+!	GENZYME	20MG/20ML (1MG/ML)	N021673	001	Dec 28, 2004	Apr CFTG
	<u>CLOFAZIMINE</u>						
	CAPSULE;ORAL						
	LAMPRENE						
	+ @	NOVARTIS	50MG	N019500	002	Dec 15, 1986	Aug DISC
	<u>CLOFIBRATE</u>						
	CAPSULE;ORAL						
	CLOFIBRATE						
	@	USL PHARMA	500MG	A070531	001	Jun 16, 1986	Jun CAHN
	<u>CLOMIPRAMINE HYDROCHLORIDE</u>						
	CAPSULE;ORAL						
	CLOMIPRAMINE HYDROCHLORIDE						
AB		SANDOZ	25MG	A074953	001	Jun 25, 1997	Feb CMFD
AB			50MG	A074953	002	Jun 25, 1997	Feb CMFD
AB			75MG	A074953	003	Jun 25, 1997	Feb CMFD
	<u>CLONAZEPAM</u>						
	TABLET;ORAL						
	CLONAZEPAM						
	@	MYLAN PHARMS INC	0.5MG	A074940	001	Oct 30, 1997	Mar DISC
	@		1MG	A074940	002	Oct 30, 1997	Mar DISC
	@		2MG	A074940	003	Oct 30, 1997	Mar DISC
AB		PRINSTON INC	0.5MG	A077856	001	Jun 28, 2006	Feb CAHN
AB			1MG	A077856	002	Jun 28, 2006	Feb CAHN
AB			2MG	A077856	003	Jun 28, 2006	Feb CAHN

CLONIDINE HYDROCHLORIDE

TABLET;ORAL		CLONIDINE HYDROCHLORIDE					
	CHARTWELL MOLECULES	0.1MG		A 071785	002	Apr 05, 1988	Jul CMS1
		0.2MG		A 071785	003	Apr 05, 1988	Jul CMS1
	@	0.3MG		A 071785	001	Apr 05, 1988	Feb CAHN
AB	PRINSTON INC	0.1MG		A 077901	001	Mar 09, 2007	Feb CAHN
AB		0.2MG		A 077901	002	Mar 09, 2007	Feb CAHN
AB		0.3MG		A 077901	003	Mar 09, 2007	Feb CAHN
TABLET, EXTENDED RELEASE;ORAL		CLONIDINE HYDROCHLORIDE					
AB2	ACTAVIS ELIZABETH	0.1MG		A 202792	001	May 15, 2015	Apr CAHN
AB1		0.1MG		A 203320	001	May 15, 2015	Apr CAHN
	@	0.2MG		A 202792	002	May 15, 2015	Apr CAHN
	@	0.2MG		A 203320	002	May 15, 2015	Apr CAHN

CLOPIDOGREL BISULFATE

TABLET;ORAL		CLOPIDOGREL BISULFATE					
AB	ACME LABS	EQ 75MG BASE		A 078004	001	May 17, 2012	Jul CAHN
AB	ALLIED PHARMA INC	EQ 75MG BASE		A 078004	001	May 17, 2012	Mar CAHN
AB	CSPC OUYI PHARM CO	EQ 75MG BASE		A 204359	001	Feb 02, 2017	Jan NEWA

CLORAZEPATE DIPOTASSIUM

CAPSULE;ORAL		CLORAZEPATE DIPOTASSIUM					
	AUROLIFE PHARMA LLC	3.75MG		A 072112	002	Aug 11, 2017	Aug CMS1
		7.5MG		A 072112	003	Aug 11, 2017	Aug CMS1
TABLET;ORAL		CLORAZEPATE DIPOTASSIUM					
AB	TARO PHARM	3.75MG		A 075731	003	Apr 27, 2000	Mar CAHN
AB		7.5MG		A 075731	002	Apr 27, 2000	Mar CAHN
AB		15MG		A 075731	001	Apr 27, 2000	Mar CAHN

CLOTRIMAZOLE

SOLUTION;TOPICAL		CLOTRIMAZOLE					
AT	! TARO	1%		A 074580	001	Jul 29, 1996	Apr CAHN
	LOTRIMIN						
	+ @ SCHERING PLOUGH	1%		N 017613	001		Jul CRLD

CLOZAPINE

SUSPENSION;ORAL		VERSACLOZ					
>D>	+! JAZZ PHARMS III	50MG/ML		N 203479	001	Feb 06, 2013	Sep CAHN
>A>	+! TASMAN PHARMA	50MG/ML		N 203479	001	Feb 06, 2013	Sep CAHN
TABLET;ORAL		CLOZAPINE					
AB	MAYNE PHARMA	50MG		A 203807	003	Aug 22, 2017	Aug NEWA
AB		200MG		A 203807	004	Aug 22, 2017	Aug NEWA

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL		PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE					
	@ PHARM ASSOC	10MG/5ML;6.25MG/5ML		A 089647	001	Dec 22, 1988	May CAHN

CODEINE SULFATE

SOLUTION;ORAL		CODEINE SULFATE					
	@ WEST-WARD PHARMS INT	30MG/5ML		N 202245	001	Jun 30, 2011	Jan CAHN
TABLET;ORAL		CODEINE SULFATE					
AB	+ WEST-WARD PHARMS INT	15MG		N 022402	001	Jul 16, 2009	Jan CAHN
AB	+	30MG		N 022402	002	Jul 16, 2009	Jan CAHN
AB	+!	60MG		N 022402	003	Jul 16, 2009	Jan CAHN

>A>	<u>COPANLISIB DIHYDROCHLORIDE</u>								
>A>	POWDER; IV (INFUSION)								
>A>	ALIQOFA								
>A>	+! BAYER HEALTHCARE	60MG/VIAL			N209936	001	Sep 14, 2017	Sep	NEWA
	<u>CORTICOTROPIN</u>								
	INJECTABLE; INJECTION								
	PURIFIED CORTROPHIN GEL								
	@ ANI PHARMS INC	40 UNITS/ML			N008975	001		May	CAHN
	@	80 UNITS/ML			N008975	002		May	CAHN
	<u>CORTICOTROPIN-ZINC HYDROXIDE</u>								
	INJECTABLE; INJECTION								
	CORTROPHIN-ZINC								
	@ ANI PHARMS INC	40 UNITS/ML			N009854	001		May	CAHN
	<u>COSYNTROPIN</u>								
	SOLUTION; INTRAVENOUS								
	COSYNTROPIN								
	@ SANDOZ INC	0.25MG/ML (0.25MG/ML)			N022028	001	Feb 21, 2008	May	CAHN
	<u>CROMOLYN SODIUM</u>								
	CONCENTRATE; ORAL								
	GASTROCROM								
AA	+! MYLAN SPECIALITY LP	100MG/5ML			N020479	001	Feb 29, 1996	Mar	CAHN
	SOLUTION; INHALATION								
	CROMOLYN SODIUM								
	@ BAUSCH AND LOMB	10MG/ML			A075585	001	Dec 21, 2000	Jul	DISC
AN		10MG/ML			A075585	001	Dec 21, 2000	Feb	CAHN
	INTAL								
>D>	@ KING PHARMS LLC	10MG/ML			N018596	001	May 28, 1982	Sep	CRLD
>A>	+ @	10MG/ML			N018596	001	May 28, 1982	Sep	CRLD
	@	10MG/ML			N018596	001	May 28, 1982	May	CAHN
	<u>CYANOCOBALAMIN</u>								
	INJECTABLE; INJECTION								
	CYANOCOBALAMIN								
AP	MYLAN LABS LTD	1MG/ML			A204829	001	Jun 05, 2017	May	NEWA
	DODEX								
	@ ACCORD HLTHCARE	1MG/ML			A083022	001		Jun	CAHN
	<u>CYCLOBENZAPRINE HYDROCHLORIDE</u>								
	TABLET; ORAL								
	CYCLOBENZAPRINE HYDROCHLORIDE								
AB	JUBILANT CADISTA	7.5MG			A077563	003	Aug 25, 2017	Aug	NEWA
AB	OXFORD PHARMS	5MG			A077209	002	Feb 03, 2006	May	CMS1
AB	PRINSTON INC	5MG			A077797	001	Feb 28, 2007	Feb	CAHN
AB		10MG			A077797	002	Feb 28, 2007	Feb	CAHN
AB	RUBICON RES PVT LTD	5MG			A208170	001	May 31, 2017	May	NEWA
AB		7.5MG			A208170	002	May 31, 2017	May	NEWA
AB		10MG			A208170	003	May 31, 2017	May	NEWA
	@ UPSHER-SMITH LABS	5MG			A072854	002	Feb 03, 2006	Jun	CAHN
	@	10MG			A072854	001	Nov 19, 1991	Jun	CAHN
	<u>CYCLOPHOSPHAMIDE</u>								
	CAPSULE; ORAL								
	CYCLOPHOSPHAMIDE								
	+ WEST-WARD PHARMS INT	25MG			N203856	001	Sep 16, 2013	Jan	CAHN
	+!	50MG			N203856	002	Sep 16, 2013	Jan	CAHN
	INJECTABLE; INJECTION								
	CYTOXAN (LYOPHILIZED)								
	+ @ BAXTER HLTHCARE	500MG/VIAL			N012142	003		Feb	CRLD
	+ @	1GM/VIAL			N012142	004	Aug 30, 1982	Feb	CRLD
	+ @	2GM/VIAL			N012142	005	Aug 30, 1982	Feb	CRLD

CYPROHEPTADINE HYDROCHLORIDE

SYRUP;ORAL

CYPROHEPTADINE HYDROCHLORIDE

>A>	AA	BIO-PHARM INC	2MG/5ML	A204823	001	Dec 27, 2016	Sep CAHN
>D>	AA	PATRIN PHARMA INC	2MG/5ML	A204823	001	Dec 27, 2016	Sep CAHN
	AA	SILARX PHARMS INC	2MG/5ML	A203191	001	Jul 13, 2017	Jul NEWA

PERIACTIN

+ @ MERCK 2MG/5ML

N013220 002 Jan CRLD

TABLET;ORAL

CYPROHEPTADINE HYDROCHLORIDE

>A>	AA	AILEX PHARMS LLC	4MG	A207555	001	Jan 31, 2017	Sep CAHN
>D>	AA	APNAR PHARMA LP	4MG	A207555	001	Jan 31, 2017	Sep CAHN
	AA		4MG	A207555	001	Jan 31, 2017	Jan NEWA
	AA	IMPAX LABS INC	4MG	A040537	001	Sep 30, 2003	Feb CAHN
	AA	SANTOS BIOTECH	4MG	A040644	001	May 30, 2006	May CAHN
	AA	ZYDUS PHARMS USA INC	4MG	A208938	001	May 19, 2017	May NEWA

CYSTEAMINE BITARTRATE

CAPSULE, DELAYED RELEASE;ORAL

PROCYSBI

+	HORIZON PHARMA USA	EQ 25MG BASE	N203389	001	Apr 30, 2013	Mar CAHN
+	!	EQ 75MG BASE	N203389	002	Apr 30, 2013	Mar CAHN

CYSTEAMINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

CYSTARAN

+! LEADIANT BIOSCI INC EQ 0.44% BASE N200740 001 Oct 02, 2012 Feb CAHN

CYTARABINE

INJECTABLE;INJECTION

CYTARABINE

AP		MYLAN LABS LTD	20MG/ML	A200915	001	Dec 13, 2011	Mar CAHN
		WEST-WARD PHARMS INT	100MG/VIAL	A071471	001	Aug 02, 1989	Mar CTEC
	!		500MG/VIAL	A071472	001	Aug 02, 1989	Mar CHRS
	!		1GM/VIAL	A074245	001	Aug 31, 1994	Mar CHRS
	!		2GM/VIAL	A074245	002	Aug 31, 1994	Mar CHRS
		CYTOSAR-U					
	@	TEVA PHARMS USA	100MG/VIAL	A075206	001	Dec 30, 1998	Mar DISC
	@		500MG/VIAL	A075206	002	Dec 30, 1998	Mar DISC
	@		1GM/VIAL	A075206	004	Dec 30, 1998	Mar DISC
	@		2GM/VIAL	A075206	003	Dec 30, 1998	Mar DISC

CYTARABINE; DAUNORUBICIN

POWDER;INTRAVENOUS

VYXEOS

+! CELATOR PHARMS 100MG;44MG N209401 001 Aug 03, 2017 Aug NEWA

DACARBAZINE

INJECTABLE;INJECTION

DACARBAZINE

AP	!	FRESENIUS KABI USA	100MG/VIAL	A075371	001	Aug 27, 1999	Feb CHRS
AP	!		200MG/VIAL	A075371	002	Aug 27, 1999	Feb CHRS
		DTIC-DOME					
	+	@ BAYER HLTHCARE	100MG/VIAL	N017575	001		Apr DISC
	+	@	200MG/VIAL	N017575	002		Apr DISC

DALBAVANCIN HYDROCHLORIDE

POWDER;IV (INFUSION)

DALVANCE

+! ALLERGAN SALES LLC EQ 500MG BASE/VIAL N021883 001 May 23, 2014 Aug CAHN

DALFAMPRIDINE

TABLET, EXTENDED RELEASE;ORAL

AMPYRA

AB	+	!	ACORDA	10MG	N022250	001	Jan 22, 2010	Jan CFTG
			DALFAMPRIDINE					
AB			ACTAVIS LABS FL INC	10MG	A206836	001	Jan 23, 2017	Jan NEWA
AB			AUROBINDO PHARMA LTD	10MG	A206811	001	Jan 23, 2017	Jan NEWA

DANTROLENE SODIUMINJECTABLE; INJECTION  
DANTROLENE SODIUM

AP	HIKMA PHARMS	20MG/VIAL	A204762	001	Jun 19, 2017	Jun	NEWA
----	--------------	-----------	---------	-----	--------------	-----	------

DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDETABLET, EXTENDED RELEASE; ORAL  
XIGDUO XR

+	ASTRAZENECA AB	EQ 2.5MG BASE; 1GM	N205649	005	Jul 28, 2017	Jul	NEWA
---	----------------	--------------------	---------	-----	--------------	-----	------

DAPAGLIFLOZIN PROPANEDIOL; SAXAGLIPTIN HYDROCHLORIDETABLET; ORAL  
QTERN

+	ASTRAZENECA AB	EQ 10MG BASE; EQ 5MG BASE	N209091	001	Feb 27, 2017	Feb	NEWA
---	----------------	---------------------------	---------	-----	--------------	-----	------

DAPSONETABLET; ORAL  
DAPSONE

AB	ACTAVIS LLC	25MG	A204380	001	Mar 23, 2017	Mar	NEWA
AB		100MG	A204380	002	Mar 23, 2017	Mar	NEWA
>D>	AB	NORTH CREEK PHARMS	25MG	A204074	001	May 10, 2016	Sep CAHN
>D>	AB		100MG	A204074	002	May 10, 2016	Sep CAHN
>A>	AB	VIRTUS PHARMS	25MG	A204074	001	May 10, 2016	Sep CAHN
>A>	AB		100MG	A204074	002	May 10, 2016	Sep CAHN

DAPTOMYCINPOWDER; INTRAVENOUS  
DAPTOMYCIN

>A>	+	SAGENT PHARMS	350MG/VIAL	N208385	001	Sep 12, 2017	Sep	NEWA
-----	---	---------------	------------	---------	-----	--------------	-----	------

DARIFENACIN HYDROBROMIDETABLET, EXTENDED RELEASE; ORAL  
DARIFENACIN

AB	MACLEODS PHARMS LTD	EQ 7.5MG BASE	A207302	001	Jul 28, 2017	Jul	NEWA
AB		EQ 15MG BASE	A207302	002	Jul 28, 2017	Jul	NEWA

DECITABINEINJECTABLE; INTRAVENOUS  
DECITABINE

AP	ACCORD HLTHCARE	50MG/VIAL	A203475	001	Feb 27, 2017	Feb	NEWA	
>A>	AP	CHEMI SPA	50MG/VIAL	A206033	001	Sep 22, 2017	Sep	NEWA
AP	PHARMASCIENCE INC	50MG/VIAL	A204607	001	May 31, 2017	May	NEWA	

DEFERASIROXGRANULE; ORAL  
JADENU SPRINKLE

+	NOVARTIS PHARMS CORP	90MG	N207968	001	May 18, 2017	May	NEWA
+		180MG	N207968	002	May 18, 2017	May	NEWA
+	!	360MG	N207968	003	May 18, 2017	May	NEWA

DEFEROXAMINE MESYLATEINJECTABLE; INJECTION  
DEFEROXAMINE MESYLATE

>A>	AP	GLAND PHARMA LTD	500MG/VIAL	A207384	001	Sep 29, 2017	Sep	NEWA
>A>	AP		2GM/VIAL	A207384	002	Sep 29, 2017	Sep	NEWA

DEFLAZACORTSUSPENSION; ORAL  
EMFLAZA

+	MARATHON PHARMS LLC	22.75MG/ML	N208685	001	Feb 09, 2017	Feb	NEWA
+	PTC THERAP	22.75MG/ML	N208685	001	Feb 09, 2017	Apr	CAHN

TABLET; ORAL  
EMFLAZA

+	MARATHON PHARMS LLC	6MG	N208684	001	Feb 09, 2017	Feb	NEWA
+		18MG	N208684	002	Feb 09, 2017	Feb	NEWA
+		30MG	N208684	003	Feb 09, 2017	Feb	NEWA
+	!	36MG	N208684	004	Feb 09, 2017	Feb	NEWA
+	PTC THERAP	6MG	N208684	001	Feb 09, 2017	Apr	CAHN
+		18MG	N208684	002	Feb 09, 2017	Apr	CAHN
+		30MG	N208684	003	Feb 09, 2017	Apr	CAHN
+	!	36MG	N208684	004	Feb 09, 2017	Apr	CAHN

DELAFLOXACIN MEGLUMINE

POWDER; IV (INFUSION)

BAXDELA

+! MELINTA THERAPS INC EQ 300MG BASE/VIAL N208611 001 Jun 19, 2017 Jun NEWA

TABLET; ORAL

BAXDELA

+! MELINTA THERAPS INC EQ 450MG BASE N208610 001 Jun 19, 2017 Jun NEWA

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

DESIPRAMINE HYDROCHLORIDE

AB	IMPAX LABS INC	10MG	A205153	001	Oct 28, 2016	Feb	CAHN
AB		25MG	A205153	002	Oct 28, 2016	Feb	CAHN
AB		50MG	A205153	003	Oct 28, 2016	Feb	CAHN
AB		75MG	A205153	004	Oct 28, 2016	Feb	CAHN
AB		100MG	A205153	005	Oct 28, 2016	Feb	CAHN
AB		150MG	A205153	006	Oct 28, 2016	Feb	CAHN

DESMETHYL PIROXICAM

CAPSULE; ORAL

PIROXICAM

SUN PHARM INDS 10MG A073536 002 Jan 23, 2008 Mar CMS1

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION

DESMOPRESSIN ACETATE

	@ HOSPIRA	0.004MG/ML	A075220	001	Aug 28, 2000	Jul	DISC
AP	SAGENT PHARMS	0.004MG/ML	A204695	001	Aug 22, 2017	Aug	NEWA
AP		0.004MG/ML	A204751	001	Aug 22, 2017	Aug	NEWA
	@ TEVA PHARMS USA	0.004MG/ML	A074888	001	Oct 15, 1997	Jul	DISC

SPRAY, METERED; NASAL

DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION)

&gt;A&gt; AB ZYDUS PHARMS USA INC 0.01MG/SPRAY A091345 001 Oct 03, 2017 Sep NEWA

NOCTIVA

+ SERENITY PHARMS LLC 0.00083MG/SPRAY N201656 001 Mar 03, 2017 Mar NEWA

+! 0.00166MG/SPRAY N201656 002 Mar 03, 2017 Mar NEWA

STIMATE

@ FERRING PHARMS INC 0.15MG/SPRAY N020355 001 Mar 07, 1994 Jun CAHN

STIMATE (NEEDS NO REFRIGERATION)

+! FERRING PHARMS INC 0.15MG/SPRAY N020355 002 Oct 24, 2007 Jun CAHN

TABLET; ORAL

DESMOPRESSIN ACETATE

AB	HERITAGE PHARMA	0.1MG	A207880	001	May 26, 2017	May	NEWA
AB		0.1MG	A207880	001	May 26, 2017	May	CAHN
AB		0.2MG	A207880	002	May 26, 2017	May	NEWA
AB		0.2MG	A207880	002	May 26, 2017	May	CAHN

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

DESOGESTREL AND ETHINYL ESTRADIOL

AB ACCORD HLTHCARE 0.15MG,N/A;0.02MG,0.01MG A209170 001 Jun 05, 2017 May NEWA

AB AUROBINDO PHARMA LTD 0.15MG,N/A;0.02MG,0.01MG A206853 001 Mar 22, 2017 Mar NEWA

KALLIGA

AB AUROBINDO PHARMA LTD 0.15MG;0.03MG A207081 001 May 17, 2017 May NEWA

DESONIDE

CREAM; TOPICAL

DESONIDE

AB GLENMARK PHARMS 0.05% A209729 001 Jul 24, 2017 Jul NEWA

LOTION; TOPICAL

DESONIDE

&gt;A&gt; AB GLENMARK PHARMS 0.05% A209494 001 Sep 26, 2017 Sep NEWA

&gt;A&gt; AB TELIGENT PHARMA INC 0.05% A207855 001 Sep 28, 2017 Sep NEWA

OINTMENT; TOPICAL

DESONIDE

&gt;A&gt; AB GLENMARK PHARMS LTD 0.05% A209996 001 Sep 15, 2017 Sep NEWA

AB HI-TECH PHARMACAL 0.05% A208836 001 Mar 27, 2017 Mar NEWA

DESOXIMETASONE

CREAM; TOPICAL

TOPICORT

AB	!	TARO	0.05%	A 073210	001	Nov 30, 1990	Apr	CAHN
AB	!		0.25%	A 073193	001	Nov 30, 1990	Apr	CAHN
	+	@	0.25%	N 017856	001		May	CAHN
		TOPICORT LP						
	+	@ TARO	0.05%	N 018309	001		May	CAHN

GEL; TOPICAL

DESOXIMETASONE

AB		RISING PHARMS INC	0.05%	A 204675	001	Aug 12, 2016	May	CAHN
		TOPICORT						
AB	!	TARO	0.05%	A 074904	001	Jul 14, 1998	Apr	CAHN
	+	@	0.05%	N 018586	001	Mar 29, 1982	May	CAHN
	+	@ TARO PHARMS NORTH	0.05%	N 018586	001	Mar 29, 1982	Jan	CRLD

OINTMENT; TOPICAL

DESOXIMETASONE

AB		RISING PHARMS INC	0.25%	A 204272	001	Nov 30, 2016	May	CAHN
>A>	AB	ZYDUS PHARMS USA INC	0.25%	A 205206	001	Sep 19, 2017	Sep	NEWA
		TOPICORT						
AB	+	! TARO	0.05%	N 018594	001	Jan 17, 1985	May	CAHN
AB	!		0.25%	A 074286	001	Jun 07, 1996	Apr	CAHN
	+	@	0.25%	N 018763	001	Sep 30, 1983	May	CAHN

SPRAY; TOPICAL

DESOXIMETASONE

AT		PERRIGO ISRAEL	0.25%	A 206441	001	Jan 20, 2017	Jan	NEWA
		TOPICORT						
AT	+	! TARO	0.25%	N 204141	001	Apr 11, 2013	Jan	CFTG

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

DESVENLAFAXINE SUCCINATE

AB		ACTAVIS LABS FL	EQ 25MG BASE	A 204065	001	Jul 29, 2016	May	CAHN
AB			EQ 50MG BASE	A 204065	002	Jul 29, 2016	May	CAHN
AB			EQ 100MG BASE	A 204065	003	Jul 29, 2016	May	CAHN
AB		WEST-WARD PHARMS INT	EQ 25MG BASE	A 204082	002	Aug 28, 2017	Aug	NEWA
>A>	AB	ZYDUS PHARMS USA INC	EQ 50MG BASE	A 204020	001	Oct 11, 2017	Sep	NEWA
>A>	AB		EQ 100MG BASE	A 204020	002	Oct 11, 2017	Sep	NEWA

DEUTETRABENAZINE

TABLET; ORAL

AUSTEDO

	+	TEVA BRANDED PHARM	6MG	N 208082	001	Apr 03, 2017	Apr	NEWA
	+		9MG	N 208082	002	Apr 03, 2017	Apr	NEWA
	+	!	12MG	N 208082	003	Apr 03, 2017	Apr	NEWA

DEXAMETHASONE

TABLET; ORAL

DEXAMETHASONE

AB		LARKEN LABS INC	1.5MG	A 201270	001	Jul 17, 2017	Jul	NEWA
BP		PAR PHARM	6MG	A 088481	001	Nov 28, 1983	May	CHRS
	@	UPSHER SMITH	0.75MG	A 087534	001		Jun	CAHN
	@		1.5MG	A 087533	001		Jun	CAHN
BP		XSPIRE PHARMA	1.5MG	A 088237	001	Apr 28, 1983	Aug	CAHN
BP			1.5MG	A 088237	001	Apr 28, 1983	Jul	CAHN

DEXAMETHASONE ACETATE

INJECTABLE; INJECTION

DEXAMETHASONE ACETATE

	@	WATSON LABS TEVA	EQ 16MG BASE/ML	A 087711	001	May 24, 1982	May	CAHN
--	---	------------------	-----------------	----------	-----	--------------	-----	------

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

AP		WEST-WARD PHARMS INT	EQ 4MG PHOSPHATE/ML	A 084282	001		Aug	CMFD
		SOLUTION/DROPS; OPHTHALMIC, OTIC						
		DEXAMETHASONE SODIUM PHOSPHATE						
AT	!	SANDOZ INC	EQ 0.1% PHOSPHATE	A 088771	001	Jan 16, 1985	Feb	CAHN

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATESUSPENSION/DROPS;OPHTHALMIC  
MAXITROL

AT	SANDOZ INC	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A 062341	001	May 22, 1984	Feb	CAHN
----	------------	---------------------------------------	----------	-----	--------------	-----	------

DEXLANSOPRAZOLECAPSULE, DELAYED RELEASE;ORAL  
DEXILANT

AB	+!	TAKEDA PHARMS USA	60MG	N 022287	002	Jan 30, 2009	Apr	CFTG
----	----	-------------------	------	----------	-----	--------------	-----	------

AB		PAR PHARM INC	60MG	A 202294	001	Apr 19, 2017	Apr	NEWA
----	--	---------------	------	----------	-----	--------------	-----	------

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL  
DEXILANT SOLUTAB

	+ @	TAKEDA PHARMS USA	30MG	N 208056	001	Jan 26, 2016	Aug	DISC
--	-----	-------------------	------	----------	-----	--------------	-----	------

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

AP		ACCORD HLTHCARE	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A 204023	001	Feb 09, 2016	Mar	CAHN
>A>	AP	JIANGSU HENGRUI MED	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A 209065	001	Sep 19, 2017	Sep	NEWA
AP		LUITPOLD PHARMS INC	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A 203773	001	May 12, 2017	May	CAHN
AP		PHARMAFORCE	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A 203773	001	May 12, 2017	May	NEWA
AP		WEST-WARD PHARMS INT	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A 205046	001	Apr 26, 2017	Apr	NEWA

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

AB		IMPAX LABS INC	25MG	A 203614	001	Jul 05, 2017	Jun	NEWA
AB			35MG	A 203614	002	Jul 05, 2017	Jun	NEWA
AB		TEVA PHARMS USA	25MG	A 202731	001	Jul 05, 2017	Jun	NEWA
AB			35MG	A 202731	004	Jul 05, 2017	Jun	NEWA

TABLET;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

>A>	AB	LANNETT	2.5MG	A 209468	001	Sep 25, 2017	Sep	NEWA
>A>	AB		5MG	A 209468	002	Sep 25, 2017	Sep	NEWA
>A>	AB		10MG	A 209468	003	Sep 25, 2017	Sep	NEWA

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

DEXEDRINE

AB	+	IMPAX LABS INC	5MG	N 017078	001		Aug	CAHN
AB	+		10MG	N 017078	002		Aug	CAHN
AB	+!		15MG	N 017078	003		Aug	CAHN

DEXTROAMPHETAMINE SULFATE

AB		NESHER PHARMS	5MG	A 209111	001	Jun 27, 2017	Jun	NEWA
AB			10MG	A 209111	002	Jun 27, 2017	Jun	NEWA
AB			15MG	A 209111	003	Jun 27, 2017	Jun	NEWA

TABLET;ORAL

DEXTROAMPHETAMINE SULFATE

	@	EPIC PHARMA LLC	5MG	A 090652	001	Mar 07, 2014	May	CAHN
	@		10MG	A 090652	002	Mar 07, 2014	May	CAHN

DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE

CAPSULE;ORAL

>A>		DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE						
>A>	AB	ACTAVIS ELIZABETH	20MG;10MG	A 202934	001	Oct 10, 2017	Sep	NEWA
		NUEDEXTA						
>D>	+!	AVANIR PHARMS	20MG;10MG	N 021879	001	Oct 29, 2010	Sep	CFTG
>A>	AB	+!	20MG;10MG	N 021879	001	Oct 29, 2010	Sep	CFTG

DEXTROSE

INJECTABLE;INJECTION

DEXTROSE 10% IN PLASTIC CONTAINER

AP	+!	ICU MEDICAL INC	10GM/100ML	N 018080	001		Feb	CAHN
----	----	-----------------	------------	----------	-----	--	-----	------



## INJECTABLE; INJECTION

		DEXTROSE 20% IN PLASTIC CONTAINER						
AP	+	ICU MEDICAL INC	20GM/100ML	N018564	001	Mar 23, 1982	Feb	CAHN
		DEXTROSE 30% IN PLASTIC CONTAINER						
AP	+	ICU MEDICAL INC	30GM/100ML	N019345	001	Jan 26, 1985	Feb	CAHN
		DEXTROSE 40% IN PLASTIC CONTAINER						
AP	+	ICU MEDICAL INC	40GM/100ML	N018562	001	Mar 23, 1982	May	CAHN
		DEXTROSE 5% IN PLASTIC CONTAINER						
AP	+	ICU MEDICAL INC	50MG/ML	N016367	002		Feb	CAHN
		DEXTROSE 50% IN PLASTIC CONTAINER						
AP	+	ICU MEDICAL INC	50GM/100ML	N018563	001	Mar 23, 1982	Feb	CAHN
		@	50GM/100ML	N019894	001	Dec 26, 1989	Jun	CAHN
		DEXTROSE 70% IN PLASTIC CONTAINER						
AP	+	ICU MEDICAL INC	70GM/100ML	N018561	001	Mar 23, 1982	Apr	CAHN
AP	+		70GM/100ML	N019893	001	Dec 26, 1989	Feb	CAHN

DEXTROSE; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER

		ICU MEDICAL INC	5GM/100ML; 21MG/100ML; 128MG/100ML; 2	N017610	001		Feb	CAHN
			34MG/100ML					

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

## INJECTABLE; INJECTION

IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER

		ICU MEDICAL INC	5GM/100ML; 30MG/100ML; 141MG/100ML; 1	N019513	001	May 08, 1986	Feb	CAHN
			5MG/100ML; 260MG/100ML; 25MG/100ML					

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER

		@ B BRAUN	5GM/100ML; 30MG/100ML; 97MG/100ML; 22	N019844	001	Jun 10, 1993	Aug	DISC
			0MG/100ML; 140MG/100ML					

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

## INJECTABLE; INJECTION

NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER

		ICU MEDICAL INC	5GM/100ML; 30MG/100ML; 37MG/100ML; 22	N017609	001		Feb	CAHN
			2MG/100ML; 526MG/100ML; 502MG/100ML					

DEXTROSE; POTASSIUM CHLORIDE

## INJECTABLE; INJECTION

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER

>D>		BAXTER HLTHCARE	5GM/100ML; 75MG/100ML	N017634	004		Sep	CRLD
>A>	+		5GM/100ML; 75MG/100ML	N017634	004		Sep	CRLD
		DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER						
>D>	AP	BAXTER HLTHCARE	5GM/100ML; 150MG/100ML	N017634	001		Sep	CRLD
>A>	AP	+	5GM/100ML; 150MG/100ML	N017634	001		Sep	CRLD
		DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER						
>D>	AP	BAXTER HLTHCARE	5GM/100ML; 224MG/100ML	N017634	003		Sep	CRLD
>A>	AP	+	5GM/100ML; 224MG/100ML	N017634	003		Sep	CRLD
		DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER						
>D>	AP	BAXTER HLTHCARE	5GM/100ML; 300MG/100ML	N017634	002		Sep	CRLD
>A>	AP	+	5GM/100ML; 300MG/100ML	N017634	002		Sep	CRLD
		POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER						
		ICU MEDICAL INC	5GM/100ML; 149MG/100ML	N018371	001		Apr	CAHN
		POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER						
AP		ICU MEDICAL INC	5GM/100ML; 224MG/100ML	N018371	003		Apr	CAHN
		POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER						
		ICU MEDICAL INC	5GM/100ML; 298MG/100ML	N018371	002		Apr	CAHN

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER

		@ B BRAUN	5GM/100ML; 150MG/100ML; 130MG/100ML; 280MG/100ML; 91MG/100ML	N019870	001	Jun 10, 1993	Aug	DISC
--	--	-----------	--	---------	-----	--------------	-----	------

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION										
	POTASSIUM CHLORIDE	10MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE	0.225%	IN PLASTIC CONTAINER					
	ICU MEDICAL INC		5GM/100ML;74.5MG/100ML;225MG/100ML	N018365	002	Jul 05, 1983	Feb	CAHN		
			5GM/100ML;149MG/100ML;225MG/100ML	N018365	006	Mar 28, 1988	Feb	CAHN		
	POTASSIUM CHLORIDE	10MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE	0.3%	IN PLASTIC CONTAINER					
	ICU MEDICAL INC		5GM/100ML;74.5MG/100ML;300MG/100ML	N018876	001	Jan 17, 1986	Jun	CAHN		
			5GM/100ML;149MG/100ML;300MG/100ML	N018876	006	Mar 28, 1988	Jun	CAHN		
	POTASSIUM CHLORIDE	10MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE	0.45%	IN PLASTIC CONTAINER					
AP	ICU MEDICAL INC		5GM/100ML;74.5MG/100ML;450MG/100ML	N018362	005	Mar 28, 1988	Feb	CAHN		
AP			5GM/100ML;74.5MG/100ML;450MG/100ML	N018362	009	Jul 05, 1983	Feb	CAHN		
	POTASSIUM CHLORIDE	10MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE	0.9%	IN PLASTIC CONTAINER					
AP	ICU MEDICAL INC		5GM/100ML;74.5MG/100ML;900MG/100ML	N019691	002	Mar 24, 1988	Apr	CAHN		
AP			5GM/100ML;149MG/100ML;900MG/100ML	N019691	004	Mar 24, 1988	Apr	CAHN		
	POTASSIUM CHLORIDE	15MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE	0.225%	IN PLASTIC CONTAINER					
	ICU MEDICAL INC		5GM/100ML;224MG/100ML;225MG/100ML	N018365	008	Mar 28, 1988	Feb	CAHN		
	POTASSIUM CHLORIDE	15MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE	0.3%	IN PLASTIC CONTAINER					
	ICU MEDICAL INC		5GM/100ML;224MG/100ML;300MG/100ML	N018876	007	Mar 28, 1988	Jun	CAHN		
	POTASSIUM CHLORIDE	15MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE	0.45%	IN PLASTIC CONTAINER					
AP	ICU MEDICAL INC		5GM/100ML;224MG/100ML;450MG/100ML	N018362	006	Mar 28, 1988	Feb	CAHN		
	POTASSIUM CHLORIDE	15MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE	0.9%	IN PLASTIC CONTAINER					
AP	ICU MEDICAL INC		5GM/100ML;224MG/100ML;900MG/100ML	N019691	006	Mar 24, 1988	Apr	CAHN		
	POTASSIUM CHLORIDE	20MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE	0.225%	IN PLASTIC CONTAINER					
	ICU MEDICAL INC		5GM/100ML;149MG/100ML;225MG/100ML	N018365	001		Feb	CAHN		
			5GM/100ML;298MG/100ML;225MG/100ML	N018365	009	Mar 28, 1988	Feb	CAHN		
	POTASSIUM CHLORIDE	20MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE	0.3%	IN PLASTIC CONTAINER					
	ICU MEDICAL INC		5GM/100ML;298MG/100ML;300MG/100ML	N018876	008	Mar 28, 1988	Jun	CAHN		
	POTASSIUM CHLORIDE	20MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE	0.45%	IN PLASTIC CONTAINER					
AP	ICU MEDICAL INC		5GM/100ML;149MG/100ML;450MG/100ML	N018362	010	Jul 05, 1983	Feb	CAHN		
AP			5GM/100ML;298MG/100ML;450MG/100ML	N018362	007	Mar 28, 1988	Feb	CAHN		
	POTASSIUM CHLORIDE	20MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE	0.9%	IN PLASTIC CONTAINER					
AP	ICU MEDICAL INC		5GM/100ML;149MG/100ML;900MG/100ML	N019691	005	Mar 24, 1988	Apr	CAHN		
AP			5GM/100ML;298MG/100ML;900MG/100ML	N019691	008	Mar 24, 1988	Apr	CAHN		
	POTASSIUM CHLORIDE	20MEQ	IN DEXTROSE 5% IN SODIUM CHLORIDE	0.3%	IN PLASTIC CONTAINER					
	ICU MEDICAL INC		5GM/100ML;149MG/100ML;300MG/100ML	N018876	002	Jan 17, 1986	Jun	CAHN		
	POTASSIUM CHLORIDE	30MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE	0.225%	IN PLASTIC CONTAINER					
	ICU MEDICAL INC		5GM/100ML;224MG/100ML;225MG/100ML	N018365	003	Jul 05, 1983	Feb	CAHN		
	POTASSIUM CHLORIDE	30MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE	0.3%	IN PLASTIC CONTAINER					
	ICU MEDICAL INC		5GM/100ML;224MG/100ML;300MG/100ML	N018876	003	Jan 17, 1986	Jun	CAHN		
	POTASSIUM CHLORIDE	30MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE	0.45%	IN PLASTIC CONTAINER					
AP	ICU MEDICAL INC		5GM/100ML;224MG/100ML;450MG/100ML	N018362	002		Feb	CAHN		
	POTASSIUM CHLORIDE	30MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE	0.9%	IN PLASTIC CONTAINER					
AP	ICU MEDICAL INC		5GM/100ML;224MG/100ML;900MG/100ML	N019691	007	Mar 24, 1988	Apr	CAHN		
	POTASSIUM CHLORIDE	40MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE	0.225%	IN PLASTIC CONTAINER					
	ICU MEDICAL INC		5GM/100ML;298MG/100ML;225MG/100ML	N018365	004	Jul 05, 1983	Feb	CAHN		
	POTASSIUM CHLORIDE	40MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE	0.3%	IN PLASTIC CONTAINER					
	ICU MEDICAL INC		5GM/100ML;298MG/100ML;300MG/100ML	N018876	004	Mar 28, 1988	Jun	CAHN		
	POTASSIUM CHLORIDE	40MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE	0.45%	IN PLASTIC CONTAINER					
AP	ICU MEDICAL INC		5GM/100ML;298MG/100ML;450MG/100ML	N018362	003		Feb	CAHN		
	POTASSIUM CHLORIDE	40MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE	0.9%	IN PLASTIC CONTAINER					
AP	ICU MEDICAL INC		5GM/100ML;298MG/100ML;900MG/100ML	N019691	009	Mar 24, 1988	Apr	CAHN		
	POTASSIUM CHLORIDE	5MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE	0.225%	IN PLASTIC CONTAINER					
	ICU MEDICAL INC		5GM/100ML;74.5MG/100ML;225MG/100ML	N018365	005	Mar 28, 1988	Feb	CAHN		
			5GM/100ML;149MG/100ML;225MG/100ML	N018365	007	Mar 28, 1988	Feb	CAHN		
	POTASSIUM CHLORIDE	5MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE	0.3%	IN PLASTIC CONTAINER					
	ICU MEDICAL INC		5GM/100ML;74.5MG/100ML;300MG/100ML	N018876	005	Mar 28, 1988	Jun	CAHN		
			5GM/100ML;149MG/100ML;300MG/100ML	N018876	009	Mar 28, 1988	Jun	CAHN		
	POTASSIUM CHLORIDE	5MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE	0.45%	IN PLASTIC CONTAINER					
AP	ICU MEDICAL INC		5GM/100ML;74.5MG/100ML;450MG/100ML	N018362	008	Mar 28, 1988	Feb	CAHN		
AP			5GM/100ML;149MG/100ML;450MG/100ML	N018362	004	Mar 28, 1988	Feb	CAHN		
	POTASSIUM CHLORIDE	5MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE	0.9%	IN PLASTIC CONTAINER					
AP	ICU MEDICAL INC		5GM/100ML;74.5MG/100ML;900MG/100ML	N019691	001	Mar 24, 1988	Apr	CAHN		
AP			5GM/100ML;149MG/100ML;900MG/100ML	N019691	003	Mar 24, 1988	Apr	CAHN		

DEXTROSE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN 10GM/100ML;900MG/100ML N019631 015 Feb 24, 1988 Aug CTEC

DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

+! ICU MEDICAL INC 5GM/100ML;225MG/100ML N017606 001 Feb CAHN

INJECTABLE; INJECTION

	DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
	+!	ICU MEDICAL INC	5GM/100ML;300MG/100ML	N017799	001	Feb CAHN
	DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
AP		ICU MEDICAL INC	5GM/100ML;450MG/100ML	N017607	001	Feb CAHN
	DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
AP	+!	ICU MEDICAL INC	5GM/100ML;900MG/100ML	N017585	001	Aug CRLD
AP			5GM/100ML;900MG/100ML	N017585	001	Feb CAHN

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

MD-76R

	+ @	LIEBEL-FLARSHEIM	66%;10%	N019292	001	Sep 29, 1989	Aug DISC
	RENOGRAFIN-76						
	+!	BRACCO	66%;10%	N010040	001		Aug CTEC

DIAZEPAM

TABLET; ORAL

DIAZEPAM

@ UPSHER-SMITH LABS

@

@

@ VIRTUS PHARMS

@

@

			2MG	A070302	001	Dec 20, 1985	Jun CAHN
			5MG	A070303	001	Dec 20, 1985	Jun CAHN
			10MG	A070304	001	Dec 20, 1985	Jun CAHN
			2MG	A070462	001	Feb 25, 1986	Feb CAHN
			5MG	A070463	001	Feb 25, 1986	Feb CAHN
			10MG	A070464	001	Feb 25, 1986	Feb CAHN

DICHLORPHENAMIDE

TABLET; ORAL

KEVEYIS

	+!	STRONGBRIDGE US	50MG	N011366	002	Aug 07, 2015	Aug CRLD
--	----	-----------------	------	---------	-----	--------------	----------

DICLOFENAC POTASSIUM

TABLET; ORAL

DICLOFENAC POTASSIUM

@ WATSON LABS TEVA

			50MG	A075152	001	Nov 27, 1998	May CAHN
--	--	--	------	---------	-----	--------------	----------

DICLOFENAC SODIUM

SOLUTION; TOPICAL

DICLOFENAC SODIUM

AT		ACTAVIS LABS UT INC	2%	A207238	001	May 15, 2017	May NEWA
>A>	AT	ANDA REPOSITORY	1.5%	A202393	001	Nov 24, 2014	Sep CAHN
AT	!	APOTEX INC	1.5%	A202027	001	May 27, 2014	Jul CHRS
AT		RICONPHARMA LLC	1.5%	A206715	001	Aug 07, 2017	Jul NEWA
>D>	AT	TWI PHARMS INC	1.5%	A202393	001	Nov 24, 2014	Sep CAHN
AT			1.5%	A202393	001	Nov 24, 2014	Mar CAHN

PENNSAID

AT	+!	HORIZON PHARMA	2%	N204623	001	Jan 16, 2014	May CFTG
----	----	----------------	----	---------	-----	--------------	----------

SOLUTION/DROPS; OPHTHALMIC

DICLOFENAC SODIUM

AT		SANDOZ INC	0.1%	A078031	001	Feb 06, 2008	Feb CAHN
----	--	------------	------	---------	-----	--------------	----------

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM

@ ALLIED PHARMA INC

@

			50MG	A074986	001	Feb 26, 1999	Apr CAHN
			75MG	A074986	002	Feb 26, 1999	Apr CAHN
AB		UNIQUE PHARM LABS	25MG	A090066	001	Dec 01, 2010	Aug CAHN
AB			50MG	A090066	002	Dec 01, 2010	Aug CAHN
AB			75MG	A077863	003	Jun 08, 2007	Aug CAHN

TABLET, EXTENDED RELEASE; ORAL

DICLOFENAC SODIUM

@ ACTAVIS ELIZABETH

AB	!	DEXCEL LTD	100MG	A075910	001	Jan 07, 2002	Apr DISC
----	---	------------	-------	---------	-----	--------------	----------

VOLTAREN-XR

	+ @	NOVARTIS	100MG	N020254	001	Mar 08, 1996	Jul CRLD
--	-----	----------	-------	---------	-----	--------------	----------

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM AND MISOPROSTOL

AB		EAGLE PHARMS	50MG;0.2MG	A200540	001	Mar 14, 2014	Jan CAHN
AB			75MG;0.2MG	A200540	002	Mar 14, 2014	Jan CAHN
AB		EXELA HOLDINGS	50MG;0.2MG	A200540	001	Mar 14, 2014	Mar CAHN
AB			75MG;0.2MG	A200540	002	Mar 14, 2014	Mar CAHN

DICYCLOMINE HYDROCHLORIDE

INJECTABLE; INJECTION  
 DICYCLOMINE HYDROCHLORIDE  
 AP LUITPOLD PHARMS INC 10MG/ML A208353 001 Feb 17, 2017 Feb NEWA

DIDANOSINE

CAPSULE, DELAYED REL PELLETS; ORAL  
 DIDANOSINE

@ MYLAN PHARMS INC 125MG A090788 001 Apr 08, 2010 May DISC  
 @ 200MG A090788 002 Apr 08, 2010 May DISC  
 @ 250MG A090788 003 Apr 08, 2010 May DISC  
 @ 400MG A090788 004 Apr 08, 2010 May DISC

FOR SOLUTION; ORAL

DIDANOSINE

@ AUROBINDO PHARMA 10MG/ML A078112 001 Mar 08, 2007 Jul DISC

VIDEX

+! BRISTOL-MYERS SQUIBB 10MG/ML N020156 001 Oct 09, 1991 Jul CTEC

TABLET, FOR SUSPENSION; ORAL

DIDANOSINE

@ AUROBINDO 100MG A077275 001 Aug 14, 2012 Jul DISC  
 @ 150MG A077275 002 Aug 14, 2012 Jul DISC  
 @ 200MG A077275 003 Aug 14, 2012 Jul DISC

DIENOGEST; ESTRADIOL VALERATE

TABLET; ORAL

NATAZIA

+! BAYER HLTHCARE N/A, 2MG, 3MG, N/A, N/A; 3MG, 2MG, 2MG, 1M N022252 001 May 06, 2010 Apr CTEC  
 G, N/A

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL

DIETHYLPROPION HYDROCHLORIDE

@ EPIC PHARMA LLC 25MG A040828 001 Nov 05, 2008 May CAHN

DIFLORASONE DIACETATE

CREAM; TOPICAL

PSORCON

>D> @ TARO PHARMS NORTH 0.05% N020205 001 Nov 20, 1992 Sep CRLD  
 >A> + @ 0.05% N020205 001 Nov 20, 1992 Sep CRLD

OINTMENT; TOPICAL

DIFLORASONE DIACETATE

AB RICONPHARMA LLC 0.05% A207440 001 Feb 27, 2017 Feb NEWA  
 AB ! TARO 0.05% A075331 001 May 14, 1999 Apr CAHN  
 PSORCON  
 + @ PHARMACIA AND UPJOHN 0.05% N019260 001 Aug 28, 1985 Mar CRLD

DIFLUNISAL

TABLET; ORAL

DIFLUNISAL

@ ALLIED PHARMA INC 250MG A073562 001 Nov 27, 1992 Jul CAHN  
 @ 500MG A073563 001 Nov 27, 1992 Jul CAHN  
 AB ZYDUS PHARMS USA INC 500MG A203547 001 Jun 16, 2017 Jun NEWA

DIGOXIN

ELIXIR; ORAL

DIGOXIN

+! WEST-WARD PHARMS INT 0.05MG/ML N021648 001 Aug 26, 2004 Jan CAHN

INJECTABLE; INJECTION

DIGOXIN

AP SANDOZ INC 0.25MG/ML A040481 001 Aug 21, 2003 Mar CAHN  
 AP WEST-WARD PHARMS INT 0.25MG/ML A083391 001 Jul CAHN

LANOXIN

AP +! COVIS PHARMA BV 0.25MG/ML N009330 002 May CAHN

LANOXIN PEDIATRIC

+! COVIS PHARMA BV 0.1MG/ML N009330 004 May CAHN

DIHYDROERGOTAMINE MESYLATE

INJECTABLE; INJECTION  
DIHYDROERGOTAMINE MESYLATE

>A>	AP	HIKMA PHARMS	1MG/ML	A206621	001	Sep 15, 2017	Sep	NEWA
	AP	WEST-WARD PHARMS INT	1MG/ML	A040453	001	Jun 09, 2003	Jan	CAHN

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL  
DILTIAZEM HYDROCHLORIDE

AB3		SUN PHARM INDS LTD	120MG	A203023	001	Jun 08, 2017	May	NEWA
AB3			180MG	A203023	002	Jun 08, 2017	May	NEWA
AB3			240MG	A203023	003	Jun 08, 2017	May	NEWA
AB3			300MG	A203023	004	Jun 08, 2017	May	NEWA
AB3			360MG	A203023	005	Jun 08, 2017	May	NEWA
AB3		ZYDUS PHARMS USA INC	120MG	A206534	001	Aug 08, 2017	Jul	NEWA
AB4			120MG	A206641	001	Aug 11, 2017	Jul	NEWA
AB3			180MG	A206534	002	Aug 08, 2017	Jul	NEWA
AB4			180MG	A206641	002	Aug 11, 2017	Jul	NEWA
AB3			240MG	A206534	003	Aug 08, 2017	Jul	NEWA
AB4			240MG	A206641	003	Aug 11, 2017	Jul	NEWA
AB3			300MG	A206534	004	Aug 08, 2017	Jul	NEWA
AB4			300MG	A206641	004	Aug 11, 2017	Jul	NEWA
AB3			360MG	A206534	005	Aug 08, 2017	Jul	NEWA
AB4			360MG	A206641	005	Aug 11, 2017	Jul	NEWA
AB4			420MG	A206641	006	Aug 11, 2017	Jul	NEWA

INJECTABLE; INJECTION  
DILTIAZEM HYDROCHLORIDE

AP	!	ATHENEX INC	5MG/ML	A074617	001	Feb 28, 1996	Mar	CAHN
AP		WEST-WARD PHARMS INT	5MG/ML	A078538	001	Dec 17, 2008	Jan	CAHN

TABLET; ORAL

DILTIAZEM HYDROCHLORIDE

@	CHARTWELL MOLECULES	30MG	A074093	001	Nov 05, 1992	Feb	CAHN
@		60MG	A074093	002	Nov 05, 1992	Feb	CAHN
@		90MG	A074093	003	Nov 05, 1992	Feb	CAHN
@		120MG	A074093	004	Nov 05, 1992	Feb	CAHN

DIMENHYDRINATE

INJECTABLE; INJECTION  
DIMENHYDRINATE

@	WATSON LABS TEVA	50MG/ML	A080615	001		May	CAHN
---	------------------	---------	---------	-----	--	-----	------

DIPHENHYDRAMINE HYDROCHLORIDE

ELIXIR; ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

!	PHARM ASSOC	12.5MG/5ML	A087513	001	Feb 10, 1982	May	CAHN
---	-------------	------------	---------	-----	--------------	-----	------

INJECTABLE; INJECTION

DIPHENHYDRAMINE HYDROCHLORIDE

@	WATSON LABS TEVA	10MG/ML	A080873	001		May	CAHN
@		50MG/ML	A080873	002		May	CAHN

DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE

@	WATSON LABS TEVA	50MG/ML	A080873	003		May	CAHN
---	------------------	---------	---------	-----	--	-----	------

DIPYRIDAMOLE

INJECTABLE; INJECTION

DIPYRIDAMOLE

AP	!	ATHENEX INC	5MG/ML	A074939	001	Apr 13, 1998	Mar	CAHN
----	---	-------------	--------	---------	-----	--------------	-----	------

TABLET; ORAL

DIPYRIDAMOLE

	IDT AUSTRALIA LTD	50MG	A086944	001	Feb 25, 1992	Aug	CMS1
		75MG	A086944	003	Feb 25, 1992	Aug	CMS1

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL

DISOPYRAMIDE PHOSPHATE

>A>	AB	MAYNE PHARMA	EQ 150MG BASE	A070173	002	May 31, 1985	Sep	CMS1
-----	----	--------------	---------------	---------	-----	--------------	-----	------

DISULFIRAM

TABLET; ORAL  
DISULFIRAM

AB	CHARTWELL MOLECULES	250MG	A091563	001	Dec 31, 2012	Jan	CAHN
AB		500MG	A091563	002	Dec 31, 2012	Jan	CAHN
	@ WATSON LABS TEVA	500MG	A086890	001		May	CAHN

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE; ORAL  
DIVALPROEX SODIUM

AB	PRINSTON INC	EQ 125MG VALPROIC ACID	A090210	001	Nov 30, 2009	Feb	CAHN
AB		EQ 250MG VALPROIC ACID	A090210	002	Nov 30, 2009	Feb	CAHN
AB		EQ 500MG VALPROIC ACID	A090210	003	Nov 30, 2009	Feb	CAHN
AB	UPSHER-SMITH LABS	EQ 125MG VALPROIC ACID	A078182	001	Jul 29, 2008	Jun	CAHN
AB		EQ 250MG VALPROIC ACID	A078182	002	Jul 29, 2008	Jun	CAHN
AB		EQ 500MG VALPROIC ACID	A078182	003	Jul 29, 2008	Jun	CAHN

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION  
DOBUTREX

	+ @ LILLY	EQ 12.5MG BASE/ML	N017820	002		Aug	CRLD
--	-----------	-------------------	---------	-----	--	-----	------

DOCETAXEL

INJECTABLE; INJECTION  
DOCEFREZ

	+ @ SUN PHARMA GLOBAL	20MG/VIAL	N022534	001	May 03, 2011	Aug	DISC
	+ @	80MG/VIAL	N022534	002	May 03, 2011	Aug	DISC
		DOCETAXEL					
AP	ACTAVIS LLC	20MG/ML (20MG/ML)	N203551	001	Apr 12, 2013	Feb	CAHN
AP		80MG/4ML (20MG/ML)	N203551	002	Apr 12, 2013	Feb	CAHN
		140MG/7ML (20MG/ML)	N203551	003	Apr 12, 2013	Feb	CAHN
AP	DFB ONCOLOGY LTD	20MG/ML (20MG/ML)	A206177	001	Jan 20, 2017	Jan	NEWA
AP		80MG/4ML (20MG/ML)	A206177	002	Jan 20, 2017	Jan	NEWA
		200MG/10ML (20MG/ML)	A206177	003	Jan 20, 2017	Jan	NEWA
	+ @ HOSPIRA INC	120MG/6ML (20MG/ML)	N022234	006	Jun 23, 2016	Aug	DISC
	+	160MG/8ML (20MG/ML)	N022234	007	Jan 24, 2017	Jan	NEWA
AP	INGENUS PHARMS LLC	20MG/2ML (10MG/ML)	A207563	001	Aug 31, 2017	Aug	NEWA
AP		80MG/8ML (10MG/ML)	A207563	002	Aug 31, 2017	Aug	NEWA
AP		160MG/16ML (10MG/ML)	A207563	003	Aug 31, 2017	Aug	NEWA
AP	JIANGSU HENGRUI MED	20MG/ML (20MG/ML)	A207252	001	Aug 09, 2017	Jul	NEWA
	!	40MG/ML	A203170	001	Feb 15, 2017	Jan	NEWA
AP		80MG/4ML (20MG/ML)	A207252	002	Aug 09, 2017	Jul	NEWA
AP		160MG/8ML (20MG/ML)	A207252	003	Aug 09, 2017	Jul	NEWA
	@ PFIZER LABS	20MG/2ML (10MG/ML)	N202356	001	Mar 13, 2014	Jan	DISC
	@	80MG/8ML (10MG/ML)	N202356	002	Mar 13, 2014	Jan	DISC
	@	130MG/13ML (10MG/ML)	N202356	003	Mar 13, 2014	Jan	DISC
	@	200MG/20ML (10MG/ML)	N202356	004	Mar 13, 2014	Jan	DISC

DOFETILIDE

CAPSULE; ORAL  
DOFETILIDE

AB	MAYNE PHARMA INC	0.125MG	A207058	001	Jun 06, 2016	Feb	CAHN
AB		0.25MG	A207058	002	Jun 06, 2016	Feb	CAHN
AB		0.5MG	A207058	003	Jun 06, 2016	Feb	CAHN

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL  
DONEPEZIL HYDROCHLORIDE

AB	ACI HEALTHCARE LTD	5MG	A078662	001	May 31, 2011	Jun	CAHN	
AB		10MG	A078662	002	May 31, 2011	Jun	CAHN	
AB	ALLIED PHARMA INC	5MG	A078662	001	May 31, 2011	Mar	CAHN	
AB		10MG	A078662	002	May 31, 2011	Mar	CAHN	
>A>	AB	CADILA PHARMS LTD	5MG	A204609	001	Sep 19, 2017	Sep	NEWA
>A>	AB		10MG	A204609	002	Sep 19, 2017	Sep	NEWA
AB	VIVIMED GLOBAL	5MG	A090551	001	May 31, 2011	Aug	CAHN	
AB		10MG	A090551	002	May 31, 2011	Aug	CAHN	
AB	ZHEJIANG HISUN PHARM	23MG	A202410	001	Mar 24, 2017	Mar	NEWA	
AB	ZYDUS PHARMS USA INC	23MG	A203162	001	Aug 31, 2017	Aug	NEWA	

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL  
MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE

AB	AMNEAL PHARMS	10MG;14MG	A208328	001	Jan 27, 2017	Jan	NEWA
AB		10MG;28MG	A208328	002	Jan 27, 2017	Jan	NEWA
	NAMZARIC						
AB	+ FOREST LABS LLC	10MG;14MG	N206439	001	Dec 23, 2014	Jan	CFTG
AB	+!	10MG;28MG	N206439	002	Dec 23, 2014	Jan	CFTG

DOPAMINE HYDROCHLORIDE

INJECTABLE;INJECTION  
DOPAMINE HYDROCHLORIDE  
@ TELIGENT

40MG/ML N018656 001 Jun 28, 1983 May CAHN

>D> DORIPENEM

>D> INJECTABLE;IV (INFUSION)  
>D> DORIBAX

>D>	+ SHIONOGI INC	250MG/VIAL	N022106	002	Oct 05, 2010	Sep	DISC
>A>	+ @	250MG/VIAL	N022106	002	Oct 05, 2010	Sep	DISC
>D>	+!	500MG/VIAL	N022106	001	Oct 12, 2007	Sep	DISC
>A>	+ @	500MG/VIAL	N022106	001	Oct 12, 2007	Sep	DISC

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC  
DORZOLAMIDE HYDROCHLORIDE

AT	SANDOZ INC	EQ 2% BASE	A078748	001	Nov 06, 2008	Mar	CAHN
AT		EQ 2% BASE	A078981	001	Apr 13, 2009	Feb	CAHN
>D> AT	ZACH SYSTEMS	EQ 2% BASE	A091034	001	Dec 04, 2013	Sep	CAHN
>A> AT	ZAMBON SPA	EQ 2% BASE	A091034	001	Dec 04, 2013	Sep	CAHN

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC  
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

AT	SANDOZ INC	EQ 2% BASE;EQ 0.5% BASE	A090604	001	Nov 18, 2009	Mar	CAHN
>D> AT	ZACH SYSTEMS	EQ 2% BASE;EQ 0.5% BASE	A091180	001	Dec 04, 2013	Sep	CAHN
>A> AT	ZAMBON SPA	EQ 2% BASE;EQ 0.5% BASE	A091180	001	Dec 04, 2013	Sep	CAHN

DOXAPRAM HYDROCHLORIDE

INJECTABLE;INJECTION  
DOXAPRAM HYDROCHLORIDE

AP	ATHENEX INC	20MG/ML	A076266	001	Jan 10, 2003	Mar	CAHN
----	-------------	---------	---------	-----	--------------	-----	------

DOXAZOSIN MESYLATE

TABLET;ORAL  
DOXAZOSIN MESYLATE

AB	ZYDUS PHARMS USA INC	EQ 1MG BASE	A208719	001	Jul 07, 2017	Jun	NEWA
AB		EQ 2MG BASE	A208719	002	Jul 07, 2017	Jun	NEWA
AB		EQ 4MG BASE	A208719	003	Jul 07, 2017	Jun	NEWA
AB		EQ 8MG BASE	A208719	004	Jul 07, 2017	Jun	NEWA

DOXEPIN HYDROCHLORIDE

CAPSULE;ORAL  
DOXEPIN HYDROCHLORIDE

AB	AMNEAL PHARMS CO	EQ 10MG BASE	A207482	001	Jun 28, 2017	Jun	NEWA
AB		EQ 25MG BASE	A207482	002	Jun 28, 2017	Jun	NEWA
AB		EQ 50MG BASE	A207482	003	Jun 28, 2017	Jun	NEWA
AB		EQ 75MG BASE	A207482	004	Jun 28, 2017	Jun	NEWA
AB		EQ 100MG BASE	A207482	005	Jun 28, 2017	Jun	NEWA
	@ WATSON LABS TEVA	EQ 50MG BASE	A072987	001	Mar 29, 1991	May	CAHN
	CREAM;TOPICAL						
	ZONALON						
	+! MYLAN PHARMS INC	5%	N020126	001	Apr 01, 1994	Jan	CAHN

DOXERCALCIFEROL

INJECTABLE;INJECTION  
DOXERCALCIFEROL

AP	AMNEAL PHARMS CO	2MCG/ML (2MCG/ML)	A208974	001	May 24, 2017	May	NEWA
AP		4MCG/2ML (2MCG/ML)	A208974	002	May 24, 2017	May	NEWA
AP		4MCG/2ML (2MCG/ML)	A208975	001	May 24, 2017	May	NEWA

DOXORUBICIN HYDROCHLORIDE

## INJECTABLE; INJECTION

## DOXORUBICIN HYDROCHLORIDE

AP	AMNEAL PHARMS CO	20MG/VIAL	A208888	001	Feb 17, 2017	Feb	NEWA
AP		50MG/VIAL	A208888	002	Feb 17, 2017	Feb	NEWA
AP	GLAND PHARMA LTD	2MG/ML	A209825	001	Aug 11, 2017	Jul	NEWA

## INJECTABLE, LIPOSOMAL; INJECTION

## DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)

AB	DR REDDYS LABS LTD	20MG/10ML (2MG/ML)	A208657	001	May 15, 2017	May	NEWA
AB		50MG/25ML (2MG/ML)	A208657	002	May 15, 2017	May	NEWA

DOXYCYCLINE

## CAPSULE; ORAL

## DOXYCYCLINE

AB	ALEMBIC PHARMS LTD	EQ 75MG BASE	A209165	001	Jul 28, 2017	Jul	NEWA
AB		EQ 100MG BASE	A209165	002	Jul 28, 2017	Jul	NEWA
>A>	MAYNE PHARMA INC	EQ 50MG BASE	A209396	001	Sep 29, 2017	Sep	NEWA
>A>		EQ 75MG BASE	A209396	002	Sep 29, 2017	Sep	NEWA
>A>		EQ 100MG BASE	A209396	003	Sep 29, 2017	Sep	NEWA

## TABLET; ORAL

## DOXYCYCLINE

>A>	AB	ZYDUS PHARMS USA INC	EQ 50MG BASE	A209582	001	Sep 28, 2017	Sep	NEWA
>A>	AB		EQ 75MG BASE	A209582	002	Sep 28, 2017	Sep	NEWA
>A>	AB		EQ 100MG BASE	A209582	003	Sep 28, 2017	Sep	NEWA
>A>	AB		EQ 150MG BASE	A209582	004	Sep 28, 2017	Sep	NEWA

DOXYCYCLINE HYCLATE

## CAPSULE, DELAYED RELEASE; ORAL

## DOXYCYCLINE HYCLATE

## @ MEDICIS

EQ 75MG BASE

A065281 001 Dec 21, 2005 Jul DISC

## @

EQ 100MG BASE

A065281 002 Dec 21, 2005 Jul DISC

## INJECTABLE; INJECTION

## DOXYCYCLINE

>A>	AP	ZYDUS PHARMS USA INC	EQ 100MG BASE/VIAL	A207757	001	Sep 28, 2017	Sep	NEWA
>A>	AP		EQ 200MG BASE/VIAL	A207757	002	Sep 28, 2017	Sep	NEWA

## VIBRAMYCIN

## + @ PFIZER

EQ 100MG BASE/VIAL

N050442 002

Jan CRLD

## + @

EQ 200MG BASE/VIAL

N050442 001

Jan CRLD

## TABLET; ORAL

## ACTICLATE

AB	+	AQUA PHARMS LLC	EQ 75MG BASE	N205931	001	Jul 25, 2014	Jun	CFTG
AB	+	!	EQ 150MG BASE	N205931	002	Jul 25, 2014	Jun	CFTG

## DOXYCYCLINE HYCLATE

>A>	AB	AMNEAL PHARMS CO	EQ 75MG BASE	A209372	001	Oct 06, 2017	Sep	NEWA
>A>	AB		EQ 150MG BASE	A209372	002	Oct 06, 2017	Sep	NEWA
		CARIBE HOLDINGS	EQ 50MG BASE	A062269	003		Mar	CMFD
		@	EQ 50MG BASE	A062269	003		Jan	CAHN
	AB		EQ 100MG BASE	A062269	002	Nov 08, 1982	Jan	CAHN
		@ EPIC PHARMA LLC	EQ 20MG BASE	A065182	001	May 13, 2005	May	CAHN
>A>	AB	LUPIN LTD	EQ 75MG BASE	A208818	001	Sep 27, 2017	Sep	NEWA
>A>	AB		EQ 150MG BASE	A208818	002	Sep 27, 2017	Sep	NEWA
	AB	MAYNE PHARMA INC	EQ 75MG BASE	A208765	001	Jun 14, 2017	May	NEWA
	AB		EQ 150MG BASE	A208765	002	Jun 14, 2017	May	NEWA
	AB	NOVEL LABS INC	EQ 100MG BASE	A207558	001	Sep 06, 2017	Aug	NEWA

DRONABINOL

## SOLUTION; ORAL

## SYNDROS

+	!	INSYS DEV CO INC	5MG/ML	N205525	001	Mar 23, 2017	Mar	NEWA
---	---	------------------	--------	---------	-----	--------------	-----	------

DROSPIRENONE; ETHINYL ESTRADIOL

## TABLET; ORAL

## DROSPIRENONE AND ETHINYL ESTRADIOL

AB		PII	3MG;0.02MG	A203291	001	Jul 18, 2017	Jul	NEWA
----	--	-----	------------	---------	-----	--------------	-----	------

DULOXETINE HYDROCHLORIDE

## CAPSULE, DELAYED REL PELLETS; ORAL

## DULOXETINE HYDROCHLORIDE

AB		MACLEODS PHARMS LTD	EQ 20MG BASE	A204815	001	Mar 23, 2017	Mar	NEWA
AB			EQ 30MG BASE	A204815	002	Mar 23, 2017	Mar	NEWA
AB			EQ 60MG BASE	A204815	003	Mar 23, 2017	Mar	NEWA



CAPSULE, DELAYED REL PELLETS;ORAL  
DULOXETINE HYDROCHLORIDE

AB	PRINSTON INC	EQ 20MG BASE	A206653	001	May 18, 2017	May	NEWA
AB		EQ 30MG BASE	A206653	002	May 18, 2017	May	NEWA
AB		EQ 60MG BASE	A206653	003	May 18, 2017	May	NEWA
AB	ZYDUS HLTHCARE	EQ 20MG BASE	A090739	001	Jan 08, 2014	Apr	CAHN
AB		EQ 30MG BASE	A090739	002	Jan 08, 2014	Apr	CAHN
AB		EQ 60MG BASE	A090739	003	Jan 08, 2014	Apr	CAHN

DUTASTERIDE

CAPSULE;ORAL  
DUTASTERIDE

AB	AMNEAL PHARMS	0.5MG	A203118	001	Nov 20, 2015	May	CAHN
AB	MARKSANS PHARMA	0.5MG	A204376	001	Apr 07, 2017	Mar	NEWA
>A> AB	ZYDUS PHARMS USA INC	0.5MG	A204373	001	Oct 04, 2017	Sep	NEWA

DYPHYLLINE

TABLET;ORAL  
LUFYLLIN

	@ MYLAN SPECIALITY LP	200MG	A084566	001		Mar	CAHN
	@	400MG	A084566	002		Mar	CAHN

ECONAZOLE NITRATE

AEROSOL, FOAM;TOPICAL  
ECOZA

+!	CHEMO RESEARCH SL	1%	N205175	001	Oct 24, 2013	May	CAHN
----	-------------------	----	---------	-----	--------------	-----	------

CREAM;TOPICAL  
SPECTAZOLE

>D>	+ @ ALVOGEN MALTA	1%	N018751	001	Dec 23, 1982	Sep	CMFD
>A> AB	+	1%	N018751	001	Dec 23, 1982	Sep	CMFD
	+ @	1%	N018751	001	Dec 23, 1982	Mar	CMS1

EDARAVONE

SOLUTION;IV (INFUSION)  
RADICAVA

+!	MITSUBISHI TANABE	30MG/100ML (0.3MG/ML)	N209176	001	May 05, 2017	May	NEWA
----	-------------------	-----------------------	---------	-----	--------------	-----	------

EDROPHONIUM CHLORIDE

INJECTABLE;INJECTION  
TENSILON

+	@ TELIGENT	10MG/ML	N007959	001		Apr	CAHN
	TENSILON PRESERVATIVE FREE						
+	@ TELIGENT	10MG/ML	N007959	002		Apr	CAHN

ELETRIPTAN HYDROBROMIDE

TABLET;ORAL

ELETRIPTAN HYDROBROMIDE

AB	AJANTA PHARMA LTD	EQ 20MG BASE	A205186	001	Aug 29, 2017	Aug	NEWA
AB		EQ 40MG BASE	A205186	002	Aug 29, 2017	Aug	NEWA
AB	MYLAN PHARMS INC	EQ 20MG BASE	A205152	001	Aug 11, 2017	Jul	NEWA
AB		EQ 40MG BASE	A205152	002	Aug 11, 2017	Jul	NEWA
AB	TEVA PHARMS USA	EQ 20MG BASE	A202040	001	Jun 27, 2017	Jun	NEWA
AB		EQ 40MG BASE	A202040	002	Jun 27, 2017	Jun	NEWA
AB	ZYDUS PHARMS USA INC	EQ 20MG BASE	A206409	001	Jun 16, 2017	Jun	NEWA
AB		EQ 40MG BASE	A206409	002	Jun 16, 2017	Jun	NEWA
	RELPAK						
AB	+ PFIZER IRELAND	EQ 20MG BASE	N021016	001	Dec 26, 2002	Jun	CFTG
AB	+!	EQ 40MG BASE	N021016	002	Dec 26, 2002	Jun	CFTG

ELVITEGRAVIR

TABLET;ORAL  
VITEKTA

+	@ GILEAD SCIENCES INC	85MG	N203093	001	Sep 24, 2014	May	DISC
+	@	150MG	N203093	002	Sep 24, 2014	May	DISC

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

AB	TEVA PHARMS USA	200MG;300MG	A090894	001	Jun 08, 2017	May	NEWA
	TRUVADA						
AB	+! GILEAD	200MG;300MG	N021752	001	Aug 02, 2004	May	CFTG

ENALAPRIL MALEATESOLUTION;ORAL  
EPANED

+! SILVERGATE PHARMS 1MG/ML N208686 001 Sep 20, 2016 Jul CRLD

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

@ UPSHER-SMITH LABS 5MG;12.5MG

A076116 001 Sep 19, 2001 Jun CAHN

@ 10MG;25MG

A076116 002 Sep 19, 2001 Jun CAHN

ENALAPRILAT

INJECTABLE;INJECTION

ENALAPRILAT

AP ! ATHENEX INC 1.25MG/ML

A075634 001 Aug 22, 2000 Mar CAHN

VASOTEC

+ @ BIOVAIL LABS INTL 1.25MG/ML

N019309 001 Feb 09, 1988 Mar CRLD

ENASIDENIB MESYLATE

TABLET;ORAL

IDHIFA

+ CELGENE CORP EQ 50MG BASE

N209606 001 Aug 01, 2017 Aug NEWA

+! EQ 100MG BASE

N209606 002 Aug 01, 2017 Aug NEWA

ENTACAPONE

TABLET;ORAL

ENTACAPONE

AB AJANTA PHARMA LTD 200MG

A205792 001 Aug 31, 2017 Aug NEWA

AB MACLEODS PHARMS LTD 200MG

A207210 001 Jun 05, 2017 May NEWA

@ MYLAN PHARMS INC 200MG

A202394 001 May 13, 2013 May DISC

ENTECAVIR

TABLET;ORAL

ENTECAVIR

AB ACCORD HLTHCARE 0.5MG

A205824 001 Aug 25, 2017 Aug NEWA

AB 1MG

A205824 002 Aug 25, 2017 Aug NEWA

&gt;A&gt; AB PRINSTON INC 0.5MG

A208782 001 Oct 10, 2017 Sep NEWA

&gt;A&gt; AB 1MG

A208782 002 Oct 10, 2017 Sep NEWA

AB SANDOZ INC 0.5MG

A206672 001 May 11, 2017 May NEWA

AB 1MG

A206672 002 May 11, 2017 May NEWA

AB ZYDUS PHARMS USA INC 0.5MG

A206745 001 Jun 23, 2017 Jun NEWA

AB 1MG

A206745 002 Jun 23, 2017 Jun NEWA

EPHEDRINE SULFATE

SOLUTION;INTRAVENOUS

AKOVAZ

AP +! FLAMEL IRELAND LTD 50MG/ML (50MG/ML)

N208289 001 Apr 29, 2016 Mar CTEC

EPHEDRINE SULFATE

AP AKORN INC 50MG/ML (50MG/ML)

N208609 001 Mar 01, 2017 Mar NEWA

AP SANDOZ INC 50MG/ML (50MG/ML)

A209784 001 Aug 23, 2017 Aug NEWA

SOLUTION;IV (INFUSION)

CORPHEDRA

PAR STERILE PRODUCTS 50MG/ML (50MG/ML)

N208943 001 Jan 27, 2017 Jan NEWA

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

EPINASTINE HYDROCHLORIDE

AT AKORN 0.05%

A204055 001 May 05, 2017 Apr NEWA

AT SANDOZ INC 0.05%

A203384 001 Dec 07, 2016 Mar CAHN

EPINEPHRINE

INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS

ADRENACLICK

BX +! IMPAX LABS INC EQ 0.15MG/DELIVERY

N020800 003 Nov 25, 2009 Jun CAHN

BX +! EQ 0.3MG/DELIVERY

N020800 004 Nov 25, 2009 Jun CAHN

TWINJECT 0.15

@ IMPAX LABS INC EQ 0.15MG/DELIVERY

N020800 002 May 28, 2004 Jun CAHN

TWINJECT 0.3

@ IMPAX LABS INC EQ 0.3MG/DELIVERY

N020800 001 May 30, 2003 Jun CAHN

SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS  
ADRENALIN

+!	PAR STERILE PRODUCTS	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N204200	001	Dec 07, 2012	Aug CDFR
+!		EQ 30MG BASE/30ML (EQ 1MG BASE/ML)	N204640	001	Dec 18, 2013	Aug CDFR
	SYMJEPI					
+!	ADAMIS PHARMS CORP	0.3MG/ML (0.3MG/ML)	N207534	001	Jun 15, 2017	Jun NEWA

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

## INJECTABLE; INJECTION

## LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

@	BELMORA LLC	0.01MG/ML;2%	A080504	004	Oct 19, 1983	Feb CAHN
@		0.02MG/ML;2%	A080504	005	Oct 19, 1983	Feb CAHN
@	WEST-WARD PHARMS INT	0.01MG/ML;1%	A080406	001		Mar CAHN
@		0.01MG/ML;2%	A080406	002		Mar CAHN

EPLERENONE

## TABLET; ORAL

## EPLERENONE

AB	ACCORD HLTHCARE	25MG	A206922	001	Jul 13, 2017	Jul NEWA
AB		50MG	A206922	002	Jul 13, 2017	Jul NEWA
AB	MYLAN PHARMS INC	25MG	A203896	001	Feb 02, 2017	Jan NEWA
AB		50MG	A203896	002	Feb 02, 2017	Jan NEWA

EPTIFIBATIDE

## INJECTABLE; INJECTION

## EPTIFIBATIDE

AP	AKORN	2MG/ML	A204589	001	Apr 18, 2017	Apr NEWA
AP		75MG/100ML	A204589	002	Apr 18, 2017	Apr NEWA
AP	AMNEAL PHARMS	2MG/ML	A205581	001	Dec 08, 2016	May CAHN
AP		75MG/100ML	A205581	002	Dec 08, 2016	May CAHN

ERGOLOID MESYLATES

## TABLET; ORAL

## ERGOLOID MESYLATES

!	SUN PHARM INDS	1MG	A081113	001	Oct 31, 1991	May CHRS
	HYDERGINE					
+	@ NOVARTIS	1MG	N017993	001		May DISC

ERYTHROMYCIN

## GEL; TOPICAL

## E-GLADES

@	MYLAN PHARMS INC	2%	A065009	001	Mar 18, 2002	Jan CAHN	
	ERYGEL						
AT	+!	MYLAN PHARMS INC	2%	N050617	001	Oct 21, 1987	Jan CAHN
	ERYTHROMYCIN						
AT		PERRIGO CO	2%	A063211	001	Jan 29, 1993	Apr CAHN
AT		TELIGENT PHARMA INC	2%	A208154	001	Jul 19, 2017	Jul NEWA

## SOLUTION; TOPICAL

## A/T/S

@	TARO	2%	A062405	001	Nov 18, 1982	Apr CAHN	
	ERYTHROMYCIN						
@	FOUGERA PHARMS	2%	A064187	001	Sep 30, 1997	Aug DISC	
AT	!	PERRIGO NEW YORK	2%	A063038	001	Jan 11, 1991	Aug CHRS

## SWAB; TOPICAL

## ERYCETTE

>D>	@	JOHNSON AND JOHNSON	2%	N050594	001	Feb 15, 1985	Sep CRLD
>A>	+	@	2%	N050594	001	Feb 15, 1985	Sep CRLD
	ERYTHROMYCIN						
AT	!	MYLAN PHARMS INC	2%	A064128	001	Jul 03, 1996	Jan CAHN
	!	PERRIGO CO	2%	A064126	001	Jul 03, 1996	Apr CAHN

ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL

## GRANULE; ORAL

## ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL

@	BARR	EQ 200MG BASE/5ML;EQ 600MG BASE/5ML	A062759	001	May 20, 1988	Jul DISC
---	------	--	---------	-----	--------------	----------

ESCITALOPRAM OXALATE

TABLET; ORAL

ESCITALOPRAM OXALATE

AB	AMNEAL PHARMS	EQ 5MG BASE	A205619	001	May 17, 2017	May	NEWA
AB		EQ 10MG BASE	A205619	002	May 17, 2017	May	NEWA
AB		EQ 20MG BASE	A205619	003	May 17, 2017	May	NEWA

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS; ORAL

ESOMEPRAZOLE MAGNESIUM

AB	KREMERS URBAN PHARMS	EQ 20MG BASE	A205563	001	Sep 01, 2017	Aug	NEWA
AB		EQ 40MG BASE	A205563	002	Sep 01, 2017	Aug	NEWA
	FOR SUSPENSION, DELAYED RELEASE; ORAL						
	NEXIUM						
+	ASTRAZENECA PHARMS	EQ 10MG BASE/PACKET	N022101	001	Feb 27, 2008	May	CRLD

ESOMEPRAZOLE SODIUM

INJECTABLE; INTRAVENOUS

ESOMEPRAZOLE SODIUM

AP	!	AUROBINDO PHARMA LTD	EQ 20MG BASE/VIAL	A204657	001	Aug 10, 2016	May	CHRS
AP			EQ 40MG BASE/VIAL	A204657	002	Aug 10, 2016	Aug	CHRS
AP	!		EQ 40MG BASE/VIAL	A204657	002	Aug 10, 2016	May	CHRS
AP		DEVA HOLDING AS	EQ 40MG BASE/VIAL	A207181	001	Mar 06, 2017	Feb	NEWA
AP		MYLAN LABS LTD	EQ 20MG BASE/VIAL	A202686	001	May 17, 2017	May	NEWA
AP			EQ 40MG BASE/VIAL	A202686	002	May 17, 2017	May	NEWA
	NEXIUM IV							
+	@	ASTRAZENECA PHARMS	EQ 20MG BASE/VIAL	N021689	001	Mar 31, 2005	May	DISC
AP	+	!	EQ 40MG BASE/VIAL	N021689	002	Mar 31, 2005	Aug	CMFD
	+	@	EQ 40MG BASE/VIAL	N021689	002	Mar 31, 2005	May	DISC

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL

ESTRADERM

+	@	NOVARTIS	0.05MG/24HR	N019081	002	Sep 10, 1986	May	DISC
+	@		0.1MG/24HR	N019081	003	Sep 10, 1986	May	DISC
		VIVELLE						
	@	NOVARTIS	0.05MG/24HR	N020323	002	Oct 28, 1994	May	DISC
	@		0.1MG/24HR	N020323	004	Oct 28, 1994	May	DISC

GEL, METERED; TRANSDERMAL

ELESTRIN

+	!	MYLAN SPECIALITY LP	0.06% (0.87GM/ACTIVATION)	N021813	001	Dec 15, 2006	Mar	CAHN
---	---	---------------------	---------------------------	---------	-----	--------------	-----	------

SPRAY; TRANSDERMAL

EVAMIST

+	!	PERRIGO PHARMA INTL	1.53MG/SPRAY	N022014	001	Jul 27, 2007	May	CAHN
---	---	---------------------	--------------	---------	-----	--------------	-----	------

TABLET; VAGINAL

ESTRADIOL

AB		TEVA PHARMS USA	10MCG	A206388	001	Jul 21, 2017	Jul	NEWA
----	--	-----------------	-------	---------	-----	--------------	-----	------

ESTRADIOL ACETATE

TABLET; ORAL

FEMTRACE

+	@	APIL	0.45MG	N021633	001	Aug 20, 2004	Jun	DISC
+	@		0.9MG	N021633	002	Aug 20, 2004	Jun	DISC
+	@		1.8MG	N021633	003	Aug 20, 2004	Jun	DISC

ESTRADIOL VALERATE

INJECTABLE; INJECTION

ESTRADIOL VALERATE

@	SANDOZ INC	10MG/ML	A040628	001	Oct 04, 2007	Apr	CAHN
@		20MG/ML	A040628	002	Oct 04, 2007	Apr	CAHN
@		40MG/ML	A040628	003	Oct 04, 2007	Apr	CAHN

ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

ESTRADIOL AND NORETHINDRONE ACETATE

AB		MYLAN LABS LTD	0.5MG; 0.1MG	A207261	001	Feb 10, 2017	Jan	NEWA
AB			1MG; 0.5MG	A207261	002	Feb 10, 2017	Jan	NEWA

ESTROGENS, CONJUGATED SYNTHETIC A

TABLET; ORAL

CENESTIN

+ @	TEVA BRANDED PHARM	0.3MG	N020992	001	Jun 21, 2002	Aug	CRLD
+ @		0.45MG	N020992	005	Feb 05, 2004	Aug	CRLD
+ @		0.625MG	N020992	002	Mar 24, 1999	Aug	CRLD
+ @		0.9MG	N020992	003	Mar 24, 1999	Aug	CRLD
+ @		1.25MG	N020992	004	Mar 13, 2000	Aug	CRLD

ESTROGENS, CONJUGATED SYNTHETIC B

TABLET; ORAL

ENJUVIA

@	TEVA BRANDED PHARM	0.3MG	N021443	001	Dec 20, 2004	Aug	DISC
		0.3MG	N021443	001	Dec 20, 2004	Apr	CAHN
@		0.45MG	N021443	002	Dec 20, 2004	Aug	DISC
		0.45MG	N021443	002	Dec 20, 2004	Apr	CAHN
@		0.625MG	N021443	003	May 10, 2004	Apr	CAHN
@		0.9MG	N021443	005	Apr 27, 2007	Aug	DISC
		0.9MG	N021443	005	Apr 27, 2007	Apr	CAHN
@		1.25MG	N021443	004	May 10, 2004	Apr	CAHN

ESTROGENS, ESTERIFIED

TABLET; ORAL

MENEST

	MONARCH PHARMS	0.3MG	A084951	001		Jun	CAHN
		0.625MG	A084948	001		Jun	CAHN
		1.25MG	A084950	001		Jun	CAHN
!		2.5MG	A084949	001		Jun	CAHN

ESTRONE

INJECTABLE; INJECTION

ESTRONE

@	WATSON LABS TEVA	5MG/ML	A085239	001		May	CAHN
---	------------------	--------	---------	-----	--	-----	------

ESTROPIPATE

TABLET; ORAL

ESTROPIPATE

@	BARR	0.75MG	A040135	001	Nov 27, 1996	May	DISC
@		1.5MG	A040135	002	Nov 27, 1996	May	DISC
@		3MG	A040135	003	Nov 27, 1996	May	DISC
!	WATSON LABS TEVA	3MG	A081215	001	Sep 23, 1993	May	CHRS
AB		3MG	A081215	001	Sep 23, 1993	Feb	CAHN
	OGEN .625						
@	PHARMACIA AND UPJOHN	0.75MG	A083220	001		May	DISC
	OGEN 1.25						
@	PHARMACIA AND UPJOHN	1.5MG	A083220	002		May	DISC
	OGEN 2.5						
@	PHARMACIA AND UPJOHN	3MG	A083220	003		May	DISC

ETELCALCETIDE

SOLUTION; INTRAVENOUS

PARSABIV

+	!	KAI PHARMS INC	2.5MG/0.5ML (2.5MG/0.5ML)	N208325	001	Feb 07, 2017	Feb	NEWA
+	!		5MG/ML (5MG/ML)	N208325	002	Feb 07, 2017	Feb	NEWA
+	!		10MG/2ML (5MG/ML)	N208325	003	Feb 07, 2017	Feb	NEWA

ETHACRYNIC ACID

TABLET; ORAL

ETHACRYNIC ACID

AB		PAR PHARM INC	25MG	A208501	001	Jul 21, 2017	Jul	NEWA
AB		WEST-WARD PHARMS INT	25MG	A207262	001	Feb 23, 2017	Feb	NEWA

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET; ORAL-21

ZOVIA 1/35E-21

@	WATSON PHARMS TEVA	0.035MG;1MG	A072720	001	Dec 30, 1991	Mar	CAHN
---	--------------------	-------------	---------	-----	--------------	-----	------

ETHINYL ESTRADIOL; LEVONORGESTREL

## TABLET; ORAL

		LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL							
>A>	AB	MYLAN LABS LTD	0.02MG, 0.15MG; 0.025MG, 0.15MG; 0.03MG, 0.15MG; 0.01MG, N/A	A206053	001	Oct 02, 2017	Sep	NEWA	
		LO SIMPESE							
	AB	AUROBINDO PHARMA LTD	0.02MG, 0.01MG; 0.01MG, N/A	A206852	001	Apr 28, 2017	Apr	NEWA	
	AB	AUROBINDO PHARMA LTD	0.03MG, 0.01MG; 0.15MG, N/A	A206851	001	Apr 07, 2017	Mar	NEWA	
		TABLET; ORAL-28							
		ELIFEMME							
	AB	LABS LEON FARMA	0.03MG, 0.04MG, 0.03MG; 0.05MG, 0.075MG, 0.125MG	A202507	001	Dec 04, 2015	Feb	CAHN	

ETHINYL ESTRADIOL; NORELGESTROMINFILM, EXTENDED RELEASE; TRANSDERMAL  
XULANE

	AB	!	MYLAN TECHNOLOGIES	0.035MG/24HR; 0.15MG/24HR	A200910	001	Apr 16, 2014	Mar	CAHN
--	----	---	--------------------	---------------------------	---------	-----	--------------	-----	------

ETHINYL ESTRADIOL; NORETHINDRONE

## TABLET; ORAL-21

## NORETHIN 1/35E-21

@ WATSON PHARMS TEVA 0.035MG; 1MG

A071480 001 Apr 12, 1988 Mar CAHN

NORETHINDRONE AND ETHINYL ESTRADIOL

@ WATSON PHARMS TEVA 0.035MG; 1MG

A070685 001 Jan 29, 1987 Mar CAHN

NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)

@ WATSON LABS TEVA 0.035MG, 0.035MG; 0.5MG, 1MG

A071041 001 Sep 24, 1991 May CAHN

## TABLET; ORAL-28

NORETHINDRONE AND ETHINYL ESTRADIOL

	AB		ACCORD HLTHCARE	0.035MG; 1MG	A206864	001	Apr 28, 2017	Apr	NEWA
>D>	AB		MYLAN LABS LTD	0.035MG; 0.5MG	A200488	001	Oct 21, 2015	Sep	DISC
>A>		@		0.035MG; 0.5MG	A200488	001	Oct 21, 2015	Sep	DISC
>D>	AB			0.035MG; 1MG	A200489	001	Oct 21, 2015	Sep	DISC
>A>		@		0.035MG; 1MG	A200489	001	Oct 21, 2015	Sep	DISC
	AB		WATSON LABS TEVA	0.035MG; 1MG	A070687	001	Jan 29, 1987	May	CAHN
			NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)						
			WATSON LABS TEVA	0.035MG, 0.035MG; 0.5MG, 1MG	A071044	001	Apr 01, 1988	May	CAHN
			TABLET, CHEWABLE; ORAL						
			NEXESTA FE						
	AB		AUROBINDO PHARMA LTD	0.035MG; 0.4MG	A207535	001	Feb 02, 2017	Jan	NEWA
			NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE						
	AB		ACCORD HLTHCARE	0.035MG; 0.4MG	A207066	001	Mar 29, 2017	Mar	NEWA

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

## TABLET; ORAL

## AUROVELA 24 FE

	AB		AUROBINDO PHARMA LTD	0.02MG; 1MG	A207504	001	Jun 15, 2017	Jun	NEWA
--	----	--	----------------------	-------------	---------	-----	--------------	-----	------

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

	AB		MYLAN LABS LTD	0.0025MG; 0.5MG	A207260	001	Feb 02, 2017	Jan	NEWA
--	----	--	----------------	-----------------	---------	-----	--------------	-----	------

## TABLET; ORAL-21

## AUROVELA 1.5/30

	AB		AUROBINDO PHARMA LTD	0.03MG; 1.5MG	A207581	001	Jun 26, 2017	Jun	NEWA
--	----	--	----------------------	---------------	---------	-----	--------------	-----	------

## AUROVELA 1/20

	AB		AUROBINDO PHARMA LTD	0.02MG; 1MG	A207506	001	Jun 16, 2017	Jun	NEWA
--	----	--	----------------------	-------------	---------	-----	--------------	-----	------

## TABLET; ORAL-28

## AUROVELA FE 1.5/30

	AB		AUROBINDO PHARMA LTD	0.03MG; 1.5MG	A207580	001	Jun 15, 2017	May	NEWA
--	----	--	----------------------	---------------	---------	-----	--------------	-----	------

## AUROVELA FE 1/20

	AB		AUROBINDO PHARMA LTD	0.02MG; 1MG	A207505	001	Jun 16, 2017	Jun	NEWA
--	----	--	----------------------	-------------	---------	-----	--------------	-----	------

## LOESTRIN FE 1/20

	AB	+	APIL	0.02MG; 1MG	N017354	001		Jul	CRLD
--	----	---	------	-------------	---------	-----	--	-----	------

## TABLET, CHEWABLE; ORAL

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

	AB		AMNEAL PHARMS	0.02MG; 1MG	A207514	001	Sep 11, 2017	Aug	NEWA
>A>	AB		MYLAN LABS LTD	0.02MG; 1MG	A206120	001	Sep 12, 2017	Sep	NEWA

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28

NORGESTIMATE AND ETHINYL ESTRADIOL

>A>	AB	AMNEAL PHARMS	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A203873	001	May 12, 2016	Sep	CAHN
>D>	AB	HAUPT PHARMA	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A203873	001	May 12, 2016	Sep	CAHN

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-28

NORGESTREL AND ETHINYL ESTRADIOL

AB		MYLAN LABS LTD	0.05MG;0.5MG	A202875	001	May 08, 2017	Apr	NEWA
AB	!	WATSON LABS	0.05MG;0.5MG	A075406	002	Dec 15, 1999	May	CTEC

ETHOSUXIMIDE

SYRUP; ORAL

ETHOSUXIMIDE

AA		PHARM ASSOC	250MG/5ML	A040253	001	Nov 22, 2000	May	CAHN
AA	!	PARKE-DAVIS	250MG/5ML	A080258	001		Mar	CAHN

ETIDRONATE DISODIUM

TABLET; ORAL

DIDRONEL

+	@	APIL	200MG	N017831	001		Jun	DISC
+	@		400MG	N017831	002		Jun	DISC
		ETIDRONATE DISODIUM						
		MYLAN	200MG	A075800	001	Jan 24, 2003	Jun	CTEC
	!		400MG	A075800	002	Jan 24, 2003	Jun	CHRS

ETODOLAC

CAPSULE; ORAL

ETODOLAC

	@	CHARTWELL MOLECULES	200MG	A074842	001	Jul 17, 1997	Mar	CAHN
	@		300MG	A074842	002	Jul 17, 1997	Mar	CAHN
	@	CHARTWELL PHARMS LLC	200MG	A074842	001	Jul 17, 1997	Jan	CAHN
	@		300MG	A074842	002	Jul 17, 1997	Jan	CAHN
	@	ECI PHARMS LLC	300MG	A074929	001	Jan 30, 1998	Apr	CAHN
		LODINE						
+	@	WYETH PHARMS INC	300MG	N018922	003	Jan 31, 1991	Jul	CRLD
		ETODOLAC						
	@	CHARTWELL MOLECULES	400MG	A074841	001	Jun 27, 1997	Jan	CAHN
	@	MYLAN PHARMS INC	400MG	A075104	001	Feb 06, 1998	May	DISC
AB			400MG	A075104	001	Feb 06, 1998	Mar	CAHN
	@		500MG	A075104	002	Nov 20, 1998	May	DISC
AB			500MG	A075104	002	Nov 20, 1998	Mar	CAHN

ETOMIDATE

INJECTABLE; INJECTION

ETOMIDATE

AP		AUROBINDO PHARMA LTD	2MG/ML	A206126	001	Feb 24, 2017	Feb	NEWA
AP		GLAND PHARMA LTD	2MG/ML	A209058	001	Apr 18, 2017	Apr	NEWA
AP		MYLAN LABS LTD	2MG/ML	A201044	001	Feb 07, 2017	Jan	NEWA
AP		WEST-WARD PHARMS INT	2MG/ML	A074593	001	Nov 04, 1996	Jan	CAHN

ETOPOSIDE

CAPSULE; ORAL

VEPESID

>D>		@ DAVA PHARMS INC	50MG	N019557	001	Dec 30, 1986	Sep	CRLD
>A>	+	@	50MG	N019557	001	Dec 30, 1986	Sep	CRLD
>D>		@	100MG	N019557	002	Dec 30, 1986	Sep	CRLD
>A>	+	@	100MG	N019557	002	Dec 30, 1986	Sep	CRLD

EXAMETAZIME

POWDER; INTRAVENOUS

DRAX EXAMETAZIME

AP		JUBILANT DRAXIMAGE	0.5MG/VIAL	N208870	001	Aug 17, 2017	Aug	NEWA
----	--	--------------------	------------	---------	-----	--------------	-----	------

EXEMESTANE

## TABLET; ORAL

## EXEMESTANE

AB	MYLAN PHARMS INC	25MG	A203315	001	Mar 10, 2017	Feb	NEWA
AB	UPSHER-SMITH LABS	25MG	A209208	001	Jul 26, 2017	Aug	CAHN
AB		25MG	A209208	001	Jul 26, 2017	Jul	NEWA

EZETIMIBE

## TABLET; ORAL

## EZETIMIBE

AB	AMNEAL PHARMS CO	10MG	A208803	001	Jun 12, 2017	May	NEWA
AB	APOTEX INC	10MG	A208332	001	Jun 12, 2017	May	NEWA
AB	AUROBINDO PHARMA LTD	10MG	A209838	001	Aug 25, 2017	Aug	NEWA
AB	OHM LABS INC	10MG	A207311	001	Jun 12, 2017	May	NEWA
AB	SANDOZ INC	10MG	A203931	001	Jun 12, 2017	May	NEWA
AB	TEVA PHARMS USA	10MG	A078724	001	Jun 12, 2017	May	NEWA
AB	WATSON LABS INC	10MG	A200831	001	Jun 12, 2017	May	NEWA
AB	ZYDUS PHARMS USA INC	10MG	A204331	001	Jun 12, 2017	May	NEWA

EZETIMIBE; SIMVASTATIN

## TABLET; ORAL

## EZETIMIBE AND SIMVASTATIN

AB	DR REDDYS LABS INTL	10MG;10MG	A200909	001	Apr 26, 2017	Apr	NEWA
AB		10MG;20MG	A200909	002	Apr 26, 2017	Apr	NEWA
AB		10MG;40MG	A200909	003	Apr 26, 2017	Apr	NEWA
AB		10MG;80MG	A200909	004	Apr 26, 2017	Apr	NEWA
AB	DR REDDYS LABS SA	10MG;10MG	A200909	001	Apr 26, 2017	May	CAHN
AB		10MG;20MG	A200909	002	Apr 26, 2017	May	CAHN
AB		10MG;40MG	A200909	003	Apr 26, 2017	May	CAHN
AB		10MG;80MG	A200909	004	Apr 26, 2017	May	CAHN
AB	IMPAX LABS INC	10MG;10MG	A201890	001	Apr 26, 2017	Apr	NEWA
AB		10MG;20MG	A201890	002	Apr 26, 2017	Apr	NEWA
AB		10MG;40MG	A201890	003	Apr 26, 2017	Apr	NEWA
AB		10MG;80MG	A201890	004	Apr 26, 2017	Apr	NEWA
AB	WATSON LABS INC	10MG;10MG	A202968	001	Apr 26, 2017	Apr	NEWA
AB		10MG;20MG	A202968	002	Apr 26, 2017	Apr	NEWA
AB		10MG;40MG	A202968	003	Apr 26, 2017	Apr	NEWA
AB		10MG;80MG	A202968	004	Apr 26, 2017	Apr	NEWA
	VYTORIN						
AB	+ MSD INTL	10MG;10MG	N021687	001	Jul 23, 2004	Apr	CFTG
AB	+	10MG;20MG	N021687	002	Jul 23, 2004	Apr	CFTG
AB	+	10MG;40MG	N021687	003	Jul 23, 2004	Apr	CFTG
AB	+	10MG;80MG	N021687	004	Jul 23, 2004	Apr	CFTG

FAMCICLOVIR

## TABLET; ORAL

## FAMCICLOVIR

AB	! TEVA PHARMS	500MG	A077487	003	Aug 24, 2007	Jan	CHRS
	FAMVIR						
	+ @ NOVARTIS	125MG	N020363	003	Dec 11, 1995	Jan	DISC
	+ @	250MG	N020363	001	Apr 26, 1996	Jan	DISC
	+ @	500MG	N020363	002	Jun 29, 1994	Jan	DISC

FAMOTIDINE

## INJECTABLE; INJECTION

## FAMOTIDINE

AP	ATHENEX INC	10MG/ML	A075651	001	Apr 16, 2001	Mar	CAHN
AP		10MG/ML	A075684	001	Apr 16, 2001	Mar	CAHN
	@ WEST-WARD PHARMS INT	10MG/ML	A075799	001	Apr 30, 2002	Aug	CAHN
	FAMOTIDINE PRESERVATIVE FREE						
AP	ATHENEX INC	10MG/ML	A075622	001	Apr 16, 2001	Mar	CAHN
AP		10MG/ML	A075825	001	Apr 17, 2001	Mar	CAHN
	@ WEST-WARD PHARMS INT	10MG/ML	A075789	001	Apr 30, 2002	Aug	CAHN
	TABLET; ORAL						
	FAMOTIDINE						
AB	PERRIGO R AND D	20MG	A077352	002	Jul 27, 2005	Apr	CAHN
AB		40MG	A077352	001	Jul 27, 2005	Apr	CAHN



FELBAMATE

SUSPENSION;ORAL							
FELBAMATE							
AB	TARO PHARM	600MG/5ML	A206314	001	Jun 16, 2017	Jun	NEWA
FELBATOL							
AB	+! MYLAN SPECIALITY LP	600MG/5ML	N020189	003	Jul 29, 1993	Mar	CAHN
TABLET;ORAL							
FELBAMATE							
AB	IMPAX LABS INC	400MG	A202284	001	Nov 04, 2015	Feb	CAHN
AB		600MG	A202284	002	Nov 04, 2015	Feb	CAHN
AB	TARO PHARM	400MG	A207093	001	Apr 20, 2017	Apr	NEWA
AB		600MG	A207093	002	Apr 20, 2017	Apr	NEWA
AB	ZYDUS PHARMS USA INC	400MG	A208970	001	May 30, 2017	May	NEWA
AB		600MG	A208970	002	May 30, 2017	May	NEWA
FELBATOL							
AB	+ MYLAN SPECIALITY LP	400MG	N020189	001	Jul 29, 1993	Mar	CAHN
AB	+!	600MG	N020189	002	Jul 29, 1993	Mar	CAHN

FENOFIBRATE

CAPSULE;ORAL							
FENOFIBRATE (MICRONIZED)							
AB	GLENMARK PHARMS LTD	67MG	A205566	001	Apr 07, 2017	Mar	NEWA
AB		134MG	A205566	002	Apr 07, 2017	Mar	NEWA
AB		200MG	A205566	003	Apr 07, 2017	Mar	NEWA
AB	! IMPAX LABS	200MG	A075868	003	Oct 27, 2003	Jun	CHRS
AB	INVAGEN PHARMS	67MG	A207378	001	Mar 28, 2017	Mar	NEWA
AB		134MG	A207378	002	Mar 28, 2017	Mar	NEWA
AB		200MG	A207378	003	Mar 28, 2017	Mar	NEWA
AB	RHODES PHARMS	200MG	A075753	003	Apr 09, 2002	Jun	CHRS
TABLET;ORAL							
FENOFIBRATE							
AB	! IMPAX LABS	160MG	A076509	002	Mar 26, 2008	Mar	CHRS
AB	RHODES PHARMS	160MG	A076433	002	May 13, 2005	Mar	CHRS
AB	SUN PHARM INDS LTD	48MG	A200884	001	Sep 07, 2017	Aug	NEWA
AB		145MG	A200884	002	Sep 07, 2017	Aug	NEWA
TRICOR							
	+ @ ABBVIE INC	54MG	N021203	001	Sep 04, 2001	Aug	CAHN
	+ @	160MG	N021203	003	Sep 04, 2001	Aug	CAHN

FENOLDOPAM MESYLATE

INJECTABLE;INJECTION							
FENOLDOPAM MESYLATE							
AP	SANDOZ INC	EQ 10MG BASE/ML	A077155	001	Feb 15, 2005	Mar	CAHN

FENOPROFEN CALCIUM

CAPSULE;ORAL							
NALFON							
	+! XSPIRE PHARMA	EQ 200MG BASE	N017604	003		Aug	CAHN
	@	EQ 300MG BASE	N017604	002		Aug	CAHN
	+	EQ 400MG BASE	N017604	004	Jul 21, 2009	Aug	CAHN
TABLET;ORAL							
FENOPROFEN CALCIUM							
	@ WATSON LABS TEVA	EQ 600MG BASE	A072407	001	Aug 17, 1988	May	CAHN
	! XSPIRE PHARMA	EQ 600MG BASE	A072267	001	Aug 17, 1988	Aug	CAHN

FENTANYL

FILM, EXTENDED RELEASE;TRANSDERMAL							
FENTANYL-100							
AB	3M DRUG DELIVERY	100MCG/HR	A202097	005	Nov 04, 2016	Mar	CAHN
AB	ACTAVIS LABS UT INC	100MCG/HR	A076709	004	Aug 20, 2007	Mar	CAHN
AB	MAYNE PHARMA	100MCG/HR	A077062	004	Aug 20, 2007	Mar	CAHN
FENTANYL-12							
AB	3M DRUG DELIVERY	12.5MCG/HR	A202097	001	Nov 04, 2016	Mar	CAHN
FENTANYL-25							
AB	3M DRUG DELIVERY	25MCG/HR	A202097	002	Nov 04, 2016	Mar	CAHN
AB	ACTAVIS LABS UT INC	25MCG/HR	A076709	001	Aug 20, 2007	Mar	CAHN
AB	MAYNE PHARMA	25MCG/HR	A077062	001	Aug 20, 2007	Mar	CAHN
FENTANYL-50							
AB	3M DRUG DELIVERY	50MCG/HR	A202097	003	Nov 04, 2016	Mar	CAHN
AB	ACTAVIS LABS UT INC	50MCG/HR	A076709	002	Aug 20, 2007	Mar	CAHN
AB	MAYNE PHARMA	50MCG/HR	A077062	002	Aug 20, 2007	Mar	CAHN

FILM, EXTENDED RELEASE;TRANSDERMAL  
FENTANYL-75

AB	3M DRUG DELIVERY	75MCG/HR	A202097	004	Nov 04, 2016	Mar	CAHN
AB	ACTAVIS LABS UT INC	75MCG/HR	A076709	003	Aug 20, 2007	Mar	CAHN
AB	MAYNE PHARMA	75MCG/HR	A077062	003	Aug 20, 2007	Mar	CAHN

SPRAY;SUBLINGUAL  
SUBSYS

+	INSYS DEV CO INC	0.1MG	N202788	001	Jan 04, 2012	May	CAHN
+		0.2MG	N202788	002	Jan 04, 2012	May	CAHN
+	!	0.4MG	N202788	003	Jan 04, 2012	May	CAHN
+		0.6MG	N202788	004	Jan 04, 2012	May	CAHN
+		0.8MG	N202788	005	Jan 04, 2012	May	CAHN
+		1.2MG	N202788	006	Aug 30, 2012	May	CAHN
+		1.6MG	N202788	007	Aug 30, 2012	May	CAHN

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL  
FESOTERODINE FUMARATE

AB	AUROBINDO PHARMA LTD	4MG	A205007	001	Feb 17, 2017	Feb	NEWA
AB		8MG	A205007	002	Feb 17, 2017	Feb	NEWA
>A>	AB	ZYDUS PHARMS USA INC	A204946	001	Oct 03, 2017	Sep	NEWA
>A>	AB		A204946	002	Oct 03, 2017	Sep	NEWA

FINASTERIDE

TABLET;ORAL  
FINASTERIDE

AB	ACCORD HLTHCARE	1MG	A091643	001	Nov 05, 2013	Mar	CAHN
AB	ACTAVIS TOTOWA TEVA	5MG	A077914	001	Mar 28, 2007	May	CAHN

FLUCONAZOLE

FOR SUSPENSION;ORAL  
FLUCONAZOLE

AB	AUROBINDO PHARMA LTD	50MG/5ML	A079150	001	Sep 18, 2009	Jan	CAHN
AB		200MG/5ML	A079150	002	Sep 18, 2009	Jan	CAHN

INJECTABLE;INJECTION

	DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER							
+	@	PFIZER	200MG/100ML (2MG/ML)	N019950	003	Sep 29, 1992	Mar	DISC
+	@		400MG/200ML (2MG/ML)	N019950	005	Jul 08, 1994	Mar	DISC
	DIFLUCAN IN SODIUM CHLORIDE 0.9%							
+	@	PFIZER	200MG/100ML (2MG/ML)	N019950	001	Jan 29, 1990	Mar	DISC
+	@		400MG/200ML (2MG/ML)	N019950	006	Jan 29, 1990	Mar	DISC
	DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
+	@	PFIZER	200MG/100ML (2MG/ML)	N019950	002	Jan 29, 1990	Mar	DISC
+	@		400MG/200ML (2MG/ML)	N019950	004	Jan 29, 1990	Mar	DISC
	FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER							
AP	!	HOSPIRA	200MG/100ML (2MG/ML)	A076304	001	Jul 29, 2004	Mar	CHRS
AP	!		400MG/200ML (2MG/ML)	A076304	002	Jul 29, 2004	Mar	CHRS
AP		RENAISSANCE SSA LLC	200MG/100ML (2MG/ML)	A077988	001	May 26, 2010	Aug	CAHN
AP			400MG/200ML (2MG/ML)	A077988	002	May 26, 2010	Aug	CAHN
	FLUCONAZOLE IN SODIUM CHLORIDE 0.9%							
AP		BAXTER HLTHCARE CORP	200MG/100ML (2MG/ML)	A077947	001	May 26, 2010	Aug	CAHN
AP			400MG/200ML (2MG/ML)	A077947	002	May 26, 2010	Aug	CAHN
	WEST-WARD PHARMS INT							
AP			100MG/50ML (2MG/ML)	A076087	002	Sep 26, 2008	Jan	CAHN
AP			200MG/100ML (2MG/ML)	A076087	001	Jul 29, 2004	Jan	CAHN
AP			400MG/200ML (2MG/ML)	A076087	003	Jul 29, 2004	Jan	CAHN
	FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
AP	!	ACS DOBFAR INFO SA	200MG/100ML (2MG/ML)	A079104	001	Jul 30, 2009	Mar	CHRS
AP	!		400MG/200ML (2MG/ML)	A079104	002	Jul 30, 2009	Mar	CHRS
	RENAISSANCE SSA LLC							
AP			100MG/50ML (2MG/ML)	A077909	003	Apr 20, 2015	Aug	CAHN
AP			200MG/100ML (2MG/ML)	A077909	001	May 26, 2010	Aug	CAHN
AP			400MG/200ML (2MG/ML)	A077909	002	May 26, 2010	Aug	CAHN
AP		WEST-WARD PHARMS INT	200MG/100ML (2MG/ML)	A078107	001	Jul 30, 2008	Jan	CAHN
AP			400MG/200ML (2MG/ML)	A078107	002	Jul 30, 2008	Jan	CAHN

TABLET;ORAL

	FLUCONAZOLE							
AB		UNIQUE PHARM LABS	50MG	A076957	001	Sep 28, 2005	Aug	CAHN
AB			100MG	A076957	002	Sep 28, 2005	Aug	CAHN
AB			150MG	A076957	004	Feb 27, 2017	Aug	CAHN
AB			150MG	A076957	004	Feb 27, 2017	Feb	NEWA
AB			200MG	A076957	003	Sep 28, 2005	Aug	CAHN
AB		ZYDUS PHARMS USA INC	50MG	A208963	001	Feb 16, 2017	Feb	NEWA
AB			100MG	A208963	002	Feb 16, 2017	Feb	NEWA

TABLET;ORAL  
FLUCONAZOLE

AB		150MG	A208963	003	Feb 16, 2017	Feb	NEWA
AB		200MG	A208963	004	Feb 16, 2017	Feb	NEWA

FLUCYDOSINE

CAPSULE;ORAL  
FLUCYDOSINE

AB	NOVEL LABS INC	250MG	A204652	001	Jul 07, 2017	Jun	NEWA
AB		500MG	A204652	002	Jul 07, 2017	Jun	NEWA

FLUDARABINE PHOSPHATE

INJECTABLE;INJECTION  
FLUDARABINE PHOSPHATE

AP	ACTAVIS LLC	50MG/2ML (25MG/ML)	A203738	001	Feb 28, 2017	Feb	NEWA
----	-------------	--------------------	---------	-----	--------------	-----	------

FLUDEOXYGLUCOSE F-18

INJECTABLE;INTRAVENOUS  
FLUDEOXYGLUCOSE F18

>A>	AP	JUBILANT DRAXIMAGE	20-300mCi/ML	A203920	001	Jun 23, 2015	Sep	CAHN
>D>	AP	TRIAD ISOTOPES INC	20-300mCi/ML	A203920	001	Jun 23, 2015	Sep	CAHN

FLUMAZENIL

INJECTABLE;INJECTION  
FLUMAZENIL

	@	BAXTER HLTHCARE CORP	0.5MG/5ML (0.1MG/ML)	A076755	002	Oct 12, 2004	Aug	CAHN
	@		1MG/10ML (0.1MG/ML)	A076755	001	Oct 12, 2004	Aug	CAHN
AP		SANDOZ INC	0.5MG/5ML (0.1MG/ML)	A077071	001	May 03, 2005	Apr	CAHN
AP			1MG/10ML (0.1MG/ML)	A077071	002	May 03, 2005	Apr	CAHN
AP		WEST-WARD PHARMS INT	0.5MG/5ML (0.1MG/ML)	A076256	002	Oct 12, 2004	Jan	CAHN
AP			0.5MG/5ML (0.1MG/ML)	A076787	002	Oct 12, 2004	Jan	CAHN
AP			1MG/10ML (0.1MG/ML)	A076256	001	Oct 12, 2004	Jan	CAHN
AP			1MG/10ML (0.1MG/ML)	A076787	001	Oct 12, 2004	Jan	CAHN

FLUNISOLIDE

AEROSOL, METERED;INHALATION  
AEROSPAN HFA

	+	MYLAN SPECIALITY LP	0.078MG/INH	N021247	001	Jan 27, 2006	Mar	CAHN
--	---	---------------------	-------------	---------	-----	--------------	-----	------

FLUOCINOLONE ACETONIDE

CREAM;TOPICAL  
FLUOCINOLONE ACETONIDE

AT		FOUGERA PHARMS INC	0.01%	A088170	001	Dec 16, 1982	Jan	CAHN
AT			0.025%	A088169	001	Dec 16, 1982	Jan	CAHN
	@	TARO	0.01%	A040035	001	Oct 31, 1994	Apr	CAHN
	@		0.025%	A040042	001	Oct 31, 1994	Apr	CAHN

OIL/DROPS;OTIC  
FLUOCINOLONE ACETONIDE

AT		PERRIGO ISRAEL	0.01%	A202849	001	Jul 17, 2017	Jul	NEWA
----	--	----------------	-------	---------	-----	--------------	-----	------

OINTMENT;TOPICAL  
FLUOCINOLONE ACETONIDE

AT		FOUGERA PHARMS INC	0.025%	A088168	001	Dec 16, 1982	Jan	CAHN
AT		TARO	0.025%	A040041	001	Sep 15, 1994	Apr	CAHN

SOLUTION;TOPICAL  
FLUOCINOLONE ACETONIDE

AT		FOUGERA PHARMS INC	0.01%	A088167	001	Dec 16, 1982	Jan	CAHN
----	--	--------------------	-------	---------	-----	--------------	-----	------

FLUOCINONIDE

CREAM;TOPICAL  
FLUOCINONIDE

AB1		FOUGERA PHARMS INC	0.05%	A073030	001	Oct 17, 1994	Jan	CAHN
AB		PERRIGO ISRAEL	0.1%	A090256	001	Jan 14, 2014	Apr	CAHN
AB1		TARO	0.05%	A071500	001	Jun 10, 1987	Mar	CMFD
		FLUOCINONIDE EMULSIFIED BASE						
AB2		G AND W LABS INC	0.05%	A074204	001	Jun 13, 1995	May	CMFD

GEL;TOPICAL  
FLUOCINONIDE

AB		FOUGERA PHARMS INC	0.05%	A072933	001	Dec 30, 1994	Jan	CAHN
AB	!	TARO	0.05%	A074935	001	Jul 29, 1997	Apr	CAHN

## OINTMENT;TOPICAL

	FLUOCINONIDE						
AB	NOVEL LABS INC	0.05%	A207538	001	Jul 31, 2017	Jul	NEWA
AB	! TARO	0.05%	A075008	001	Jun 30, 1999	Apr	CAHN

## SOLUTION;TOPICAL

	FLUOCINONIDE						
AT	NOVEL LABS INC	0.05%	A206003	001	Jul 21, 2017	Jul	NEWA
AT	! TARO	0.05%	A074799	001	Dec 31, 1996	Apr	CAHN
	LIDEX						
AT	+ CNTY LINE PHARMS	0.05%	N018849	001	Apr 06, 1984	Mar	CRLD

FLUOROURACIL

## CREAM;TOPICAL

	FLUOROURACIL						
AB	MYLAN PHARMS INC	0.5%	A203122	001	Apr 20, 2015	Jun	CAHN

## INJECTABLE;INJECTION

	FLUOROURACIL						
AP	SAGENT PHARMS	500MG/10ML (50MG/ML)	A203608	001	May 11, 2017	May	NEWA
AP		1GM/20ML (50MG/ML)	A203608	002	May 11, 2017	May	NEWA
	@ SANDOZ	2.5GM/50ML (50MG/ML)	A091299	001	May 02, 2011	Jul	DISC
	@	5GM/100ML (50MG/ML)	A091299	002	May 02, 2011	Jul	DISC
	+ @ SPECTRUM PHARMS	500MG/10ML (50MG/ML)	N012209	001		Jan	CRLD
	+ @	2.5GM/50ML (50MG/ML)	N012209	002	Jul 29, 2016	Aug	DISC

## SOLUTION;TOPICAL

	FLUOROURACIL						
AT	TARO PHARM	2%	A076526	001	Nov 05, 2003	Mar	CAHN
AT		5%	A076526	002	Nov 05, 2003	Mar	CAHN

FLUOXETINE HYDROCHLORIDE

## CAPSULE;ORAL

	FLUOXETINE HYDROCHLORIDE						
	@ MYLAN	EQ 10MG BASE	A075207	001	Jan 30, 2002	Jun	DISC
	@	EQ 20MG BASE	A075207	002	Jan 30, 2002	Jun	DISC
	@	EQ 40MG BASE	A075207	003	May 25, 2007	Jun	DISC

## SOLUTION;ORAL

	FLUOXETINE HYDROCHLORIDE						
AA	AUROBINDO PHARMA LTD	EQ 20MG BASE/5ML	A079209	001	Mar 20, 2009	Jan	CAHN
AA	! PHARM ASSOC	EQ 20MG BASE/5ML	A076015	001	Jan 30, 2002	May	CAHN

## TABLET;ORAL

	FLUOXETINE HYDROCHLORIDE						
AB	ALEMBIC PHARMS LTD	EQ 10MG BASE	A208698	001	Apr 05, 2017	Mar	NEWA
AB		EQ 20MG BASE	A208698	002	Apr 05, 2017	Mar	NEWA
	+! ALVOGEN	EQ 60MG BASE	N202133	001	Oct 06, 2011	Jan	CAHN

FLUOXYMESTERONE

## TABLET;ORAL

	FLUOXYMESTERONE						
	! USL PHARMA	10MG	A088342	001	Oct 21, 1983	Jun	CAHN

FLUPHENAZINE HYDROCHLORIDE

## CONCENTRATE;ORAL

	FLUPHENAZINE HYDROCHLORIDE						
	@ ANI PHARMS INC	5MG/ML	A073058	001	Aug 30, 1991	Jan	CAHN
	! PHARM ASSOC	5MG/ML	A074725	001	Sep 16, 1996	May	CAHN

## ELIXIR;ORAL

	FLUPHENAZINE HYDROCHLORIDE						
	! PHARM ASSOC	2.5MG/5ML	A040146	001	Aug 21, 1996	May	CAHN
>D>	PROLIXIN						
>D>	@ APOTHECON	2.5MG/5ML	N012145	003		Sep	DISC
>A>	+ @	2.5MG/5ML	N012145	003		Sep	DISC

FLURANDRENOLIDE

## CREAM;TOPICAL

	FLURANDRENOLIDE						
AT	CINTEX SVCS	0.05%	A205342	001	Apr 13, 2016	Jun	CAHN

## LOTION;TOPICAL

	FLURANDRENOLIDE						
AT	CINTEX SVCS	0.05%	A205343	001	Dec 22, 2016	Jun	CAHN

FLURAZEPAM HYDROCHLORIDE

CAPSULE;ORAL

FLURAZEPAM HYDROCHLORIDE

@ AUROLIFE PHARMA LLC	15MG	A071717	002	Jul 31, 1991	Jan CMS1
-----------------------	------	---------	-----	--------------	----------

FLUTAMIDE

CAPSULE;ORAL

EULEXIN

>D>	@ SCHERING	125MG	N018554	001	Jan 27, 1989	Sep CRLD
>A>	+ @	125MG	N018554	001	Jan 27, 1989	Sep CRLD
	FLUTAMIDE					
	@ MYLAN	125MG	A076224	001	May 09, 2003	Jun DISC

FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE

&gt;A&gt; POWDER; INHALATION

&gt;A&gt; TRELEGY ELLIPTA

>A>	+!	GLAXOSMITHKLINE	0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH	N209482	001	Sep 18, 2017	Sep NEWA
-----	----	-----------------	--	---------	-----	--------------	----------

FLUTICASONE PROPIONATE

POWDER; INHALATION

ARMONAIR RESPICLICK

+	TEVA PHARM	0.055MG/INH	N208798	001	Jan 27, 2017	Jan NEWA
+		0.113MG/INH	N208798	002	Jan 27, 2017	Jan NEWA
+!		0.232MG/INH	N208798	003	Jan 27, 2017	Jan NEWA

SPRAY, METERED;NASAL

FLONASE

+	@ GLAXOSMITHKLINE	0.05MG/SPRAY	N020121	001	Oct 19, 1994	Jul CRLD	
AB	!	WEST-WARD PHARMS INT	0.05MG/SPRAY	A076504	001	Feb 22, 2006	Jul CHRS
>A>		XHANCE					
>A>	+!	OPTNOSE US	0.093MG	N209022	001	Sep 18, 2017	Sep NEWA

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

POWDER; INHALATION

AIRDUO RESPICLICK

+	TEVA PHARM	0.055MG/INH;EQ 0.014MG BASE/INH	N208799	001	Jan 27, 2017	Jan NEWA
+		0.113MG/INH;EQ 0.014MG BASE/INH	N208799	002	Jan 27, 2017	Jan NEWA
+!		0.232MG/INH;EQ 0.014MG BASE/INH	N208799	003	Jan 27, 2017	Jan NEWA

FLUVASTATIN SODIUM

CAPSULE;ORAL

FLUVASTATIN SODIUM

AB	!	MYLAN PHARMS INC	EQ 40MG BASE	A090595	002	Apr 11, 2012	May CHRS
		LESCOL					
	+	@ NOVARTIS	EQ 20MG BASE	N020261	001	Dec 31, 1993	May DISC
	+	@	EQ 40MG BASE	N020261	002	Dec 31, 1993	May DISC

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE;ORAL

FLUVOXAMINE MALEATE

AB	!	ACTAVIS ELIZABETH	150MG	A091482	002	Nov 18, 2013	Apr CHRS
		LUVOX CR					
	+	@ JAZZ PHARMS	100MG	N022033	001	Feb 28, 2008	Apr DISC
	+	@	150MG	N022033	002	Feb 28, 2008	Apr DISC

TABLET;ORAL

FLUVOXAMINE MALEATE

		@ ECI PHARMS LLC	25MG	A075900	001	Feb 23, 2006	May CAHN
		@	50MG	A075900	002	Feb 23, 2006	May CAHN
		@	100MG	A075900	003	Feb 23, 2006	May CAHN
		@ UPSHER-SMITH LABS	25MG	A075887	001	Jan 05, 2001	Jun CAHN
AB		@	25MG	A075888	001	Nov 29, 2000	Jun CAHN
		@	50MG	A075887	002	Jan 05, 2001	Jun CAHN
AB		@	50MG	A075888	002	Nov 29, 2000	Jun CAHN
		@	100MG	A075887	003	Jan 05, 2001	Jun CAHN
AB	!		100MG	A075888	003	Nov 29, 2000	Jun CAHN

FOLIC ACID

TABLET; ORAL  
FOLIC ACID

@ CONTRACT PHARMACAL 1MG A085061 001 Mar DISC

FORMOTEROL FUMARATE

POWDER; INHALATION  
FORADIL

+ @ NOVARTIS 0.012MG/INH N020831 001 Feb 16, 2001 Feb DISC

FORMOTEROL FUMARATE; GLYCOPYRROLATE

AEROSOL, METERED; INHALATION  
BEVESPI AEROSPHERE

+! ASTRAZENECA PHARMS 0.0048MG/INH;0.0090MG/INH N208294 001 Apr 25, 2016 Mar CAHN

FOSCARNET SODIUM

INJECTABLE; INJECTION  
FOSCARNET SODIUM

>D> HOSPIRA 2.4GM/100ML A077174 001 May 31, 2005 Sep DISC

>D> AP @ 2.4GM/100ML A077174 001 May 31, 2005 Sep DISC

>A> FOSCAVIR

>D> AP +! CLINIGEN HLTHCARE 2.4GM/100ML N020068 001 Sep 27, 1991 Sep CTEC

>A> +! 2.4GM/100ML N020068 001 Sep 27, 1991 Sep CTEC

FOSINOPRIL SODIUM

TABLET; ORAL  
FOSINOPRIL SODIUM

AB @ UPSHER-SMITH LABS 10MG A076188 001 Oct 08, 2004 Jun CAHN

AB @ 10MG A076483 001 Apr 23, 2004 Jun CAHN

AB @ 20MG A076188 002 Oct 08, 2004 Jun CAHN

AB @ 20MG A076483 002 Apr 23, 2004 Jun CAHN

AB @ 40MG A076188 003 Oct 08, 2004 Jun CAHN

AB @ 40MG A076483 003 Apr 23, 2004 Jun CAHN

MONOPRIL

+ @ BRISTOL MYERS SQUIBB 10MG N019915 002 May 16, 1991 Jan CRLD

+ @ 20MG N019915 003 May 16, 1991 Jan CRLD

+ @ 40MG N019915 004 Mar 28, 1995 Jan CRLD

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION  
FOSPHENYTOIN SODIUM

AP FRESENIUS KABI USA EQ 50MG PHENYTOIN NA/ML A078052 001 Aug 06, 2007 Jun CMFD

AP @ HOSPIRA EQ 50MG PHENYTOIN NA/ML A078158 001 Aug 06, 2007 Mar DISC

AP WEST-WARD PHARMS INT EQ 50MG PHENYTOIN NA/ML A077481 001 Aug 06, 2007 Jan CAHN

AP EQ 50MG PHENYTOIN NA/ML A077989 001 Aug 06, 2007 Jan CAHN

FUROSEMIDE

INJECTABLE; INJECTION  
FUROSEMIDE

AP @ ACCORD HLTHCARE 10MG/ML A070017 001 Dec 15, 1986 Jun CAHN

AP BAXTER HLTHCARE CORP 10MG/ML A202747 001 Jan 27, 2014 Aug CAHN

TABLET; ORAL

FUROSEMIDE

AB IPCA LABS LTD 20MG A078010 001 Sep 18, 2006 Aug CTEC

BX 20MG A078010 001 Sep 18, 2006 Apr CTEC

AB 40MG A078010 002 Sep 18, 2006 Aug CTEC

BX 40MG A078010 002 Sep 18, 2006 Apr CTEC

AB 80MG A078010 003 Sep 18, 2006 Aug CTEC

BX 80MG A078010 003 Sep 18, 2006 Apr CTEC

AB PRINSTON INC 20MG A076796 001 Mar 26, 2004 Feb CAHN

AB 40MG A076796 002 Mar 26, 2004 Feb CAHN

AB 80MG A076796 003 Mar 26, 2004 Feb CAHN

@ SUN PHARM INDS INC 20MG A091258 001 Apr 01, 2014 May DISC

@ 40MG A091258 002 Apr 01, 2014 May DISC

@ 80MG A091258 003 Apr 01, 2014 May DISC

@ WATSON LABS TEVA 20MG A070449 001 Nov 22, 1985 May CAHN

@ 80MG A070528 001 Jan 07, 1986 May CAHN

AB WEST-WARD PHARMS INT 20MG N018823 001 Nov 10, 1983 Jan CAHN

AB 40MG N018823 002 Nov 10, 1983 Jan CAHN

GABAPENTIN

CAPSULE;ORAL

GABAPENTIN

AB	AUROBINDO PHARMA LTD	100MG	A078787	001	Jan 31, 2008	Jan	CAHN
AB		300MG	A078787	002	Jan 31, 2008	Jan	CAHN
AB		400MG	A078787	003	Jan 31, 2008	Jan	CAHN
AB	EPIC PHARMA LLC	100MG	A207099	001	Mar 24, 2017	Mar	NEWA
AB		300MG	A207099	002	Mar 24, 2017	Mar	NEWA
AB		400MG	A207099	003	Mar 24, 2017	Mar	NEWA

TABLET;ORAL

GABAPENTIN

AB	GLENMARK PHARMS LTD	600MG	A077662	001	Aug 18, 2006	May	CAHN
AB		800MG	A077662	002	Aug 18, 2006	May	CAHN
AB	TEVA PHARMS USA	600MG	A205807	001	Mar 10, 2017	Feb	NEWA
AB		800MG	A205807	002	Mar 10, 2017	Feb	NEWA

GADOTERATE MEGLUMINE

SOLUTION;INTRAVENOUS

DOTAREM

>D>	+!	GUERBET	1.884GM/5ML (376.9MG/ML)	N204781	005	Mar 31, 2017	Sep	CMS1
>A>	+!		1.8845GM/5ML (376.9MG/ML)	N204781	005	Mar 31, 2017	Sep	CMS1
	+!		1.884GM/5ML (376.9MG/ML)	N204781	005	Mar 31, 2017	Aug	NEWA

GALANTAMINE HYDROBROMIDE

TABLET;ORAL

GALANTAMINE HYDROBROMIDE

AB	YABAO PHARM	EQ 4MG BASE	A077604	001	Feb 06, 2009	Jul	CMFD
AB		EQ 8MG BASE	A077604	002	Feb 06, 2009	Jul	CMFD
AB		EQ 12MG BASE	A077604	003	Feb 06, 2009	Jul	CMFD

GANCICLOVIR

SOLUTION;IV (INFUSION)

GANCICLOVIR

+!	EXELA PHARMA SCS LLC	500MG/250ML (2MG/ML)	N209347	001	Feb 17, 2017	Feb	NEWA
----	----------------------	----------------------	---------	-----	--------------	-----	------

GATIFLOXACIN

SOLUTION/DROPS;OPHTHALMIC

GATIFLOXACIN

AT	SANDOZ INC	0.5%	A204227	001	Jul 11, 2016	Feb	CAHN
----	------------	------	---------	-----	--------------	-----	------

GEMCITABINE HYDROCHLORIDE

INJECTABLE;INJECTION

GEMCITABINE HYDROCHLORIDE

AP	APOTEX INC	200MG/5.26ML (38MG/ML)	A206776	001	May 23, 2017	May	NEWA
AP		1GM/26.3ML (38MG/ML)	A206776	002	May 23, 2017	May	NEWA
AP		2GM/52.6ML (38MG/ML)	A206776	003	May 23, 2017	May	NEWA

SOLUTION;IV (INFUSION)

GEMCITABINE HYDROCHLORIDE

+!	ACCORD HLTHCARE	1GM/10ML (100MG/ML)	N209604	002	Aug 03, 2017	Aug	NEWA
+!		1.5GM/15ML (100MG/ML)	N209604	003	Aug 03, 2017	Aug	NEWA
+!		2GM/20ML (100MG/ML)	N209604	004	Aug 03, 2017	Aug	NEWA
+!		200MG/2ML (100MG/ML)	N209604	001	Aug 03, 2017	Aug	NEWA

GEMFIBROZIL

TABLET;ORAL

GEMFIBROZIL

AB	CARIBE HOLDINGS	600MG	A078012	001	Mar 26, 2007	Jan	CAHN
----	-----------------	-------	---------	-----	--------------	-----	------

GEMIFLOXACIN MESYLATE

TABLET;ORAL

FACTIVE

AB	+!	LG CHEM LTD	EQ 320MG BASE	N021158	001	Apr 04, 2003	Mar	CAHN
----	----	-------------	---------------	---------	-----	--------------	-----	------

GENTAMICIN SULFATE

CREAM;TOPICAL

GENTAMICIN SULFATE

AT	!	FOUGERA PHARMS INC	EQ 0.1% BASE	A062531	001	Jul 05, 1984	Jan	DISC
		PERRIGO NEW YORK	EQ 0.1% BASE	A062307	001		Jan	CHRS
		TARO	EQ 0.1% BASE	A062427	001	May 26, 1983	Jan	DISC

OINTMENT;TOPICAL

	GENTAMICIN SULFATE						
AT	FOUGERA PHARMS INC	EQ 0.1% BASE	A062533	001	Oct 05, 1984	Jan	CAHN
	SOLUTION/DROPS;OPHTHALMIC						
	GENTAMICIN SULFATE						
AT	SANDOZ INC	EQ 0.3% BASE	A062196	001		Mar	CAHN

GLATIRAMER ACETATE

	INJECTABLE;SUBCUTANEOUS						
	COPAXONE						
>D>	+!	TEVA PHARMS USA	40MG/ML	N020622	003	Jan 28, 2014	Sep CFTG
>A>	AP	+!	40MG/ML	N020622	003	Jan 28, 2014	Sep CFTG
>A>		GLATIRAMER ACETATE					
>A>	AP	MYLAN PHARMS INC	20MG/ML	A091646	001	Oct 03, 2017	Sep NEWA
>A>	AP		40MG/ML	A206936	001	Oct 03, 2017	Sep NEWA

GLECAPREVIR; PIBRENTASVIR

	TABLET;ORAL						
	MAVYRET						
	+!	ABBVIE INC	100MG;40MG	N209394	001	Aug 03, 2017	Aug NEWA

GLIMEPIRIDE

	TABLET;ORAL						
	GLIMEPIRIDE						
	@	EPIC PHARMA LLC	1MG	A077274	001	Oct 06, 2005	May CAHN
	@		2MG	A077274	002	Oct 06, 2005	May CAHN
	@		4MG	A077274	003	Oct 06, 2005	May CAHN
AB		PRINSTON INC	1MG	A077370	001	Dec 23, 2005	Feb CAHN
AB			2MG	A077370	002	Dec 23, 2005	Feb CAHN
AB			4MG	A077370	003	Dec 23, 2005	Feb CAHN
AB			8MG	A077370	004	Dec 23, 2005	Feb CAHN

GLIPIZIDE

	TABLET;ORAL						
	GLIPIZIDE						
AB		WATSON LABS TEVA	5MG	A074223	001	Feb 27, 1995	May CAHN
AB			10MG	A074223	002	Feb 27, 1995	May CAHN
	TABLET, EXTENDED RELEASE;ORAL						
	GLIPIZIDE						
AB		AUROBINDO PHARMA LTD	2.5MG	A206928	001	May 12, 2017	May NEWA
AB			5MG	A206928	002	May 12, 2017	May NEWA
AB			10MG	A206928	003	May 12, 2017	May NEWA

GLIPIZIDE; METFORMIN HYDROCHLORIDE

	TABLET;ORAL						
	GLIPIZIDE AND METFORMIN HYDROCHLORIDE						
AB		EPIC PHARMA LLC	2.5MG;250MG	A077507	001	Oct 27, 2005	May CAHN
AB			2.5MG;500MG	A077507	002	Oct 27, 2005	May CAHN
AB			5MG;500MG	A077507	003	Oct 27, 2005	May CAHN
	METAGLIP						
	+ @	BRISTOL MYERS SQUIBB	2.5MG;250MG	N021460	001	Oct 21, 2002	Jan CRLD
	+ @		2.5MG;500MG	N021460	002	Oct 21, 2002	Jan CRLD
	+ @		5MG;500MG	N021460	003	Oct 21, 2002	Jan CRLD

GLUTETHIMIDE

	TABLET;ORAL						
	GLUTETHIMIDE						
	@	UPSHER-SMITH LABS	500MG	A083234	002		Jun CAHN

GLYBURIDE

	TABLET;ORAL						
	GLYBURIDE						
AB1		EPIC PHARMA LLC	1.25MG	A076257	001	Jun 27, 2002	May CAHN
AB1			2.5MG	A076257	002	Jun 27, 2002	May CAHN
AB1			5MG	A076257	003	Jun 27, 2002	May CAHN
AB2		IMPAX LABS INC	1.25MG	A206079	001	Sep 30, 2015	Feb CAHN
AB2			2.5MG	A206079	002	Sep 30, 2015	Feb CAHN
AB2			5MG	A206079	003	Sep 30, 2015	Feb CAHN



GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL		GLUCOVANCE							
	+ @	BRISTOL MYERS SQUIBB	2.5MG; 500MG	N021178	002	Jul 31, 2000	Aug	DISC	
	+ @		5MG; 500MG	N021178	003	Jul 31, 2000	Aug	DISC	
		GLYBURIDE AND METFORMIN HYDROCHLORIDE							
AB	!	AUROBINDO PHARMA	2.5MG; 500MG	A077870	002	Nov 14, 2007	Aug	CHRS	
	@	IMPAX LABS INC	1.25MG; 250MG	A076731	001	Nov 19, 2004	Feb	CAHN	
	@		2.5MG; 500MG	A076731	002	Nov 19, 2004	Feb	CAHN	
	@		5MG; 500MG	A076731	003	Nov 19, 2004	Feb	CAHN	

GLYCINE

SOLUTION; IRRIGATION		GLYCINE 1.5% IN PLASTIC CONTAINER							
AT		ICU MEDICAL INC	1.5GM/100ML	N018315	001		Feb	CAHN	

GLYCOPYRROLATE

INJECTABLE; INJECTION		GLYCOPYRROLATE							
AP		AMNEAL PHARMS CO	0.2MG/ML	A208973	001	Jun 15, 2017	Jun	NEWA	
AP		SOMERSET THERAPS LLC	0.2MG/ML	A207639	001	Jun 23, 2017	Jun	NEWA	
POWDER; INHALATION		SEEBRI							
	+!	SUNOVION PHARMS INC	15.6MCG/INH	N207923	001	Oct 29, 2015	Jan	CAHN	
TABLET; ORAL		GLYCOPYRROLATE							
	@	EPIC PHARMA LLC	1MG	A040568	001	Dec 22, 2004	May	CAHN	
	@		2MG	A040568	002	Dec 22, 2004	May	CAHN	
AA		SANTOS BIOTECH	1MG	A091182	001	Feb 03, 2014	May	CAHN	
AA			2MG	A091182	002	Feb 03, 2014	May	CAHN	

GLYCOPYRROLATE ; INDACATEROL MALEATE

POWDER; INHALATION		UTIBRON							
	+!	SUNOVION PHARMS INC	15.6MCG/INH; 27.5MCG/INH	N207930	001	Oct 29, 2015	Jan	CAHN	

GONADORELIN HYDROCHLORIDE

INJECTABLE; INJECTION		FACTREL							
	@	WEST-WARD PHARMS INT	EQ 0.1MG BASE/VIAL	N018123	001	Sep 30, 1982	Mar	CAHN	
	@		EQ 0.2MG BASE/VIAL	N018123	002	Sep 30, 1982	Mar	CAHN	
	@		EQ 0.5MG BASE/VIAL	N018123	003	Sep 30, 1982	Mar	CAHN	

GONADOTROPIN, CHORIONIC

INJECTABLE; INJECTION		CHORIONIC GONADOTROPIN							
	+!	FERRING	5,000 UNITS/VIAL	N017016	006		Jan	CMFD	

GOSERELIN ACETATE

IMPLANT; IMPLANTATION		ZOLADEX							
	+!	TERSERA THERAPS LLC	EQ 3.6MG BASE	N019726	001	Dec 29, 1989	May	CAHN	
	+!		EQ 10.8MG BASE	N020578	001	Jan 11, 1996	May	CAHN	

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC		NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN							
AT		AMRING PHARMS	0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML	A065187	001	Oct 28, 2005	Mar	CAHN	
		NEOSPORIN							
AT	!	MONARCH PHARMS	0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML	A060582	001		Apr	CAHN	

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION		GRANISETRON HYDROCHLORIDE							
	@	BAXTER HLTHCARE CORP	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078197	001	Dec 31, 2007	Aug	CAHN	
	@		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078198	001	Jun 30, 2008	Aug	CAHN	
	@		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078198	002	Jun 30, 2008	Aug	CAHN	
AP		MYLAN LABS LTD	EQ 0.1MG BASE/ML (EQ 0.1MG	A203454	001	Apr 04, 2017	Mar	NEWA	

## INJECTABLE; INJECTION

## GRANISETRON HYDROCHLORIDE

		BASE/ML)				
AP		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A 203454	002	Apr 04, 2017	Mar NEWA
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A 203453	001	Jan 31, 2017	Jan NEWA
AP	SANDOZ INC	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A 078534	001	Apr 30, 2009	Mar CAHN
AP		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A 078531	001	Apr 30, 2009	Mar CAHN
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A 078531	002	Apr 30, 2009	Mar CAHN
AP	WEST-WARD PHARMS INT	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A 077913	001	Jun 26, 2008	Jan CAHN
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A 077186	001	Jun 30, 2008	Jan CAHN
AP		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A 077187	001	Jun 30, 2008	Jan CAHN
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A 077177	001	Dec 31, 2007	Jan CAHN

## TABLET; ORAL

## GRANISETRON HYDROCHLORIDE

	@ EPIC PHARMA LLC	EQ 1MG BASE	A 078260	001	Dec 31, 2007	May CAHN
AB	TARO PHARM	EQ 1MG BASE	A 090817	001	May 28, 2010	Mar CAHN

GRISEOFULVIN, MICROCRYSTALLINE

## TABLET; ORAL

## FULVICIN-U/F

>A>	@ CHARTWELL RX	250MG	A 060569	002		Sep CAHN
>A>	@	500MG	A 060569	001		Sep CAHN
>D>	@ ELORAC	250MG	A 060569	002		Sep CAHN
>D>	@	500MG	A 060569	001		Sep CAHN

GRISEOFULVIN, MICROSIZE

## SUSPENSION; ORAL

## GRISEOFULVIN

AB	CHARTWELL RX	125MG/5ML	A 065200	001	Mar 02, 2005	Jun CAHN
----	--------------	-----------	----------	-----	--------------	----------

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

## TABLET; ORAL

## FULVICIN P/G

>A>	@ CHARTWELL RX	125MG	A 061996	001		Sep CAHN
>A>	@	250MG	A 061996	002		Sep CAHN
>D>	@ ELORAC	125MG	A 061996	001		Sep CAHN
>D>	@	250MG	A 061996	002		Sep CAHN
FULVICIN P/G 165						
>A>	@ CHARTWELL RX	165MG	A 061996	003	Apr 06, 1982	Sep CAHN
>D>	@ ELORAC	165MG	A 061996	003	Apr 06, 1982	Sep CAHN
FULVICIN P/G 330						
>A>	@ CHARTWELL RX	330MG	A 061996	004	Apr 06, 1982	Sep CAHN
>D>	@ ELORAC	330MG	A 061996	004	Apr 06, 1982	Sep CAHN

GRISEOFULVIN, ULTRAMICROSIZED

## TABLET; ORAL

## GRISEOFULVIN, ULTRAMICROSIZED

>A>	AB	IMPAX LABS INC	125MG	A 204371	001	Jan 09, 2014	Sep CAHN
>A>	AB		250MG	A 204371	002	Jan 09, 2014	Sep CAHN
>D>	AB	RICONPHARMA LLC	125MG	A 204371	001	Jan 09, 2014	Sep CAHN
>D>	AB		250MG	A 204371	002	Jan 09, 2014	Sep CAHN

GUAIFENESIN; HYDROCODONE BITARTRATE

## SOLUTION; ORAL

## OBREDON

+	@ SOVEREIGN PHARMS	200MG/5ML; 2.5MG/5ML	N 205474	001	Nov 14, 2014	Aug DISC
---	--------------------	----------------------	----------	-----	--------------	----------

HALCINONIDE

## CREAM; TOPICAL

## HALOG-E

	@ SUN PHARM INDS INC	0.1%	N 018234	001		Aug CAHN
--	----------------------	------	----------	-----	--	----------

## OINTMENT; TOPICAL

## HALOG

+	! SUN PHARM INDS INC	0.1%	N 017824	001		Aug CAHN
---	----------------------	------	----------	-----	--	----------

## SOLUTION; TOPICAL

## HALOG

	@ SUN PHARM INDS INC	0.1%	N 017823	001		Aug CAHN
--	----------------------	------	----------	-----	--	----------

HALOBETASOL PROPIONATE

CREAM; TOPICAL		HALOBETASOL PROPIONATE					
AB	! G AND W LABS	0.05%	A078162	001	Apr 24, 2007	Apr	CHRS
ULTRAVATE							
AB	+ SUN PHARM INDS LTD	0.05%	N019967	001	Dec 27, 1990	Apr	CHRS
AB	+!	0.05%	N019967	001	Dec 27, 1990	Mar	CAHN
OINTMENT; TOPICAL		HALOBETASOL PROPIONATE					
AB	! G AND W LABS	0.05%	A077721	001	Sep 07, 2006	Jun	CHRS
AB	PERRIGO ISRAEL	0.05%	A076872	001	Dec 16, 2004	Apr	CAHN
ULTRAVATE							
AB	+ RANBAXY	0.05%	N019968	001	Dec 17, 1990	Jun	CHRS

HALOPERIDOL

TABLET; ORAL		HALOPERIDOL					
>A>	@ ANDA REPOSITORY	0.5MG	A071156	001	Jan 02, 1987	Sep	CAHN
>A>	@	1MG	A071157	001	Jan 02, 1987	Sep	CAHN
>A>	@	2MG	A071172	001	Jan 02, 1987	Sep	CAHN
>A>	@	5MG	A071212	001	Jan 07, 1988	Sep	CAHN
>A>	@	10MG	A071173	001	Jan 07, 1988	Sep	CAHN
>A>	@	20MG	A071177	001	Jan 07, 1988	Sep	CAHN
>D>	@ FRONTIDA BIOPHARM	0.5MG	A071156	001	Jan 02, 1987	Sep	CAHN
>D>	@	1MG	A071157	001	Jan 02, 1987	Sep	CAHN
>D>	@	2MG	A071172	001	Jan 02, 1987	Sep	CAHN
>D>	@	5MG	A071212	001	Jan 07, 1988	Sep	CAHN
>D>	@	10MG	A071173	001	Jan 07, 1988	Sep	CAHN
>D>	@	20MG	A071177	001	Jan 07, 1988	Sep	CAHN
>D>	@	20MG	A071177	001	Jan 07, 1988	Feb	CAHN

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION		HALOPERIDOL DECANOATE					
AO	GLAND PHARMA LTD	EQ 50MG BASE/ML	A205241	001	May 12, 2017	May	NEWA
AO		EQ 100MG BASE/ML	A205241	002	May 12, 2017	May	NEWA
	@ SANDOZ INC	EQ 50MG BASE/ML	A076463	001	Jun 24, 2005	Mar	CAHN
	@	EQ 100MG BASE/ML	A076463	002	Jun 24, 2005	Mar	CAHN

HALOPERIDOL LACTATE

CONCENTRATE; ORAL		HALOPERIDOL					
AA	PHARM ASSOC	EQ 2MG BASE/ML	A073037	001	Feb 26, 1993	May	CAHN
INJECTABLE; INJECTION		HALOPERIDOL					
AP	AKORN	EQ 5MG BASE/ML	A204849	001	Sep 06, 2017	Aug	NEWA
	@ BAXTER HLTHCARE CORP	EQ 5MG BASE/ML	A076791	001	Aug 25, 2004	Aug	CAHN
	@	EQ 5MG BASE/ML	A076828	001	Aug 25, 2004	Aug	CAHN
	@ SANDOZ INC	EQ 5MG BASE/ML	A076464	001	Sep 29, 2004	Mar	CAHN

HEPARIN SODIUM

INJECTABLE; INJECTION		HEPARIN SODIUM					
AP	GLAND PHARMA LTD	5,000 UNITS/ML	A205323	001	Feb 06, 2017	Jan	NEWA
	@ WEST-WARD PHARMS INT	1,000 UNITS/ML	N017007	001		Jul	CAHN
	@	2,500 UNITS/ML	N017007	007		Jul	CAHN
	@	5,000 UNITS/ML	N017007	002		Jul	CAHN
	@	5,000 UNITS/0.5ML	N017007	010		Jul	CAHN
	@	7,500 UNITS/ML	N017007	003		Jul	CAHN
	@	10,000 UNITS/ML	N017007	004		Jul	CAHN
	@	15,000 UNITS/ML	N017007	005		Jul	CAHN
	@	20,000 UNITS/ML	N017007	006		Jul	CAHN

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL		HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE					
AA	ABHAI LLC	1.5MG/5ML; 5MG/5ML	A207487	001	Feb 21, 2017	Feb	NEWA
AA	BIO-PHARM INC	1.5MG/5ML; 5MG/5ML	A204765	001	Mar 06, 2017	Feb	NEWA
AA	NOVEL LABS INC	1.5MG/5ML; 5MG/5ML	A203535	001	Feb 13, 2017	Jan	NEWA
AA	PADDOCK LLC	1.5MG/5ML; 5MG/5ML	A205731	001	Feb 15, 2017	Jan	NEWA

TABLET;ORAL

HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

AA	AVANTHI INC	1.5MG;5MG	A207176	001	Aug 07, 2017	Jul	NEWA
	TUSSIGON						
AA	KING PHARMS	1.5MG;5MG	A088508	001	Jul 30, 1985	Feb	CAHN

HYDRALAZINE HYDROCHLORIDE

TABLET;ORAL

HYDRALAZINE HYDROCHLORIDE

>A>	@ ANDA REPOSITORY	10MG	A089359	001	Jul 25, 1986	Sep	CAHN
>A>	@	25MG	A089258	001	May 05, 1986	Sep	CAHN
>A>	@	50MG	A089259	001	May 05, 1986	Sep	CAHN
>A>	@	100MG	A088729	001	Apr 11, 1985	Sep	CAHN
>D>	@ FRONTIDA BIOPHARM	10MG	A089359	001	Jul 25, 1986	Sep	CAHN
>D>	@	25MG	A089258	001	May 05, 1986	Sep	CAHN
>D>	@	50MG	A089259	001	May 05, 1986	Sep	CAHN
>D>	@	100MG	A088729	001	Apr 11, 1985	Sep	CAHN
>D>	@ SANDOZ	50MG	A085088	001		Sep	CAHN
>D> AA	SCIEGEN PHARMS INC	10MG	A205236	001	May 26, 2017	Sep	CAHN
AA		10MG	A205236	001	May 26, 2017	May	NEWA
>D> AA		25MG	A205236	002	May 26, 2017	Sep	CAHN
AA		25MG	A205236	002	May 26, 2017	May	NEWA
>D> AA		50MG	A205236	003	May 26, 2017	Sep	CAHN
AA		50MG	A205236	003	May 26, 2017	May	NEWA
>D> AA		100MG	A205236	004	May 26, 2017	Sep	CAHN
AA		100MG	A205236	004	May 26, 2017	May	NEWA
>A> AA	TECH ORGANIZED	10MG	A205236	001	May 26, 2017	Sep	CAHN
>A> AA		25MG	A205236	002	May 26, 2017	Sep	CAHN
>A> AA		50MG	A205236	003	May 26, 2017	Sep	CAHN
>A> AA		100MG	A205236	004	May 26, 2017	Sep	CAHN
	@ UPSHER-SMITH LABS	10MG	A083241	001		Jun	CAHN
	@	25MG	A083560	001		Jun	CAHN
	@	50MG	A083561	001		Jun	CAHN
>A>	@	50MG	A085088	001		Sep	CAHN

HYDROCHLOROTHIAZIDE

CAPSULE;ORAL

HYDROCHLOROTHIAZIDE

AB	PRINSTON INC	12.5MG	A075907	001	Sep 17, 2002	Feb	CAHN
----	--------------	--------	---------	-----	--------------	-----	------

TABLET;ORAL

HYDROCHLOROTHIAZIDE

>D> AB	JUBILANT CADISTA	25MG	A040809	001	Sep 04, 2007	Sep	DISC
>A>	@	25MG	A040809	001	Sep 04, 2007	Sep	DISC
>D> AB		50MG	A040809	002	Sep 04, 2007	Sep	DISC
>A>	@	50MG	A040809	002	Sep 04, 2007	Sep	DISC
AB	PRINSTON INC	25MG	A040412	001	Mar 29, 2002	Feb	CAHN
AB		50MG	A040412	002	Mar 29, 2002	Feb	CAHN
>D> AB	SCIEGEN PHARMS INC	25MG	A203018	001	Jul 23, 2014	Sep	CAHN
>D> AB		50MG	A203018	002	Jul 23, 2014	Sep	CAHN
>A> AB	TECH ORGANIZED	25MG	A203018	001	Jul 23, 2014	Sep	CAHN
>A> AB		50MG	A203018	002	Jul 23, 2014	Sep	CAHN
	@ WATSON LABS TEVA	50MG	A083232	001		May	CAHN

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET;ORAL

IRBESARTAN AND HYDROCHLOROTHIAZIDE

AB	ATLAS PHARMS LLC	12.5MG;150MG	A203036	001	Jan 15, 2016	Mar	CAHN
AB		12.5MG;300MG	A203036	002	Jan 15, 2016	Mar	CAHN
AB		25MG;300MG	A203036	003	Jan 15, 2016	Mar	CAHN
>A> AB	UNICHEM LABS LTD	12.5MG;150MG	A207018	001	Sep 19, 2017	Sep	NEWA
>A> AB		12.5MG;300MG	A207018	002	Sep 19, 2017	Sep	NEWA
AB	WEST-WARD PHARMS INT	25MG;300MG	A090351	003	Jun 08, 2017	May	NEWA

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET;ORAL

LISINOPRIL AND HYDROCHLOROTHIAZIDE

AB	INVAGEN PHARMS	12.5MG;10MG	A204058	001	May 23, 2017	May	NEWA
AB		12.5MG;20MG	A204058	002	May 23, 2017	May	NEWA
AB		25MG;20MG	A204058	003	May 23, 2017	May	NEWA
	PRINZIDE						
+	@ MERCK	12.5MG;10MG	N019778	003	Nov 18, 1993	Jan	CRLD
+	@	12.5MG;20MG	N019778	001	Feb 16, 1989	Jan	CRLD

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET;ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

AB	UNICHEM LABS LTD	12.5MG;50MG	A204832	001	Jul 21, 2017	Jul	NEWA
AB		12.5MG;100MG	A204832	002	Jul 21, 2017	Jul	NEWA
AB		25MG;100MG	A204832	003	Jul 21, 2017	Jul	NEWA

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET;ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

	@ CHARTWELL RX	12.5MG;7.5MG	A090096	001	Sep 25, 2008	Mar	CAHN
	@	12.5MG;15MG	A090096	002	Sep 25, 2008	Mar	CAHN
	@	25MG;15MG	A090096	003	Sep 25, 2008	Mar	CAHN
AB	HERITAGE PHARMS INC	12.5MG;7.5MG	A202150	001	Mar 07, 2014	Jan	CMS1
AB		12.5MG;15MG	A202150	002	Mar 07, 2014	Jan	CMS1
AB		25MG;15MG	A202150	003	Mar 07, 2014	Jan	CMS1

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

AB	ALEMBIC PHARMS LTD	12.5MG;20MG	A204233	001	Apr 24, 2017	Apr	NEWA
AB		12.5MG;40MG	A204233	002	Apr 24, 2017	Apr	NEWA
AB		25MG;40MG	A204233	003	Apr 24, 2017	Apr	NEWA
AB	AUROBINDO PHARMA LTD	12.5MG;20MG	A205391	001	Apr 24, 2017	Apr	NEWA
AB		12.5MG;40MG	A205391	002	Apr 24, 2017	Apr	NEWA
AB		25MG;40MG	A205391	003	Apr 24, 2017	Apr	NEWA
AB	PRINSTON INC	12.5MG;20MG	A207804	001	Apr 24, 2017	Apr	NEWA
AB		12.5MG;40MG	A207804	002	Apr 24, 2017	Apr	NEWA
AB		25MG;40MG	A207804	003	Apr 24, 2017	Apr	NEWA
AB	TEVA PHARMS USA	12.5MG;20MG	A200532	001	Apr 24, 2017	Apr	NEWA
AB		12.5MG;40MG	A200532	002	Apr 24, 2017	Apr	NEWA
AB		25MG;40MG	A200532	003	Apr 24, 2017	Apr	NEWA
AB	TORRENT PHARMS LTD	12.5MG;20MG	A206515	001	May 03, 2017	Apr	NEWA
AB		12.5MG;40MG	A206515	002	May 03, 2017	Apr	NEWA
AB		25MG;40MG	A206515	003	May 03, 2017	Apr	NEWA

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	INVAGEN PHARMS	12.5MG;EQ 10MG BASE	A201356	001	Apr 20, 2011	Jun	CMS1
AB		12.5MG;EQ 20MG BASE	A201356	002	Apr 20, 2011	Jun	CMS1
AB		25MG;EQ 20MG BASE	A201356	003	Apr 20, 2011	Jun	CMS1
	@ SUN PHARM INDS LTD	12.5MG;EQ 10MG BASE	A078211	001	Mar 04, 2009	Jun	DISC
	@	12.5MG;EQ 20MG BASE	A078211	002	Mar 04, 2009	Jun	DISC
	@	25MG;EQ 20MG BASE	A078211	003	Mar 04, 2009	Jun	DISC

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET;ORAL

SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE

	@ UPSHER SMITH	25MG;25MG	A087553	001		Jun	CAHN
--	----------------	-----------	---------	-----	--	-----	------

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET;ORAL

TELMISARTAN AND HYDROCHLOROTHIAZIDE

AB	ZYDUS PHARMS USA INC	12.5MG;40MG	A204221	001	Aug 15, 2017	Jul	NEWA
AB		12.5MG;80MG	A204221	002	Aug 15, 2017	Jul	NEWA
AB		25MG;80MG	A204221	003	Aug 15, 2017	Jul	NEWA

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

VALSARTAN AND HYDROCHLOROTHIAZIDE

AB	ALEMBIC PHARMS LTD	12.5MG;80MG	A201662	001	Mar 21, 2013	May	CAHN
AB		12.5MG;160MG	A201662	002	Mar 21, 2013	May	CAHN
AB		12.5MG;320MG	A201662	003	Mar 21, 2013	May	CAHN
AB		25MG;160MG	A201662	004	Mar 21, 2013	May	CAHN
AB		25MG;320MG	A201662	005	Mar 21, 2013	May	CAHN
AB	WATSON LABS TEVA	12.5MG;80MG	A091519	001	Mar 21, 2013	May	CAHN
AB		12.5MG;160MG	A091519	002	Mar 21, 2013	May	CAHN
AB		12.5MG;320MG	A091519	003	Mar 21, 2013	May	CAHN
AB		25MG;160MG	A091519	004	Mar 21, 2013	May	CAHN
AB		25MG;320MG	A091519	005	Mar 21, 2013	May	CAHN

HYDROCODONE BITARTRATE

TABLET, EXTENDED RELEASE;ORAL  
VANTRELA ER

+	TEVA BRANDED PHARM	15MG	N207975	001	Jan 17, 2017	Jan	NEWA
+		30MG	N207975	002	Jan 17, 2017	Jan	NEWA
+		45MG	N207975	003	Jan 17, 2017	Jan	NEWA
+		60MG	N207975	004	Jan 17, 2017	Jan	NEWA
+		90MG	N207975	005	Jan 17, 2017	Jan	NEWA

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET;ORAL  
HYDROCODONE BITARTRATE AND IBUPROFEN

>D>	AB	AMNEAL PHARMS NY	7.5MG;200MG	A076642	001	Oct 12, 2004	Sep	CHRS
>A>	AB	!	7.5MG;200MG	A076642	001	Oct 12, 2004	Sep	CHRS
>D>		VICOPROFEN						
>D>	AB	+! ABBVIE	7.5MG;200MG	N020716	001	Sep 23, 1997	Sep	DISC
>A>		+ @	7.5MG;200MG	N020716	001	Sep 23, 1997	Sep	DISC

HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL  
HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

>D>	AA	TRIS PHARMA INC	5MG/5ML;60MG/5ML	A203839	001	Oct 28, 2014	Sep	DISC
>A>		@	5MG/5ML;60MG/5ML	A203839	001	Oct 28, 2014	Sep	DISC

HYDROCORTISONE

CREAM;TOPICAL  
HYDROCORTISONE

AT	!	FOUGERA PHARMS INC	1%	A080693	003		Jan	CAHN
AT	!		2.5%	A089414	001	Dec 16, 1986	Jan	CAHN
		SYNACORT						
		@ MEDICIS	1%	A087458	001		Jul	DISC
		@	2.5%	A087457	001		Jul	DISC

LOTION;TOPICAL  
STIE-CORT

		@ PERRIGO CO	1%	A089066	001	Nov 25, 1985	Apr	CAHN
AT			2.5%	A089074	001	Nov 26, 1985	Apr	CAHN

OINTMENT;TOPICAL  
HYDROCORTISONE

AT	!	FOUGERA PHARMS INC	2.5%	A081203	001	May 28, 1993	Jan	CAHN
AT		HYDROCORTISONE IN ABSORBASE						
AT		CMP PHARMA INC	1%	A088138	001	Sep 06, 1985	Apr	CAHN

TABLET;ORAL  
HYDROCORTISONE

AB		PII	5MG	A207029	001	Apr 27, 2017	Apr	NEWA
AB			10MG	A207029	002	Apr 27, 2017	Apr	NEWA
AB			20MG	A207029	003	Apr 27, 2017	Apr	NEWA

HYDROCORTISONE ACETATE

AEROSOL, METERED;RECTAL  
CORTIFOAM

		+! MYLAN SPECIALITY LP	10%	N017351	001	Feb 10, 1982	Mar	CAHN
--	--	------------------------	-----	---------	-----	--------------	-----	------

CREAM;TOPICAL

>D>		HYDROCORTISONE ACETATE						
>D>	!	FERNDALE LABS	2.5%	A040259	001	Jul 29, 1999	Sep	DISC
>A>		@	2.5%	A040259	001	Jul 29, 1999	Sep	DISC

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

CREAM;TOPICAL  
CORTISPORIN

		+! MONARCH PHARMS	0.5%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050218	001	Aug 09, 1985	Feb	CAHN
--	--	-------------------	---------------------------------------	---------	-----	--------------	-----	------

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL, METERED;TOPICAL  
EPIFOAM

BX		MYLAN SPECIALITY LP	1%;1%	A086457	001		Mar	CAHN
		PROCTOFOAM HC						
BX		MYLAN SPECIALITY LP	1%;1%	A086195	001		Mar	CAHN

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

>D>		A-HYDROCORT						
>D>	AP	HOSPIRA	EQ 100MG BASE/VIAL	A 040666	001	Apr 06, 2006	Sep	DISC
>A>		@	EQ 100MG BASE/VIAL	A 040666	001	Apr 06, 2006	Sep	DISC
		SOLU-CORTEF						
>D>	AP	+! PHARMACIA AND UPJOHN	EQ 100MG BASE/VIAL	N 009866	001		Sep	CTEC
>A>		+!	EQ 100MG BASE/VIAL	N 009866	001		Sep	CTEC

HYDROCORTISONE VALERATE

CREAM; TOPICAL

		HYDROCORTISONE VALERATE						
AB	!	TARO	0.2%	A 075042	001	Aug 25, 1998	Apr	CAHN
		OINTMENT; TOPICAL						
		HYDROCORTISONE VALERATE						
	!	TARO	0.2%	A 075043	001	Aug 25, 1998	Apr	CAHN

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

		CORTISPORIN						
AT	+!	MONARCH PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N 050479	001		Apr	CAHN
		NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE						
AT		AMRING PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A 065216	001	Oct 31, 2005	Mar	CAHN
AT		SANDOZ INC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A 062423	001	Aug 25, 1983	Feb	CAHN

SUSPENSION/DROPS; OPHTHALMIC

		CORTISPORIN						
	@	MONARCH PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N 050169	001		Apr	CAHN
		NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE						
	!	SANDOZ INC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A 062874	001	May 11, 1988	Feb	CAHN
		SUSPENSION/DROPS; OTIC						
		NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE						
AT		AMRING PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A 065219	001	May 01, 2006	Mar	CAHN
AT		SANDOZ INC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A 062488	001	Nov 06, 1985	Feb	CAHN

HYDROFLUMETHIAZIDE

TABLET; ORAL

		SALURON						
>D>	AB	+! SHIRE LLC	50MG	N 011949	001		Sep	CTEC
>A>		+!	50MG	N 011949	001		Sep	CTEC

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

		DILAUDID						
AP	+!	FRESENIUS KABI USA	1MG/ML	N 019034	003	Apr 30, 2009	Jan	CAHN
AP	+!		2MG/ML	N 019034	004	Apr 30, 2009	Jan	CAHN
AP	+!		4MG/ML	N 019034	005	Apr 30, 2009	Jan	CAHN
		DILAUDID-HP						
AP	+!	FRESENIUS KABI USA	10MG/ML	N 019034	001	Jan 11, 1984	Jan	CAHN
	@		250MG/VIAL	N 019034	002	Aug 04, 1994	Jan	CAHN
		HYDROMORPHONE HYDROCHLORIDE						
>D>	AP	HOSPIRA	10MG/ML	A 074598	001	Jun 19, 1997	Sep	DISC
>A>		@	10MG/ML	A 074598	001	Jun 19, 1997	Sep	DISC
		SOLUTION; ORAL						
		DILAUDID						
AA	+!	RHODES PHARMS	5MG/5ML	N 019891	001	Dec 07, 1992	Jun	CAHN
		TABLET; ORAL						
		DILAUDID						
AB	+	PURDUE PHARM PRODS	4MG	N 019892	002	Nov 09, 2007	May	CAHN
AB	+!		8MG	N 019892	001	Dec 07, 1992	May	CAHN
AB	+	RHODES PHARMS	2MG	N 019892	003	Nov 09, 2007	Jun	CAHN
AB	+		4MG	N 019892	002	Nov 09, 2007	Jun	CAHN
AB	+!		8MG	N 019892	001	Dec 07, 1992	Jun	CAHN

TABLET, EXTENDED RELEASE;ORAL									
HYDROMORPHONE HYDROCHLORIDE									
>A>	AB	PADDOCK LLC	32MG	A204278	004	Sep 20, 2017	Sep	NEWA	
<u>HYDROXOCOBALAMIN</u>									
INJECTABLE; INJECTION									
HYDROXOCOBALAMIN									
!		ACTAVIS LLC	1MG/ML	A085998	001		Feb	CAHN	
<u>HYDROXYZINE HYDROCHLORIDE</u>									
INJECTABLE; INJECTION									
VISTARIL									
+	@	PFIZER	25MG/ML	N011111	001		Jan	CRLD	
+	@		50MG/ML	N011111	002		Jan	CRLD	
TABLET; ORAL									
HYDROXYZINE HYDROCHLORIDE									
	@	AUROLIFE PHARMA LLC	10MG	A087871	002	Dec 20, 1982	Jan	CMS1	
	@		25MG	A087871	003	Dec 20, 1982	Jan	CMS1	
>A>	AB	BAYSHORE PHARMS LLC	10MG	A207120	001	Mar 29, 2017	Sep	CAHN	
>A>	AB		50MG	A207122	001	Mar 29, 2017	Sep	CAHN	
>D>	AB	NUVO PHARM INC	10MG	A207120	001	Mar 29, 2017	Sep	CAHN	
	AB		10MG	A207120	001	Mar 29, 2017	Mar	NEWA	
	AB		25MG	A207121	001	Mar 29, 2017	Mar	NEWA	
>D>	AB		50MG	A207122	001	Mar 29, 2017	Sep	CAHN	
	AB		50MG	A207122	001	Mar 29, 2017	Mar	NEWA	
	AB	PRINSTON INC	10MG	A040579	001	May 27, 2005	Feb	CAHN	
	AB		25MG	A040574	001	May 27, 2005	Feb	CAHN	
	AB		50MG	A040580	001	May 27, 2005	Feb	CAHN	
		@ SUN PHARM INDS INC	10MG	A040899	001	Jun 10, 2008	Apr	DISC	
		@	25MG	A040899	002	Jun 10, 2008	Apr	DISC	
		@	50MG	A040899	003	Jun 10, 2008	Apr	DISC	
<u>IBANDRONATE SODIUM</u>									
TABLET; ORAL									
IBANDRONATE SODIUM									
	@	MYLAN PHARMS INC	EQ 150MG BASE	A078995	001	Mar 19, 2012	May	DISC	
AB		WATSON LABS TEVA	EQ 150MG BASE	A079003	001	Mar 20, 2012	May	CAHN	
<u>IBUPROFEN</u>									
SUSPENSION; ORAL									
IBUPROFEN									
AB	!	ACTAVIS MID ATLANTIC	100MG/5ML	A074978	001	Mar 25, 1998	May	CAHN	
AB		TARO	100MG/5ML	A209204	001	Jun 23, 2017	Jun	NEWA	
MOTRIN									
+	@	MCNEIL CONSUMER	100MG/5ML	N019842	001	Sep 19, 1989	Jan	CRLD	
TABLET; ORAL									
IBUPROFEN									
	@	MYLAN PHARMS INC	400MG	A070045	001	Sep 24, 1985	Mar	CAHN	
	@	PLIVA	400MG	A071666	001	Jun 18, 1987	Aug	CAHN	
	@		600MG	A071667	001	Jun 18, 1987	Aug	CAHN	
	@		800MG	A071668	001	Jun 18, 1987	Aug	CAHN	
<u>IBUPROFEN; OXYCODONE HYDROCHLORIDE</u>									
TABLET; ORAL									
OXYCODONE HYDROCHLORIDE AND IBUPROFEN									
	@	WATSON LABS	400MG; 5MG	A078394	001	Nov 26, 2007	Jun	DISC	
BX			400MG; 5MG	A078394	001	Nov 26, 2007	Apr	CTEC	
<u>ICOSAPENT ETHYL</u>									
CAPSULE; ORAL									
VASCEPA									
+		AMARIN PHARMS	500MG	N202057	002	Feb 16, 2017	Mar	NEWA	
<u>IDOXURIDINE</u>									
SOLUTION/DROPS; OPHTHALMIC									
DENDRID									
+	@	ALCON	0.1%	N014169	001		Jul	DISC	



IFOSFAMIDE; MESNA

INJECTABLE; INTRAVENOUS  
IFOSFAMIDE/MESNA KIT  
@ TEVA PHARMS USA

1GM/20ML; 1GM/10ML  
(50MG/ML; 100MG/ML)  
@  
3GM/60ML; 1GM/10ML  
(50MG/ML; 100MG/ML)

A075874 001 Feb 26, 2002 Mar DISC  
A075874 002 Feb 26, 2002 Mar DISC

IMATINIB MESYLATE

TABLET; ORAL

IMATINIB MESYLATE

AB MYLAN PHARMS INC  
AB

EQ 100MG BASE  
EQ 400MG BASE

A204644 001 Jun 21, 2017 Jun NEWA  
A204644 002 Jun 21, 2017 Jun NEWA

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

AB MALLINCKRODT INC  
AB  
OXFORD PHARMS  
@ PAR PHARM

10MG  
25MG  
10MG  
25MG  
10MG

A087846 002 May 22, 1984 Aug CMS1  
A087846 003 May 22, 1984 Aug CMS1  
A040751 003 Feb 28, 2008 May CMS1  
A040751 002 Feb 28, 2008 May CMS1  
A089422 001 Jul 14, 1987 Jul DISC

IMIPRAMINE PAMOATE

CAPSULE; ORAL

IMIPRAMINE PAMOATE

@ MYLAN PHARMS INC  
@  
@  
@

EQ 75MG HCL  
EQ 100MG HCL  
EQ 125MG HCL  
EQ 150MG HCL

A202338 001 Jun 28, 2013 Jun DISC  
A202338 002 Jun 28, 2013 Jun DISC  
A202338 003 Jun 28, 2013 Jun DISC  
A202338 004 Jun 28, 2013 Jun DISC

INDACATEROL MALEATE

POWDER; INHALATION

ARCAPTA NEOHALER

+! SUNOVION PHARMS INC

EQ 75MCG BASE

N022383 001 Jul 01, 2011 Jan CAHN

INDOMETHACIN

CAPSULE; ORAL

INDOMETHACIN

@ CHARTWELL MOLECULES  
@  
@

25MG  
50MG  
50MG

AB JUBILANT GENERICS  
AB

N018829 002 Aug 06, 1984 Feb CAHN  
A070651 001 Mar 05, 1986 Apr CAHN  
N018829 001 Aug 06, 1984 Feb CAHN  
A205215 001 Aug 25, 2017 Aug NEWA  
A205215 002 Aug 25, 2017 Aug NEWA

CAPSULE, EXTENDED RELEASE; ORAL

INDOMETHACIN

AB CHARTWELL RX  
AB  
AB  
@ WATSON LABS INC  
>A> AB ZYDUS PHARMS USA INC

75MG  
75MG  
75MG  
75MG  
75MG

A200529 001 Nov 30, 2010 Jun CAHN  
A203501 001 Jun 22, 2017 Jun NEWA  
A204853 001 May 08, 2017 Apr NEWA  
A202572 001 Dec 09, 2013 Feb DISC  
A202711 001 Sep 25, 2017 Sep NEWA

INDOMETHACIN SODIUM

INJECTABLE; INJECTION

INDOMETHACIN SODIUM

AP NAVINTA LLC

EQ 1MG BASE/VIAL

A206561 001 Jul 19, 2017 Jul NEWA

INSULIN ASPART RECOMBINANT

>A> SOLUTION; IV (INFUSION), SUBCUTANEOUS

>A> FIASP

>A> +! NOVO NORDISK INC

1000 UNITS/10ML (100 UNITS/ML)

N208751 001 Sep 29, 2017 Sep NEWA

>A> SOLUTION; SUBCUTANEOUS

>A> FIASP FLEXTOUCH

>A> +! NOVO NORDISK INC

300 UNITS/3ML (100 UNITS/ML)

N208751 002 Sep 29, 2017 Sep NEWA

IODIPAMIDE MEGLUMINE

INJECTABLE; INJECTION

CHOLOGRAFIN MEGLUMINE

+ @ BRACCO

52%

N009321 003 Aug DISC

IODIXANOL

INJECTABLE; INJECTION  
VISIPAQUE 270  
@ GE HEALTHCARE

55%

N020808 001 Aug 29, 1997 Aug DISC

IOPAMIDOL

INJECTABLE; INJECTION  
SCANLUX-300

AP MYLAN IRELAND LTD 61%  
AP SANOCHEMIA CORP USA 61%  
SCANLUX-370  
AP MYLAN IRELAND LTD 76%  
AP SANOCHEMIA CORP USA 76%

A090394 001 Jun 18, 2010 Jan CAHN  
A090394 001 Jun 18, 2010 Feb CAHN  
A090394 002 Jun 18, 2010 Jan CAHN  
A090394 002 Jun 18, 2010 Feb CAHN

IOPROMIDE

INJECTABLE; INJECTION  
ULTRAVIST 150

+ @ BAYER HLTHCARE 31.2%  
ULTRAVIST 300 IN PLASTIC CONTAINER  
+ @ BAYER HLTHCARE 62.3%

N020220 004 May 10, 1995 Aug DISC  
N020220 005 Nov 18, 2008 Aug DISC

IPRATROPIUM BROMIDE

SOLUTION; INHALATION  
IPRATROPIUM BROMIDE

@ BAUSCH AND LOMB INC 0.02%

A075835 001 Oct 15, 2001 Jul DISC

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION  
IRINOTECAN HYDROCHLORIDE

AP INGENUS PHARMS LLC 40MG/2ML (20MG/ML)  
AP 100MG/5ML (20MG/ML)  
AP INTAS PHARMS USA 40MG/2ML (20MG/ML)  
AP 100MG/5ML (20MG/ML)  
@ SANDOZ INC 40MG/2ML (20MG/ML)  
@ 100MG/5ML (20MG/ML)  
AP WEST-WARD PHARMS INT 40MG/2ML (20MG/ML)  
AP 100MG/5ML (20MG/ML)

A206935 001 May 26, 2017 May NEWA  
A206935 002 May 26, 2017 May NEWA  
A203054 001 Aug 31, 2017 Aug NEWA  
A203054 002 Aug 31, 2017 Aug NEWA  
A090137 001 Nov 12, 2009 Jul DISC  
A090137 002 Nov 12, 2009 Jul DISC  
A078753 001 Dec 24, 2008 Jan CAHN  
A078753 002 Dec 24, 2008 Jan CAHN

INJECTABLE, LIPOSOMAL; IV (INFUSION)  
ONIVYDE

+! IPSEN INC EQ 43MG BASE/10ML (EQ 4.3MG  
BASE/ML)

N207793 001 Oct 22, 2015 Apr CAHN

ISONIAZID

INJECTABLE; INJECTION  
ISONIAZID

! SANDOZ INC 100MG/ML

A040648 001 Jul 05, 2005 Mar CAHN

SYRUP; ORAL  
ISONIAZID

! CMP PHARMA INC 50MG/5ML

A088235 001 Nov 10, 1983 Apr CAHN

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION  
ISOPROTERENOL HYDROCHLORIDE

AP NEXUS PHARMS 0.2MG/ML  
ISUPREL  
AP +! HOSPIRA 0.2MG/ML

A206961 001 Aug 02, 2017 Jul NEWA  
N010515 001 Jul CTEC

ISOSORBIDE DINITRATE

TABLET; SUBLINGUAL  
ISOSORBIDE DINITRATE

@ WATSON LABS TEVA 5MG

A086031 001 Sep 29, 1987 May CAHN

TABLET, EXTENDED RELEASE; ORAL  
ISOSORBIDE DINITRATE

@ IMPAX LABS INC 40MG

A040723 001 Mar 17, 2008 Feb CAHN

ISOTRETINOIN

CAPSULE;ORAL  
ABSORICA

BX	+	SUN PHARM INDS INC	10MG	N021951	001	May 25, 2012	Aug	CAHN
BX	+		20MG	N021951	002	May 25, 2012	Aug	CAHN
			25MG	N021951	005	Aug 15, 2014	Aug	CAHN
BX	+		30MG	N021951	003	May 25, 2012	Aug	CAHN
			35MG	N021951	006	Aug 15, 2014	Aug	CAHN
BX	+		40MG	N021951	004	May 25, 2012	Aug	CAHN

ISOTRETINOIN

>A>	AB	AMNEAL PHARMS NY	10MG	A207792	001	Sep 29, 2017	Sep	NEWA
>A>	AB		20MG	A207792	002	Sep 29, 2017	Sep	NEWA
>A>	AB		30MG	A207792	003	Sep 29, 2017	Sep	NEWA
>A>	AB		40MG	A207792	004	Sep 29, 2017	Sep	NEWA

ISRADIPINE

CAPSULE;ORAL  
DYNACIRC

>D>		@ SMITHKLINE BEECHAM	2.5MG	N019546	001	Dec 20, 1990	Sep	CRLD
>A>		+ @	2.5MG	N019546	001	Dec 20, 1990	Sep	CRLD
>D>		@	5MG	N019546	002	Dec 20, 1990	Sep	CRLD
>A>		+ @	5MG	N019546	002	Dec 20, 1990	Sep	CRLD

ISRADIPINE

AB		WATSON LABS TEVA	2.5MG	A077317	001	Jan 05, 2006	May	CAHN
AB	!		5MG	A077317	002	Jan 05, 2006	May	CAHN

ITRACONAZOLE

CAPSULE;ORAL  
ITRACONAZOLE

AB		ALKEM LABS LTD	100MG	A208591	001	Jun 12, 2017	May	NEWA
AB		JUBILANT GENERICS	100MG	A203445	001	Feb 23, 2017	Feb	NEWA
>A>	AB	ZYDUS PHARMS USA INC	100MG	A204672	001	Sep 19, 2017	Sep	NEWA

KANAMYCIN SULFATE

INJECTABLE;INJECTION  
KANAMYCIN

		@ WEST-WARD PHARMS INT	EQ 75MG BASE/2ML	A062324	001		Jan	CAHN
		@	EQ 500MG BASE/2ML	A062324	002		Jan	CAHN
		@	EQ 1GM BASE/3ML	A062324	003		Jan	CAHN

KETOCONAZOLE

AEROSOL, FOAM;TOPICAL  
EXTINA

AT	+	MYLAN PHARMS INC	2%	N021738	001	Jun 12, 2007	Jan	CAHN
		CREAM;TOPICAL NIZORAL						
		+ @ JANSSEN PHARMA	2%	N019084	001	Dec 31, 1985	May	CRLD

KETOPROFEN

CAPSULE;ORAL  
KETOPROFEN

		HERITAGE PHARMS INC	25MG	A074014	001	Jan 29, 1993	Feb	CAHN
AB			50MG	A074014	002	Jan 29, 1993	Feb	CAHN
AB			75MG	A074014	003	Jan 29, 1993	Feb	CAHN

KETOROLAC TROMETHAMINE

INJECTABLE;INJECTION  
KETOROLAC TROMETHAMINE

		@ BAXTER HLTHCARE CORP	15MG/ML	A075631	002	Jun 29, 2001	Aug	CAHN
		@	30MG/ML	A075631	001	Jun 29, 2001	Aug	CAHN
>A>	AP	CYCLE PHARMS LTD	30MG/ML	A209900	001	Sep 15, 2017	Sep	NEWA
		@ SANDOZ INC	15MG/ML	A076271	001	Oct 06, 2004	Mar	CAHN
			30MG/ML	A076271	002	Oct 06, 2004	Mar	CAHN

SOLUTION/DROPS;OPHTHALMIC  
ACUVAIL

>D>	AT	+	ALLERGAN	0.45%	N022427	001	Jul 22, 2009	Sep	CTEC
>A>		+		0.45%	N022427	001	Jul 22, 2009	Sep	CTEC
		KETOROLAC TROMETHAMINE							
		SANDOZ INC	0.5%	A076583	001	Nov 05, 2009	Feb	CAHN	

L-GLUTAMINEFOR SOLUTION;ORAL  
ENDARI

+	EMMAUS MEDCL	5GM/PACKET	N208587	001	Jul 07, 2017	Jul	NEWA
	NUTRESTORE						
+	EMMAUS MEDCL	5GM/PACKET	N021667	001	Jun 10, 2004	Jul	CAHN

LABETALOL HYDROCHLORIDEINJECTABLE;INJECTION  
LABETALOL HYDROCHLORIDE

	@ BAXTER HLTHCARE CORP	5MG/ML	A076051	001	Jul 05, 2002	Aug	CAHN
AP	SAGENT AGILA LLC	5MG/ML	A079134	001	Feb 03, 2010	Feb	CAHN

TABLET;ORAL

LABETALOL HYDROCHLORIDE

>D>	AB	ALLIED PHARMA INC	100MG	A075215	001	Jul 29, 1999	Sep	CAHN
>D>	AB		200MG	A075215	002	Jul 29, 1999	Sep	CAHN
>D>	AB		300MG	A075215	003	Jul 29, 1999	Sep	CAHN
>A>	AB	INNOGENIX	100MG	A075215	001	Jul 29, 1999	Sep	CAHN
>A>	AB		200MG	A075215	002	Jul 29, 1999	Sep	CAHN
>A>	AB		300MG	A075215	003	Jul 29, 1999	Sep	CAHN
>A>	AB	ZYDUS PHARMS USA INC	100MG	A207743	001	Sep 19, 2017	Sep	NEWA
>A>	AB		200MG	A207743	002	Sep 19, 2017	Sep	NEWA
>A>	AB		300MG	A207743	003	Sep 19, 2017	Sep	NEWA

LACOSAMIDE

TABLET;ORAL

LACOSAMIDE

AB	AMNEAL PHARMS	50MG	A204857	001	Sep 09, 2016	May	CAHN
AB		100MG	A204857	002	Sep 09, 2016	May	CAHN
AB		150MG	A204857	003	Sep 09, 2016	May	CAHN
AB		200MG	A204857	004	Sep 09, 2016	May	CAHN

LACTULOSE

SOLUTION;ORAL

LACTULOSE

AA	PHARM ASSOC	10GM/15ML	A074623	001	Jul 30, 1996	May	CAHN
----	-------------	-----------	---------	-----	--------------	-----	------

LAMIVUDINE

TABLET;ORAL

LAMIVUDINE

AB	CIPLA LTD	150MG	A077221	001	Mar 03, 2017	Feb	NEWA
AB		300MG	A077221	002	Mar 03, 2017	Feb	NEWA
AB	ECI PHARMS LLC	150MG	A203586	001	Nov 21, 2016	Aug	CAHN

LAMIVUDINE; ZIDOVUDINE

TABLET;ORAL

LAMIVUDINE AND ZIDOVUDINE

AB	AUROBINDO PHARMA LTD	150MG;300MG	A077558	001	May 05, 2017	Apr	NEWA
BX	PHARMACARE	150MG;300MG	N022018	001	Mar 17, 2017	Mar	NEWA

LAMOTRIGINE

TABLET;ORAL

LAMOTRIGINE

	@ MYLAN LABS LTD	25MG	A078443	001	Feb 11, 2009	Mar	CAHN
	@	100MG	A078443	002	Feb 11, 2009	Mar	CAHN
	@	150MG	A078443	003	Feb 11, 2009	Mar	CAHN
	@	200MG	A078443	004	Feb 11, 2009	Mar	CAHN

TABLET, CHEWABLE;ORAL

LAMOTRIGINE

AB	GLENMARK PHARMS LTD	5MG	A079099	001	Feb 19, 2009	May	CAHN
AB		25MG	A079099	002	Feb 19, 2009	May	CAHN
	@ MYLAN	5MG	A076630	001	Jan 22, 2009	Jun	DISC
	@	25MG	A076630	002	Jan 22, 2009	Jun	DISC

TABLET, EXTENDED RELEASE;ORAL

LAMOTRIGINE

AB	ACTAVIS ELIZABETH	250MG	A203733	001	Nov 13, 2013	Apr	CAHN
AB	HANDA PHARMS LLC	25MG	A202887	001	Jun 17, 2013	Jan	CAHN
AB		50MG	A202887	002	Jun 17, 2013	Jan	CAHN
AB		100MG	A202887	003	Jun 17, 2013	Jan	CAHN
AB		200MG	A202887	004	Jun 17, 2013	Jan	CAHN

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL  
LANSOPRAZOLE

AB	INVENTIA HLTHCARE	15MG	A205868	001	Aug 30, 2017	Aug NEWA
AB		30MG	A205868	002	Aug 30, 2017	Aug NEWA
>A>	KREMERS URBAN PHARMS	15MG	A207156	001	Sep 28, 2017	Sep NEWA
>A>		30MG	A207156	002	Sep 28, 2017	Sep NEWA
TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING;ORAL PREVACID						
>D>	+ TAKEDA PHARMS USA	15MG	N021428	001	Aug 30, 2002	Sep CTEC
>A>	AB +	15MG	N021428	001	Aug 30, 2002	Sep CTEC
>D>	+!	30MG	N021428	002	Aug 30, 2002	Sep CTEC
>A>	AB +!	30MG	N021428	002	Aug 30, 2002	Sep CTEC
TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL LANSOPRAZOLE						
>A>	AB TEVA PHARMS USA	15MG	A208784	001	Sep 21, 2017	Sep NEWA
>A>	AB	30MG	A208784	002	Sep 21, 2017	Sep NEWA

LANTHANUM CARBONATE

TABLET, CHEWABLE;ORAL  
FOSRENOL

AB	+ SHIRE LLC	EQ 500MG BASE	N021468	002	Oct 26, 2004	Jul CFTG
AB	+	EQ 750MG BASE	N021468	003	Nov 23, 2005	Jul CFTG
AB	+!	EQ 1GM BASE	N021468	004	Nov 23, 2005	Jul CFTG
LANTHANUM CARBONATE						
AB	NATCO PHARMA LTD	EQ 500MG BASE	A090978	001	Aug 11, 2017	Jul NEWA
AB		EQ 750MG BASE	A090978	002	Aug 11, 2017	Jul NEWA
AB		EQ 1GM BASE	A090978	003	Aug 11, 2017	Jul NEWA

LATANOPROST

SOLUTION/DROPS;OPHTHALMIC  
LATANOPROST

AT	AMRING PHARMS	0.005%	A200925	001	Mar 22, 2011	Mar CAHN
AT	SANDOZ INC	0.005%	A091449	001	Mar 22, 2011	Feb CAHN

LETROZOLE

TABLET;ORAL  
LETROZOLE

@	KREMERS URBAN PHARMS	2.5MG	A091098	001	Jun 03, 2011	Jun DISC
@	LANNETT HOLDINGS INC	2.5MG	A202048	001	Oct 29, 2014	Jun DISC

LETROZOLE; RIBOCICLIB SUCCINATE

TABLET, TABLET;ORAL  
KISQALI FEMARA CO-PACK (COPACKAGED)

+!	NOVARTIS PHARMS CORP	2.5MG,N/A;N/A,EQ 200MG BASE	N209935	001	May 04, 2017	May NEWA
----	----------------------	-----------------------------	---------	-----	--------------	----------

LEUCOVORIN CALCIUM

INJECTABLE;INJECTION  
LEUCOVORIN CALCIUM PRESERVATIVE FREE

AP	MYLAN LABS LTD	EQ 100MG BASE/VIAL	A203800	001	May 19, 2017	May NEWA
AP		EQ 200MG BASE/VIAL	A203800	002	May 19, 2017	May NEWA
AP		EQ 350MG BASE/VIAL	A203800	003	May 19, 2017	May NEWA

TABLET;ORAL  
LEUCOVORIN CALCIUM

@	EPIC PHARMA LLC	EQ 5MG BASE	A074544	001	Aug 28, 1997	May CAHN
@		EQ 25MG BASE	A074544	002	Aug 28, 1997	May CAHN
WELLCOVORIN						
+	@ GLAXOSMITHKLINE	EQ 5MG BASE	N018342	001	Jul 08, 1983	Jun CRLD
+	@	EQ 25MG BASE	N018342	002	Jul 08, 1983	Jun CRLD

LEVALBUTEROL HYDROCHLORIDE

SOLUTION;INHALATION  
LEVALBUTEROL HYDROCHLORIDE

AN	AUROBINDO PHARMA LTD	EQ 0.25% BASE	A207628	001	Jan 31, 2017	Jan NEWA
----	----------------------	---------------	---------	-----	--------------	----------

LEVETIRACETAM

INJECTABLE; IV (INFUSION)

LEVETIRACETAM

AP	JUBILANT GENERICS	500MG/5ML (100MG/ML)	A206838	001	Jun 02, 2016	Jul	CAHN
----	-------------------	----------------------	---------	-----	--------------	-----	------

SOLUTION; ORAL

LEVETIRACETAM

AA	ALLIED PHARMA INC	100MG/ML	A078582	001	Jan 15, 2009	Mar	CAHN
AA	AUROBINDO PHARMA LTD	100MG/ML	A079063	001	Jan 15, 2009	Jan	CAHN

TABLET; ORAL

LEVETIRACETAM

AB	ACI HEALTHCARE LTD	250MG	A078042	001	Jan 15, 2009	Jun	CAHN
AB		500MG	A078042	002	Jan 15, 2009	Jun	CAHN
AB		750MG	A078042	003	Jan 15, 2009	Jun	CAHN
AB		1GM	A078042	004	Jan 15, 2009	Jun	CAHN
>A>	ACIC PHARMS	250MG	A090767	001	Jul 28, 2010	Sep	CAHN
>A>		500MG	A090767	002	Jul 28, 2010	Sep	CAHN
>A>		750MG	A090767	003	Jul 28, 2010	Sep	CAHN
>A>		1GM	A090767	004	Jul 28, 2010	Sep	CAHN
AB	ALLIED PHARMA INC	250MG	A078042	001	Jan 15, 2009	Mar	CAHN
AB		500MG	A078042	002	Jan 15, 2009	Mar	CAHN
AB		750MG	A078042	003	Jan 15, 2009	Mar	CAHN
AB		1GM	A078042	004	Jan 15, 2009	Mar	CAHN
>D>	METHAPHARM	250MG	A090767	001	Jul 28, 2010	Sep	CAHN
>D>		500MG	A090767	002	Jul 28, 2010	Sep	CAHN
>D>		750MG	A090767	003	Jul 28, 2010	Sep	CAHN
>D>		1GM	A090767	004	Jul 28, 2010	Sep	CAHN

ROWEEPPRA

AB	LOTUS PHARM CO LTD	250MG	A090906	002	Oct 31, 2016	Apr	NEWA
AB		500MG	A090906	001	Nov 05, 2010	Apr	CTNA
AB		750MG	A090906	003	Oct 31, 2016	Apr	NEWA
AB		1GM	A090906	004	Oct 31, 2016	Apr	NEWA

TABLET, EXTENDED RELEASE; ORAL

LEVETIRACETAM

AB	ECI PHARMS LLC	500MG	A204754	001	Aug 26, 2016	Mar	CAHN
AB		750MG	A204754	002	Aug 26, 2016	Mar	CAHN
	@ MYLAN PHARMS INC	500MG	A200475	001	Dec 19, 2011	Apr	DISC
	@	750MG	A200475	002	Dec 19, 2011	Apr	DISC
	@	1GM	A200475	003	Dec 07, 2015	Apr	DISC
>A>	PHARMTAK INC	500MG	A207175	001	Sep 28, 2017	Sep	NEWA
>A>		750MG	A207175	002	Sep 28, 2017	Sep	NEWA
AB	PRINSTON INC	500MG	A202533	001	Jul 20, 2012	Feb	CAHN
AB		750MG	A202533	002	Jul 20, 2012	Feb	CAHN
AB	VIRTUS PHARMS	500MG	A091291	001	Sep 12, 2011	Feb	CAHN
AB		750MG	A091291	002	Sep 12, 2011	Feb	CAHN

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

LEVOBUNOLOL HYDROCHLORIDE

	@ BAUSCH AND LOMB	0.25%	A074307	001	Mar 04, 1994	Jul	DISC
AT	SANDOZ INC	0.5%	A074850	001	Oct 28, 1996	Feb	CAHN

LEVOCARNITINE

INJECTABLE; INJECTION

CARNITOR

AP	+! LEADIANT BIOSCI INC	200MG/ML	N020182	001	Dec 16, 1992	Mar	CAHN
----	------------------------	----------	---------	-----	--------------	-----	------

SOLUTION; ORAL

CARNITOR

	@ LEADIANT BIOSCI INC	1GM/10ML	N018948	002	Apr 27, 1988	Mar	CAHN
AA	+!	1GM/10ML	N019257	001	Apr 10, 1986	Mar	CAHN

CARNITOR SF

AA	+ LEADIANT BIOSCI INC	1GM/10ML	N019257	002	Mar 28, 2007	Mar	CAHN
----	-----------------------	----------	---------	-----	--------------	-----	------

TABLET; ORAL

CARNITOR

AB	+! LEADIANT BIOSCI INC	330MG	N018948	001	Dec 27, 1985	Mar	CAHN
AB	LEVOCARNITINE						
AB	IMPAX LABS INC	330MG	A076858	001	Sep 20, 2004	Feb	CAHN

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AA		SILARX PHARMS INC	2.5MG/ML	A204599	001	May 15, 2017	May NEWA
----	--	-------------------	----------	---------	-----	--------------	----------

XYZAL

AA	+	SANOFI-AVENTIS US	2.5MG/5ML	N022157	001	Jan 28, 2008	Jul CAHN
----	---	-------------------	-----------	---------	-----	--------------	----------

TABLET;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

>A>	AB	ALLIED PHARMA INC	5MG	A202046	001	Sep 17, 2013	Sep CAHN
-----	----	-------------------	-----	---------	-----	--------------	----------

AB			5MG	A204323	001	Dec 20, 2016	Apr CAHN
----	--	--	-----	---------	-----	--------------	----------

>D>	AB	MICRO LABS LTD INDIA	5MG	A202046	001	Sep 17, 2013	Sep CAHN
-----	----	----------------------	-----	---------	-----	--------------	----------

XYZAL

AB	+	SANOFI-AVENTIS US	5MG	N022064	001	May 25, 2007	Jul CAHN
----	---	-------------------	-----	---------	-----	--------------	----------

LEVOFLOXACIN

INJECTABLE;INJECTION

LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER

+	@	JANSSEN PHARMS	EQ 250MG/50ML (EQ 5MG/ML)	N020635	002	Dec 20, 1996	Jan CRLD
---	---	----------------	---------------------------	---------	-----	--------------	----------

+	@		EQ 500MG/100ML (EQ 5MG/ML)	N020635	003	Dec 20, 1996	Jan CRLD
---	---	--	----------------------------	---------	-----	--------------	----------

+	@		EQ 750MG/150ML (EQ 5MG/ML)	N020635	005	Dec 20, 1996	Jan CRLD
---	---	--	----------------------------	---------	-----	--------------	----------

LEVOFLOXACIN

AP		BAXTER HLTHCARE CORP	EQ 500MG/20ML (EQ 25MG/ML)	A091436	001	Jun 05, 2013	Aug CAHN
----	--	----------------------	----------------------------	---------	-----	--------------	----------

AP		SAGENT AGILA LLC	EQ 500MG/20ML (EQ 25MG/ML)	A200560	001	Jun 20, 2011	Jun CAHN
----	--	------------------	----------------------------	---------	-----	--------------	----------

AP			EQ 750MG/30ML (EQ 25MG/ML)	A200560	002	Jun 20, 2011	Jun CAHN
----	--	--	----------------------------	---------	-----	--------------	----------

AP		ZYDUS PHARMS USA INC	EQ 500MG/20ML (EQ 25MG/ML)	A205968	001	Jun 01, 2017	May NEWA
----	--	----------------------	----------------------------	---------	-----	--------------	----------

AP			EQ 750MG/30ML (EQ 25MG/ML)	A205968	002	Jun 01, 2017	May NEWA
----	--	--	----------------------------	---------	-----	--------------	----------

LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE CORP	EQ 250MG/50ML (EQ 5MG/ML)	A091397	001	Aug 08, 2013	Aug CAHN
----	--	----------------------	---------------------------	---------	-----	--------------	----------

AP			EQ 500MG/100ML (EQ 5MG/ML)	A091397	002	Aug 08, 2013	Aug CAHN
----	--	--	----------------------------	---------	-----	--------------	----------

AP			EQ 750MG/150ML (EQ 5MG/ML)	A091397	003	Aug 08, 2013	Aug CAHN
----	--	--	----------------------------	---------	-----	--------------	----------

SOLUTION;ORAL

LEVAQUIN

+	@	JANSSEN PHARMS	250MG/10ML	N021721	001	Oct 21, 2004	Aug DISC
---	---	----------------	------------	---------	-----	--------------	----------

LEVOFLOXACIN

!		HI TECH PHARMA	250MG/10ML	A091678	001	Jun 20, 2011	Aug CHRS
---	--	----------------	------------	---------	-----	--------------	----------

SOLUTION/DROPS;OPHTHALMIC

LEVOFLOXACIN

AT		WATSON LABS TEVA	0.5%	A076826	001	Feb 10, 2011	Feb CAHN
----	--	------------------	------	---------	-----	--------------	----------

TABLET;ORAL

LEVOFLOXACIN

@		MYLAN	250MG	A076276	001	Jun 20, 2011	Jul DISC
---	--	-------	-------	---------	-----	--------------	----------

@			500MG	A076276	002	Jun 20, 2011	Jul DISC
---	--	--	-------	---------	-----	--------------	----------

@			750MG	A077097	001	Jun 20, 2011	Jun DISC
---	--	--	-------	---------	-----	--------------	----------

LEVOLEUCOVORIN CALCIUM

POWDER;IV (INFUSION)

LEVOLEUCOVORIN CALCIUM

AP		ACTAVIS LLC	EQ 50MG BASE/VIAL	A206516	001	Feb 13, 2017	Jan NEWA
----	--	-------------	-------------------	---------	-----	--------------	----------

+	!		EQ 175MG BASE/VIAL	N208723	001	Sep 29, 2016	May CRLD
---	---	--	--------------------	---------	-----	--------------	----------

AP		AMNEAL PHARMS CO	EQ 50MG BASE/VIAL	A207547	001	Feb 13, 2017	Jan NEWA
----	--	------------------	-------------------	---------	-----	--------------	----------

SOLUTION;IV (INFUSION)

LEVOLEUCOVORIN CALCIUM

AP		AMNEAL PHARMS CO	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A207548	001	Sep 08, 2017	Aug NEWA
----	--	------------------	--	---------	-----	--------------	----------

LEVONORDEFRIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

ISOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN

@		SEPTODONT INC	0.05MG/ML;2%	A084697	001		May CAHN
---	--	---------------	--------------	---------	-----	--	----------

MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFRIN

@		BELMORA LLC	0.05MG/ML;2%	A084850	002	Oct 21, 1983	Feb CAHN
---	--	-------------	--------------	---------	-----	--------------	----------

LEVOTHYROXINE SODIUM

CAPSULE;ORAL

TIROSINT

>A>	+	INSTITUT BIOCHIMIQUE	0.175MG	N021924	011	Apr 25, 2017	Sep NEWA
-----	---	----------------------	---------	---------	-----	--------------	----------

>A>	+		0.200MG	N021924	012	Apr 25, 2017	Sep NEWA
-----	---	--	---------	---------	-----	--------------	----------

SOLUTION;ORAL

TIROSINT-SOL

+	@	INSTITUT BIOCHIMIQUE	13MCG/ML	N206977	001	Dec 15, 2016	Jun DISC
---	---	----------------------	----------	---------	-----	--------------	----------

SOLUTION;ORAL  
TIROSINT-SOL

+ @	25MCG/ML	N206977	002	Dec 15, 2016	Jun	DISC
+ @	50MCG/ML	N206977	003	Dec 15, 2016	Jun	DISC
+ @	75MCG/ML	N206977	004	Dec 15, 2016	Jun	DISC
+ @	88MCG/ML	N206977	005	Dec 15, 2016	Jun	DISC
+ @	100MCG/ML	N206977	006	Dec 15, 2016	Jun	DISC
+ @	112MCG/ML	N206977	007	Dec 15, 2016	Jun	DISC
+ @	125MCG/ML	N206977	008	Dec 15, 2016	Jun	DISC
+ @	137MCG/ML	N206977	009	Dec 15, 2016	Jun	DISC
+ @	150MCG/ML	N206977	010	Dec 15, 2016	Jun	DISC
+ @	175MCG/ML	N206977	011	Dec 15, 2016	Jun	DISC
+ @	200MCG/ML	N206977	012	Dec 15, 2016	Jun	DISC

LEVOTHYROXINE SODIUM \*\*

\*\*See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL  
LEVOLET

>A>	@ GENUS LIFESCIENCES	0.025MG	N021137	001	Jun 06, 2003	Sep	CAHN
>A>	@	0.05MG	N021137	002	Jun 06, 2003	Sep	CAHN
>A>	@	0.075MG	N021137	003	Jun 06, 2003	Sep	CAHN
>A>	@	0.088MG	N021137	004	Jun 06, 2003	Sep	CAHN
>A>	@	0.1MG	N021137	005	Jun 06, 2003	Sep	CAHN
>A>	@	0.112MG	N021137	006	Jun 06, 2003	Sep	CAHN
>A>	@	0.125MG	N021137	007	Jun 06, 2003	Sep	CAHN
>A>	@	0.137MG	N021137	008	Jun 06, 2003	Sep	CAHN
>A>	@	0.15MG	N021137	009	Jun 06, 2003	Sep	CAHN
>A>	@	0.175MG	N021137	010	Jun 06, 2003	Sep	CAHN
>A>	@	0.2MG	N021137	011	Jun 06, 2003	Sep	CAHN
>A>	@	0.3MG	N021137	012	Jun 06, 2003	Sep	CAHN
>D>	@ LEHIGH VALLEY	0.025MG	N021137	001	Jun 06, 2003	Sep	CAHN
>D>	@	0.05MG	N021137	002	Jun 06, 2003	Sep	CAHN
>D>	@	0.075MG	N021137	003	Jun 06, 2003	Sep	CAHN
>D>	@	0.088MG	N021137	004	Jun 06, 2003	Sep	CAHN
>D>	@	0.1MG	N021137	005	Jun 06, 2003	Sep	CAHN
>D>	@	0.112MG	N021137	006	Jun 06, 2003	Sep	CAHN
>D>	@	0.125MG	N021137	007	Jun 06, 2003	Sep	CAHN
>D>	@	0.137MG	N021137	008	Jun 06, 2003	Sep	CAHN
>D>	@	0.15MG	N021137	009	Jun 06, 2003	Sep	CAHN
>D>	@	0.175MG	N021137	010	Jun 06, 2003	Sep	CAHN
>D>	@	0.2MG	N021137	011	Jun 06, 2003	Sep	CAHN
>D>	@	0.3MG	N021137	012	Jun 06, 2003	Sep	CAHN
>D>	LEVOTHROID						
>D>	+ @ LLOYD	0.025MG	N021116	001	Oct 24, 2002	Sep	CTNA
>D>	+ @	0.05MG	N021116	002	Oct 24, 2002	Sep	CTNA
>D>	+ @	0.075MG	N021116	003	Oct 24, 2002	Sep	CTNA
>D>	+ @	0.088MG	N021116	010	Oct 24, 2002	Sep	CTNA
>D>	+ @	0.1MG	N021116	004	Oct 24, 2002	Sep	CTNA
>D>	+ @	0.112MG	N021116	011	Oct 24, 2002	Sep	CTNA
>D>	+ @	0.125MG	N021116	005	Oct 24, 2002	Sep	CTNA
>D>	+ @	0.137MG	N021116	012	Dec 07, 2004	Sep	CTNA
>D>	+ @	0.15MG	N021116	006	Oct 24, 2002	Sep	CTNA
>D>	+ @	0.175MG	N021116	007	Oct 24, 2002	Sep	CTNA
>D>	+ @	0.2MG	N021116	008	Oct 24, 2002	Sep	CTNA
>D>	+ @	0.3MG	N021116	009	Oct 24, 2002	Sep	CTNA

LEVOXYL

AB1, AB3	+ KING PHARMS	0.025MG	N021301	001	May 25, 2001	May	CAHN
AB1, AB3	+	0.05MG	N021301	002	May 25, 2001	May	CAHN
AB1, AB3	+	0.075MG	N021301	003	May 25, 2001	May	CAHN
AB1, AB3	+	0.088MG	N021301	004	May 25, 2001	May	CAHN
AB1, AB3	+	0.1MG	N021301	005	May 25, 2001	May	CAHN
AB1, AB3	+	0.112MG	N021301	006	May 25, 2001	May	CAHN
AB1, AB3	+	0.125MG	N021301	007	May 25, 2001	May	CAHN
AB1, AB3	+	0.137MG	N021301	008	May 25, 2001	May	CAHN
AB1, AB3	+	0.15MG	N021301	009	May 25, 2001	May	CAHN
AB1, AB3	+	0.175MG	N021301	010	May 25, 2001	May	CAHN



TABLET;ORAL							
LEVOXYL							
AB3							
AB1, AB3	+!	0.2MG	N021301	011	May 25, 2001	May	CAHN
	+ @	0.3MG	N021301	012	May 25, 2001	May	CAHN
>A>	THYRO-TABS						
>A>	+ @ LLOYD	0.025MG	N021116	001	Oct 24, 2002	Sep	CTNA
>A>	+ @	0.05MG	N021116	002	Oct 24, 2002	Sep	CTNA
>A>	+ @	0.075MG	N021116	003	Oct 24, 2002	Sep	CTNA
>A>	+ @	0.088MG	N021116	010	Oct 24, 2002	Sep	CTNA
>A>	+ @	0.1MG	N021116	004	Oct 24, 2002	Sep	CTNA
>A>	+ @	0.112MG	N021116	011	Oct 24, 2002	Sep	CTNA
>A>	+ @	0.125MG	N021116	005	Oct 24, 2002	Sep	CTNA
>A>	+ @	0.137MG	N021116	012	Dec 07, 2004	Sep	CTNA
>A>	+ @	0.15MG	N021116	006	Oct 24, 2002	Sep	CTNA
>A>	+ @	0.175MG	N021116	007	Oct 24, 2002	Sep	CTNA
>A>	+ @	0.2MG	N021116	008	Oct 24, 2002	Sep	CTNA
>A>	+ @	0.3MG	N021116	009	Oct 24, 2002	Sep	CTNA
<u>LIDOCAINE</u>							
OINTMENT;TOPICAL							
LIDOCAINE							
AT	ALKEM LABS LTD	5%	A207810	001	Mar 10, 2017	Feb	NEWA
AT	! FOUGERA PHARMS INC	5%	A080198	001		Jan	CAHN
>A>	AT RICONPHARMA LLC	5%	A208604	001	Sep 20, 2017	Sep	NEWA
>A>	AT VITRUVIAS THERAP	5%	A208822	001	Sep 25, 2017	Sep	NEWA
XYLOCAINE							
	+ @ ASTRAZENECA	5%	N008048	001		Jan	CRLD
<u>LIDOCAINE HYDROCHLORIDE</u>							
INJECTABLE;INJECTION							
LIDOCAINE HYDROCHLORIDE							
	@ BELMORA LLC	2%	A080504	001		Feb	CAHN
<u>LIDOCAINE; TETRACAINE</u>							
CREAM;TOPICAL							
PLIAGLIS							
	+! TARO PHARMS	7%;7%	N021717	001	Jun 29, 2006	May	CAHN
<u>LINACLOTIDE</u>							
CAPSULE;ORAL							
LINZESS							
	+ FOREST LABS LLC	72MCG	N202811	003	Jan 25, 2017	Jan	NEWA
<u>LINEZOLID</u>							
SOLUTION;IV (INFUSION)							
LINEZOLID							
AP	HQ SPCLT PHARMA	200MG/100ML (2MG/ML)	A207001	001	Jul 07, 2017	Jun	NEWA
AP		600MG/300ML (2MG/ML)	A207001	002	Jul 07, 2017	Jun	NEWA
AP	SAGENT PHARMS	200MG/100ML (2MG/ML)	A204696	001	Mar 02, 2017	Feb	NEWA
AP		600MG/300ML (2MG/ML)	A204696	002	Mar 02, 2017	Feb	NEWA
TABLET;ORAL							
LINEZOLID							
AB	ZYDUS PHARMS USA INC	600MG	A206097	001	Feb 22, 2017	Feb	NEWA
<u>LIOTHYRONINE SODIUM</u>							
TABLET;ORAL							
CYTOMEL							
AB	+ KING PHARMS	EQ 0.005MG BASE	N010379	001		Mar	CAHN
AB	+!	EQ 0.025MG BASE	N010379	002		Mar	CAHN
AB	+!	EQ 0.05MG BASE	N010379	003		Mar	CAHN
<u>LISDEXAMFETAMINE DIMESYLATE</u>							
TABLET, CHEWABLE;ORAL							
VYVANSE							
	+ SHIRE DEV LLC	10MG	N208510	001	Jan 28, 2017	Jan	NEWA
	+!	20MG	N208510	002	Jan 28, 2017	Jan	NEWA
	+!	30MG	N208510	003	Jan 28, 2017	Jan	NEWA
	+!	40MG	N208510	004	Jan 28, 2017	Jan	NEWA
	+!	50MG	N208510	005	Jan 28, 2017	Jan	NEWA
	+!	60MG	N208510	006	Jan 28, 2017	Apr	CHRS

TABLET, CHEWABLE;ORAL  
VYVANSE

+		60MG	N208510	006	Jan 28, 2017	Jan NEWA
---	--	------	---------	-----	--------------	----------

LISINOPRIL

TABLET;ORAL  
LISINOPRIL

AB	PRINSTON INC	2.5MG	A075743	001	Jul 01, 2002	Feb CAHN
AB		5MG	A075743	002	Jul 01, 2002	Feb CAHN
AB		10MG	A075743	003	Jul 01, 2002	Feb CAHN
AB		20MG	A075743	004	Jul 01, 2002	Feb CAHN
AB		30MG	A075743	005	Jul 01, 2002	Feb CAHN
AB		40MG	A075743	006	Jul 01, 2002	Feb CAHN

LITHIUM CARBONATE

CAPSULE;ORAL  
LITHIUM CARBONATE

AB	MYLAN PHARMS INC	150MG	A076243	002	Feb 24, 2003	Jan CAHN
AB		300MG	A076243	001	Jun 27, 2002	Jan CAHN
AB		600MG	A078763	001	Apr 15, 2008	Jan CAHN
AB	+ WEST-WARD PHARMS INT	150MG	N017812	002	Jan 28, 1987	Jan CAHN
AB	+	300MG	N017812	001		Jan CAHN
AB	+	600MG	N017812	003	Jan 28, 1987	Jan CAHN

TABLET;ORAL  
LITHIUM CARBONATE

AB	#! WEST-WARD PHARMS INT	300MG	N018558	001	Jan 29, 1982	Jan CAHN
----	-------------------------	-------	---------	-----	--------------	----------

TABLET, EXTENDED RELEASE;ORAL  
LITHIUM CARBONATE

AB	UNIQUE PHARM LABS	450MG	A205663	001	Jun 05, 2017	May NEWA
----	-------------------	-------	---------	-----	--------------	----------

LITHIUM CITRATE

SYRUP;ORAL  
LITHIUM CITRATE

AA	#! WEST-WARD PHARMS INT	EQ 300MG CARBONATE/5ML	N018421	001		Jan CAHN
----	-------------------------	------------------------	---------	-----	--	----------

LORAZEPAM

INJECTABLE;INJECTION  
LORAZEPAM

AP	SAGENT AGILA LLC	2MG/ML	A200217	001	Apr 04, 2017	Mar NEWA
AP		2MG/ML	A200542	001	Apr 28, 2017	Apr NEWA
AP		4MG/ML	A200217	002	Apr 04, 2017	Mar NEWA
AP		4MG/ML	A200542	002	Apr 28, 2017	Apr NEWA
	@ WEST-WARD PHARMS INT	2MG/ML	A074496	001	Sep 28, 1998	Mar CAHN
	@	4MG/ML	A074496	002	Sep 28, 1998	Mar CAHN

TABLET;ORAL  
LORAZEPAM

>A>	@ ANDA REPOSITORY	0.5MG	A072553	001	Mar 29, 1991	Sep CAHN
>A>	@	1MG	A072554	001	Mar 29, 1991	Sep CAHN
>A>	@	2MG	A072555	001	Mar 29, 1991	Sep CAHN
>D>	@ FRONTIDA BIOPHARM	0.5MG	A072553	001	Mar 29, 1991	Sep CAHN
>D>	@	1MG	A072554	001	Mar 29, 1991	Sep CAHN
>D>	@	2MG	A072555	001	Mar 29, 1991	Sep CAHN
AB	SANDOZ	0.5	A071141	002	Apr 21, 1987	Apr CMS1
AB		1MG	A071141	003	Apr 21, 1987	Apr CMS1

LOSARTAN POTASSIUM

TABLET;ORAL  
LOSARTAN POTASSIUM

AB	HETERO LABS LTD V	25MG	A203835	001	Aug 12, 2015	Jul CTEC
AB		50MG	A203835	002	Aug 12, 2015	Jul CTEC
AB		100MG	A203835	003	Aug 12, 2015	Jul CTEC
>D>	AB MICRO LABS LTD INDIA	25MG	A091541	001	Sep 24, 2012	Sep CAHN
>D>	AB	50MG	A091541	002	Sep 24, 2012	Sep CAHN
>D>	AB	100MG	A091541	003	Sep 24, 2012	Sep CAHN
AB	UPSHER-SMITH LABS	25MG	A090544	001	Oct 06, 2010	Jun CAHN
AB		50MG	A090544	002	Oct 06, 2010	Jun CAHN
AB		100MG	A090544	003	Oct 06, 2010	Jun CAHN
>A>	AB VIVA HLTHCARE	25MG	A091541	001	Sep 24, 2012	Sep CAHN
>A>	AB	50MG	A091541	002	Sep 24, 2012	Sep CAHN
>A>	AB	100MG	A091541	003	Sep 24, 2012	Sep CAHN
AB	VIVIMED GLOBAL	25MG	A090382	001	Oct 06, 2010	Aug CAHN
AB		50MG	A090382	002	Oct 06, 2010	Aug CAHN

## TABLET;ORAL

	LOSARTAN POTASSIUM						
AB		100MG		A090382	003	Oct 06, 2010	Aug CAHN

LOVASTATIN

## TABLET;ORAL

## LOVASTATIN

	@ MYLAN	10MG		A075935	001	Dec 17, 2001	Mar DISC
	@	20MG		A075935	002	Dec 17, 2001	Mar DISC
	@	40MG		A075935	003	Dec 17, 2001	Mar DISC

## TABLET, EXTENDED RELEASE;ORAL

## ALTOPREV

	@ COVIS PHARMA BV	10MG		N021316	001	Jun 26, 2002	Apr CAHN
	+	20MG		N021316	002	Jun 26, 2002	Apr CAHN
	+	40MG		N021316	003	Jun 26, 2002	Apr CAHN
	+	60MG		N021316	004	Jun 26, 2002	Apr CAHN

LOXAPINE

## POWDER; INHALATION

## ADASUVE

>D>	+	ALEXZA PHARMS	10MG	N022549	001	Dec 21, 2012	Sep CAHN
>A>	+	GALEN UK	10MG	N022549	001	Dec 21, 2012	Sep CAHN

MAFENIDE ACETATE

## FOR SOLUTION;TOPICAL

## MAFENIDE ACETATE

>A>	AT	NOVAST LABS LTD	5%	A206716	001	Jul 31, 2017	Sep CAHN
>D>	AT	RICONPHARMA LLC	5%	A206716	001	Jul 31, 2017	Sep CAHN
	AT		5%	A206716	001	Jul 31, 2017	Jul NEWA

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

## INJECTABLE;INJECTION

## NORMOSOL-R IN PLASTIC CONTAINER

	ICU MEDICAL INC	30MG/100ML;37MG/100ML;222MG/100ML; 526MG/100ML;502MG/100ML		N017586	001		Feb CAHN
--	-----------------	---	--	---------	-----	--	----------

## SOLUTION;IRRIGATION

## PHYSIOSOL IN PLASTIC CONTAINER

	ICU MEDICAL INC	30MG/100ML;37MG/100ML;222MG/100ML; 526MG/100ML;502MG/100ML		N017637	002	Jul 08, 1982	Feb CAHN
--	-----------------	---	--	---------	-----	--------------	----------

MAGNESIUM SULFATE ANHYDROUS; POTASSIUM SULFATE; SODIUM SULFATE

## SOLUTION;ORAL

## SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE

AA		NOVEL LABS INC	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	A202511	001	Feb 23, 2017	Feb NEWA
		SUPREP BOWEL PREP KIT					
AA	+	BRAINTREE LABS	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	N022372	001	Aug 05, 2010	Feb CFTG

MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE

## SOLUTION;ORAL

## SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE

AA		NOVEL LABS INC	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	A202511	001	Feb 23, 2017	May CAIN
		SUPREP BOWEL PREP KIT					
AA	+	BRAINTREE LABS	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	N022372	001	Aug 05, 2010	May CAIN

MALATHION

## LOTION;TOPICAL

## OVIDE

AT	+	TARO PHARM	0.5%	N018613	001	Aug 02, 1982	May CAHN
----	---	------------	------	---------	-----	--------------	----------

MANNITOL

## INJECTABLE;INJECTION

## MANNITOL 10% IN PLASTIC CONTAINER

AP		ICU MEDICAL INC	10GM/100ML	N019603	002	Jan 08, 1987	Feb CAHN
----	--	-----------------	------------	---------	-----	--------------	----------

## MANNITOL 15% IN PLASTIC CONTAINER

AP		ICU MEDICAL INC	15GM/100ML	N019603	003	Jan 08, 1990	Feb CAHN
----	--	-----------------	------------	---------	-----	--------------	----------

## MANNITOL 20% IN PLASTIC CONTAINER

AP		ICU MEDICAL INC	20GM/100ML	N019603	004	Jan 08, 1990	Feb CAHN
----	--	-----------------	------------	---------	-----	--------------	----------

## MANNITOL 5% IN PLASTIC CONTAINER

AP		ICU MEDICAL INC	5GM/100ML	N019603	001	Jan 08, 1987	Feb CAHN
----	--	-----------------	-----------	---------	-----	--------------	----------

MANNITOL; SORBITOL

SOLUTION; IRRIGATION

SORBITOL-MANNITOL IN PLASTIC CONTAINER

ICU MEDICAL INC

540MG/100ML; 2.7GM/100ML

N018316 001

Feb CAHN

MAPROTILINE HYDROCHLORIDE

TABLET; ORAL

MAPROTILINE HYDROCHLORIDE

@ WATSON LABS TEVA 25MG

A072162 001 Jun 01, 1988

May CAHN

@ 50MG

A072163 001 Jun 01, 1988

May CAHN

MEBENDAZOLE

TABLET, CHEWABLE; ORAL

EMVERM

! IMPAX LABS INC 100MG

A073580 001 Jan 04, 1995

Jun CAHN

MECAMYLAMINE HYDROCHLORIDE

TABLET; ORAL

MECAMYLAMINE HYDROCHLORIDE

! NEXGEN PHARMA 2.5MG

A204054 001 Mar 19, 2013

May CHRS

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

AA AMNEAL PHARMS 12.5MG

A201451 001 Feb 23, 2011

May CAHN

AA 25MG

A201451 002 Feb 23, 2011

May CAHN

@ 50MG

A201451 003 Feb 23, 2011

May CAHN

@ PLIVA 25MG

A088734 001 Dec 11, 1985

Aug CAHN

MECLOFENAMATE SODIUM

CAPSULE; ORAL

MECLOFENAMATE SODIUM

@ WATSON LABS TEVA EQ 100MG BASE

A071469 001 Apr 15, 1987

May CAHN

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

MEDROXYPROGESTERONE ACETATE

AB @ SANDOZ INC 150MG/ML

A078711 001 May 20, 2009

Jun DISC

AB 150MG/ML

A078711 001 May 20, 2009

Mar CAHN

AB TEVA PHARMS USA 150MG/ML

A076553 001 Jul 28, 2004

Jan CAHN

TABLET; ORAL

MEDROXYPROGESTERONE ACETATE

@ USL PHARMA 10MG

A088484 001 Jul 26, 1984

Jun CAHN

MEFENAMIC ACID

CAPSULE; ORAL

MEFENAMIC ACID

&gt;D&gt; AB MICRO LABS LTD 250MG

A090562 001 Nov 19, 2010

Sep CAHN

&gt;A&gt; AB VIVA HLTHCARE 250MG

A090562 001 Nov 19, 2010

Sep CAHN

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL

LARIAM

&gt;D&gt; @ ROCHE 250MG

N019591 001 May 02, 1989

Sep CRLD

&gt;A&gt; + @ 250MG

N019591 001 May 02, 1989

Sep CRLD

MEFLOQUINE HYDROCHLORIDE

AB ! BARR 250MG

A076392 001 Dec 29, 2003

Apr CHRS

@ SANDOZ 250MG

A076175 001 Feb 20, 2002

Apr DISC

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGACE

+ @ BRISTOL MYERS SQUIBB 40MG/ML

N020264 001 Sep 10, 1993

Feb DISC

MEGESTROL ACETATE

AB HI-TECH PHARMACAL 40MG/ML

A203960 001 Jun 09, 2017

May NEWA

AB ! WEST-WARD PHARMS INT 40MG/ML

A075997 001 Feb 15, 2002

Feb CHRS

MELOXICAM

>D>	SUSPENSION;ORAL							
>D>	MOBIC							
>D>	+! BOEHRINGER INGELHEIM	7.5MG/5ML		N021530	001	Jun 01, 2004	Sep	DISC
>A>	+ @	7.5MG/5ML		N021530	001	Jun 01, 2004	Sep	DISC
	TABLET;ORAL							
	MELOXICAM							
>A>	@ ANDA REPOSITORY	7.5MG		A077935	001	Jul 19, 2006	Sep	CAHN
>A>	@	15MG		A077935	002	Jul 19, 2006	Sep	CAHN
>D>	@ FRONTIDA BIOPHARM	7.5MG		A077935	001	Jul 19, 2006	Sep	CAHN
>D>	@	15MG		A077935	002	Jul 19, 2006	Sep	CAHN
	@ SUN PHARM INDS INC	7.5MG		A077937	001	Jul 19, 2006	Apr	DISC
	@	15MG		A077937	002	Jul 19, 2006	Apr	DISC

MELPHALAN

	TABLET;ORAL							
	ALKERAN							
AB	+! APOTEX INC	2MG		N014691	002		Mar	CFTG
	MELPHALAN							
AB	ALVOGEN MALTA	2MG		A207809	001	Mar 22, 2017	Mar	NEWA

MELPHALAN HYDROCHLORIDE

	INJECTABLE;INJECTION							
	ALKERAN							
	+ @ APOTEX INC	EQ 50MG BASE/VIAL		N020207	001	Nov 18, 1992	May	DISC
	MELPHALAN HYDROCHLORIDE							
AP	! MYLAN INSTITUTIONAL	EQ 50MG BASE/VIAL		A090270	001	Jun 09, 2009	May	CHRS
AP	SAGENT PHARMS	EQ 50MG BASE/VIAL		A201379	001	Feb 28, 2017	Feb	NEWA
	POWDER;IV (INFUSION)							
	EVOMELA							
	+! SPECTRUM PHARMS	EQ 50MG BASE/VIAL		N207155	001	Mar 10, 2016	Aug	CRLD

MEMANTINE HYDROCHLORIDE

	CAPSULE, EXTENDED RELEASE;ORAL							
	MEMANTINE HYDROCHLORIDE							
AB	AMNEAL PHARMS	7MG		A205825	001	Oct 12, 2016	May	CAHN
AB		14MG		A205825	002	Oct 12, 2016	May	CAHN
AB		21MG		A205825	003	Oct 12, 2016	May	CAHN
AB		28MG		A205825	004	Oct 12, 2016	May	CAHN
AB	ANCHEN PHARMS	7MG		A205784	001	Jun 09, 2017	May	NEWA
AB		14MG		A205784	002	Jun 09, 2017	May	NEWA
AB		21MG		A205784	003	Jun 09, 2017	May	NEWA
AB		28MG		A205784	004	Jun 09, 2017	May	NEWA
AB	ZYDUS PHARMS USA INC	7MG		A203293	001	Aug 03, 2017	Jul	NEWA
AB		14MG		A203293	002	Aug 03, 2017	Jul	NEWA
AB		21MG		A203293	003	Aug 03, 2017	Jul	NEWA
AB		28MG		A203293	004	Aug 03, 2017	Jul	NEWA
	TABLET;ORAL							
	MEMANTINE HYDROCHLORIDE							
AB	AMNEAL PHARMS	5MG		A090041	001	Apr 10, 2015	May	CAHN
AB		10MG		A090041	002	Apr 10, 2015	May	CAHN
AB	STRIDES PHARMA	5MG		A202350	001	May 23, 2017	May	NEWA
AB		10MG		A202350	002	May 23, 2017	May	NEWA
AB	UPSHER-SMITH LABS	5MG		A090043	001	Jul 31, 2015	Jun	CAHN
AB		10MG		A090043	002	Jul 31, 2015	Jun	CAHN
AB	ZYDUS PHARMS USA INC	5MG		A090961	001	Jul 10, 2017	Jun	NEWA
AB		10MG		A090961	002	Jul 10, 2017	Jun	NEWA

MEPENZOLATE BROMIDE

	TABLET;ORAL							
	CANTIL							
	+ @ SANOFI AVENTIS US	25MG		N010679	003		Aug	DISC

MEPERIDINE HYDROCHLORIDE

	INJECTABLE;INJECTION							
	MEPERIDINE HYDROCHLORIDE							
AP	WEST-WARD PHARMS INT	25MG/ML		A080445	001		Jan	CAHN
AP		25MG/ML		A080455	007		Jan	CAHN
AP		50MG/ML		A080445	002		Jan	CAHN
AP		50MG/ML		A080455	008		Jan	CAHN
AP		75MG/ML		A080445	003		Jan	CAHN

INJECTABLE; INJECTION									
MEPERIDINE HYDROCHLORIDE									
AP		75MG/ML		A080455	009			Jan	CAHN
AP		100MG/ML		A080445	004			Jan	CAHN
AP		100MG/ML		A080455	010			Jan	CAHN
MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE									
AP	!	ICU MEDICAL INC	10MG/ML	A088432	001	Aug 16, 1984		Apr	CAHN
	@	MALLINCKRODT INC	10MG/ML	A040163	001	May 12, 1997		Mar	CAHN
AP		WEST-WARD PHARMS INT	10MG/ML	A081002	001	Jul 30, 1993		Apr	CAHN
<u>MEPIVACAINE HYDROCHLORIDE</u>									
INJECTABLE; INJECTION									
ISOCAINE HYDROCHLORIDE									
AP	!	SEPTODONT INC	3%	A080925	001			May	CAHN
MEPIVACAINE HYDROCHLORIDE									
	@	BELMORA LLC	3%	A083559	001			Feb	CAHN
<u>MERCAPTOPURINE</u>									
TABLET; ORAL									
MERCAPTOPURINE									
AB		DR REDDYS LABS SA	50MG	A040461	001	Feb 11, 2004		Jun	CAHN
<u>MEROPENEM</u>									
INJECTABLE; INJECTION									
MEROPENEM									
AP		AUROBINDO PHARMA LTD	500MG/VIAL	A205835	001	Mar 27, 2017		Mar	NEWA
AP			1GM/VIAL	A205835	002	Mar 27, 2017		Mar	NEWA
	@	SANDOZ	500MG/VIAL	A091201	001	Mar 29, 2011		Jun	DISC
	@		1GM/VIAL	A091201	002	Mar 29, 2011		Jun	DISC
MERREM									
AP	+	PFIZER	500MG/VIAL	N050706	003	Jun 21, 1996		Jun	CAHN
AP	+		1GM/VIAL	N050706	001	Jun 21, 1996		Jun	CAHN
<u>MEROPENEM; VABORBACTAM</u>									
POWDER; IV (INFUSION)									
VABOMERE									
	+	REMPEX PHARMS MEDCNS	1GM/VIAL; 1GM/VIAL	N209776	001	Aug 29, 2017		Aug	NEWA
<u>MESALAMINE</u>									
ENEMA; RECTAL									
ROWASA									
AB	+	MYLAN SPECIALITY LP	4GM/60ML	N019618	001	Dec 24, 1987		Mar	CAHN
SFROWASA									
AB	+	MYLAN SPECIALITY LP	4GM/60ML	N019618	002	Jun 20, 2008		Mar	CAHN
TABLET, DELAYED RELEASE; ORAL									
ASACOL HD									
AB	+	APIL	800MG	N021830	001	May 29, 2008		Jul	CFTG
LIALDA									
AB	+	SHIRE	1.2GM	N022000	001	Jan 16, 2007		May	CFTG
MESALAMINE									
AB		ZYDUS PHARMS USA INC	800MG	A203286	001	Jul 21, 2017		Jul	NEWA
AB			1.2GM	A091640	001	Jun 05, 2017		May	NEWA
<u>METAXALONE</u>									
TABLET; ORAL									
METAXALONE									
AB		ACTAVIS LABS FL INC	800MG	A203695	001	Jun 15, 2017		Jun	NEWA
	@	EPIC PHARMA LLC	640MG	N022503	001	Jun 01, 2015		May	CAHN
		IMPAX LABS INC	400MG	A040486	001	Feb 27, 2015		Feb	CAHN
AB		SCIEGEN PHARMS INC	800MG	A207466	001	Aug 31, 2017		Aug	NEWA
SKELAXIN									
	+	@ KING PHARMS	400MG	N013217	001			May	CAHN
AB	+		800MG	N013217	003	Aug 30, 2002		May	CAHN
<u>METFORMIN HYDROCHLORIDE</u>									
TABLET; ORAL									
METFORMIN HYDROCHLORIDE									
	@	MYLAN PHARMS INC	500MG	A075969	001	Jan 29, 2002		May	DISC
	@		850MG	A075969	002	Jan 29, 2002		May	DISC
	@		1GM	A075969	003	Jan 29, 2002		May	DISC
	@	WATSON LABS FLORIDA	500MG	A075961	001	Jan 25, 2002		Mar	DISC
	@		850MG	A075961	002	Jan 25, 2002		Mar	DISC

TABLET;ORAL

	METFORMIN HYDROCHLORIDE							
	@	1GM	A075961	003	Jan 25, 2002	Mar	DISC	
	TABLET, EXTENDED RELEASE;ORAL							
	METFORMIN HYDROCHLORIDE							
AB1	INTELLIPHARMACEUTICS	500MG	A202306	001	Feb 23, 2017	Feb	NEWA	
AB		750MG	A202306	002	Feb 23, 2017	Feb	NEWA	
AB1	TORRENT PHARMS LTD	500MG	A090014	001	Dec 30, 2009	Apr	CAHN	

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET;ORAL

ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE  
TEVA 500MG;EQ 1MG BASE

A077337 005 May 19, 2017 May NEWA

METHACHOLINE CHLORIDE

FOR SOLUTION;INHALATION  
PROVOCHOLINE

>D>	+	METHAPHARM	1600MG/VIAL	N019193	002	Aug 29, 2016	Sep	DISC
>A>	+	@	1600MG/VIAL	N019193	002	Aug 29, 2016	Sep	DISC

METHADONE HYDROCHLORIDE

CONCENTRATE;ORAL

METHADOSE

AA	+	MALLINCKRODT INC	10MG/ML	N017116	002		Apr	CAHN
		POWDER;FOR RX COMPOUNDING						
		METHADONE HYDROCHLORIDE						
		MALLINCKRODT INC	50GM/BOT	N006383	002		Apr	CAHN
			100GM/BOT	N006383	003		Apr	CAHN
			500GM/BOT	N006383	004		Apr	CAHN

SYRUP;ORAL

DOLOPHINE HYDROCHLORIDE  
@ WEST-WARD PHARMS INT 10MG/30ML

N006134 004 Jan CAHN

TABLET;ORAL

DOLOPHINE HYDROCHLORIDE

AA	+	WEST-WARD PHARMS INT	5MG	N006134	002		Jan	CAHN
AA	+		10MG	N006134	010		Jan	CAHN
		METHADONE HYDROCHLORIDE						
AA		EPIC PHARMA LLC	5MG	A090065	001	Aug 18, 2015	May	CAHN
AA			10MG	A090065	002	Aug 18, 2015	May	CAHN

TABLET, FOR SUSPENSION;ORAL

METHADONE HYDROCHLORIDE

AA	+	WEST-WARD PHARMS INT	40MG	N017058	001		Jan	CAHN
----	---	----------------------	------	---------	-----	--	-----	------

METHENAMINE HIPPURATE

TABLET;ORAL

METHENAMINE HIPPURATE

AB		IMPAX LABS INC	1GM	A076411	001	Jun 20, 2003	Feb	CAHN
----	--	----------------	-----	---------	-----	--------------	-----	------

METHIMAZOLE

TABLET;ORAL

METHIMAZOLE

	@	ECI PHARMS LLC	15MG	A040619	003	Jul 12, 2005	May	CAHN
		TAPAZOLE						
AB		KING PHARMS LLC	5MG	A040320	001	Mar 31, 2000	Feb	CAHN
AB			10MG	A040320	002	Mar 31, 2000	Feb	CAHN

METHOCARBAMOL

SOLUTION;IM-IV

METHOCARBAMOL

AP		LUITPOLD PHARMS INC	1GM/10ML (100MG/ML)	A207496	001	Jun 22, 2017	Jun	NEWA
AP		RENAISSANCE PHARMA	1GM/10ML (100MG/ML)	A208116	001	Jan 19, 2017	Jan	NEWA
AP		RENAISSANCE SSA LLC	1GM/10ML (100MG/ML)	A208116	001	Jan 19, 2017	Mar	CAHN
AP		SAGENT PHARMS	1GM/10ML (100MG/ML)	A205404	001	Jul 18, 2017	Jul	NEWA
AP		SOMERSET THERAPS LLC	1GM/10ML (100MG/ML)	A207522	001	Jul 31, 2017	Jul	NEWA

TABLET;ORAL

METHOCARBAMOL

AA		ATLAS PHARMS LLC	500MG	A203550	001	Feb 08, 2017	Jan	NEWA
AA			750MG	A203550	002	Feb 08, 2017	Jan	NEWA
AA		BEXIMCO PHARMS USA	500MG	A208507	001	Jul 21, 2017	Jul	NEWA
AA			750MG	A208507	002	Jul 21, 2017	Jul	NEWA
	@	UPSHER SMITH	500MG	A087453	001		Jun	CAHN

TABLET;ORAL  
METHOCARBAMOL  
@

750MG

A 087454 001

Jun CAHN

METHOTREXATE

SOLUTION;SUBCUTANEOUS  
OTREXUP PFS

+	ANTARES PHARMA INC	10MG/0.4ML (10MG/0.4ML)	N204824	009	May 31, 2017	Jul	NEWA
+		15MG/0.6ML (15MG/0.6ML)	N204824	010	May 31, 2017	Jul	NEWA
+		17.5MG/0.7ML (17.5MG/0.7ML)	N204824	011	May 31, 2017	Jul	NEWA
+		20MG/0.8ML (20MG/0.8ML)	N204824	012	May 31, 2017	Jul	NEWA
+		22.5MG/0.9ML (22.5MG/0.9ML)	N204824	013	May 31, 2017	Jul	NEWA
+		25MG/ML (25MG/ML)	N204824	014	May 31, 2017	Jul	NEWA
	RASUVO						
@	MEDAC PHARMA INC	27.5MG/0.55ML (27.5MG/0.55ML)	N205776	009	Jul 10, 2014	Jun	DISC

METHOTREXATE SODIUM

INJECTABLE;INJECTION  
METHOTREXATE SODIUM PRESERVATIVE FREE

AP	PHARMACHEMIE BV	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A 040843	002	Jan 11, 2010	Apr	CMS1
AP		EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A 040843	003	Feb 27, 2012	Apr	CMS1
AP		EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A 040843	004	Jan 11, 2010	Apr	CMS1

SOLUTION;ORAL  
XATMEP

+	SILVERGATE PHARMS	EQ 2.5MG BASE/ML	N208400	001	Apr 25, 2017	Apr	NEWA
---	-------------------	------------------	---------	-----	--------------	-----	------

TABLET;ORAL

	METHOTREXATE SODIUM						
AB	ORION CORP ORION	EQ 2.5MG BASE	A201749	001	May 21, 2015	Jul	CAHN
AB	ZYDUS PHARMS USA INC	EQ 2.5MG BASE	A207812	001	Jan 13, 2017	Jan	NEWA

METHYLDOPATE HYDROCHLORIDE

INJECTABLE;INJECTION  
METHYLDOPATE HYDROCHLORIDE

!	LUITPOLD	50MG/ML	A 071279	001	Oct 02, 1987	Jan	CTEC
---	----------	---------	----------	-----	--------------	-----	------

METHYLERGONOVINE MALEATE

INJECTABLE;INJECTION  
METHYLERGONOVINE MALEATE

>A>	AP	BRECKENRIDGE PHARM	0.2MG/ML	A 040889	001	Sep 13, 2010	Sep	CAHN
>D>	AP	ERGOJECT	0.2MG/ML	A 040889	001	Sep 13, 2010	Sep	CAHN

METHYLPHENIDATE

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL  
COTEMPLA XR-ODT

+	NEOS THERAPS INC	8.6MG	N205489	001	Jun 19, 2017	Jun	NEWA
+		17.3MG	N205489	002	Jun 19, 2017	Jun	NEWA
+		25.9MG	N205489	003	Jun 19, 2017	Jun	NEWA

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL  
METHYLPHENIDATE HYDROCHLORIDE

AB2	IMPAX LABS INC	10MG	A205105	001	Jul 28, 2016	Feb	CAHN
AB2		20MG	A205105	002	Jul 28, 2016	Feb	CAHN
AB2		30MG	A205105	003	Jul 28, 2016	Feb	CAHN
AB2		40MG	A205105	004	Jul 28, 2016	Feb	CAHN
AB2		50MG	A205105	005	Jul 28, 2016	Feb	CAHN
AB2		60MG	A205105	006	Jul 28, 2016	Feb	CAHN
!	MAYNE PHARMA	60MG	A 078458	004	Jun 23, 2016	Feb	CHRS

SOLUTION;ORAL

METHYLPHENIDATE HYDROCHLORIDE

>A>	AA	BRECKENRIDGE PHARM	5MG/5ML	A201466	001	Nov 12, 2013	Sep	CAHN
>A>	AA		10MG/5ML	A201466	002	Nov 12, 2013	Sep	CAHN
>D>	AA	NOSTRUM LABS INC	5MG/5ML	A201466	001	Nov 12, 2013	Sep	CAHN
>D>	AA		10MG/5ML	A201466	002	Nov 12, 2013	Sep	CAHN

TABLET;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB	ABHAI INC	5MG	A206932	001	May 11, 2017	Apr	NEWA	
AB		10MG	A206932	002	May 11, 2017	Apr	NEWA	
AB		20MG	A206932	003	May 11, 2017	Apr	NEWA	
>A>	AB	BRECKENRIDGE PHARM	5MG	A207587	001	Mar 03, 2017	Sep	CAHN



## TABLET;ORAL

## METHYLPHENIDATE HYDROCHLORIDE

>A>	AB		10MG	A207587	002	Mar 03, 2017	Sep CAHN
>A>	AB		20MG	A207587	003	Mar 03, 2017	Sep CAHN
	AB	IMPAX LABS INC	5MG	A091159	001	Mar 12, 2014	Feb CAHN
	AB		10MG	A091159	002	Mar 12, 2014	Feb CAHN
	AB		20MG	A091159	003	Mar 12, 2014	Feb CAHN
>D>	AB	NOSTRUM LABS INC	5MG	A207587	001	Mar 03, 2017	Sep CAHN
	AB		5MG	A207587	001	Mar 03, 2017	Feb NEWA
>D>	AB		10MG	A207587	002	Mar 03, 2017	Sep CAHN
	AB		10MG	A207587	002	Mar 03, 2017	Feb NEWA
>D>	AB		20MG	A207587	003	Mar 03, 2017	Sep CAHN
	AB		20MG	A207587	003	Mar 03, 2017	Feb NEWA

## TABLET, CHEWABLE;ORAL

## METHYLPHENIDATE HYDROCHLORIDE

>A>	AB	BRECKENRIDGE PHARM	2.5MG	A204954	001	Jan 26, 2017	Sep CAHN
>A>	AB		5MG	A204954	002	Jan 26, 2017	Sep CAHN
>A>	AB		10MG	A204954	003	Jan 26, 2017	Sep CAHN
>D>	AB	NOSTRUM LABS INC	2.5MG	A204954	001	Jan 26, 2017	Sep CAHN
	AB		2.5MG	A204954	001	Jan 26, 2017	Jan NEWA
>D>	AB		5MG	A204954	002	Jan 26, 2017	Sep CAHN
	AB		5MG	A204954	002	Jan 26, 2017	Jan NEWA
>D>	AB		10MG	A204954	003	Jan 26, 2017	Sep CAHN
	AB		10MG	A204954	003	Jan 26, 2017	Jan NEWA

## TABLET, EXTENDED RELEASE;ORAL

## METHYLPHENIDATE HYDROCHLORIDE

	AB	IMPAX LABS INC	18MG	A208607	001	Jul 14, 2017	Jul NEWA
	AB		27MG	A208607	002	Jul 14, 2017	Jul NEWA
	AB		36MG	A208607	003	Jul 14, 2017	Jul NEWA
	AB		54MG	A208607	004	Jul 14, 2017	Jul NEWA
	AB	OSMOTICA	18MG	A205327	001	Jul 28, 2017	Jul NEWA
	AB		27MG	A205327	002	Jul 28, 2017	Jul NEWA
	AB		36MG	A205327	003	Jul 28, 2017	Jul NEWA
	AB		54MG	A205327	004	Jul 28, 2017	Jul NEWA
			72MG	A205327	005	Jul 28, 2017	Jul NEWA
		RITALIN-SR					
	AB	+ NOVARTIS	20MG	N018029	001	Mar 30, 1982	Feb CRLD

METHYLPREDNISOLONE ACETATE

## INJECTABLE;INJECTION

## METHYLPREDNISOLONE ACETATE

	AB	SANDOZ INC	40MG/ML	A040719	001	Jan 29, 2009	Mar CAHN
	AB		40MG/ML	A040794	001	Mar 05, 2009	Jul CAHN
	AB		80MG/ML	A040719	002	Jan 29, 2009	Mar CAHN
	AB		80MG/ML	A040794	002	Mar 05, 2009	Jul CAHN

METHYLTESTOSTERONE

## TABLET;ORAL

## ANDROID 10

## @ VALEANT PHARMS NORTH 10MG

A086450 001 May CAHN

METIPRANOLOL HYDROCHLORIDE

## SOLUTION/DROPS;OPHTHALMIC

## METIPRANOLOL

AT SANDOZ INC 0.3%

A075720 001 Aug 06, 2001 Feb CAHN

METOCLOPRAMIDE HYDROCHLORIDE

## SOLUTION;ORAL

## METOCLOPRAMIDE HYDROCHLORIDE

AA PHARM ASSOC EQ 5MG BASE/5ML

A072744 001 May 28, 1991 May CAHN

## TABLET;ORAL

## METOCLOPRAMIDE HYDROCHLORIDE

## @ SUN PHARM INDS EQ 5MG BASE

A071536 002 Jan 16, 1997 May DISC

METOPROLOL SUCCINATE

## TABLET, EXTENDED RELEASE;ORAL

## TOPROL-XL

	AB	+ ARALEZ PHARMS	EQ 25MG TARTRATE	N019962	004	Feb 05, 2001	Jan CAHN
	AB	+	EQ 50MG TARTRATE	N019962	001	Jan 10, 1992	Jan CAHN
	AB	+	EQ 100MG TARTRATE	N019962	002	Jan 10, 1992	Jan CAHN
	AB	+	EQ 200MG TARTRATE	N019962	003	Jan 10, 1992	Jan CAHN

METOPROLOL TARTRATEINJECTABLE; INJECTION  
METOPROLOL TARTRATE

AP	BAXTER HLTHCARE CORP	1MG/ML	A 078950	001	Apr 29, 2013	Aug	CAHN
AP	SANDOZ INC	1MG/ML	A 077360	001	Oct 02, 2007	Mar	CAHN
AP	WEST-WARD PHARMS INT	1MG/ML	A 076495	001	Jul 07, 2003	Jan	CAHN

TABLET; ORAL  
LOPRESSOR

>D>	AB	US PHARMS HOLDINGS I	50MG	N 017963	001		Sep	CRLD
>A>	AB	+	50MG	N 017963	001		Sep	CRLD
>D>	AB		100MG	N 017963	002		Sep	CRLD
>A>	AB	+	100MG	N 017963	002		Sep	CRLD
		METOPROLOL TARTRATE						
AB	SUN PHARM INDS	50MG	A 073654	003	Dec 21, 1993	Jul	CMS1	

METRONIDAZOLECAPSULE; ORAL  
METRONIDAZOLE

AB	ALEMBIC PHARMS LTD	375MG	A 079065	001	Jun 23, 2009	May	CAHN
----	--------------------	-------	----------	-----	--------------	-----	------

GEL; TOPICAL  
METRONIDAZOLE

AB	TARO PHARM	1%	A 204651	001	Mar 14, 2017	Feb	NEWA
----	------------	----	----------	-----	--------------	-----	------

GEL; VAGINAL  
NUVESSA

+	!	CHEMO RESEARCH SL	1.3%	N 205223	001	Mar 24, 2014	Aug	CAHN
---	---	-------------------	------	----------	-----	--------------	-----	------

INJECTABLE; INJECTION  
METRONIDAZOLE

@	WEST-WARD PHARMS INT	500MG/100ML	N 018907	001	Mar 30, 1984	May	CAHN
---	----------------------	-------------	----------	-----	--------------	-----	------

METRONIDAZOLE IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE CORP	500MG/100ML	A 078084	001	Mar 31, 2008	Aug	CAHN
AP	MYLAN LABS LTD	500MG/100ML	A 205531	001	May 09, 2017	Apr	NEWA

TABLET; ORAL  
METRONIDAZOLE

>D>	AB	ALLIED PHARMA INC	250MG	A 070772	001	Jul 16, 1986	Sep	CAHN
>D>	AB		500MG	A 070773	001	Jul 16, 1986	Sep	CAHN
		@ CHARTWELL MOLECULES	250MG	N 018845	001	Aug 18, 1983	Jun	CAHN
		@	500MG	N 018930	001	Aug 18, 1983	Jun	CAHN
>A>	AB	INNOGENIX	250MG	A 070772	001	Jul 16, 1986	Sep	CAHN
>A>	AB		500MG	A 070773	001	Jul 16, 1986	Sep	CAHN
>A>	AB	LUPIN LTD	250MG	A 209096	001	Sep 12, 2017	Sep	NEWA
>A>	AB		500MG	A 209096	002	Sep 12, 2017	Sep	NEWA
AB	ORIT LABS LLC	250MG	A 208681	001	Jun 20, 2017	Jun	NEWA	
AB		500MG	A 208681	002	Jun 20, 2017	Jun	NEWA	
AB	VIVIMED GLOBAL	250MG	A 070040	001	Jan 29, 1985	Aug	CAHN	
AB		500MG	A 070039	001	Jan 29, 1985	Aug	CAHN	

TABLET, EXTENDED RELEASE; ORAL  
METRONIDAZOLE

AB	ALEMBIC PHARMS LTD	750MG	A 090222	001	May 05, 2010	May	CAHN
----	--------------------	-------	----------	-----	--------------	-----	------

MICONAZOLE NITRATESUPPOSITORY; VAGINAL  
MICONAZOLE NITRATE

AB	ACTAVIS PHARMA	200MG	A 073508	001	Nov 19, 1993	May	CAHN
----	----------------	-------	----------	-----	--------------	-----	------

MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDEOINTMENT; TOPICAL  
VUSION

+	!	MYLAN PHARMS INC	0.25%; 81.35%; 15%	N 021026	001	Feb 16, 2006	Jan	CAHN
---	---	------------------	--------------------	----------	-----	--------------	-----	------

MIDAZOLAM HYDROCHLORIDEINJECTABLE; INJECTION  
MIDAZOLAM HYDROCHLORIDE

@	BAXTER HLTHCARE CORP	EQ 1MG BASE/ML	A 075637	001	Oct 31, 2000	Aug	CAHN
@		EQ 5MG BASE/ML	A 075637	002	Oct 31, 2000	Aug	CAHN
	FRESENIUS KABI USA	EQ 5MG BASE/ML	A 208878	001	Mar 28, 2017	Mar	NEWA
AP	WEST-WARD PHARMS INT	EQ 1MG BASE/ML	A 075243	001	Jun 20, 2000	Jan	CAHN
AP		EQ 1MG BASE/ML	A 075247	002	Jun 23, 2000	Jan	CAHN
AP		EQ 1MG BASE/ML	A 075324	001	Jun 20, 2000	Mar	CAHN
AP		EQ 1MG BASE/ML	A 075421	002	Jun 20, 2000	Jan	CAHN
AP		EQ 5MG BASE/ML	A 075243	002	Jun 20, 2000	Jan	CAHN
AP		EQ 5MG BASE/ML	A 075247	001	Jun 23, 2000	Jan	CAHN

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

AP		EQ 5MG BASE/ML	A075324	002	Jun 20, 2000	Mar	CAHN
AP		EQ 5MG BASE/ML	A075421	001	Jun 20, 2000	Jan	CAHN
	MIDAZOLAM HYDROCHLORIDE	PRESERVATIVE FREE					
AP	SAGENT AGILA LLC	EQ 1MG BASE/ML	A090315	001	Nov 29, 2010	May	CAHN
AP		EQ 5MG BASE/ML	A090315	002	Nov 29, 2010	May	CAHN

SYRUP; ORAL

MIDAZOLAM HYDROCHLORIDE

	@ SUN PHARM INDS LTD	EQ 2MG BASE/ML	A076058	001	Mar 15, 2002	May	DISC
--	----------------------	----------------	---------	-----	--------------	-----	------

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

MIDODRINE HYDROCHLORIDE

>D>	AB	APOTEX INC	2.5MG	A077746	001	Sep 12, 2006	Sep	CTEC
>A>	BX		2.5MG	A077746	001	Sep 12, 2006	Sep	CTEC
>D>	AB		5MG	A077746	002	Sep 12, 2006	Sep	CTEC
>A>	BX		5MG	A077746	002	Sep 12, 2006	Sep	CTEC
>D>	AB		10MG	A077746	003	Sep 12, 2006	Sep	CTEC
>A>	BX		10MG	A077746	003	Sep 12, 2006	Sep	CTEC

ORVATEN

AB	UPSHER-SMITH LABS	2.5MG	A076725	001	Nov 03, 2004	Jun	CAHN
AB		5MG	A076725	002	Nov 03, 2004	Jun	CAHN
AB		10MG	A076725	003	Nov 03, 2004	Jun	CAHN

PROAMATINE

	+ @ SHIRE LLC	2.5MG	N019815	001	Sep 06, 1996	Feb	CRLD
	+ @	5MG	N019815	002	Sep 06, 1996	Feb	CRLD
	+ @	10MG	N019815	003	Mar 20, 2002	Feb	CRLD

MIDOSTAURIN

CAPSULE; ORAL

RYDAPT

+!	NOVARTIS PHARMS CORP	25MG	N207997	001	Apr 28, 2017	Apr	NEWA
----	----------------------	------	---------	-----	--------------	-----	------

MILNACIPRAN HYDROCHLORIDE

TABLET; ORAL

MILNACIPRAN HYDROCHLORIDE

>D>	@	LIBERTY PHARMA INC	12.5MG	A205071	001	Jan 27, 2016	Sep	CAHN
>D>	@		25MG	A205071	002	Jan 27, 2016	Sep	CAHN
>D>	@		50MG	A205071	003	Jan 27, 2016	Sep	CAHN
>D>	@		100MG	A205071	004	Jan 27, 2016	Sep	CAHN
>A>	@	WINDLAS HLTHCARE	12.5MG	A205071	001	Jan 27, 2016	Sep	CAHN
>A>	@		25MG	A205071	002	Jan 27, 2016	Sep	CAHN
>A>	@		50MG	A205071	003	Jan 27, 2016	Sep	CAHN
>A>	@		100MG	A205071	004	Jan 27, 2016	Sep	CAHN

SAVELLA

AB	+ ALLERGAN SALES LLC	12.5MG	N022256	001	Jan 14, 2009	Feb	CAHN
AB	+	25MG	N022256	002	Jan 14, 2009	Feb	CAHN
AB	+!	50MG	N022256	003	Jan 14, 2009	Feb	CAHN
AB	+	100MG	N022256	004	Jan 14, 2009	Feb	CAHN

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

	@ BAXTER HLTHCARE CORP	EQ 1MG BASE/ML	A076427	001	Sep 21, 2004	Aug	CAHN
AP	WEST-WARD PHARMS INT	EQ 1MG BASE/ML	A075530	001	May 28, 2002	Jan	CAHN
AP		EQ 1MG BASE/ML	A075660	001	May 28, 2002	Jan	CAHN
	@	EQ 1MG BASE/ML	A075852	001	May 28, 2002	Mar	CAHN

MILRINONE LACTATE IN DEXTROSE 5%

AP	RENAISSANCE SSA LLC	EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A077151	002	Jul 20, 2005	Aug	CAHN
----	---------------------	---------------------------------------	---------	-----	--------------	-----	------

MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER

	@ RENAISSANCE SSA LLC	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A077151	001	Jul 20, 2005	Aug	CAHN
--	-----------------------	---------------------------------------	---------	-----	--------------	-----	------

	@ WEST-WARD PHARMS INT	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A075510	001	May 28, 2002	Mar	CAHN
--	------------------------	---------------------------------------	---------	-----	--------------	-----	------

AP		EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A078113	001	May 21, 2008	Jan	CAHN
----	--	---------------------------------------	---------	-----	--------------	-----	------

AP		EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A078113	002	May 21, 2008	Jan	CAHN
----	--	---------------------------------------	---------	-----	--------------	-----	------

PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER

	+ @ SANOFI AVENTIS US	EQ 10MG BASE/100ML	N020343	001	Aug 09, 1994	Jan	CRLD
	+ @	EQ 15MG BASE/100ML	N020343	002	Aug 09, 1994	Jan	CRLD

INJECTABLE; INJECTION

PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER

+ @	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	N020343	003	Aug 09, 1994	Jan	CRLD
+ @	EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	N020343	004	Aug 09, 1994	Jan	CRLD

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

DYNACIN

>D>	@ CNTY LINE PHARMS	EQ 50MG BASE	A063067	003	Aug 14, 1990	Sep	CMFD
>A>	AB	EQ 50MG BASE	A063067	003	Aug 14, 1990	Sep	CMFD

MINOCYCLINE HYDROCHLORIDE

AB	WATSON LABS TEVA	EQ 50MG BASE	A063181	001	Dec 30, 1991	May	CAHN
----	------------------	--------------	---------	-----	--------------	-----	------

CAPSULE, EXTENDED RELEASE; ORAL

XIMINO

	SUN PHARM INDS LTD	EQ 45MG BASE	N201922	001	Jul 11, 2012	Apr	CMFD
		EQ 90MG BASE	N201922	003	Jul 11, 2012	Apr	CMFD
		EQ 135MG BASE	N201922	005	Jul 11, 2012	Apr	CMFD

TABLET, EXTENDED RELEASE; ORAL

MINOCYCLINE HYDROCHLORIDE

@	BARR LABS INC	EQ 80MG BASE	A065485	007	Apr 26, 2017	Apr	DISC
		EQ 80MG BASE	A065485	007	Apr 26, 2017	Apr	NEWA
@		EQ 105MG BASE	A065485	008	Apr 26, 2017	Apr	DISC
		EQ 105MG BASE	A065485	008	Apr 26, 2017	Apr	NEWA
@	MYLAN PHARMS INC	EQ 45MG BASE	A090911	001	Jul 20, 2010	May	DISC
@		EQ 80MG BASE	A203443	002	Aug 22, 2014	May	DISC
@		EQ 90MG BASE	A090911	002	Jul 20, 2010	May	DISC
@		EQ 105MG BASE	A203443	003	Aug 22, 2014	May	DISC
@		EQ 135MG BASE	A090911	003	Jul 20, 2010	May	DISC
	MINOLIRA						
	DR REDDYS LABS LTD	EQ 105MG BASE	N209269	001	May 08, 2017	May	NEWA
		EQ 135MG BASE	N209269	002	May 08, 2017	May	NEWA

MIRABEGRON

TABLET, EXTENDED RELEASE; ORAL

MYRBETRIQ

+!	APGDI	25MG	N202611	001	Jun 28, 2012	Feb	CHRS
----	-------	------	---------	-----	--------------	-----	------

MIRTAZAPINE

TABLET; ORAL

MIRTAZAPINE

	@ UPSHER-SMITH LABS	15MG	A076189	001	Jun 19, 2003	Jun	CAHN
AB		15MG	A076219	001	Jun 19, 2003	Jun	CAHN
	@	30MG	A076189	002	Jun 19, 2003	Jun	CAHN
AB		30MG	A076219	002	Jun 19, 2003	Jun	CAHN
	@	45MG	A076189	003	Jun 19, 2003	Jun	CAHN
AB		45MG	A076219	003	Jun 19, 2003	Jun	CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

MIRTAZAPINE

AB	AUROBINDO PHARMA LTD	15MG	A077376	002	Dec 08, 2005	Jan	CAHN
AB		30MG	A077376	003	Dec 08, 2005	Jan	CAHN
AB		45MG	A077376	004	Feb 28, 2006	Jan	CAHN
AB	ZYDUS PHARMS USA INC	15MG	A205798	001	Jun 01, 2017	May	NEWA
AB		30MG	A205798	002	Jun 01, 2017	May	NEWA
AB		45MG	A205798	003	Jun 01, 2017	May	NEWA

MITOMYCIN

INJECTABLE; INJECTION

MITOMYCIN

AP	WEST-WARD PHARMS INT	5MG/VIAL	A064117	001	Apr 19, 1995	Jan	CAHN
AP		5MG/VIAL	A064180	001	Dec 23, 1999	Jan	CAHN
AP		20MG/VIAL	A064117	002	Apr 19, 1995	Jan	CAHN
AP		20MG/VIAL	A064180	002	Dec 23, 1999	Jan	CAHN

MUTAMYCIN

+ @	BRISTOL	5MG/VIAL	N050450	001		Jan	CRLD
+ @		20MG/VIAL	N050450	002		Jan	CRLD

MODAFINIL

TABLET;ORAL

MODAFINIL

AB	ALEMBIC PHARMS LTD	100MG	A202700	001	Oct 18, 2012	May	CAHN
AB		200MG	A202700	002	Oct 18, 2012	May	CAHN
AB	APPCO PHARMA LLC	100MG	A207196	001	Aug 16, 2017	Aug	NEWA
AB		200MG	A207196	002	Aug 16, 2017	Aug	NEWA
>A>	ZYDUS PHARMS USA INC	100MG	A209966	001	Sep 14, 2017	Sep	NEWA
>A>		200MG	A209966	002	Sep 14, 2017	Sep	NEWA

MOEXIPRIL HYDROCHLORIDE

TABLET;ORAL

MOEXIPRIL HYDROCHLORIDE

AB	CHARTWELL RX	7.5MG	A077536	001	Nov 30, 2006	Apr	CAHN
AB		15MG	A077536	002	Nov 30, 2006	Apr	CAHN

MOLINDONE HYDROCHLORIDE

TABLET;ORAL

MOLINDONE HYDROCHLORIDE

	EPIC PHARMA LLC	5MG	A090453	001	Mar 20, 2015	May	CAHN
		10MG	A090453	002	Mar 20, 2015	May	CAHN
!		25MG	A090453	003	Mar 20, 2015	May	CAHN

MOMETASONE FUROATE

LOTION;TOPICAL

MOMETASONE FUROATE

AB	PERRIGO ISRAEL	0.1%	A077180	001	Apr 06, 2005	Apr	CAHN
	SPRAY, METERED;NASAL						
	MOMETASONE FUROATE						
AB	AMNEAL PHARMS	EQ 0.05MG BASE/SPRAY	A207989	001	Apr 03, 2017	Mar	NEWA

MONTELUKAST SODIUM

TABLET;ORAL

MONTELUKAST SODIUM

AB	CSPC OUYI PHARM CO	EQ 10MG BASE	A209012	001	Apr 24, 2017	Apr	NEWA
AB	PERRIGO R AND D	EQ 10MG BASE	A206112	001	Apr 26, 2017	Apr	NEWA
	TABLET, CHEWABLE;ORAL						
	MONTELUKAST SODIUM						
AB	CSPC OUYI PHARM CO	EQ 4MG BASE	A209011	001	Apr 18, 2017	Apr	NEWA
AB		EQ 5MG BASE	A209011	002	Apr 18, 2017	Apr	NEWA

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

MORPHINE SULFATE

	ACTAVIS ELIZABETH	30MG	A079040	001	Jan 16, 2013	Apr	CAHN
		45MG	A079040	002	Jan 16, 2013	Apr	CAHN
		60MG	A079040	003	Jan 16, 2013	Apr	CAHN
		75MG	A079040	004	Jan 16, 2013	Apr	CAHN
		90MG	A079040	005	Jan 16, 2013	Apr	CAHN
!		120MG	A079040	006	Jan 16, 2013	Apr	CAHN
AB	UPSHER-SMITH LABS	10MG	A202104	001	Jun 03, 2013	Jun	CAHN
AB		20MG	A202104	002	Jun 03, 2013	Jun	CAHN
AB		30MG	A202104	003	Jun 03, 2013	Jun	CAHN
AB		50MG	A202104	004	Jun 03, 2013	Jun	CAHN
AB		60MG	A202104	005	Jun 03, 2013	Jun	CAHN
AB		80MG	A202104	006	Jun 03, 2013	Jun	CAHN
AB		100MG	A202104	007	Jun 03, 2013	Jun	CAHN

INJECTABLE;INJECTION

MORPHINE SULFATE

+	@ HOSPIRA INC	15MG/ML	N202515	005	Nov 14, 2011	Aug	DISC
	@ ICU MEDICAL INC	0.5MG/ML	N019917	001	Oct 30, 1992	Jun	CAHN
AP	+	1MG/ML	N019916	001	Oct 30, 1992	Apr	CAHN
	+	5MG/ML	N019916	002	Oct 27, 2006	Apr	CAHN
	@ MALLINCKRODT INC	1MG/ML	N020631	001	Jul 03, 1996	Apr	CAHN
	@	2MG/ML	N020631	002	Jul 03, 1996	Apr	CAHN

SOLUTION;ORAL

MORPHINE SULFATE

AA	HI-TECH PHARMACAL	100MG/5ML	A208809	001	Jul 06, 2017	Jun	NEWA
AA	RHODES PHARMS	10MG/5ML	A206308	001	Jun 22, 2017	Jun	NEWA
AA		100MG/5ML	A206308	002	Jun 22, 2017	Jun	NEWA
AA	+ WEST-WARD PHARMS INT	10MG/5ML	N022195	001	Mar 17, 2008	Jan	CAHN

SOLUTION;ORAL							
MORPHINE SULFATE							
AA	+		20MG/5ML	N022195	002	Mar 17, 2008	Jan CAHN
AA	+	!	100MG/5ML	N022195	003	Jan 25, 2010	Jan CAHN
TABLET;ORAL							
MORPHINE SULFATE							
	+		WEST-WARD PHARMS INT 15MG	N022207	001	Mar 17, 2008	Jan CAHN
	+	!	30MG	N022207	002	Mar 17, 2008	Jan CAHN
TABLET, EXTENDED RELEASE;ORAL							
ARYMO ER							
	+		EGALET 15MG	N208603	001	Jan 09, 2017	Jan NEWA
	+		30MG	N208603	002	Jan 09, 2017	Jan NEWA
	+		60MG	N208603	003	Jan 09, 2017	Jan NEWA
MORPHABOND ER							
	+		DAIICHI SANKYO INC 15MG	N206544	001	Oct 02, 2015	Jan CTNA
	+		30MG	N206544	002	Oct 02, 2015	Jan CTNA
	+		60MG	N206544	003	Oct 02, 2015	Jan CTNA
	+	!	100MG	N206544	004	Oct 02, 2015	Jan CTNA
MORPHINE SULFATE							
AB			ACTAVIS ELIZABETH 15MG	A203849	001	Apr 06, 2015	Apr CAHN
AB			30MG	A203849	002	Apr 06, 2015	Apr CAHN
AB			60MG	A203849	003	Apr 06, 2015	Apr CAHN
AB			100MG	A203849	004	Apr 06, 2015	Apr CAHN
AB			200MG	A203849	005	Apr 06, 2015	Apr CAHN
AB			EPIC PHARMA LLC 15MG	A091357	001	Jun 23, 2016	May CAHN
AB			30MG	A091357	002	Jun 23, 2016	May CAHN
AB			60MG	A091357	003	Jun 23, 2016	May CAHN
AB			100MG	A091357	004	Jun 23, 2016	May CAHN
AB			200MG	A091357	005	Jun 23, 2016	May CAHN
AB			SUN PHARM INDS 15MG	A205634	001	Aug 25, 2016	Mar CAHN
AB			30MG	A205634	002	Aug 25, 2016	Mar CAHN
AB			60MG	A205634	003	Aug 25, 2016	Mar CAHN
AB			100MG	A205634	004	Aug 25, 2016	Mar CAHN
AB			200MG	A205634	005	Aug 25, 2016	Mar CAHN
<u>MOXIFLOXACIN HYDROCHLORIDE</u>							
SOLUTION;IV (INFUSION)							
AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER							
AP	+	!	BAYER HLTHCARE 400MG/250ML (1.6MG/ML)	N021277	001	Nov 30, 2001	Apr CFTG
MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER							
AP			MYLAN LABS LTD 400MG/250ML (1.6MG/ML)	A205833	001	May 05, 2017	Apr NEWA
SOLUTION/DROPS;OPHTHALMIC							
MOXIFLOXACIN HYDROCHLORIDE							
AT1			APOTEX INC EQ 0.5% BASE	A090080	001	Jun 30, 2017	Jun NEWA
>A>	AT1		AUROBINDO PHARMA LTD EQ 0.5% BASE	A206242	001	Oct 04, 2017	Sep NEWA
TABLET;ORAL							
MOXIFLOXACIN HYDROCHLORIDE							
>A>	AB		MSN LABS PVT LTD EQ 400MG BASE	A208682	001	Sep 22, 2017	Sep NEWA
	AB		NOVEL LABS INC EQ 400MG BASE	A207285	001	Feb 13, 2017	Jan NEWA
<u>MUPIROCIN</u>							
OINTMENT;TOPICAL							
MUPIROCIN							
AB	!		PERRIGO NEW YORK 2%	A065123	001	Nov 07, 2003	May CHRS
<u>MUPIROCIN CALCIUM</u>							
CREAM;TOPICAL							
MUPIROCIN							
AB			GLENMARK PHARMS INC EQ 2% BASE	A201587	001	Jan 24, 2013	May CAHN
<u>MYCOPHENOLATE MOFETIL</u>							
CAPSULE;ORAL							
MYCOPHENOLATE MOFETIL							
>D>	AB		JUBILANT CADISTA 250MG	A090762	001	Dec 15, 2014	Sep DISC
>A>		@	250MG	A090762	001	Dec 15, 2014	Sep DISC
TABLET;ORAL							
MYCOPHENOLATE MOFETIL							
>D>	AB		JUBILANT CADISTA 500MG	A090661	001	Dec 15, 2014	Sep DISC
>A>		@	500MG	A090661	001	Dec 15, 2014	Sep DISC

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

INJECTABLE; INJECTION

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

AP	AKORN INC	500MG/VIAL	A204043	001	Feb 28, 2017	Feb	NEWA
AP	MYLAN LABS LTD	500MG/VIAL	A203859	001	Mar 31, 2017	Mar	NEWA
AP	ZYDUS PHARMS USA INC	500MG/VIAL	A204473	001	Aug 31, 2017	Aug	NEWA

MYCOPHENOLIC ACID

TABLET, DELAYED RELEASE; ORAL

MYCOPHENOLIC ACID

AB	ACCORD HLTHCARE	180MG	A202555	001	Aug 23, 2017	Aug	NEWA
AB		360MG	A202555	002	Aug 23, 2017	Aug	NEWA

NABILONE

CAPSULE; ORAL

CESAMET

+!	MYLAN SPECIALITY LP	1MG	N018677	001	Dec 26, 1985	Mar	CAHN
----	---------------------	-----	---------	-----	--------------	-----	------

NADOLOL

TABLET; ORAL

NADOLOL

AB	AMNEAL PHARMS CO	20MG	A208832	001	Jun 02, 2017	May	NEWA	
AB		40MG	A208832	002	Jun 02, 2017	May	NEWA	
AB		80MG	A208832	003	Jun 02, 2017	May	NEWA	
>A>	AB	LUPIN LTD	20MG	A209309	001	Oct 05, 2017	Sep	NEWA
>A>	AB		40MG	A209309	002	Oct 05, 2017	Sep	NEWA
>A>	AB		80MG	A209309	003	Oct 05, 2017	Sep	NEWA
AB	ZYDUS PHARMS USA INC	20MG	A207761	001	Jul 28, 2017	Jul	NEWA	
AB		40MG	A207761	002	Jul 28, 2017	Jul	NEWA	
AB		80MG	A207761	003	Jul 28, 2017	Jul	NEWA	

NAFTIFINE HYDROCHLORIDE

CREAM; TOPICAL

NAFTIFINE HYDROCHLORIDE

AB	TOLMAR	2%	A206960	001	Apr 10, 2017	Mar	NEWA
----	--------	----	---------	-----	--------------	-----	------

NALDEMEDINE TOSYLATE

TABLET; ORAL

SYMPROIC

+!	SHIONOGI INC	EQ 0.2MG BASE	N208854	001	Mar 23, 2017	Mar	NEWA
----	--------------	---------------	---------	-----	--------------	-----	------

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE

@ WEST-WARD PHARMS INT 0.4MG/ML

@ 0.4MG/ML

NALOXONE HYDROCHLORIDE

AP	AKORN	0.4MG/ML	A208871	001	Feb 28, 2017	Feb	NEWA
AP		0.4MG/ML	A208872	001	Mar 14, 2017	Feb	NEWA
AP	SOMERSET THERAPS LLC	0.4MG/ML	A207633	001	Aug 08, 2017	Jul	NEWA
AP		0.4MG/ML	A207634	001	Jul 26, 2017	Jul	NEWA

SOLUTION; INTRAMUSCULAR, SUBCUTANEOUS

EVZIO

+	@ KALEO INC	0.4MG/0.4ML (0.4MG/0.4ML)	N205787	001	Apr 03, 2014	Aug	DISC
---	-------------	---------------------------	---------	-----	--------------	-----	------

SPRAY, METERED; NASAL

NARCAN

+	ADAPT	2MG/SPRAY	N208411	002	Jan 24, 2017	Jan	NEWA
---	-------	-----------	---------	-----	--------------	-----	------

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

NALTREXONE HYDROCHLORIDE

AB	APOTEX INC	50MG	A207905	001	Jul 21, 2017	Jul	NEWA
----	------------	------	---------	-----	--------------	-----	------

NANDROLONE DECANOATE

INJECTABLE; INJECTION

NANDROLONE DECANOATE

!	LUITPOLD PHARMS INC	200MG/ML	A091252	001	Aug 30, 2010	Jun	CAHN
---	---------------------	----------	---------	-----	--------------	-----	------

NAPROXEN

TABLET; ORAL

NAPROXEN

AB	AUROBINDO PHARMA LTD	250MG	A200429	001	Nov 08, 2011	Jan	CAHN
AB		375MG	A200429	002	Nov 08, 2011	Jan	CAHN
AB		500MG	A200429	003	Nov 08, 2011	Jan	CAHN
	@ CHARTWELL MOLECULES	250MG	A074410	001	Apr 28, 1995	May	CAHN
	@	375MG	A074410	002	Apr 28, 1995	May	CAHN
	@	500MG	A074410	003	Apr 28, 1995	May	CAHN
	@ HIKMA INTL PHARMS	250MG	A076494	001	Jan 14, 2004	May	DISC
	@	375MG	A076494	002	Jan 14, 2004	May	DISC
	@	500MG	A076494	003	Jan 14, 2004	May	DISC
	@ WATSON LABS TEVA	250MG	A074163	001	Feb 10, 1995	May	CAHN
	@	375MG	A074163	002	Feb 10, 1995	May	CAHN
	@	500MG	A074163	003	Feb 10, 1995	May	CAHN

NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM

AB	GLENMARK PHARMS LTD	EQ 250MG BASE	A078314	001	Apr 27, 2007	May	CAHN
AB		EQ 500MG BASE	A078314	002	Apr 27, 2007	May	CAHN

NATAMYCIN

SUSPENSION; OPHTHALMIC

NATACYN

+!	NOVARTIS PHARMS CORP	5%	N050514	001		Jan	CAHN
----	----------------------	----	---------	-----	--	-----	------

NEBIVOLOL HYDROCHLORIDE

TABLET; ORAL

NEBIVOLOL HYDROCHLORIDE

	@ GLENMARK PHARMS LTD	EQ 2.5MG BASE	A203821	001	May 25, 2017	May	DISC
AB		EQ 2.5MG BASE	A203821	001	May 25, 2017	May	NEWA
	@	EQ 5MG BASE	A203821	002	May 25, 2017	May	DISC
AB		EQ 5MG BASE	A203821	002	May 25, 2017	May	NEWA
	@	EQ 10MG BASE	A203821	003	May 25, 2017	May	DISC
AB		EQ 10MG BASE	A203821	003	May 25, 2017	May	NEWA
	@	EQ 20MG BASE	A203821	004	May 25, 2017	May	DISC
AB		EQ 20MG BASE	A203821	004	May 25, 2017	May	NEWA

NEBIVOLOL HYDROCHLORIDE; VALSARTAN

TABLET; ORAL

BYVALSON

+!	FOREST LABS LLC	EQ 5MG BASE; 80MG	N206302	001	Jun 03, 2016	May	CRLD
----	-----------------	-------------------	---------	-----	--------------	-----	------

NELFINAVIR MESYLATE

POWDER; ORAL

VIRACEPT

@ AGOURON PHARMS

EQ 50MG BASE/SCOOPFUL

N020778	001	Mar 14, 1997	Jan	CAHN
---------	-----	--------------	-----	------

TABLET; ORAL

VIRACEPT

+!	AGOURON PHARMS	EQ 250MG BASE	N020779	001	Mar 14, 1997	Jan	CAHN
+!		EQ 625MG BASE	N021503	001	Apr 30, 2003	Jan	CAHN

NEOMYCIN SULFATE

TABLET; ORAL

NEOMYCIN SULFATE

>A>	AA	BRECKENRIDGE PHARM	500MG	A065468	001	Mar 29, 2010	Sep	CAHN
>D>	AA	OMAN PHARM PRODUCTS	500MG	A065468	001	Mar 29, 2010	Sep	CAHN

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION; IRRIGATION

NEOSPORIN G.U. IRRIGANT

AT	!	MONARCH PHARMS	EQ 40MG BASE/ML; 200,000 UNITS/ML	A060707	001		Apr	CAHN
----	---	----------------	-----------------------------------	---------	-----	--	-----	------

NEOSTIGMINE METHYLSULFATE

SOLUTION; INTRAVENOUS

NEOSTIGMINE METHYLSULFATE

>A>	AP	AMPHASTAR PHARMS INC	5MG/10ML (0.5MG/ML)	A209933	001	Sep 25, 2017	Sep	NEWA
>A>	AP		10MG/10ML (1MG/ML)	A209933	002	Sep 25, 2017	Sep	NEWA
AP		PAR STERILE PRODUCTS	5MG/10ML (0.5MG/ML)	A208405	001	Apr 26, 2017	Apr	NEWA
AP			10MG/10ML (1MG/ML)	A208405	002	Apr 26, 2017	Apr	NEWA



NERATINIB MALEATE

TABLET; ORAL

NERLYNX

+! PUMA BIOTECH EQ 40MG BASE N208051 001 Jul 17, 2017 Jul NEWA

NEVIRAPINE

SUSPENSION; ORAL

NEVIRAPINE

AA CIPLA LTD 50MG/5ML A207684 001 Aug 03, 2017 Jul NEWA

TABLET; ORAL

NEVIRAPINE

&gt;D&gt; AB SCIEGEN PHARMS INC 200MG A203176 001 May 22, 2012 Sep CAHN

&gt;A&gt; AB TECH ORGANIZED 200MG A203176 001 May 22, 2012 Sep CAHN

TABLET, EXTENDED RELEASE; ORAL

NEVIRAPINE

AB AUROBINDO PHARMA LTD 400MG A207698 001 Feb 28, 2017 Mar CAHN

AB AUROBINDO PHARMA USA 400MG A207698 001 Feb 28, 2017 Feb NEWA

&gt;A&gt; AB MACLEODS PHARMS LTD 400MG A206879 001 Oct 06, 2017 Sep NEWA

&gt;D&gt; AB SCIEGEN PHARMS INC 100MG A207467 001 Jul 31, 2017 Sep CAHN

AB 100MG A207467 001 Jul 31, 2017 Jul NEWA

&gt;D&gt; AB 400MG A207467 002 Jul 31, 2017 Sep CAHN

AB 400MG A207467 002 Jul 31, 2017 Jul NEWA

&gt;A&gt; AB TECH ORGANIZED 100MG A207467 001 Jul 31, 2017 Sep CAHN

&gt;A&gt; AB 400MG A207467 002 Jul 31, 2017 Sep CAHN

NIACIN

TABLET; ORAL

NIACOR

AA ! UPSHER-SMITH LABS 500MG A040378 001 May 03, 2000 Jun CAHN

TABLET, EXTENDED RELEASE; ORAL

NIACIN

AB LANNETT 500MG A203899 001 Jun 16, 2017 Jun NEWA

AB 1GM A203899 002 Jun 16, 2017 Jun NEWA

NICARDIPINE HYDROCHLORIDE

INJECTABLE; INJECTION

NICARDIPINE HYDROCHLORIDE

AP WEST-WARD PHARMS INT 25MG/10ML (2.5MG/ML) A078714 001 Dec 28, 2009 Jan CAHN

INJECTABLE; INTRAVENOUS

NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE

EXELA PHARMA SCIENCE 20MG/200ML (0.1MG/ML) N022276 002 Apr 07, 2016 Feb NEWA

40MG/200ML (0.2MG/ML) N022276 003 Apr 07, 2016 Feb NEWA

NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL

AFEDITAB CR

AB1 WATSON LABS TEVA 30MG A075128 001 Mar 10, 2000 May CAHN

NIFEDIPINE

@ MYLAN LABS LTD 30MG A090602 001 Sep 13, 2010 May DISC

AB2 30MG A090602 001 Sep 13, 2010 Mar CAHN

@ 60MG A090602 002 Sep 13, 2010 May DISC

AB2 60MG A090602 002 Sep 13, 2010 Mar CAHN

@ 90MG A090602 003 Sep 13, 2010 May DISC

AB2 90MG A090602 003 Sep 13, 2010 Mar CAHN

AB2 OSMOTICA PHARM US 90MG A077410 001 Oct 03, 2007 Jun CAHN

NIRAPARIB TOSYLATE

CAPSULE; ORAL

ZEJULA

+! TESARO INC EQ 100MG BASE N208447 001 Mar 27, 2017 Mar NEWA

NISOLDIPINE

TABLET, EXTENDED RELEASE; ORAL

SULAR

AB +! COVIS PHARMA BV 8.5MG N020356 008 Jan 02, 2008 May CAHN

+ @ 10MG N020356 001 Feb 02, 1995 May CAHN

AB +! 17MG N020356 007 Jan 02, 2008 May CAHN

+ @ 20MG N020356 002 Feb 02, 1995 May CAHN

+ @ 25.5MG N020356 006 Jan 02, 2008 May CAHN

+ @ 30MG N020356 003 Feb 02, 1995 May CAHN

AB +! 34MG N020356 005 Jan 02, 2008 May CAHN

TABLET, EXTENDED RELEASE;ORAL  
SULAR

+ @ 40MG N020356 004 Feb 02, 1995 May CAHN

NITISINONE

TABLET;ORAL  
NITYR

+ CYCLE PHARMS LTD 2MG N209449 001 Jul 26, 2017 Jul NEWA  
+ 5MG N209449 002 Jul 26, 2017 Jul NEWA  
+! 10MG N209449 003 Jul 26, 2017 Jul NEWA

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

## CAPSULE;ORAL

## NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

AB AMNEAL PHARMS 75MG;25MG A207372 001 May 15, 2017 May NEWA

NITROGLYCERIN

FILM, EXTENDED RELEASE;TRANSDERMAL  
NITRO-DUR

AB1 +! USPHARMA 0.1MG/HR N020145 001 Apr 04, 1995 Jun CAHN  
AB1 +! 0.2MG/HR N020145 002 Apr 04, 1995 Jun CAHN  
+! 0.3MG/HR N020145 003 Apr 04, 1995 Jun CAHN  
AB1 +! 0.4MG/HR N020145 004 Apr 04, 1995 Jun CAHN  
AB1 +! 0.6MG/HR N020145 005 Apr 04, 1995 Jun CAHN  
+! 0.8MG/HR N020145 006 Apr 04, 1995 Jun CAHN

OINTMENT;TRANSDERMAL  
NITROGLYCERIN

! FOUGERA PHARMS INC 2% A087355 001 Jul 08, 1988 Jan CAHN

## TABLET;SUBLINGUAL

## NITROGLYCERIN

>A> AB GLENMARK PHARMS LTD 0.3MG A206391 001 Sep 19, 2017 Sep NEWA  
>A> AB 0.4MG A206391 002 Sep 19, 2017 Sep NEWA  
>A> AB 0.6MG A206391 003 Sep 19, 2017 Sep NEWA

NOREPINEPHRINE BITARTRATE

## INJECTABLE;INJECTION

## NOREPINEPHRINE BITARTRATE

AP BAXTER HLTHCARE CORP EQ 1MG BASE/ML A040859 001 Mar 27, 2012 Aug CAHN  
AP WEST-WARD PHARMS INT EQ 1MG BASE/ML A040462 001 Oct 31, 2003 Jan CAHN

NORTRIPTYLINE HYDROCHLORIDE

## CAPSULE;ORAL

## NORTRIPTYLINE HYDROCHLORIDE

@ MYLAN EQ 10MG BASE A074234 001 Jul 26, 1993 Jun DISC  
@ EQ 25MG BASE A074234 002 Jul 26, 1993 Jun DISC  
@ EQ 50MG BASE A074234 003 Jul 26, 1993 Jun DISC  
@ EQ 75MG BASE A074234 004 Jul 26, 1993 Jun DISC  
AB TARO PHARM EQ 10MG BASE A075520 004 May 08, 2000 Mar CAHN  
AB EQ 25MG BASE A075520 003 May 08, 2000 Mar CAHN  
AB EQ 50MG BASE A075520 001 May 08, 2000 Mar CAHN  
AB EQ 75MG BASE A075520 002 May 08, 2000 Mar CAHN

## SOLUTION;ORAL

## NORTRIPTYLINE HYDROCHLORIDE

AA ! PHARM ASSOC EQ 10MG BASE/5ML A075606 001 Aug 28, 2000 May CAHN

NYSTATIN

## CREAM;TOPICAL

## NYSTATIN

>A> AT CROWN LABS INC 100,000 UNITS/GM A207733 001 Sep 26, 2017 Sep NEWA

## OINTMENT;TOPICAL

## NYSTATIN

>A> AT G AND W LABS INC 100,000 UNITS/GM A209114 001 Oct 06, 2017 Sep NEWA

## PASTILLE;ORAL

## MYCOSTATIN

@ DELCOR ASSET CORP 200,000 UNITS N050619 001 Apr 09, 1987 Jun CAHN

## POWDER;TOPICAL

## NYSTATIN

AT LYNE 100,000 UNITS/GM A208838 001 May 30, 2017 May NEWA  
AT NESHER PHARMS 100,000 UNITS/GM A208581 001 Jun 08, 2017 May NEWA  
AT UPSHER-SMITH LABS 100,000 UNITS/GM A065183 001 May 03, 2005 Jun CAHN

## SUSPENSION; ORAL

## NYSTATIN

	@ ALLIED PHARMA INC	100,000 UNITS/ML	A062832	001	Dec 27, 1991	Jul	CAHN
AA	FOUGERA PHARMS INC	100,000 UNITS/ML	A062517	001	Jun 07, 1984	Jan	CAHN
AA	PHARM ASSOC	100,000 UNITS/ML	A203621	001	Jan 07, 2016	May	CAHN
AA	TARO PHARM	100,000 UNITS/ML	A062876	001	Feb 29, 1988	Apr	CAHN

## TABLET; ORAL

## NYSTATIN

	@ USL PHARMA	500,000 UNITS	A062524	001	Nov 26, 1985	Jun	CAHN
--	--------------	---------------	---------	-----	--------------	-----	------

NYSTATIN; TRIAMCINOLONE ACETONIDE

## CREAM; TOPICAL

## MYCOLOG-II

	@ MYLAN PHARMS INC	100,000 UNITS/GM;0.1%	A062606	001	May 15, 1985	Jan	CAHN
		NYSTATIN AND TRIAMCINOLONE ACETONIDE					
AT	FOUGERA PHARMS INC	100,000 UNITS/GM;0.1%	A062599	001	Oct 08, 1985	Jan	CAHN
AT	PERRIGO UK FINCO	100,000 UNITS/GM;0.1%	A208479	001	Aug 14, 2017	Jul	NEWA

## OINTMENT; TOPICAL

## MYCOLOG-II

	@ MYLAN PHARMS INC	100,000 UNITS/GM;0.1%	A060572	001	Jun 28, 1985	Jan	CAHN
		NYSTATIN AND TRIAMCINOLONE ACETONIDE					
AT	AKORN	100,000 UNITS/GM;0.1%	A207217	001	Aug 04, 2017	Jul	NEWA
AT	DR REDDYS LABS LTD	100,000 UNITS/GM;0.1%	A207741	001	Jan 31, 2017	Jan	NEWA
AT	FOUGERA PHARMS INC	100,000 UNITS/GM;0.1%	A062602	001	Oct 09, 1985	Jan	CAHN

OCTREOTIDE ACETATE

## INJECTABLE; INJECTION

## OCTREOTIDE ACETATE

>D>	AP	SUN PHARM INDS	EQ 0.05MG BASE/ML	A077329	001	Mar 04, 2008	Sep	DISC
>A>		@	EQ 0.05MG BASE/ML	A077329	001	Mar 04, 2008	Sep	DISC
>D>	AP		EQ 0.1MG BASE/ML	A077329	002	Mar 04, 2008	Sep	DISC
>A>		@	EQ 0.1MG BASE/ML	A077329	002	Mar 04, 2008	Sep	DISC
>D>	AP		EQ 0.5MG BASE/ML	A077329	003	Mar 04, 2008	Sep	DISC
>A>		@	EQ 0.5MG BASE/ML	A077329	003	Mar 04, 2008	Sep	DISC

OFLOXACIN

## SOLUTION/DROPS; OPHTHALMIC

## OFLOXACIN

AT	SANDOZ INC	0.3%	A076231	001	May 14, 2004	Feb	CAHN
----	------------	------	---------	-----	--------------	-----	------

## SOLUTION/DROPS; OTIC

## OFLOXACIN

AT	SANDOZ INC	0.3%	A078222	001	Mar 17, 2008	Feb	CAHN
----	------------	------	---------	-----	--------------	-----	------

OLANZAPINE

## TABLET; ORAL

## OLANZAPINE

AB	HIKMA PHARMS	2.5MG	A204866	001	Jun 16, 2017	Jun	NEWA
AB		5MG	A204866	002	Jun 16, 2017	Jun	NEWA
AB		7.5MG	A204866	003	Jun 16, 2017	Jun	NEWA
AB		10MG	A204866	004	Jun 16, 2017	Jun	NEWA
AB		15MG	A204866	005	Jun 16, 2017	Jun	NEWA
AB		20MG	A204866	006	Jun 16, 2017	Jun	NEWA
	@ MYLAN PHARMS INC	2.5MG	A076866	001	Apr 23, 2012	Jun	DISC
AB		2.5MG	A076866	001	Apr 23, 2012	Mar	CAHN
	@	5MG	A076866	002	Apr 23, 2012	Jun	DISC
AB		5MG	A076866	002	Apr 23, 2012	Mar	CAHN
	@	7.5MG	A076866	003	Apr 23, 2012	Jun	DISC
AB		7.5MG	A076866	003	Apr 23, 2012	Mar	CAHN
	@	10MG	A076866	004	Apr 23, 2012	Jun	DISC
AB		10MG	A076866	004	Apr 23, 2012	Mar	CAHN
	@	15MG	A076866	005	Apr 23, 2012	Jun	DISC
AB		15MG	A076866	005	Apr 23, 2012	Mar	CAHN
	@	20MG	A076866	006	Apr 23, 2012	Jun	DISC
AB		20MG	A076866	006	Apr 23, 2012	Mar	CAHN

## TABLET, ORALLY DISINTEGRATING; ORAL

## OLANZAPINE

AB	AJANTA PHARMA LTD	5MG	A204320	001	May 30, 2017	May	NEWA
AB		10MG	A204320	002	May 30, 2017	May	NEWA
AB		15MG	A204320	003	May 30, 2017	May	NEWA
AB		20MG	A204320	004	May 30, 2017	May	NEWA

OLAPARIB

CAPSULE;ORAL

LYNPARZA

+! ASTRAZENECA PHARMS 50MG N206162 001 Dec 19, 2014 Mar CRLD

TABLET;ORAL

LYNPARZA

+ ASTRAZENECA PHARMS 100MG N208558 001 Aug 17, 2017 Aug NEWA

+! 150MG N208558 002 Aug 17, 2017 Aug NEWA

OLIVE OIL; SOYBEAN OIL

INJECTABLE;INJECTION

CLINOLIPID 20%

+ @ BAXTER HLTHCARE CORP 16% (160GM/1000ML);4%  
(40GM/1000ML) N204508 001 Oct 03, 2013 Jul DISCOLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL

AB	ACCORD HLTHCARE	5MG	A207662	001	Apr 24, 2017	Apr	NEWA
AB		20MG	A207662	002	Apr 24, 2017	Apr	NEWA
AB		40MG	A207662	003	Apr 24, 2017	Apr	NEWA
AB	ALEMBIC PHARMS LTD	5MG	A203012	001	Apr 24, 2017	Apr	NEWA
AB		20MG	A203012	002	Apr 24, 2017	Apr	NEWA
AB		40MG	A203012	003	Apr 24, 2017	Apr	NEWA
AB	ALKEM LABS LTD	5MG	A206763	001	Apr 24, 2017	Apr	NEWA
AB		20MG	A206763	002	Apr 24, 2017	Apr	NEWA
AB		40MG	A206763	003	Apr 24, 2017	Apr	NEWA
AB	AUROBINDO PHARMA LTD	5MG	A204798	001	Apr 24, 2017	Apr	NEWA
AB		20MG	A204798	002	Apr 24, 2017	Apr	NEWA
AB		40MG	A204798	003	Apr 24, 2017	Apr	NEWA
AB	GLENMARK PHARMS LTD	5MG	A203281	001	May 25, 2017	May	NEWA
AB		20MG	A203281	002	May 25, 2017	May	NEWA
AB		40MG	A203281	003	May 25, 2017	May	NEWA
AB	JUBILANT GENERICS	5MG	A205482	001	Apr 24, 2017	Apr	NEWA
AB		20MG	A205482	002	Apr 24, 2017	Apr	NEWA
AB		40MG	A205482	003	Apr 24, 2017	Apr	NEWA
AB	LUPIN LTD	5MG	A206631	001	Apr 27, 2017	Apr	NEWA
AB		20MG	A206631	002	Apr 27, 2017	Apr	NEWA
AB		40MG	A206631	003	Apr 27, 2017	Apr	NEWA
AB	MACLEODS PHARMS LTD	5MG	A204814	001	Apr 24, 2017	Apr	NEWA
AB		20MG	A204814	002	Apr 24, 2017	Apr	NEWA
AB		40MG	A204814	003	Apr 24, 2017	Apr	NEWA
AB	TEVA PHARMS USA	5MG	A091079	001	Apr 24, 2017	Apr	NEWA
AB		20MG	A091079	002	Apr 24, 2017	Apr	NEWA
AB		40MG	A091079	003	Apr 24, 2017	Apr	NEWA
AB	TORRENT PHARMS LTD	5MG	A202375	001	Apr 24, 2017	Apr	NEWA
AB		20MG	A202375	002	Apr 24, 2017	Apr	NEWA
AB		40MG	A202375	003	Apr 24, 2017	Apr	NEWA
AB	ZYDUS PHARMS USA INC	5MG	A205192	001	Apr 24, 2017	Apr	NEWA
AB		20MG	A205192	002	Apr 24, 2017	Apr	NEWA
AB		40MG	A205192	003	Apr 24, 2017	Apr	NEWA

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

AT	CIPLA LTD	EQ 0.1% BASE	A206046	001	Jul 26, 2017	Jul	NEWA
AT	WOCKHARDT LTD	EQ 0.1% BASE	A200810	001	Jun 28, 2017	Jun	NEWA
>D> AT	ZACH SYSTEM SPA	EQ 0.1% BASE	A204706	001	Dec 07, 2015	Sep	CAHN
>A> AT	ZAMBON SPA	EQ 0.1% BASE	A204706	001	Dec 07, 2015	Sep	CAHN

SPRAY, METERED;NASAL

OLOPATADINE HYDROCHLORIDE

AB PERRIGO ISRAEL 0.665MG/SPRAY A202853 001 Jan 31, 2017 Jan NEWA

OLSALAZINE SODIUM

CAPSULE;ORAL

DIPENTUM

+! MYLAN SPECIALITY LP 250MG N019715 001 Jul 31, 1990 Mar CAHN

OMACETAXINE MEPESUCCINATEPOWDER; SUBCUTANEOUS  
SYNRIBO

+! TEVA PHARMS INTL 3.5MG/VIAL N203585 001 Oct 26, 2012 Apr CAHN

OMEGA-3-ACID ETHYL ESTERSCAPSULE; ORAL  
OMEGA-3-ACID ETHYL ESTERSAB AMNEAL PHARMS 1GM CONTAINS AT LEAST 900MG OF THE A204940 001 Nov 27, 2015 May CAHN  
ETHYL ESTERS OF OMEGA-3 FATTY>A> AB STRIDES PHARMA 1GM CONTAINS AT LEAST 900MG OF THE A203893 001 Sep 19, 2017 Sep NEWA  
ACIDS  
ETHYL ESTERS OF OMEGA-3 FATTY  
ACIDSOMEGA-3-ACID ETHYL ESTERS TYPE ACAPSULE; ORAL  
OMTRYG>A> + @ OSMOTICA 1.2GM CONTAINS AT LEAST 900MG OF N204977 001 Apr 23, 2014 Sep DISC  
THE ETHYL ESTERS OF OMEGA-3 FATTY  
ACIDS>A> +! 1.2GM CONTAINS AT LEAST 900MG OF N204977 001 Apr 23, 2014 Sep CAHN  
THE ETHYL ESTERS OF OMEGA-3 FATTY  
ACIDS>D> +! TRYGG 1.2GM CONTAINS AT LEAST 900MG OF N204977 001 Apr 23, 2014 Sep CAHN  
THE ETHYL ESTERS OF OMEGA-3 FATTY  
ACIDSOMEPRAZOLECAPSULE, DELAYED REL PELLETS; ORAL  
OMEPRAZOLEAB AUROBINDO PHARMA LTD 10MG A203270 001 Aug 19, 2015 Jan CAHN  
AB 20MG A203270 002 Aug 19, 2015 Jan CAHN  
AB 40MG A203270 003 Aug 19, 2015 Jan CAHN  
AB BRECKENRIDGE PHARM 10MG A203481 001 Jul 03, 2017 Jun NEWA  
AB 20MG A203481 002 Jul 03, 2017 Jun NEWA  
AB 40MG A203481 003 Jul 03, 2017 Jun NEWA  
AB TEVA PHARMS USA 20MG A204661 001 Jun 13, 2017 May NEWA  
AB 40MG A204661 002 Jun 13, 2017 May NEWAOMEPRAZOLE MAGNESIUMFOR SUSPENSION, DELAYED RELEASE; ORAL  
PRILOSEC+ COVIS PHARMA BV EQ 2.5MG BASE/PACKET N022056 001 Mar 20, 2008 May CAHN  
+! EQ 10MG BASE/PACKET N022056 002 Mar 20, 2008 May CAHNOMEPRAZOLE; SODIUM BICARBONATEFOR SUSPENSION; ORAL  
OMEPRAZOLE AND SODIUM BICARBONATEAB AJANTA PHARMA LTD 20MG/PACKET; 1.68GM/PACKET A205545 001 Jul 27, 2016 Jan CTEC  
AB 40MG/PACKET; 1.68GM/PACKET A205545 002 Jul 27, 2016 Jan CTEC  
AB PAR PHARM 20MG/PACKET; 1.68GM/PACKET A079182 001 Apr 19, 2013 Jan CMFD  
AB 40MG/PACKET; 1.68GM/PACKET A079182 002 Apr 19, 2013 Jan CMFD

ZEGERID

AB + SANTARUS INC 20MG/PACKET; 1.68GM/PACKET N021636 001 Jun 15, 2004 Jan CTEC  
AB +! 40MG/PACKET; 1.68GM/PACKET N021636 002 Dec 21, 2004 Jan CTECONDANSETRONTABLET, ORALLY DISINTEGRATING; ORAL  
ONDANSETRON@ CHARTWELL MOLECULES 4MG A076506 001 Dec 26, 2006 Mar CAHN  
@ 8MG A076506 002 Dec 26, 2006 Mar CAHN  
@ 16MG A077406 001 Dec 26, 2006 Mar CAHN  
@ 24MG A077406 002 Dec 26, 2006 Mar CAHNONDANSETRON HYDROCHLORIDEINJECTABLE; INJECTION  
ONDANSETRON HYDROCHLORIDEAP ! BAXTER HLTHCARE CORP EQ 2MG BASE/ML A078288 001 Feb 22, 2013 Aug CAHN  
AP MYLAN LABS LTD EQ 2MG BASE/ML A204906 001 Jul 31, 2017 Jul NEWA  
AP SANDOZ INC EQ 2MG BASE/ML A077430 001 Jun 27, 2007 Mar CAHN  
AP WEST-WARD PHARMS INT EQ 2MG BASE/ML A076967 001 Dec 26, 2006 Jan CAHN

## INJECTABLE; INJECTION

## ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

AP	!	BAXTER HLTHCARE CORP	EQ 2MG BASE/ML	A078287	001	Feb 22, 2013	Aug	CAHN
AP		SANDOZ INC	EQ 2MG BASE/ML	A077551	001	Jun 27, 2007	Mar	CAHN
AP		WEST-WARD PHARMS INT	EQ 2MG BASE/ML	A077011	001	Dec 26, 2006	Jan	CAHN
AP			EQ 2MG BASE/ML	A077541	001	Dec 26, 2006	Jan	CAHN

ORPHENADRINE CITRATE

## INJECTABLE; INJECTION

## NORFLEX

@ TELIGENT 30MG/ML

N013055 001 Apr CAHN

## TABLET, EXTENDED RELEASE; ORAL

## NORFLEX

+ @ MEDICIS 100MG

N012157 001 Aug CRLD

OSELTAMIVIR PHOSPHATE

## CAPSULE; ORAL

## OSELTAMIVIR PHOSPHATE

AB		AMNEAL PHARMS	EQ 30MG BASE	A209093	001	May 17, 2017	May	NEWA	
AB			EQ 45MG BASE	A209093	002	May 17, 2017	May	NEWA	
AB			EQ 75MG BASE	A209093	003	May 17, 2017	May	NEWA	
>A>	AB	MACLEODS PHARMS LTD	EQ 30MG BASE	A207211	001	Sep 14, 2017	Sep	NEWA	
>A>	AB		EQ 45MG BASE	A207211	002	Sep 14, 2017	Sep	NEWA	
>A>	AB		EQ 75MG BASE	A207211	003	Sep 14, 2017	Sep	NEWA	
AB		NESHER PHARMS	EQ 30MG BASE	A208578	001	Feb 24, 2017	Feb	NEWA	
AB			EQ 45MG BASE	A208578	002	Feb 24, 2017	Feb	NEWA	
AB			EQ 75MG BASE	A208578	003	Feb 24, 2017	Feb	NEWA	
		FOR SUSPENSION; ORAL							
>A>		OSELTAMIVIR PHOSPHATE							
>A>	AB	NESHER PHARMS	EQ 6MG BASE/ML	A209113	001	Sep 14, 2017	Sep	NEWA	
		TAMIFLU							
>D>	+	!	ROCHE	EQ 6MG BASE/ML	N021246	002	Mar 21, 2011	Sep	CFTG
>A>	AB	+	!	EQ 6MG BASE/ML	N021246	002	Mar 21, 2011	Sep	CFTG

OSPHEMIFENE

## TABLET; ORAL

## OSPHEMIFENE

+! DUCHESNAY 60MG

N203505 001 Feb 26, 2013 Mar CAHN

OXACILLIN SODIUM

## INJECTABLE; INJECTION

## OXACILLIN SODIUM

AP		RENAISSANCE SSA LLC	EQ 1GM BASE/VIAL	A206681	001	Sep 11, 2017	Aug	NEWA
AP			EQ 2GM BASE/VIAL	A206681	002	Sep 11, 2017	Aug	NEWA
AP		WOCKHARDT BIO AG	EQ 1GM BASE/VIAL	A207147	001	Jul 31, 2017	Jul	NEWA
AP			EQ 2GM BASE/VIAL	A207147	002	Jul 31, 2017	Jul	NEWA

OXALIPLATIN

## INJECTABLE; IV (INFUSION)

## ELOXATIN

+ @ SANOFI AVENTIS US 200MG/40ML (5MG/ML)

N021759 003 Nov 17, 2006 Jan CRLD

## OXALIPLATIN

AP		ACCORD HLTHCARE	50MG/10ML (5MG/ML)	A207474	001	Mar 21, 2017	Mar	NEWA
AP			100MG/20ML (5MG/ML)	A207474	002	Mar 21, 2017	Mar	NEWA
AP			200MG/40ML (5MG/ML)	A207474	003	Mar 21, 2017	Mar	NEWA
AP		CIPLA LTD	50MG/10ML (5MG/ML)	A208523	001	Feb 10, 2017	Jan	NEWA
AP			100MG/20ML (5MG/ML)	A208523	002	Feb 10, 2017	Jan	NEWA
AP		FRESENIUS KABI USA	50MG/10ML (5MG/ML)	A090030	001	Jan 31, 2017	Jan	NEWA
AP			100MG/20ML (5MG/ML)	A090030	002	Jan 31, 2017	Jan	NEWA
AP			200MG/40ML (5MG/ML)	A090030	003	Jan 31, 2017	Jan	NEWA
AP		GLAND PHARMA LTD	50MG/10ML (5MG/ML)	A207325	001	Feb 10, 2017	Jan	NEWA
AP			50MG/VIAL	A207385	001	May 23, 2017	May	NEWA
AP			100MG/20ML (5MG/ML)	A207325	002	Feb 10, 2017	Jan	NEWA
AP			100MG/VIAL	A207385	002	May 23, 2017	May	NEWA
AP		LUITPOLD PHARMS INC	50MG/10ML (5MG/ML)	A204378	001	May 12, 2017	May	NEWA
AP			100MG/20ML (5MG/ML)	A204378	002	May 12, 2017	May	NEWA
AP	!	QILU PHARM CO LTD	200MG/40ML (5MG/ML)	A204368	003	Jun 07, 2016	Jan	CTEC
AP		SANJA PHARMS CO	50MG/10ML (5MG/ML)	A205529	001	Sep 06, 2017	Aug	NEWA
AP			100MG/20ML (5MG/ML)	A205529	002	Sep 06, 2017	Aug	NEWA

OXANDROLONE

TABLET; ORAL

OXANDROLONE

AB	UPSHER-SMITH LABS	2.5MG	A 076761	001	Dec 01, 2006	Jun	CAHN
AB		10MG	A 078033	001	Mar 22, 2007	Jun	CAHN

OXAPROZIN

TABLET; ORAL

OXAPROZIN

AB	AMNEAL PHARMS CO	600MG	A 208633	001	May 04, 2017	Apr	NEWA
----	------------------	-------	----------	-----	--------------	-----	------

OXAZEPAM

CAPSULE; ORAL

OXAZEPAM

AB	ACTAVIS ELIZABETH	10MG	A 072253	002	Apr 14, 1988	May	CMS1
AB		15MG	A 072253	003	Apr 14, 1988	May	CMS1
>A>	@ ANDA REPOSITORY	10MG	A 071026	002	Aug 10, 1987	Sep	CAHN
>A>	@	15MG	A 071026	003	Aug 10, 1987	Sep	CAHN
>A>	@	30MG	A 071026	001	Aug 10, 1987	Sep	CAHN
>D>	@ FRONTIDA BIOPHARM	10MG	A 071026	002	Aug 10, 1987	Sep	CAHN
>D>	@	15MG	A 071026	003	Aug 10, 1987	Sep	CAHN
>D>	@	30MG	A 071026	001	Aug 10, 1987	Sep	CAHN
	@ WATSON LABS TEVA	10MG	A 072952	001	Sep 28, 1990	May	CAHN

TABLET; ORAL

OXAZEPAM

	@ SUN PHARM INDS	15MG	A 070683	001	Jan 16, 1987	Jan	CAHN
--	------------------	------	----------	-----	--------------	-----	------

OXCARBAZEPINE

TABLET; ORAL

OXCARBAZEPINE

AB	GLENMARK PHARMS LTD	150MG	A 077802	001	Oct 09, 2007	May	CAHN
AB		300MG	A 077802	002	Oct 09, 2007	May	CAHN
AB		600MG	A 077802	003	Oct 09, 2007	May	CAHN
>D>	AB JUBILANT CADISTA	150MG	A 090239	001	Jan 25, 2010	Sep	DISC
>A>	@	150MG	A 090239	001	Jan 25, 2010	Sep	DISC
AB		150MG	A 090239	001	Jan 25, 2010	Apr	CAHN
>D>	AB	300MG	A 090239	002	Jan 25, 2010	Sep	DISC
>A>	@	300MG	A 090239	002	Jan 25, 2010	Sep	DISC
AB		300MG	A 090239	002	Jan 25, 2010	Apr	CAHN
>D>	AB	600MG	A 090239	003	Jan 25, 2010	Sep	DISC
>A>	@	600MG	A 090239	003	Jan 25, 2010	Sep	DISC
AB		600MG	A 090239	003	Jan 25, 2010	Apr	CAHN

OXTRIPHYLLINE

TABLET, EXTENDED RELEASE; ORAL

CHOLEDYL SA

>D>	! WARNER CHILCOTT LLC	600MG	A 086742	001		Sep	DISC
>A>	@	600MG	A 086742	001		Sep	DISC

OXYBUTYNIN CHLORIDE

SYRUP; ORAL

DITROPAN

	+ @ ORTHO MCNEIL JANSSEN	5MG/5ML	N 018211	001		Jan	CRLD
--	--------------------------	---------	----------	-----	--	-----	------

OXYBUTYNIN CHLORIDE

AA	PHARM ASSOC	5MG/5ML	A 075137	001	Dec 18, 1998	May	CAHN
----	-------------	---------	----------	-----	--------------	-----	------

TABLET; ORAL

OXYBUTYNIN CHLORIDE

>A>	AB UPSHER-SMITH LABS	5MG	A 074625	001	Jul 31, 1996	Sep	CAHN
>D>	AB USL PHARMA	5MG	A 074625	001	Jul 31, 1996	Sep	CAHN
AB		5MG	A 074625	001	Jul 31, 1996	Jun	CAHN

TABLET, EXTENDED RELEASE; ORAL

OXYBUTYNIN CHLORIDE

AB	UNIQUE PHARM LABS	5MG	A 206121	001	May 27, 2016	Aug	CAHN
AB		10MG	A 206121	002	May 27, 2016	Aug	CAHN
AB		15MG	A 206121	003	May 27, 2016	Aug	CAHN
AB	ZYDUS PHARMS USA INC	5MG	A 202332	001	Jun 26, 2017	Jun	NEWA
AB		10MG	A 202332	002	Jun 26, 2017	Jun	NEWA
AB		15MG	A 202332	003	Jun 26, 2017	Jun	NEWA

OXYCODONE HYDROCHLORIDE

## SOLUTION;ORAL

## OXYCODONE HYDROCHLORIDE

AA	ABHAI LLC	5MG/5ML	A208593	001	Jul 21, 2017	Jul	NEWA
AA		100MG/5ML	A208593	002	Jul 21, 2017	Jul	NEWA
AA	ANI PHARMS INC	100MG/5ML	A203447	001	Aug 30, 2017	Aug	NEWA
AA	HI-TECH PHARMACAL	5MG/5ML	A208817	001	Aug 10, 2017	Jul	NEWA
AA		100MG/5ML	A208795	001	Aug 07, 2017	Jul	NEWA
AA	PHARM ASSOC	100MG/5ML	A206822	001	Aug 15, 2017	Jul	NEWA
AA	WES PHARMA INC	100MG/5ML	A209897	001	Sep 06, 2017	Aug	NEWA

## TABLET;ORAL

## OXYCODONE HYDROCHLORIDE

AB	ASCENT PHARMS INC	15MG	A207418	001	Aug 07, 2017	Jul	NEWA
AB		30MG	A207418	002	Aug 07, 2017	Jul	NEWA
AB	EPIC PHARMA LLC	5MG	A090895	001	Aug 24, 2009	May	CAHN
AB		15MG	A090895	002	Aug 24, 2009	May	CAHN
AB		30MG	A090895	003	Aug 24, 2009	May	CAHN
AB	NOVEL LABS INC	5MG	A204021	001	Jun 12, 2017	May	NEWA
AB		10MG	A204021	002	Jun 12, 2017	May	NEWA
AB		15MG	A204021	003	Jun 12, 2017	May	NEWA
AB		20MG	A204021	004	Jun 12, 2017	May	NEWA
AB		30MG	A204021	005	Jun 12, 2017	May	NEWA

## ROXYBOND

## DAIICHI SANKYO INC

		5MG	N209777	001	Apr 20, 2017	Aug	CAHN
		15MG	N209777	002	Apr 20, 2017	Aug	CAHN
		30MG	N209777	003	Apr 20, 2017	Aug	CAHN
	INSPIRION DELIVERY	5MG	N209777	001	Apr 20, 2017	Apr	NEWA
		15MG	N209777	002	Apr 20, 2017	Apr	NEWA
		30MG	N209777	003	Apr 20, 2017	Apr	NEWA

OXYMETAZOLINE HYDROCHLORIDE

## CREAM;TOPICAL

## RHOFADÉ

+!	ALLERGAN INC	1%	N208552	001	Jan 18, 2017	Jan	NEWA
----	--------------	----	---------	-----	--------------	-----	------

OXYMETHOLONE

## TABLET;ORAL

## ANADROL-50

+!	MYLAN SPECIALITY LP	50MG	N016848	001		Mar	CAHN
----	---------------------	------	---------	-----	--	-----	------

OXYMORPHONE HYDROCHLORIDE

## INJECTABLE;INJECTION

## OPANA

+ @	ENDO PHARMS	1MG/ML	N011707	002		Aug	DISC
-----	-------------	--------	---------	-----	--	-----	------

## TABLET;ORAL

## OXYMORPHONE HYDROCHLORIDE

AB	EPIC PHARMA LLC	5MG	A201187	001	Dec 15, 2014	May	CAHN
AB		10MG	A201187	002	Dec 15, 2014	May	CAHN

## TABLET, EXTENDED RELEASE;ORAL

## OPANA ER

+ @	ENDO PHARMS	5MG	N201655	001	Dec 09, 2011	Aug	DISC
+ @		7.5MG	N201655	002	Dec 09, 2011	Aug	DISC
+ @		10MG	N201655	003	Dec 09, 2011	Aug	DISC
+ @		15MG	N201655	004	Dec 09, 2011	Aug	DISC
+ @		20MG	N201655	005	Dec 09, 2011	Aug	DISC
+ @		30MG	N201655	006	Dec 09, 2011	Aug	DISC
+ @		40MG	N201655	007	Dec 09, 2011	Aug	DISC

## OXYMORPHONE HYDROCHLORIDE

AB	ACTAVIS ELIZABETH	5MG	A079046	003	Jul 11, 2013	Apr	CAHN
AB		7.5MG	A079046	001	Dec 13, 2010	Apr	CAHN
AB		10MG	A079046	004	Jul 11, 2013	Apr	CAHN
AB		15MG	A079046	002	Dec 13, 2010	Apr	CAHN
AB		20MG	A079046	005	Jul 11, 2013	Apr	CAHN
AB		30MG	A079046	006	Jul 11, 2013	Apr	CAHN
AB		40MG	A079046	007	Jul 11, 2013	Apr	CAHN
	@ PAR PHARM	5MG	A200792	001	Oct 24, 2014	May	DISC
	@	7.5MG	A200792	002	Oct 24, 2014	May	DISC
	@	10MG	A200792	003	Oct 24, 2014	May	DISC
	@	15MG	A200792	004	Oct 24, 2014	May	DISC
	@	20MG	A200792	005	Oct 24, 2014	May	DISC
	@	30MG	A200792	006	Oct 24, 2014	May	DISC



TABLET, EXTENDED RELEASE;ORAL  
 OXYMORPHONE HYDROCHLORIDE  
 @ 40MG

A200792 007 Oct 24, 2014 May DISC

OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC  
 TERRAMYCIN W/ POLYMYXIN B SULFATE

! CASPER PHARMA LLC EQ 5MG BASE/GM;10,000 UNITS/GM

A061015 001 Jul CAHN

PALONOSETRON HYDROCHLORIDE

SOLUTION;INTRAVENOUS  
 PALONOSETRON HYDROCHLORIDE

>D> DR REDDYS LABS LTD EQ 0.075MG BASE/1.5ML (EQ 0.05MG  
 BASE/ML)

N203050 001 Mar 01, 2016 Sep DISC

>A> @ EQ 0.075MG BASE/1.5ML (EQ 0.05MG  
 BASE/ML)

N203050 001 Mar 01, 2016 Sep DISC

>D> EQ 0.25MG BASE/5ML (EQ 0.05MG  
 BASE/ML)

N203050 002 Mar 01, 2016 Sep DISC

>A> @ EQ 0.25MG BASE/5ML (EQ 0.05MG  
 BASE/ML)

N203050 002 Mar 01, 2016 Sep DISC

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE, DELAYED RELEASE;ORAL  
 PERTZYE

>A> + DIGESTIVE CARE INC 90,750USP UNITS;24,000USP  
 UNITS;86,250USP UNITS

N022175 004 Jul 13, 2017 Sep NEWA

PANTOPRAZOLE SODIUM

POWDER; IV (INFUSION)  
 PANTOPRAZOLE SODIUM

EXELA PHARMA SCS LLC EQ 40MG BASE/VIAL

N209463 001 Jun 30, 2017 Jun NEWA

TABLET, DELAYED RELEASE;ORAL  
 PANTOPRAZOLE SODIUM

>D> AB SUN PHARM INDS LTD EQ 20MG BASE

A077058 001 Sep 10, 2007 Sep DISC

>A> @ EQ 20MG BASE

A077058 001 Sep 10, 2007 Sep DISC

AB EQ 20MG BASE

A077058 001 Sep 10, 2007 Mar CAHN

>D> AB EQ 40MG BASE

A077058 002 Sep 10, 2007 Sep DISC

>A> @ EQ 40MG BASE

A077058 002 Sep 10, 2007 Sep DISC

AB EQ 40MG BASE

A077058 002 Sep 10, 2007 Mar CAHN

PARICALCITOL

CAPSULE;ORAL  
 PARICALCITOL

AB AMNEAL PHARMS 1MCG

A204327 001 Jan 13, 2016 May CAHN

AB 2MCG

A204327 002 Jan 13, 2016 May CAHN

AB 4MCG

A204327 003 Jan 13, 2016 May CAHN

SOLUTION;INTRAVENOUS  
 PARICALCITOL

AP AMNEAL PHARMS CO 0.002MG/ML (0.002MG/ML)

A206699 001 Mar 09, 2017 Feb NEWA

AP 0.005MG/ML (0.005MG/ML)

A206699 002 Mar 09, 2017 Feb NEWA

AP 0.01MG/2ML (0.005MG/ML)

A206699 003 Mar 09, 2017 Feb NEWA

AP SANDOZ INC 0.002MG/ML (0.002MG/ML)

A091108 001 Jul 27, 2011 Apr CAHN

AP 0.005MG/ML (0.005MG/ML)

A091108 002 Jul 27, 2011 Apr CAHN

AP 0.01MG/2ML (0.005MG/ML)

A091108 003 Jul 27, 2011 Apr CAHN

PAROXETINE HYDROCHLORIDE

SUSPENSION;ORAL  
 PAXIL

>D> AB +! APOTEX TECHNOLOGIES EQ 10MG BASE/5ML

N020710 001 Jun 25, 1997 Sep CTEC

>A> +! EQ 10MG BASE/5ML

N020710 001 Jun 25, 1997 Sep CTEC

TABLET;ORAL

PAROXETINE HYDROCHLORIDE

@ MYLAN PHARMS INC EQ 10MG BASE

A075716 001 Mar 08, 2004 Apr DISC

@ EQ 20MG BASE

A075716 002 Mar 08, 2004 Apr DISC

@ EQ 30MG BASE

A075716 003 Mar 08, 2004 Apr DISC

@ EQ 40MG BASE

A075716 004 Mar 08, 2004 Apr DISC

@ UPSHER-SMITH LABS EQ 10MG BASE

A075566 001 Mar 08, 2004 Jun CAHN

@ EQ 20MG BASE

A075566 002 Mar 08, 2004 Jun CAHN

@ EQ 30MG BASE

A075566 003 Mar 08, 2004 Jun CAHN

@ EQ 40MG BASE

A075566 004 Mar 08, 2004 Jun CAHN

TABLET, EXTENDED RELEASE;ORAL  
PAROXETINE HYDROCHLORIDE

AB	LUPIN LTD	EQ 12.5MG BASE	A204134	001	Jan 20, 2017	Jan NEWA
AB		EQ 25MG BASE	A204134	002	Jan 20, 2017	Jan NEWA
AB		EQ 37.5MG BASE	A204134	003	Jan 20, 2017	Jan NEWA

PAROXETINE MESYLATE

CAPSULE;ORAL  
BRISDELLE

AB	+! SEBELA IRELAND LTD	EQ 7.5MG BASE	N204516	001	Jun 28, 2013	Jun CFTG
	PAROXETINE MESYLATE					
AB	ACTAVIS LABS FL INC	EQ 7.5MG BASE	A207139	001	Jun 20, 2017	Jun NEWA
AB	PRINSTON INC	EQ 7.5MG BASE	A207188	001	Aug 18, 2017	Aug NEWA

PENCICLOVIR

CREAM;TOPICAL  
DENA VIR

	+! MYLAN PHARMS INC	1%	N020629	001	Sep 24, 1996	Jan CAHN
--	---------------------	----	---------	-----	--------------	----------

PENICILLAMINE

TABLET;ORAL  
DEPEN

	+! MYLAN SPECIALITY LP	250MG	N019854	001		Mar CAHN
--	------------------------	-------	---------	-----	--	----------

PENICILLIN G BENZATHINE

INJECTABLE;INJECTION  
BICILLIN L-A

	+! KING PHARMS LLC	300,000 UNITS/ML	N050141	003		May CAHN
BC	+!	600,000 UNITS/ML	N050141	001		May CAHN
	PERMAPEN					
BC	CASPER PHARMA LLC	600,000 UNITS/ML	A060014	001		Jul CAHN

PENICILLIN G BENZATHINE; PENICILLIN G PROCAINE

INJECTABLE;INJECTION  
BICILLIN C-R

	+! KING PHARMS LLC	150,000 UNITS/ML;150,000 UNITS/ML	N050138	002		Apr CAHN
	+!	300,000 UNITS/ML;300,000 UNITS/ML	N050138	001		Apr CAHN
	BICILLIN C-R 900/300					
	+! KING PHARMS LLC	900,000 UNITS/2ML;300,000 UNITS/2ML	N050138	003		Apr CAHN

PENICILLIN G PROCAINE

INJECTABLE;INJECTION  
PENICILLIN G PROCAINE

	! KING PHARMS LLC	300,000 UNITS/ML	A060101	002		Jun CAHN
	!	600,000 UNITS/ML	A060101	001		Jun CAHN

PENTAMIDINE ISETHIONATE

INJECTABLE;INJECTION  
PENTAM

>D>	+! FRESENIUS KABI USA	300MG/VIAL	N019264	001	Oct 16, 1984	Sep CTEC
>A> AP	+!	300MG/VIAL	N019264	001	Oct 16, 1984	Sep CTEC
	PENTAMIDINE ISETHIONATE					
>A> AP	SETON PHARMS	300MG/VIAL	A206666	001	Sep 28, 2017	Sep NEWA

PENTOBARBITAL SODIUM

INJECTABLE;INJECTION  
PENTOBARBITAL SODIUM

AP	SAGENT PHARMS	50MG/ML	A206404	001	May 23, 2016	Apr CAHN
----	---------------	---------	---------	-----	--------------	----------

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE;ORAL  
PENTOXIFYLLINE

	@ PLIVA	400MG	A074874	001	May 25, 1999	Aug CAHN
	PENTOXIL					
AB	UPSHER-SMITH LABS	400MG	A074962	001	Mar 31, 1999	Jun CAHN
	TRENTAL					
	+ @ US PHARM HOLDINGS	400MG	N018631	001	Aug 30, 1984	Jan CRLD

PERINDOPRIL ERBUMINE

TABLET; ORAL

ACEON

+ @ SYMPLMED PHARMS LLC 2MG  
 + @ 4MG  
 + @ 8MG

N020184 001 Dec 30, 1993 May DISC  
 N020184 002 Dec 30, 1993 May DISC  
 N020184 003 Dec 30, 1993 May DISC

PERINDOPRIL ERBUMINE

AB ! AUROBINDO PHARMA 2MG  
 AB ! 4MG  
 AB ! 8MG

A079070 001 Nov 10, 2009 May CHRS  
 A079070 002 Nov 10, 2009 May CHRS  
 A079070 003 Nov 10, 2009 May CHRS

PERMETHRIN

CREAM; TOPICAL

ELIMITE

AB +! MYLAN PHARMS INC 5%  
 PERMETHRIN  
 AB ACTAVIS LABS 5%

N019855 001 Aug 25, 1989 Jan CAHN  
 A074806 001 Jan 23, 1998 May CAHN

PERPHENAZINE

TABLET; ORAL

PERPHENAZINE

AB MYLAN PHARMS INC 2MG  
 AB 4MG  
 AB 8MG  
 AB 16MG

A206691 001 Apr 14, 2017 Apr NEWA  
 A206691 002 Apr 14, 2017 Apr NEWA  
 A206691 003 Apr 14, 2017 Apr NEWA  
 A206691 004 Apr 14, 2017 Apr NEWA

PHENDIMETRAZINE TARTRATE

TABLET; ORAL

PHENDIMETRAZINE TARTRATE

@ USL PHARMA 35MG

A084399 001 Jun CAHN

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE; ORAL

PHENOXYBENZAMINE HYDROCHLORIDE

AB PAR PHARM INC 10MG

A204522 001 Jan 24, 2017 Jan NEWA

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

PHENTERMINE HYDROCHLORIDE

@ ELITE LABS INC 30MG  
 @ 30MG  
 AA 37.5MG  
 @ UPSHER-SMITH LABS 30MG  
 @ 30MG

A040227 001 Jun 18, 1997 May CAHN  
 A040448 001 Jan 22, 2003 May CAHN  
 A040228 001 Jun 19, 1997 May CAHN  
 A084487 001 Apr 09, 1982 Jun CAHN  
 A088430 001 Mar 27, 1984 Jun CAHN

TABLET; ORAL

PHENTERMINE HYDROCHLORIDE

AA ELITE LABS INC 37.5MG  
 AA KVK TECH INC 8MG  
 AA PRINSTON INC 37.5MG

A040190 001 May 30, 1997 May CAHN  
 A203436 001 Mar 17, 2017 Mar NEWA  
 A040377 001 Jan 04, 2002 Feb CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

PHENTERMINE HYDROCHLORIDE

ZYDUS PHARMS USA INC 15MG  
 30MG  
 37.5MG

A204663 001 Jun 28, 2017 Jun NEWA  
 A204663 002 Jun 28, 2017 Jun NEWA  
 A204663 003 Jun 28, 2017 Jun NEWA

PHENTOLAMINE MESYLATE

INJECTABLE; INJECTION

PHENTOLAMINE MESYLATE

AP PRECISION DOSE INC 5MG/VIAL  
 AP ! WEST-WARD PHARMS INT 5MG/VIAL  
 ! 5MG/VIAL

A207686 001 Jul 14, 2017 Jul NEWA  
 A040235 001 Mar 11, 1998 Jul CTEC  
 A040235 001 Mar 11, 1998 May CHRS

REGITINE

+ @ NOVARTIS 5MG/VIAL

N008278 003 May DISC

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION; IV (INFUSION)

VAZCULEP

+ AVADEL LEGACY 10MG/ML (10MG/ML)  
 + 50MG/5ML (10MG/ML)  
 +! 100MG/10ML (10MG/ML)

N204300 001 Jun 27, 2014 Jan CAHN  
 N204300 002 Jun 27, 2014 Jan CAHN  
 N204300 003 Jun 27, 2014 Jan CAHN

PHENYTOIN

TABLET, CHEWABLE;ORAL  
DILANTIN

AB	!	PFIZER	50MG	A 084427	001		Feb	CAHN
AB		EPIC PHARMA LLC	50MG	A 040884	001	Nov 28, 2014	May	CAHN

PHENYTOIN SODIUM

CAPSULE;ORAL  
DILANTIN

AB	!	PARKE-DAVIS	30MG EXTENDED	A 084349	001		Feb	CAHN
AB	!		100MG EXTENDED	A 084349	002		Feb	CAHN

INJECTABLE;INJECTION  
PHENYTOIN SODIUM

AP		ACELLA PHARMS LLC	50MG/ML	A 040573	001	Sep 13, 2006	May	CAHN
	@	HOSPIRA	50MG/ML	A 089521	001	Mar 17, 1987	Mar	DISC

PHYTONADIONE

INJECTABLE;INJECTION  
AQUAMEPHYTON

	+	@ TELIGENT	1MG/0.5ML	N 012223	002		Apr	CAHN
	+	@	10MG/ML	N 012223	001		Apr	CAHN

PILOCARPINE HYDROCHLORIDE

SOLUTION;OPHTHALMIC  
ISOPTO CARPINE

>D>	+	NOVARTIS PHARMS CORP	1%	N 200890	001	Jun 22, 2010	Sep	CFTG
>A>	AT		1%	N 200890	001	Jun 22, 2010	Sep	CFTG
>D>	+		2%	N 200890	002	Jun 22, 2010	Sep	CFTG
>A>	AT		2%	N 200890	002	Jun 22, 2010	Sep	CFTG
>D>	+		4%	N 200890	003	Jun 22, 2010	Sep	CFTG
>A>	AT		4%	N 200890	003	Jun 22, 2010	Sep	CFTG
>A>		PILOCARPINE HYDROCHLORIDE						
>A>	AT	AKORN INC	1%	A 204398	001	Sep 27, 2017	Sep	NEWA
>A>	AT		2%	A 204398	002	Sep 27, 2017	Sep	NEWA
>A>	AT		4%	A 204398	003	Sep 27, 2017	Sep	NEWA

TABLET;ORAL

PILOCARPINE HYDROCHLORIDE

>D>	AB	ALLIED PHARMA INC	5MG	A 076963	001	Dec 22, 2004	Sep	CAHN
	AB		5MG	A 076963	001	Dec 22, 2004	Mar	CAHN
>D>	AB		7.5MG	A 076963	002	Feb 27, 2007	Sep	CAHN
	AB		7.5MG	A 076963	002	Feb 27, 2007	Mar	CAHN
>A>	AB	INNOGENIX	5MG	A 076963	001	Dec 22, 2004	Sep	CAHN
>A>	AB		7.5MG	A 076963	002	Feb 27, 2007	Sep	CAHN
	AB	PERRIGO PHARMA INTL	5MG	A 076746	001	Nov 16, 2004	Apr	CAHN

PINDOLOL

TABLET;ORAL

PINDOLOL

AB		IDT AUSTRALIA LTD	5MG	A 073608	001	Mar 29, 1993	May	CMFD
AB			10MG	A 073609	001	Mar 29, 1993	May	CMFD
AB		ZYDUS PHARMS USA INC	5MG	A 209866	001	Aug 18, 2017	Aug	NEWA
AB			10MG	A 209866	002	Aug 18, 2017	Aug	NEWA

PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

PIOGLITAZONE HYDROCHLORIDE

AB		CIPLA LTD	EQ 15MG BASE	A 076798	001	Oct 26, 2012	Jun	CAHN
AB			EQ 30MG BASE	A 076798	002	Oct 26, 2012	Jun	CAHN
AB			EQ 45MG BASE	A 076798	003	Oct 26, 2012	Jun	CAHN
>A>	AB	PURACAP PHARM LLC	EQ 15MG BASE	A 206738	001	Oct 06, 2017	Sep	NEWA
>A>	AB		EQ 30MG BASE	A 206738	002	Oct 06, 2017	Sep	NEWA
>A>	AB		EQ 45MG BASE	A 206738	003	Oct 06, 2017	Sep	NEWA
AB		WATSON LABS TEVA	EQ 15MG BASE	A 076798	001	Oct 26, 2012	May	CAHN
AB			EQ 30MG BASE	A 076798	002	Oct 26, 2012	May	CAHN
AB			EQ 45MG BASE	A 076798	003	Oct 26, 2012	May	CAHN

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION

PIPERACILLIN AND TAZOBACTAM

AP	APOLLO PHARMS INC	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A207847	001	Jan 13, 2017	Jan	NEWA
AP		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A207847	002	Jan 13, 2017	Jan	NEWA
AP		EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A207848	002	Jan 13, 2017	Jan	NEWA
AP		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A207847	003	Jan 13, 2017	Jan	NEWA
AP	WOCKHARDT BIO AG	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A206996	001	Mar 22, 2017	Mar	NEWA
AP		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A206996	002	Mar 22, 2017	Mar	NEWA
AP		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A206996	003	Mar 22, 2017	Mar	NEWA
AP		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A207146	001	Mar 17, 2017	Mar	NEWA

PIRFENIDONE

TABLET; ORAL

ESBRIET

+	GENENTECH INC	267MG	N208780	001	Jan 11, 2017	Jan	NEWA
+	@	534MG	N208780	002	Jan 11, 2017	Jan	DISC
+	!	801MG	N208780	003	Jan 11, 2017	Jan	NEWA

PIROXICAM

CAPSULE; ORAL

PIROXICAM

AB	HIKMA PHARMS	10MG	A209256	001	Aug 11, 2017	Jul	NEWA
AB		20MG	A209256	002	Aug 11, 2017	Jul	NEWA
	@ MYLAN	10MG	A074102	001	Jul 31, 1992	Jul	DISC
	@	20MG	A074102	002	Jul 31, 1992	Jul	DISC
AB	PII	10MG	A206136	001	Jun 20, 2017	Jun	NEWA
AB		20MG	A206136	002	Jun 20, 2017	Jun	NEWA
AB	UNICHEM LABS LTD	10MG	A208340	001	Apr 13, 2017	Apr	NEWA
AB		20MG	A208340	002	Apr 13, 2017	Apr	NEWA

PITAVASTATIN CALCIUM

TABLET; ORAL

PITAVASTATIN CALCIUM

AB	ORIENT PHARMA CO LTD	EQ 1MG BASE	A205932	001	Feb 03, 2017	Jan	NEWA
AB		EQ 2MG BASE	A205932	002	Feb 03, 2017	Jan	NEWA
AB		EQ 4MG BASE	A205932	003	Feb 03, 2017	Jan	NEWA
AB	SAWAI USA	EQ 1MG BASE	A205955	001	Feb 03, 2017	Jan	NEWA
AB		EQ 2MG BASE	A205955	002	Feb 03, 2017	Jan	NEWA
AB		EQ 4MG BASE	A205955	003	Feb 03, 2017	Jan	NEWA

PITAVASTATIN MAGNESIUM

TABLET; ORAL

ZYPITAMAG

+	ZYDUS PHARMS USA INC	EQ 1MG BASE	N208379	001	Jul 14, 2017	Jul	NEWA
+		EQ 2MG BASE	N208379	002	Jul 14, 2017	Jul	NEWA
+	!	EQ 4MG BASE	N208379	003	Jul 14, 2017	Jul	NEWA

PITAVASTATIN SODIUM

TABLET; ORAL

NIKITA

>D>								
>D>	+	LUPIN LTD	EQ 1MG BASE	N209875	001	Aug 04, 2017	Sep	DISC
>A>	+	@	EQ 1MG BASE	N209875	001	Aug 04, 2017	Sep	DISC
	+		EQ 1MG BASE	N209875	001	Aug 04, 2017	Aug	NEWA
>D>	+		EQ 2MG BASE	N209875	002	Aug 04, 2017	Sep	DISC
>A>	+	@	EQ 2MG BASE	N209875	002	Aug 04, 2017	Sep	DISC
	+		EQ 2MG BASE	N209875	002	Aug 04, 2017	Aug	NEWA
>D>	+	!	EQ 4MG BASE	N209875	003	Aug 04, 2017	Sep	DISC
>A>	+	@	EQ 4MG BASE	N209875	003	Aug 04, 2017	Sep	DISC
	+	!	EQ 4MG BASE	N209875	003	Aug 04, 2017	Aug	NEWA

PLECANATIDETABLET;ORAL  
TRULANCE

+! SYNERGY PHARMS 3MG N208745 001 Jan 19, 2017 Jan NEWA

PODOFILOXSOLUTION;TOPICAL  
PODOFILOX

@ BAUSCH AND LOMB INC 0.5% A090184 001 Jul 21, 2010 Aug DISC

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION;ORAL

PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE

	@ MYLAN	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11	A090409	001	Apr 02, 2010	Apr DISC
AA	STRIDES PHARMA	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11	A204559	001	Apr 13, 2015	Apr CAHN
		.2GM/BOT				
		PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE				
AA	BRECKENRIDGE PHARM	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11	A202060	001	Mar 08, 2017	Mar CAHN
		.2GM/BOT				
AA	BRECKENRIDGE PHARMS	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11	A202060	001	Mar 08, 2017	Feb NEWA
		.2GM/BOT				
		TRILYTE				
AA	MYLAN PHARMS INC	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11	A076491	001	Feb 05, 2004	Mar CAHN
		.2GM/BOT				

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION;ORAL

COLYTE

	@ MYLAN SPECIALITY LP	120GM/PACKET;1.49GM/PACKET;3.36GM/PACKET;2.92GM/PACKET;11.36GM/PACKET	N018983	005	Oct 26, 1984	Mar CAHN
	@	227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET	N018983	004	Oct 26, 1984	Mar CAHN
	@	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	010	Jan 31, 1989	Mar CAHN
	@	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	007	Jun 12, 1987	Mar CAHN
	@	360GM/PACKET;4.47GM/PACKET;10.08GM/PACKET;8.76GM/PACKET;34.08GM/PACKET	N018983	006	Oct 26, 1984	Mar CAHN
		ET				
		COLYTE WITH FLAVOR PACKS				
AA	MYLAN SPECIALITY LP	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	012	Oct 08, 1998	Mar CAHN
		COLYTE-FLAVORED				
	@ MYLAN SPECIALITY LP	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	008	Nov 14, 1991	Mar CAHN
	@	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	009	Nov 14, 1991	Mar CAHN
		PEG 3350 AND ELECTROLYTES				
	@ MYLAN	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A090928	001	Jan 28, 2010	Apr DISC

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS;OPHTHALMIC

TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

AT SANDOZ INC 10,000 UNITS/ML;EQ 1MG BASE/ML A064211 001 Apr 13, 1998 Feb CAHN

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

KLOR-CON

AB	UPSHER-SMITH LABS	8MEQ	A203106	001	Jul 10, 2015	Jun CAHN
AB		10MEQ	A203106	002	Jul 10, 2015	Jun CAHN
		POTASSIUM CHLORIDE				
AB	ADARE PHARMS INC	8MEQ	A208864	001	Mar 17, 2017	Mar NEWA
AB		10MEQ	A208864	002	Mar 17, 2017	Mar NEWA
		INJECTABLE;INJECTION				
		POTASSIUM CHLORIDE				
	@ BAXTER HLTHCARE	2MEQ/ML	A085499	001		Apr DISC
		POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER				
AP	+ ICU MEDICAL INC	14.9MG/ML	N020161	005	Nov 30, 1992	Feb CAHN
AP	+	745MG/100ML	N020161	001	Nov 30, 1992	Feb CAHN

INJECTABLE;INJECTION							
POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER							
AP	+	ICU MEDICAL INC	29.8MG/ML	N020161	006	Aug 11, 1998	Feb CAHN
AP	+		1.49GM/100ML	N020161	002	Nov 30, 1992	Feb CAHN
POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER							
AP	+	ICU MEDICAL INC	2.24GM/100ML	N020161	003	Aug 11, 1998	Feb CAHN
POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER							
AP	+	ICU MEDICAL INC	2.98GM/100ML	N020161	004	Aug 11, 1998	Feb CAHN
TABLET, EXTENDED RELEASE;ORAL							
KLOR-CON							
AB2	+	UPSHER-SMITH LABS	8MEQ	N019123	001	Apr 17, 1986	Jun CAHN
AB2	+		10MEQ	N019123	002	Apr 17, 1986	Jun CAHN
KLOR-CON M10							
AB1		UPSHER-SMITH LABS	10MEQ	A074726	002	Aug 09, 2000	Jun CAHN
KLOR-CON M15							
		UPSHER-SMITH LABS	15MEQ	A074726	003	Jun 06, 2003	Jun CAHN
KLOR-CON M20							
AB1	!	UPSHER-SMITH LABS	20MEQ	A074726	001	Nov 20, 1998	Jun CAHN
<u>POTASSIUM CHLORIDE; SODIUM CHLORIDE</u>							
INJECTABLE;INJECTION							
POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER							
AP		ICU MEDICAL INC	149MG/100ML;450MG/100ML	A078446	001	Sep 10, 2008	Feb CAHN
POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
AP		ICU MEDICAL INC	149MG/100ML;900MG/100ML	N019686	001	Oct 17, 1988	Feb CAHN
POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
AP		ICU MEDICAL INC	298MG/100ML;900MG/100ML	N019686	002	Oct 17, 1988	Feb CAHN
<u>POTASSIUM CITRATE</u>							
TABLET, EXTENDED RELEASE;ORAL							
POTASSIUM CITRATE							
AB		IMPAX LABS INC	5MEQ	A077440	001	Jun 09, 2006	Feb CAHN
AB			10MEQ	A077440	002	Jun 09, 2006	Feb CAHN
AB		STRIDES PHARMA	5MEQ	A206813	001	Sep 11, 2017	Aug NEWA
AB			10MEQ	A206813	002	Sep 11, 2017	Aug NEWA
AB			15MEQ	A206813	003	Sep 11, 2017	Aug NEWA
<u>PRAMIPEXOLE DIHYDROCHLORIDE</u>							
TABLET;ORAL							
PRAMIPEXOLE DIHYDROCHLORIDE							
	@	ACTAVIS GRP PTC	0.125MG	A091254	001	Nov 30, 2010	Jan DISC
	@		0.25MG	A091254	002	Nov 30, 2010	Jan DISC
	@		0.5MG	A091254	003	Nov 30, 2010	Jan DISC
	@		0.75MG	A091254	004	Nov 30, 2010	Jan DISC
	@		1MG	A091254	005	Nov 30, 2010	Jan DISC
	@		1.5MG	A091254	006	Nov 30, 2010	Jan DISC
AB		ALEMBIC PHARMS LTD	0.125MG	A078894	001	Oct 08, 2010	May CAHN
AB			0.25MG	A078894	002	Oct 08, 2010	May CAHN
AB			0.5MG	A078894	003	Oct 08, 2010	May CAHN
AB			1MG	A078894	004	Oct 08, 2010	May CAHN
AB			1.5MG	A078894	005	Oct 08, 2010	May CAHN
TABLET, EXTENDED RELEASE;ORAL							
PRAMIPEXOLE DIHYDROCHLORIDE							
AB		ACTAVIS ELIZABETH	2.25MG	A203615	001	Oct 14, 2016	Apr CAHN
AB			3.75MG	A203615	002	Jan 03, 2017	Apr CAHN
AB		MACLEODS PHARMS LTD	3.75MG	A206156	007	Jan 23, 2017	Jan NEWA
<u>PRASTERONE</u>							
INSERT;VAGINAL							
INTRAROSA							
	+	AMAG PHARMS INC	6.5MG	N208470	001	Nov 16, 2016	May CAHN
<u>PRASUGREL HYDROCHLORIDE</u>							
TABLET;ORAL							
EFFIENT							
AB	+	ELI LILLY AND CO	EQ 5MG BASE	N022307	001	Jul 10, 2009	Jun CFTG
AB	+		EQ 10MG BASE	N022307	002	Jul 10, 2009	Jun CFTG
PRASUGREL							
AB		MYLAN PHARMS INC	EQ 5MG BASE	A205927	001	Jul 12, 2017	Jun NEWA
AB			EQ 10MG BASE	A205927	002	Jul 12, 2017	Jun NEWA

PRAVASTATIN SODIUM

TABLET;ORAL

PRAVASTATIN SODIUM

AB	AUROBINDO PHARMA LTD	10MG	A203367	001	Feb 02, 2017	Jan NEWA
AB		20MG	A203367	002	Feb 02, 2017	Jan NEWA
AB		40MG	A203367	003	Feb 02, 2017	Jan NEWA
AB		80MG	A203367	004	Feb 02, 2017	Jan NEWA

PRAZOSIN HYDROCHLORIDE

CAPSULE;ORAL

PRAZOSIN HYDROCHLORIDE

IDT AUSTRALIA LTD

EQ 1MG BASE  
EQ 5MG BASE

A072577	002	May 16, 1989	May CMS1
A072577	003	May 16, 1989	May CMS1

PREDNISOLONE

SYRUP;ORAL

PREDNISOLONE

AA	PHARM ASSOC	15MG/5ML	A040399	001	Mar 05, 2003	May CAHN
AA	VISTAPHARM	15MG/5ML	A040323	001	May 13, 1999	Mar CAHN

TABLET;ORAL

PREDNISOLONE

@ CHARTWELL RX

5MG

A084542	001		Apr CAHN
---------	-----	--	----------

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION;ORAL

PREDNISOLONE SODIUM PHOSPHATE

@ AMNEAL PHARMS

EQ 15MG BASE/5ML

A078345	001	Mar 10, 2009	May DISC
---------	-----	--------------	----------

AA	CHARTWELL RX	EQ 5MG BASE/5ML	A075988	001	May 25, 2004	Jun CAHN
	@ PHARM ASSOC	EQ 5MG BASE/5ML	A076123	001	Dec 23, 2002	May CAHN

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS;OPHTHALMIC

SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE

AT	! BAUSCH AND LOMB	EQ 0.23% PHOSPHATE;10%	A074449	001	Dec 29, 1995	Feb CAHN
AT	SANDOZ INC	EQ 0.23% PHOSPHATE;10%	A073630	001	May 27, 1993	Feb CAHN

PREDNISONE

TABLET;ORAL

METICORTEN

+ @ SCHERING

1MG

N009766	002		Mar CMS1
---------	-----	--	----------

+ @

5MG

N009766	001		Mar CMS1
---------	-----	--	----------

PREDNISONE

@ CHARTWELL RX

5MG

A083059	001		Apr CAHN
---------	-----	--	----------

@ CONTRACT PHARMACAL

5MG

A080209	001		Mar DISC
---------	-----	--	----------

AB	MYLAN PHARMS INC	5MG	A080292	001		Jan CAHN
----	------------------	-----	---------	-----	--	----------

AB		10MG	A088832	001	Dec 04, 1985	Jan CAHN
----	--	------	---------	-----	--------------	----------

AB		20MG	A083677	001		Jan CAHN
----	--	------	---------	-----	--	----------

AB	SUN PHARM INDS	10MG	A089246	001	Dec 04, 1985	May CAHN
----	----------------	------	---------	-----	--------------	----------

@ UPSHER SMITH

5MG

A087471	001		Jun CAHN
---------	-----	--	----------

@

20MG

A087470	001		Jun CAHN
---------	-----	--	----------

TABLET, DELAYED RELEASE;ORAL

PREDNISONE

AB	ACTAVIS LABS FL INC	1MG	A204867	001	Apr 25, 2017	Apr NEWA
----	---------------------	-----	---------	-----	--------------	----------

AB		2MG	A204867	002	Apr 25, 2017	Apr NEWA
----	--	-----	---------	-----	--------------	----------

AB		5MG	A204867	003	Apr 25, 2017	Apr NEWA
----	--	-----	---------	-----	--------------	----------

RAYOS

AB	+ HORIZON PHARMA	1MG	N202020	001	Jul 26, 2012	Apr CFTG
----	------------------	-----	---------	-----	--------------	----------

AB	+	2MG	N202020	002	Jul 26, 2012	Apr CFTG
----	---	-----	---------	-----	--------------	----------

AB	+!	5MG	N202020	003	Jul 26, 2012	Apr CFTG
----	----	-----	---------	-----	--------------	----------

PRIMIDONE

TABLET;ORAL

PRIMIDONE

>A>	AB	ANDA REPOSITORY	50MG	A040626	001	Sep 29, 2005	Sep CAHN
-----	----	-----------------	------	---------	-----	--------------	----------

>A>	AB		250MG	A040626	002	Sep 29, 2005	Sep CAHN
-----	----	--	-------	---------	-----	--------------	----------

>D>	AB	FRONTIDA BIOPHARM	50MG	A040626	001	Sep 29, 2005	Sep CAHN
-----	----	-------------------	------	---------	-----	--------------	----------

>D>	AB		250MG	A040626	002	Sep 29, 2005	Sep CAHN
-----	----	--	-------	---------	-----	--------------	----------



<u>PROBENECID</u>										
TABLET; ORAL										
BENEMID										
	+	@ MERCK	500MG		N007898	004			Jan	CRLD
PROBENECID										
AB		WATSON LABS TEVA	500MG		A084442	004	Mar 29, 1983		May	CAHN
<u>PROCAINAMIDE HYDROCHLORIDE</u>										
CAPSULE; ORAL										
PROCAINAMIDE HYDROCHLORIDE										
	@	IDT AUSTRALIA LTD	375MG		A089219	002	Jul 01, 1986		Aug	CMS1
	@		500MG		A089219	003	Jul 01, 1986		Aug	CMS1
INJECTABLE; INJECTION										
PROCAINAMIDE HYDROCHLORIDE										
	@	WEST-WARD PHARMS INT	100MG/ML		A089029	001	Apr 17, 1986		Jan	CAHN
	@		500MG/ML		A089030	001	Apr 17, 1986		Mar	CAHN
TABLET, EXTENDED RELEASE; ORAL										
PROCAINAMIDE HYDROCHLORIDE										
		IDT AUSTRALIA LTD	500MG		A089369	002	Jan 09, 1987		Aug	CMS1
			750MG		A089369	003	Aug 14, 1987		Aug	CMS1
<u>PROCARBAZINE HYDROCHLORIDE</u>										
CAPSULE; ORAL										
MATULANE										
	+	LEADIANT BIOSCI INC	EQ 50MG BASE		N016785	001			Feb	CAHN
<u>PROCHLORPERAZINE EDISYLATE</u>										
INJECTABLE; INJECTION										
PROCHLORPERAZINE EDISYLATE										
	@	ATHENEX INC	EQ 5MG BASE/ML		A040540	001	May 28, 2004		Mar	CAHN
	@	WEST-WARD PHARMS INT	EQ 5MG BASE/ML		A089523	001	May 03, 1988		Jan	CAHN
AP			EQ 5MG BASE/ML		A089903	001	Aug 29, 1989		Jan	CAHN
<u>PROCYCLIDINE HYDROCHLORIDE</u>										
TABLET; ORAL										
KEMADRIN										
	@	MONARCH PHARMS	2MG		N009818	005			Apr	CAHN
	@		5MG		N009818	003			Apr	CAHN
<u>PROGESTERONE</u>										
CAPSULE; ORAL										
PROGESTERONE										
AB		AMNEAL PHARMS NY	100MG		A207724	001	Sep 07, 2017		Aug	NEWA
AB			200MG		A207724	002	Sep 07, 2017		Aug	NEWA
AB		DR REDDYS LABS INC	100MG		A208801	001	Feb 28, 2017		Feb	NEWA
AB			200MG		A208801	002	Feb 28, 2017		Feb	NEWA
INJECTABLE; INJECTION										
PROGESTERONE										
AO	+	ACTAVIS LABS UT INC	50MG/ML		N017362	002			Feb	CAHN
<u>PROMETHAZINE HYDROCHLORIDE</u>										
SUPPOSITORY; RECTAL										
PHENERGAN										
	+	@ MYLAN PHARMS INC	50MG		N011689	001			Jan	CAHN
TABLET; ORAL										
PROMETHAZINE HYDROCHLORIDE										
		IMPAX LABS	12.5MG		A040791	002	Feb 12, 2008		Aug	CMS1
			25MG		A040791	003	Feb 12, 2008		Aug	CMS1
AB		PRINSTON INC	12.5MG		A040622	001	Jul 18, 2006		Feb	CAHN
AB			25MG		A040622	002	Jul 18, 2006		Feb	CAHN
AB			50MG		A040622	003	Jul 18, 2006		Feb	CAHN
AB		STRIDES PHARMA	12.5MG		A209177	001	Jun 30, 2017		Jun	NEWA
AB			25MG		A209177	002	Jun 30, 2017		Jun	NEWA
AB			50MG		A209177	003	Jun 30, 2017		Jun	NEWA

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL  
PROPAFENONE HYDROCHLORIDE

AB	GLENMARK PHARMS LTD	225MG	A205268	001	Sep 08, 2017	Aug NEWA
AB		325MG	A205268	002	Sep 08, 2017	Aug NEWA
AB		425MG	A205268	003	Sep 08, 2017	Aug NEWA

PROPIOMAZINE HYDROCHLORIDE

INJECTABLE;INJECTION  
LARGON

@	WEST-WARD PHARMS INT	20MG/ML	N012382	002		Jan CAHN
---	----------------------	---------	---------	-----	--	----------

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL  
INNOPRAN XL

BX	ANI PHARMS INC	80MG	N021438	001	Mar 12, 2003	Mar CAHN
BX		120MG	N021438	002	Mar 12, 2003	Mar CAHN

PROPRANOLOL HYDROCHLORIDE

BX	UPSHER SMITH	60MG	A078311	001	Mar 06, 2009	Apr CMFD
	@	60MG	A078311	001	Mar 06, 2009	Feb DISC
BX		80MG	A078311	002	Mar 06, 2009	Apr CMFD
	@	80MG	A078311	002	Mar 06, 2009	Feb DISC
BX		120MG	A078311	003	Mar 06, 2009	Apr CMFD
	@	120MG	A078311	003	Mar 06, 2009	Feb DISC
BX		160MG	A078311	004	Mar 06, 2009	Apr CMFD
	@	160MG	A078311	004	Mar 06, 2009	Feb DISC
>D> BX	UPSHER-SMITH LABS	60MG	A078311	001	Mar 06, 2009	Sep DISC
>A>	@	60MG	A078311	001	Mar 06, 2009	Sep DISC
BX		60MG	A078311	001	Mar 06, 2009	Jun CAHN
>D> BX		80MG	A078311	002	Mar 06, 2009	Sep DISC
>A>	@	80MG	A078311	002	Mar 06, 2009	Sep DISC
BX		80MG	A078311	002	Mar 06, 2009	Jun CAHN
>D> BX		120MG	A078311	003	Mar 06, 2009	Sep DISC
>A>	@	120MG	A078311	003	Mar 06, 2009	Sep DISC
BX		120MG	A078311	003	Mar 06, 2009	Jun CAHN
>D> BX		160MG	A078311	004	Mar 06, 2009	Sep DISC
>A>	@	160MG	A078311	004	Mar 06, 2009	Sep DISC
BX		160MG	A078311	004	Mar 06, 2009	Jun CAHN

INJECTABLE;INJECTION  
PROPRANOLOL HYDROCHLORIDE

AP	ATHENEX INC	1MG/ML	A075792	001	Aug 29, 2000	Mar CAHN
	@ SANDOZ INC	1MG/ML	A076400	001	Feb 26, 2003	Mar CAHN

TABLET;ORAL

INDERAL

+	@ WYETH PHARMS INC	40MG	N016418	002		Jan CRLD
---	--------------------	------	---------	-----	--	----------

PROPRANOLOL HYDROCHLORIDE

>A>	@ ANDA REPOSITORY	10MG	A070319	001	Oct 22, 1985	Sep CAHN
>A>	@	20MG	A070320	001	Oct 22, 1985	Sep CAHN
>A>	@	40MG	A070103	001	Oct 22, 1985	Sep CAHN
>A>	@	60MG	A070321	001	Sep 24, 1986	Sep CAHN
>A>	@	80MG	A070322	001	Aug 04, 1986	Sep CAHN
>D>	@ FRONTIDA BIOPHARM	10MG	A070319	001	Oct 22, 1985	Sep CAHN
>D>	@	20MG	A070320	001	Oct 22, 1985	Sep CAHN
>D>	@	40MG	A070103	001	Oct 22, 1985	Sep CAHN
>D>	@	60MG	A070321	001	Sep 24, 1986	Sep CAHN
>D>	@	80MG	A070322	001	Aug 04, 1986	Sep CAHN
	@ WATSON LABS TEVA	10MG	A070548	001	Jul 10, 1986	May CAHN
	@	20MG	A070549	001	Apr 11, 1986	May CAHN
	@	40MG	A070550	001	Apr 11, 1986	May CAHN

PROPYLTHIOURACIL

TABLET;ORAL

PROPYLTHIOURACIL

@	CHARTWELL RX	50MG	A084543	001		Apr CAHN
---	--------------	------	---------	-----	--	----------

PROTAMINE SULFATE

INJECTABLE;INJECTION

PROTAMINE SULFATE

@	WEST-WARD PHARMS INT	10MG/ML	A089474	001	Nov 05, 1986	Mar CAHN
@		10MG/ML	A089475	001	Nov 05, 1986	Jan CAHN

PYRIDOSTIGMINE BROMIDE

INJECTABLE; INJECTION  
REGONOL

AP SANDOZ INC 5MG/ML N017398 001 May CAHN  
TABLET; ORAL

PYRIDOSTIGMINE BROMIDE

@ IMPAX LABS INC 60MG A040457 001 Dec 26, 2002 Feb CAHN  
TABLET, EXTENDED RELEASE; ORAL

PYRIDOSTIGMINE BROMIDE

AB KINEDEXE UK 180MG A205464 001 Aug 15, 2017 Jul NEWA

PYRIMETHAMINE

TABLET; ORAL  
DARAPRIM

+! TURING PHARMS LLC 25MG N008578 001 May CAHN

QUETIAPINE FUMARATE

TABLET; ORAL  
QUETIAPINE FUMARATE  
@ MYLAN PHARMS INC EQ 25MG BASE  
SEROQUEL

>D> AB +! ASTRAZENECA PHARMS EQ 25MG BASE N020639 001 Sep 26, 1997 Sep CAHN  
>A> AB +! EQ 25MG BASE N020639 001 Sep 26, 1997 Sep CAHN  
>D> AB + EQ 50MG BASE N020639 007 Oct 04, 2005 Sep CAHN  
>A> AB + EQ 50MG BASE N020639 007 Oct 04, 2005 Sep CAHN  
>D> AB + EQ 100MG BASE N020639 002 Sep 26, 1997 Sep CAHN  
>A> AB + EQ 100MG BASE N020639 002 Sep 26, 1997 Sep CAHN  
>D> + @ EQ 150MG BASE N020639 004 Dec 20, 1998 Sep CAHN  
>A> + @ EQ 150MG BASE N020639 004 Dec 20, 1998 Sep CAHN  
>D> AB + EQ 200MG BASE N020639 003 Sep 26, 1997 Sep CAHN  
>A> AB + EQ 200MG BASE N020639 003 Sep 26, 1997 Sep CAHN  
>D> AB +! EQ 300MG BASE N020639 005 Jul 26, 2000 Sep CAHN  
>A> AB +! EQ 300MG BASE N020639 005 Jul 26, 2000 Sep CAHN  
>D> AB + EQ 400MG BASE N020639 006 Oct 04, 2005 Sep CAHN  
>A> AB + EQ 400MG BASE N020639 006 Oct 04, 2005 Sep CAHN

TABLET, EXTENDED RELEASE; ORAL  
QUETIAPINE FUMARATE

AB ACCORD HLTHCARE EQ 150MG BASE A090681 001 May 09, 2017 Apr NEWA  
AB EQ 200MG BASE A090681 002 May 09, 2017 Apr NEWA  
AB EQ 300MG BASE A090681 003 May 09, 2017 Apr NEWA  
AB EQ 400MG BASE A090681 004 Nov 01, 2016 Mar CAHN  
AB INTELLIPHARMACEUTICS EQ 50MG BASE A202939 001 May 09, 2017 Apr NEWA  
AB EQ 150MG BASE A202939 002 May 09, 2017 Apr NEWA  
AB EQ 200MG BASE A202939 003 May 09, 2017 Apr NEWA  
AB EQ 300MG BASE A202939 004 May 09, 2017 Apr NEWA  
AB EQ 400MG BASE A202939 005 May 09, 2017 Apr NEWA  
AB LUPIN LTD EQ 50MG BASE A204203 001 May 17, 2017 May NEWA  
AB EQ 150MG BASE A204203 002 May 17, 2017 May NEWA  
AB EQ 200MG BASE A204203 003 May 17, 2017 May NEWA  
AB EQ 300MG BASE A204203 004 May 17, 2017 May NEWA  
AB EQ 400MG BASE A204203 005 May 17, 2017 May NEWA  
AB PAR PHARM EQ 50MG BASE A090482 001 May 09, 2017 Apr NEWA  
AB EQ 150MG BASE A090482 002 May 09, 2017 Apr NEWA  
AB EQ 200MG BASE A090482 003 May 09, 2017 Apr NEWA  
AB EQ 300MG BASE A090482 004 May 09, 2017 Apr NEWA  
AB EQ 400MG BASE A090482 005 May 09, 2017 Apr NEWA  
AB PHARMADAX INC EQ 50MG BASE A206260 001 May 09, 2017 Apr NEWA  
AB EQ 150MG BASE A206260 002 May 09, 2017 Apr NEWA  
AB EQ 200MG BASE A206260 003 May 09, 2017 Apr NEWA  
AB EQ 300MG BASE A206260 004 May 09, 2017 Apr NEWA  
AB EQ 400MG BASE A206260 005 May 09, 2017 Apr NEWA

SEROQUEL XR

>D> AB + ASTRAZENECA EQ 50MG BASE N022047 001 May 17, 2007 Sep CAHN  
>A> AB + EQ 50MG BASE N022047 001 May 17, 2007 Sep CAHN  
AB + EQ 50MG BASE N022047 001 May 17, 2007 Apr CTEC  
>D> AB + EQ 150MG BASE N022047 005 Aug 11, 2008 Sep CAHN  
>A> AB + EQ 150MG BASE N022047 005 Aug 11, 2008 Sep CAHN  
AB + EQ 150MG BASE N022047 005 Aug 11, 2008 Apr CTEC  
>D> AB +! EQ 200MG BASE N022047 002 May 17, 2007 Sep CAHN  
>A> AB +! EQ 200MG BASE N022047 002 May 17, 2007 Sep CAHN  
AB +! EQ 200MG BASE N022047 002 May 17, 2007 Apr CTEC  
>D> AB + EQ 300MG BASE N022047 003 May 17, 2007 Sep CAHN

TABLET, EXTENDED RELEASE;ORAL  
SEROQUEL XR

>A>	AB	+	EQ 300MG BASE	N022047	003	May 17, 2007	Sep	CAHN
	AB	+	EQ 300MG BASE	N022047	003	May 17, 2007	Apr	CTEC
>D>	AB	+	EQ 400MG BASE	N022047	004	May 17, 2007	Sep	CAHN
>A>	AB	+	EQ 400MG BASE	N022047	004	May 17, 2007	Sep	CAHN

QUINAPRIL HYDROCHLORIDE

## TABLET;ORAL

## QUINAPRIL HYDROCHLORIDE

>D>	AB		SUN PHARM INDS LTD	EQ 5MG BASE	A090800	001	Jun 18, 2009	Sep	DISC
>A>		@		EQ 5MG BASE	A090800	001	Jun 18, 2009	Sep	DISC
>D>	AB			EQ 10MG BASE	A090800	002	Jun 18, 2009	Sep	DISC
>A>		@		EQ 10MG BASE	A090800	002	Jun 18, 2009	Sep	DISC
>D>	AB			EQ 20MG BASE	A090800	003	Jun 18, 2009	Sep	DISC
>A>		@		EQ 20MG BASE	A090800	003	Jun 18, 2009	Sep	DISC
>D>	AB			EQ 40MG BASE	A090800	004	Jun 18, 2009	Sep	DISC
>A>		@		EQ 40MG BASE	A090800	004	Jun 18, 2009	Sep	DISC

RABEPRAZOLE SODIUM

## CAPSULE, DELAYED RELEASE;ORAL

## ACIPHEX SPRINKLE

+	AVADEL PHARMS	5MG	N204736	001	Mar 26, 2013	Aug	CAHN
+	!	10MG	N204736	002	Mar 26, 2013	Aug	CAHN

## TABLET, DELAYED RELEASE;ORAL

## RABEPRAZOLE SODIUM

AB	AUROBINDO PHARMA LTD	20MG	A205761	001	Feb 17, 2017	Feb	NEWA
AB	KREMERS URBAN PHARMS	20MG	A090678	001	Nov 08, 2013	Jan	CAHN

RALTEGRAVIR POTASSIUM

## TABLET;ORAL

## ISENTRESS HD

+	MERCK SHARP DOHME	EQ 600MG BASE	N022145	002	May 26, 2017	May	NEWA
---	-------------------	---------------	---------	-----	--------------	-----	------

RAMIPRIL

## CAPSULE;ORAL

## ALTACE

AB	+	KING PHARMS LLC	1.25MG	N019901	001	Jan 28, 1991	Jul	CAHN
AB	+		2.5MG	N019901	002	Jan 28, 1991	Jul	CAHN
AB	+		5MG	N019901	003	Jan 28, 1991	Jul	CAHN
AB	+	!	10MG	N019901	004	Jan 28, 1991	Jul	CAHN

## RAMIPRIL

AB	ACCORD HLTHCARE	1.25MG	A202392	001	Apr 15, 2014	Mar	CAHN
AB		2.5MG	A202392	002	Apr 15, 2014	Mar	CAHN
AB		5MG	A202392	003	Apr 15, 2014	Mar	CAHN
AB		10MG	A202392	004	Apr 15, 2014	Mar	CAHN

RANITIDINE HYDROCHLORIDE

## INJECTABLE; INJECTION

## ZANTAC

AP	+	TELIGENT	EQ 25MG BASE/ML	N019090	001	Oct 19, 1984	Apr	CAHN	
AP	+	!	TELIGENT PHARMA INC	EQ 25MG BASE/ML	N019090	001	Oct 19, 1984	Jan	CAHN
			ZANTAC IN PLASTIC CONTAINER						
		@	TELIGENT	EQ 1MG BASE/ML	N019593	002	Sep 27, 1991	May	CAHN
		@		EQ 50MG BASE/100ML	N019593	001	Dec 17, 1986	May	CAHN

## SYRUP;ORAL

## RANITIDINE HYDROCHLORIDE

AA	AUROBINDO PHARMA LTD	EQ 15MG BASE/ML	A090623	001	Jul 28, 2010	Jan	CAHN
AA	PHARM ASSOC	EQ 15MG BASE/ML	A077405	001	Sep 21, 2007	May	CAHN

## TABLET;ORAL

## RANITIDINE HYDROCHLORIDE

AB	GLENMARK PHARMS INC	EQ 150MG BASE	A078542	001	Nov 19, 2008	May	CAHN
AB		EQ 300MG BASE	A078542	002	Nov 19, 2008	May	CAHN

RANOLAZINE

## TABLET, EXTENDED RELEASE;ORAL

## RANEXA

+	GILEAD	500MG	N021526	002	Jan 27, 2006	Feb	CTEC
+	!	1GM	N021526	001	Feb 12, 2007	Feb	CTEC

## RANOLAZINE

@	LUPIN LTD	500MG	A201046	001	Jul 29, 2013	Feb	DISC
@		1GM	A201046	002	Jul 29, 2013	Feb	DISC

RASAGILINE MESYLATE

TABLET; ORAL

RASAGILINE MESYLATE

AB	MYLAN PHARMS INC	EQ 0.5MG BASE	A201971	001	May 15, 2017	Jul	CMFD
	@	EQ 0.5MG BASE	A201971	001	May 15, 2017	Jun	DISC
AB		EQ 0.5MG BASE	A201971	001	May 15, 2017	May	NEWA
AB		EQ 1MG BASE	A201971	002	May 15, 2017	Jul	CMFD
	@	EQ 1MG BASE	A201971	002	May 15, 2017	Jun	DISC
AB		EQ 1MG BASE	A201971	002	May 15, 2017	May	NEWA

REPAGLINIDE

TABLET; ORAL

PRANDIN

AB	+ GEMINI LABS LLC	0.5MG	N020741	001	Dec 22, 1997	Feb	CAHN
AB	+	1MG	N020741	002	Dec 22, 1997	Feb	CAHN
AB	+!	2MG	N020741	003	Dec 22, 1997	Feb	CAHN

REPAGLINIDE

AB	BOSCOGEN	0.5MG	A091517	001	Apr 24, 2015	Jun	CAHN
AB		1MG	A091517	002	Apr 24, 2015	Jun	CAHN
AB		2MG	A091517	003	Apr 24, 2015	Jun	CAHN

RESERPINE

TABLET; ORAL

RESERPINE

	+ @ SANDOZ	0.1MG	N009838	001		Apr	DISC
	+ @	0.25MG	N009838	002		Apr	DISC

RIBAVIRIN

CAPSULE; ORAL

RIBASPHERE

AB	KADMON PHARMS LLC	200MG	A076203	001	Apr 06, 2004	Jan	CAHN
----	-------------------	-------	---------	-----	--------------	-----	------

TABLET; ORAL

RIBAVIRIN

AB	KADMON PHARMS LLC	200MG	A077456	001	Dec 05, 2005	Jan	CAHN
AB		400MG	A077456	002	Dec 05, 2005	Jan	CAHN
AB	!	600MG	A077456	003	Dec 05, 2005	Jan	CAHN

RIBOCICLIB SUCCINATE

TABLET; ORAL

KISQALI

	+! NOVARTIS PHARMS CORP	EQ 200MG BASE	N209092	001	Mar 13, 2017	Mar	NEWA
--	-------------------------	---------------	---------	-----	--------------	-----	------

RIFAMPIN

INJECTABLE; INJECTION

RIFAMPIN

AP	WATSON PHARMS TEVA	600MG/VIAL	A206736	001	Jan 19, 2016	Feb	CAHN
AP	WEST-WARD PHARMS INT	600MG/VIAL	A064217	001	Oct 29, 1999	Jan	CAHN

RILUZOLE

TABLET; ORAL

RILUTEK

AB	+! COVIS PHARMA BV	50MG	N020599	001	Dec 12, 1995	Aug	CAHN
----	--------------------	------	---------	-----	--------------	-----	------

RILUZOLE

AB	GLENMARK PHARMS LTD	50MG	A091394	001	Jun 18, 2013	May	CAHN
----	---------------------	------	---------	-----	--------------	-----	------

RIMANTADINE HYDROCHLORIDE

TABLET; ORAL

RIMANTADINE HYDROCHLORIDE

	@ IMPAX LABS INC	100MG	A075916	001	Nov 02, 2001	Feb	CAHN
--	------------------	-------	---------	-----	--------------	-----	------

RISPERIDONE

TABLET; ORAL

RISPERIDONE

	@ JUBILANT CADISTA	0.25MG	A078828	001	Mar 23, 2009	Apr	CAHN
	@	0.5MG	A078828	002	Mar 23, 2009	Apr	CAHN
	@	1MG	A078828	003	Mar 23, 2009	Apr	CAHN
	@	2MG	A078828	004	Mar 23, 2009	Apr	CAHN
	@	3MG	A078828	005	Mar 23, 2009	Apr	CAHN
	@	4MG	A078828	006	Mar 23, 2009	Apr	CAHN
AB	PRINSTON INC	0.25MG	A078707	001	Dec 29, 2008	Feb	CAHN
AB		0.5MG	A078707	002	Dec 29, 2008	Feb	CAHN

TABLET;ORAL  
RISPERIDONE

AB		1MG	A078707	003	Dec 29, 2008	Feb	CAHN
AB		2MG	A078707	004	Dec 29, 2008	Feb	CAHN
AB		3MG	A078707	005	Dec 29, 2008	Feb	CAHN
AB		4MG	A078707	006	Dec 29, 2008	Feb	CAHN

RITONAVIR

POWDER;ORAL  
NORVIR

+	!	ABBVIE INC	100MG/PACKET	N209512	001	Jun 07, 2017	Jun	NEWA
---	---	------------	--------------	---------	-----	--------------	-----	------

RIVASTIGMINE TARTRATE

CAPSULE;ORAL  
RIVASTIGMINE TARTRATE

>A>	AB	AJANTA PHARMA LTD	EQ 1.5MG BASE	A207797	001	Sep 28, 2017	Sep	NEWA
>A>	AB		EQ 3MG BASE	A207797	002	Sep 28, 2017	Sep	NEWA
>A>	AB		EQ 4.5MG BASE	A207797	003	Sep 28, 2017	Sep	NEWA
>A>	AB		EQ 6MG BASE	A207797	004	Sep 28, 2017	Sep	NEWA
	AB	CADILA PHARMS LTD	EQ 1.5MG BASE	A203844	001	Feb 13, 2017	Jan	NEWA
	AB		EQ 3MG BASE	A203844	002	Feb 13, 2017	Jan	NEWA
	AB		EQ 4.5MG BASE	A203844	003	Feb 13, 2017	Jan	NEWA
	AB		EQ 6MG BASE	A203844	004	Feb 13, 2017	Jan	NEWA
	AB	SUN PHARM INDS LTD	EQ 1.5MG BASE	A077131	001	Oct 22, 2007	Mar	CAHN
	AB		EQ 3MG BASE	A077131	002	Oct 22, 2007	Mar	CAHN
	AB		EQ 4.5MG BASE	A077131	003	Oct 22, 2007	Mar	CAHN
	AB		EQ 6MG BASE	A077131	004	Oct 22, 2007	Mar	CAHN

RIZATRIPTAN BENZOATE

TABLET;ORAL  
RIZATRIPTAN BENZOATE

AB		ECI PHARMS LLC	EQ 5MG BASE	A202047	001	Dec 31, 2012	Mar	CAHN
AB			EQ 10MG BASE	A202047	002	Dec 31, 2012	Mar	CAHN
AB		UNICHEM LABS LTD	EQ 5MG BASE	A207836	001	Mar 07, 2017	Feb	NEWA
AB			EQ 10MG BASE	A207836	002	Mar 07, 2017	Feb	NEWA

TABLET, ORALLY DISINTEGRATING;ORAL

RIZATRIPTAN BENZOATE

AB		GLENMARK PHARMS LTD	EQ 5MG BASE	A201914	001	Jul 01, 2013	May	CAHN
AB			EQ 10MG BASE	A201914	002	Jul 01, 2013	May	CAHN
AB		PANACEA BIOTEC LTD	EQ 5MG BASE	A204722	001	Jan 11, 2017	Jan	NEWA
AB			EQ 10MG BASE	A204722	002	Jan 11, 2017	Jan	NEWA
AB		UNICHEM LABS LTD	EQ 5MG BASE	A207835	001	Mar 07, 2017	Feb	NEWA
AB			EQ 10MG BASE	A207835	002	Mar 07, 2017	Feb	NEWA

ROCURONIUM BROMIDE

INJECTABLE;INJECTION  
ROCURONIUM BROMIDE

AP		AUROBINDO PHARMA LTD	50MG/5ML (10MG/ML)	A206206	001	Apr 12, 2017	Mar	NEWA
AP			100MG/10ML (10MG/ML)	A206206	002	Apr 12, 2017	Mar	NEWA
AP	!	SANDOZ INC	50MG/5ML (10MG/ML)	A079195	001	Dec 05, 2008	Mar	CAHN
AP	!		100MG/10ML (10MG/ML)	A079195	002	Dec 05, 2008	Mar	CAHN
AP		WEST WARD PHARM CORP	50MG/5ML (10MG/ML)	A204679	001	Feb 28, 2017	Feb	NEWA
AP			100MG/10ML (10MG/ML)	A204679	002	Feb 28, 2017	Feb	NEWA

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL  
ROPINIROLE HYDROCHLORIDE

AB		ACCORD HLTHCARE	EQ 0.25MG BASE	A204022	001	Feb 28, 2017	Apr	CAHN
AB			EQ 0.5MG BASE	A204022	002	Feb 28, 2017	Apr	CAHN
AB			EQ 1MG BASE	A204022	003	Feb 28, 2017	Apr	CAHN
AB			EQ 2MG BASE	A204022	004	Feb 28, 2017	Apr	CAHN
AB			EQ 3MG BASE	A204022	005	Feb 28, 2017	Apr	CAHN
AB			EQ 4MG BASE	A204022	006	Feb 28, 2017	Apr	CAHN
AB			EQ 5MG BASE	A204022	007	Feb 28, 2017	Apr	CAHN
AB		ACCORD HLTHCARE INC	EQ 0.25MG BASE	A204022	001	Feb 28, 2017	Feb	NEWA
AB			EQ 0.5MG BASE	A204022	002	Feb 28, 2017	Feb	NEWA
AB			EQ 1MG BASE	A204022	003	Feb 28, 2017	Feb	NEWA
AB			EQ 2MG BASE	A204022	004	Feb 28, 2017	Feb	NEWA
AB			EQ 3MG BASE	A204022	005	Feb 28, 2017	Feb	NEWA
AB			EQ 4MG BASE	A204022	006	Feb 28, 2017	Feb	NEWA
AB			EQ 5MG BASE	A204022	007	Feb 28, 2017	Feb	NEWA
	@	EPIC PHARMA LLC	EQ 0.25MG BASE	A078230	001	May 20, 2008	May	CAHN
	@		EQ 0.5MG BASE	A078230	002	May 20, 2008	May	CAHN

## TABLET;ORAL

## ROPINIROLE HYDROCHLORIDE

@	EQ 1MG BASE	A 078230	003	May 20, 2008	May CAHN
@	EQ 2MG BASE	A 078230	004	May 20, 2008	May CAHN
@	EQ 3MG BASE	A 078230	005	May 20, 2008	May CAHN
@	EQ 4MG BASE	A 078230	006	May 20, 2008	May CAHN
@	EQ 5MG BASE	A 078230	007	May 20, 2008	May CAHN

## TABLET, EXTENDED RELEASE;ORAL

## ROPINIROLE HYDROCHLORIDE

AB	ALEMBIC PHARMS LTD	EQ 2MG BASE	A 202786	001	Apr 22, 2013	May CAHN
AB		EQ 4MG BASE	A 202786	002	Apr 22, 2013	May CAHN
AB		EQ 6MG BASE	A 202786	003	Apr 22, 2013	May CAHN
AB		EQ 8MG BASE	A 202786	004	Apr 22, 2013	May CAHN
AB		EQ 12MG BASE	A 202786	005	Apr 22, 2013	May CAHN
AB	@ MYLAN PHARMS INC	EQ 3MG BASE	A 200462	002	Oct 15, 2012	Apr DISC

ROPIVACAINE HYDROCHLORIDE

## SOLUTION;INJECTION

## ROPIVACAINE HYDROCHLORIDE

AP	AKORN INC	150MG/30ML (5MG/ML)	A 203955	001	Apr 11, 2016	Jun CDFR
----	-----------	---------------------	----------	-----	--------------	----------

ROSUVASTATIN CALCIUM

## TABLET;ORAL

## ROSUVASTATIN CALCIUM

AB	ACCORD HLTHCARE	5MG	A 206434	001	Oct 31, 2016	Mar CAHN
AB		10MG	A 206434	002	Oct 31, 2016	Mar CAHN
AB		20MG	A 206434	003	Oct 31, 2016	Mar CAHN
AB		40MG	A 206434	004	Oct 31, 2016	Mar CAHN
AB	ALKEM LABS LTD	5MG	A 206465	001	Mar 21, 2017	Mar NEWA
AB		10MG	A 206465	002	Mar 21, 2017	Mar NEWA
AB		20MG	A 206465	003	Mar 21, 2017	Mar NEWA
AB		40MG	A 206465	004	Mar 21, 2017	Mar NEWA
AB	LUPIN LTD	5MG	A 205587	001	Jul 31, 2017	Jul NEWA
AB		10MG	A 205587	002	Jul 31, 2017	Jul NEWA
AB		20MG	A 205587	003	Jul 31, 2017	Jul NEWA
AB		40MG	A 205587	004	Jul 31, 2017	Jul NEWA
AB	TORRENT PHARMS LTD	5MG	A 201619	001	Oct 31, 2016	Apr CAHN
AB		10MG	A 201619	002	Oct 31, 2016	Apr CAHN
AB		20MG	A 201619	003	Oct 31, 2016	Apr CAHN
AB		40MG	A 201619	004	Oct 31, 2016	Apr CAHN

RUCAPARIB CAMSYLATE

## TABLET;ORAL

## RUBRACA

+	CLOVIS ONCOLOGY INC	EQ 250MG BASE	N 209115	003	May 01, 2017	May NEWA
---	---------------------	---------------	----------	-----	--------------	----------

SAFINAMIDE MESYLATE

## TABLET;ORAL

## XADAGO

+	NEWRON PHARMS US INC	50MG	N 207145	001	Mar 21, 2017	Mar NEWA
+	!	100MG	N 207145	002	Mar 21, 2017	Mar NEWA
+	US WORLDMEDS LLC	50MG	N 207145	001	Mar 21, 2017	Apr CAHN
+	!	100MG	N 207145	002	Mar 21, 2017	Apr CAHN

>A> SECNIDAZOLE

## &gt;A&gt; GRANULE;ORAL

## &gt;A&gt; SOLOSEC

>A>	+	SYMBIOMIX THERAP	2GM/PACKET	N 209363	001	Sep 15, 2017	Sep NEWA
-----	---	------------------	------------	----------	-----	--------------	----------

SELEGILINE HYDROCHLORIDE

## TABLET;ORAL

## SELEGILINE HYDROCHLORIDE

AB	BOSCOGEN	5MG	A 074912	001	Apr 30, 1998	May CAHN
	@ CHARTWELL MOLECULES	5MG	A 074565	001	Aug 02, 1996	Jan CAHN
	@	5MG	A 074641	001	Aug 02, 1996	Jan CAHN

SERTRALINE HYDROCHLORIDE

## CONCENTRATE;ORAL

## SERTRALINE HYDROCHLORIDE

	@ ALLIED PHARMA INC	EQ 20MG BASE/ML	A 076934	001	Jun 30, 2006	Mar CAHN
--	---------------------	-----------------	----------	-----	--------------	----------

## TABLET;ORAL

## SERTRALINE HYDROCHLORIDE

	@	ACI HEALTHCARE LTD	EQ 25MG BASE	A076881	001	Feb 06, 2007	Jun	CAHN
	@		EQ 50MG BASE	A076881	002	Feb 06, 2007	Jun	CAHN
	@		EQ 100MG BASE	A076881	003	Feb 06, 2007	Jun	CAHN
	@	ALLIED PHARMA INC	EQ 25MG BASE	A076881	001	Feb 06, 2007	Mar	CAHN
	@		EQ 50MG BASE	A076881	002	Feb 06, 2007	Mar	CAHN
	@		EQ 100MG BASE	A076881	003	Feb 06, 2007	Mar	CAHN
>A>	@	ANDA REPOSITORY	EQ 25MG BASE	A077818	001	Feb 06, 2007	Sep	CAHN
>A>	@		EQ 50MG BASE	A077818	002	Feb 06, 2007	Sep	CAHN
>A>	@		EQ 100MG BASE	A077818	003	Feb 06, 2007	Sep	CAHN
>D>	@	FRONTIDA BIOPHARM	EQ 25MG BASE	A077818	001	Feb 06, 2007	Sep	CAHN
>D>	@		EQ 50MG BASE	A077818	002	Feb 06, 2007	Sep	CAHN
>D>	@		EQ 100MG BASE	A077818	003	Feb 06, 2007	Sep	CAHN
	@	MYLAN	EQ 25MG BASE	A076671	001	Feb 06, 2007	Mar	DISC
	@		EQ 50MG BASE	A076671	002	Feb 06, 2007	Mar	DISC
	@		EQ 100MG BASE	A076671	003	Feb 06, 2007	Mar	DISC
	@	WATSON LABS TEVA	EQ 25MG BASE	A077663	001	Feb 06, 2007	May	CAHN
	@		EQ 50MG BASE	A077663	002	Feb 06, 2007	May	CAHN
	@		EQ 100MG BASE	A077663	003	Feb 06, 2007	May	CAHN

SEVELAMER CARBONATEFOR SUSPENSION;ORAL  
RENVELA

AB	+	GENZYME	800MG/PACKET	N022318	001	Aug 12, 2009	May	CFTG
AB	+	!	2.4GM/PACKET	N022318	002	Feb 18, 2009	May	CFTG
		SEVELAMER CARBONATE						
AB		AUROBINDO PHARMA LTD	800MG/PACKET	A207624	001	Jun 13, 2017	May	NEWA
AB			2.4GM/PACKET	A207624	002	Jun 13, 2017	May	NEWA
		TABLET;ORAL						
		RENVELA						
AB	+	GENZYME	800MG	N022127	001	Oct 19, 2007	Jul	CFTG
		SEVELAMER CARBONATE						
AB		AUROBINDO PHARMA LTD	800MG	A207179	001	Jul 17, 2017	Jul	NEWA
>A>	AB	DR REDDYS LABS LTD	800MG	A206094	001	Sep 29, 2017	Sep	NEWA

SILDENAFIL CITRATETABLET;ORAL  
VIAGRA

	+	PFIZER INC	EQ 25MG BASE	N020895	001	Mar 27, 1998	May	CAHN
	+		EQ 50MG BASE	N020895	002	Mar 27, 1998	May	CAHN
	+	!	EQ 100MG BASE	N020895	003	Mar 27, 1998	May	CAHN

SILODOSINCAPSULE;ORAL  
RAPAFLO

AB	+	ALLERGAN SALES LLC	4MG	N022206	001	Oct 08, 2008	Mar	CFTG
AB	+		8MG	N022206	002	Oct 08, 2008	Mar	CFTG
		SILODOSIN						
AB		SANDOZ INC	4MG	A204726	001	Mar 31, 2017	Mar	NEWA
AB			8MG	A204726	002	Mar 31, 2017	Mar	NEWA

SILVER SULFADIAZINECREAM;TOPICAL  
SILVADENE

AB	+	KING PHARMS LLC	1%	N017381	001		Aug	CAHN
----	---	-----------------	----	---------	-----	--	-----	------

SIMVASTATINSUSPENSION;ORAL  
SIMVASTATIN

	+	TCG FLUENT PHARMA	20MG/5ML	N206679	001	Apr 21, 2016	Jan	CAHN
	+	!	40MG/5ML	N206679	002	Apr 21, 2016	Jan	CAHN

TABLET;ORAL  
SIMVASTATIN

>D>	AB	MICRO LABS LTD	5MG	A090383	001	Sep 16, 2011	Sep	CAHN
>D>	AB		10MG	A090383	002	Sep 16, 2011	Sep	CAHN
>D>	AB		20MG	A090383	003	Sep 16, 2011	Sep	CAHN
>D>	AB		40MG	A090383	004	Sep 16, 2011	Sep	CAHN
>D>	AB		80MG	A090383	005	Sep 16, 2011	Sep	CAHN
	@	MYLAN PHARMS INC	5MG	A090868	001	Jun 08, 2010	May	DISC
	@		10MG	A090868	002	Jun 08, 2010	May	DISC
	@		20MG	A090868	003	Jun 08, 2010	May	DISC



TABLET;ORAL  
SIMVASTATIN

	@		40MG	A090868	004	Jun 08, 2010	May	DISC
	@		80MG	A090868	005	Jun 08, 2010	May	DISC
>A>	AB	VIVA HLTHCARE	5MG	A090383	001	Sep 16, 2011	Sep	CAHN
>A>	AB		10MG	A090383	002	Sep 16, 2011	Sep	CAHN
>A>	AB		20MG	A090383	003	Sep 16, 2011	Sep	CAHN
>A>	AB		40MG	A090383	004	Sep 16, 2011	Sep	CAHN
>A>	AB		80MG	A090383	005	Sep 16, 2011	Sep	CAHN
	AB	WATSON LABS TEVA	5MG	A076685	001	Dec 20, 2006	May	CAHN
	AB		10MG	A076685	002	Dec 20, 2006	May	CAHN
	AB		20MG	A076685	003	Dec 20, 2006	May	CAHN
	AB		40MG	A076685	004	Dec 20, 2006	May	CAHN
	AB		80MG	A076685	005	Dec 20, 2006	May	CAHN

SODIUM BENZOATE; SODIUM PHENYLACETATE

SOLUTION;IV (INFUSION)  
SODIUM PHENYLACETATE AND SODIUM BENZOATE

AP		AILEX PHARMS LLC	10%;10% (5GM/50ML;5GM/50ML)	A207096	001	Feb 24, 2016	Jul	CAHN
----	--	------------------	-----------------------------	---------	-----	--------------	-----	------

SODIUM BICARBONATE

INJECTABLE;INJECTION  
SODIUM BICARBONATE

AP	!	HOSPIRA	0.9MEQ/ML	A077394	001	Nov 09, 2005	Feb	CTEC
AP	!		1MEQ/ML	A077394	002	Nov 09, 2005	Feb	CTEC
		HOSPIRA INC	0.5MEQ/ML	A202679	001	Mar 07, 2017	Feb	NEWA
AP			0.9MEQ/ML	A202494	001	Mar 06, 2017	Feb	NEWA
>A>	AP		1MEQ/ML	A202432	001	Sep 26, 2017	Sep	NEWA
			1MEQ/ML	A202495	001	Mar 06, 2017	Feb	NEWA
AP			1MEQ/ML	A202494	002	Mar 06, 2017	Feb	NEWA
>A>	AP	INTL MEDICATION SYS	1MEQ/ML	A203449	001	Sep 19, 2017	Sep	NEWA

SODIUM CHLORIDE

INJECTABLE;INJECTION  
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	+	ICU MEDICAL INC	450MG/100ML	N018090	001		Feb	CAHN
			SODIUM CHLORIDE 0.9%					
AP		SPECTRA MDCL DEVICES	9MG/ML	A206171	001	Jul 21, 2017	Jul	NEWA
AP		WEST-WARD PHARMS INT	9MG/ML	A201850	001	Jan 20, 2012	Jan	CAHN
			SODIUM CHLORIDE 0.9%					
		WEST-WARD PHARMS INT	9MG/ML	A201833	001	Sep 24, 2013	Jan	CAHN
>A>	AP		SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
		FRESENIUS KABI USA	900MG/100ML	A207310	001	Sep 19, 2017	Sep	NEWA
AP	+	ICU MEDICAL INC	900MG/100ML	N016366	001		Feb	CAHN
AP		LABORATORIOS GRIFOLS	900MG/100ML	A207956	001	May 25, 2017	May	NEWA
AP	!	TARO	9MG/ML	A077407	001	Aug 11, 2006	Apr	CAHN
			SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER					
		+ @ ABRAXIS PHARM	234MG/ML	N019329	001	Apr 22, 1987	Jan	CRLD
			SODIUM CHLORIDE 3% IN PLASTIC CONTAINER					
AP		B BRAUN	3GM/100ML	N019635	003	Mar 09, 1988	Jul	CMFD
AP	+	BAXTER HLTHCARE	3GM/100ML	N019022	001	Nov 01, 1983	Jul	CTEC
			SODIUM CHLORIDE 5% IN PLASTIC CONTAINER					
AP		B BRAUN	5GM/100ML	N019635	004	Mar 09, 1988	Jul	CMFD
AP	+	BAXTER HLTHCARE	5GM/100ML	N019022	002	Nov 01, 1983	Jul	CTEC
			SODIUM CHLORIDE IN PLASTIC CONTAINER					
		+ HOSPIRA	2.5MEQ/ML	N018897	001	Jul 20, 1984	Mar	CRLD
			SOLUTION;IRRIGATION					
			SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
AT		ICU MEDICAL INC	900MG/100ML	N017514	001		Feb	CAHN
AT			900MG/100ML	N018314	001		Feb	CAHN

SODIUM FLUORIDE F-18

INJECTABLE;INTRAVENOUS  
SODIUM FLUORIDE F-18

>A>	AP	JUBILANT DRAXIMAGE	10-200mCi/ML	A203968	001	Oct 23, 2015	Sep	CAHN
>D>	AP	TRIAD ISOTOPES INC	10-200mCi/ML	A203968	001	Oct 23, 2015	Sep	CAHN

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION  
SODIUM NITROPRUSSIDE

AP	AKORN	25MG/ML	A208635	001	May 04, 2017	Apr	NEWA
AP	NEXUS PHARMS	25MG/ML	A207499	001	May 25, 2017	May	NEWA

SOLUTION; IV (INFUSION)  
NIPRIDE RTU IN SODIUM CHLORIDE 0.9%

+	!	EXELA PHARMA SCS LLC	50MG/100ML (0.5MG/ML)	N209387	001	Mar 08, 2017	Mar	NEWA
---	---	----------------------	-----------------------	---------	-----	--------------	-----	------

SODIUM OXYBATE

SOLUTION; ORAL  
SODIUM OXYBATE

AA	WEST-WARD PHARMS INT	500MG/ML	A202090	001	Jan 17, 2017	Jan	NEWA
----	----------------------	----------	---------	-----	--------------	-----	------

AA	+	!	JAZZ PHARMS	500MG/ML	N021196	001	Jul 17, 2002	Jan	CFTG
----	---	---	-------------	----------	---------	-----	--------------	-----	------

SODIUM PHENYL BUTYRATE

TABLET; ORAL  
SODIUM PHENYL BUTYRATE

AB	ALVOGEN MALTA	500MG	A090910	001	Nov 18, 2011	Apr	CAHN
----	---------------	-------	---------	-----	--------------	-----	------

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL  
KALEXATE

>D>	AA	KVK TECH	454GM/BOT	A040905	001	Mar 30, 2009	Sep	CHRS
-----	----	----------	-----------	---------	-----	--------------	-----	------

>A>	AA	!	454GM/BOT	A040905	001	Mar 30, 2009	Sep	CHRS
-----	----	---	-----------	---------	-----	--------------	-----	------

>D>		KAYEXALATE						
-----	--	------------	--	--	--	--	--	--

>D>	AA	+	!	CONCORDIA PHARMS INC	453.6GM/BOT	N011287	001	Sep	DISC
-----	----	---	---	----------------------	-------------	---------	-----	-----	------

>A>		+	@	453.6GM/BOT	N011287	001		Sep	DISC
-----	--	---	---	-------------	---------	-----	--	-----	------

SODIUM POLYSTYRENE SULFONATE

>A>	AA	AILEX PHARMS LLC	454GM/BOT	A206815	001	Feb 18, 2016	Sep	CAHN
-----	----	------------------	-----------	---------	-----	--------------	-----	------

AA	CMP PHARMA INC	454GM/BOT	A089910	001	Jan 19, 1989	Apr	CAHN
----	----------------	-----------	---------	-----	--------------	-----	------

AA	ECI PHARMS LLC	453.6GM/BOT	A090313	001	Dec 21, 2011	Mar	CAHN
----	----------------	-------------	---------	-----	--------------	-----	------

>D>	AA	INVATECH PHARMA	454GM/BOT	A206815	001	Feb 18, 2016	Sep	CAHN
-----	----	-----------------	-----------	---------	-----	--------------	-----	------

SUSPENSION; ORAL, RECTAL  
SPS

AA	!	CMP PHARMA INC	15GM/60ML	A087859	001	Dec 08, 1982	Apr	CAHN
----	---	----------------	-----------	---------	-----	--------------	-----	------

SOFOBUVIR; VELPATASVIR; VOXILAPREVIR

TABLET; ORAL  
VOSEVI

+	!	GILEAD SCIENCES INC	400MG;100MG;100MG	N209195	001	Jul 18, 2017	Jul	NEWA
---	---	---------------------	-------------------	---------	-----	--------------	-----	------

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION  
VALTROPIN

BX	LG CHEM LTD	5MG/VIAL	N021905	001	Apr 19, 2007	Jun	CAHN
----	-------------	----------	---------	-----	--------------	-----	------

SONIDEGIB PHOSPHATE

CAPSULE; ORAL  
ODOMZO

+	!	SUN PHARM INDS INC	EQ 200MG BASE	N205266	001	Jul 24, 2015	Mar	CAHN
---	---	--------------------	---------------	---------	-----	--------------	-----	------

+	!	SUN PHARMA GLOBAL	EQ 200MG BASE	N205266	001	Jul 24, 2015	May	CAHN
---	---	-------------------	---------------	---------	-----	--------------	-----	------

SOTALOL HYDROCHLORIDE

TABLET; ORAL  
BETAPACE

AB1	+	COVIS PHARMA BV	80MG	N019865	001	Oct 30, 1992	May	CAHN
-----	---	-----------------	------	---------	-----	--------------	-----	------

AB1	+		120MG	N019865	005	Apr 20, 1994	May	CAHN
-----	---	--	-------	---------	-----	--------------	-----	------

AB1	+	!	160MG	N019865	002	Oct 30, 1992	May	CAHN
-----	---	---	-------	---------	-----	--------------	-----	------

AB1	+		240MG	N019865	003	Oct 30, 1992	May	CAHN
-----	---	--	-------	---------	-----	--------------	-----	------

AB1	+	@	320MG	N019865	004	Oct 30, 1992	May	CAHN
-----	---	---	-------	---------	-----	--------------	-----	------

BETAPACE AF

	@	COVIS PHARMA BV	40MG	N021151	006	Apr 02, 2003	May	CAHN
--	---	-----------------	------	---------	-----	--------------	-----	------

	@		60MG	N021151	007	Apr 02, 2003	May	CAHN
--	---	--	------	---------	-----	--------------	-----	------

AB2	+		80MG	N021151	001	Feb 22, 2000	May	CAHN
-----	---	--	------	---------	-----	--------------	-----	------

	@		100MG	N021151	005	Mar 14, 2003	May	CAHN
--	---	--	-------	---------	-----	--------------	-----	------

AB2	+		120MG	N021151	002	Feb 22, 2000	May	CAHN
-----	---	--	-------	---------	-----	--------------	-----	------

AB2	+	!	160MG	N021151	003	Feb 22, 2000	May	CAHN
-----	---	---	-------	---------	-----	--------------	-----	------

TABLET;ORAL

SORINE						
AB1	UPSHER-SMITH LABS	80MG	A 075500	001	Apr 27, 2001	Jun CAHN
AB1		120MG	A 075500	004	Apr 27, 2001	Jun CAHN
AB1		160MG	A 075500	002	Apr 27, 2001	Jun CAHN
AB1		240MG	A 075500	003	Apr 27, 2001	Jun CAHN
SOTALOL HYDROCHLORIDE						
	@ MYLAN	80MG	A 075237	001	May 01, 2000	Jun DISC
	@	80MG	A 075725	001	Dec 19, 2000	Jun DISC
	@	120MG	A 075237	002	May 01, 2000	Jun DISC
	@	120MG	A 075725	002	Dec 19, 2000	Jun DISC
	@	160MG	A 075237	003	May 01, 2000	Jun DISC
	@	160MG	A 075725	003	Dec 19, 2000	Jun DISC
	@	240MG	A 075237	004	May 01, 2000	Jun DISC
	@	240MG	A 075725	004	Dec 19, 2000	Jun DISC
	@ TEVA	80MG	A 076883	001	Jul 26, 2004	Apr DISC
	@	120MG	A 076883	002	Jul 26, 2004	Apr DISC
	@	160MG	A 076883	003	Jul 26, 2004	Apr DISC
AB1	UPSHER-SMITH LABS	80MG	A 075366	001	May 01, 2000	Jun CAHN
AB1		120MG	A 075366	002	May 01, 2000	Jun CAHN
AB1		160MG	A 075366	003	May 01, 2000	Jun CAHN
AB1		240MG	A 075366	004	May 01, 2000	Jun CAHN

SOYBEAN OIL

INJECTABLE;INJECTION  
INTRALIPID 30%

>D>	AP	+!	FRESENIUS	30%	N 019942	001	Dec 30, 1993	Sep	CTEC
>A>		+!		30%	N 019942	001	Dec 30, 1993	Sep	CTEC

SPIRONOLACTONE

SUSPENSION;ORAL  
CAROSPIR

>A>		+!	CMP DEV LLC	25MG/5ML	N 209478	001	Aug 04, 2017	Sep	CAHN
>D>		+!	CMP PHARMA INC	25MG/5ML	N 209478	001	Aug 04, 2017	Sep	CAHN
		+!		25MG/5ML	N 209478	001	Aug 04, 2017	Aug	NEWA

TABLET;ORAL

SPIRONOLACTONE						
AB	ACCORD HLTHCARE	25MG	A 203512	001	Sep 19, 2016	Mar CAHN
AB		50MG	A 203512	002	Sep 19, 2016	Mar CAHN
AB		100MG	A 203512	003	Sep 19, 2016	Mar CAHN
AB	AMNEAL PHARMS	25MG	A 091426	001	Jul 02, 2010	May CAHN
AB		25MG	A 091426	001	Jul 02, 2010	May CMS1
AB		50MG	A 091426	002	Jul 02, 2010	May CAHN
AB		50MG	A 091426	002	Jul 02, 2010	May CMS1
AB		100MG	A 091426	003	Jul 02, 2010	May CAHN
AB		100MG	A 091426	003	Jul 02, 2010	May CMS1
	@ UPSHER SMITH	25MG	A 087554	001		Jun CAHN

STAVUDINE

CAPSULE;ORAL  
STAVUDINE

	@ MYLAN LABS LTD	30MG	A 078775	001	Jan 05, 2009	May DISC
AB		30MG	A 078775	001	Jan 05, 2009	Mar CAHN
	@	40MG	A 078775	002	Jan 05, 2009	May DISC
AB		40MG	A 078775	002	Jan 05, 2009	Mar CAHN

FOR SOLUTION;ORAL

	@ AUROBINDO PHARMA	1MG/ML	A 077774	001	Dec 29, 2008	Jul DISC
--	--------------------	--------	----------	-----	--------------	----------

STERILE WATER FOR INJECTION

LIQUID;N/A

STERILE WATER FOR INJECTION						
AP	WEST-WARD PHARMS INT	100%	A 206369	001	Sep 02, 2015	Jan CAHN
	STERILE WATER FOR INJECTION IN PLASTIC CONTAINER					
AP	+!	ICU MEDICAL INC	N 018233	001		Feb CAHN
AP	+!		N 019869	001	Dec 26, 1989	Apr CAHN
AP		TARO	A 077393	001	Aug 11, 2006	Apr CAHN

STERILE WATER FOR IRRIGATION

LIQUID; IRRIGATION

STERILE WATER IN PLASTIC CONTAINER

AT	ICU MEDICAL INC	100%	N017513	001		Feb	CAHN
AT		100%	N018313	001		Feb	CAHN

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION

ANECTINE

AP	+	SANDOZ INC	20MG/ML	N008453	002		May	CAHN
	@		50MG/ML	N008453	003		May	CAHN
	@		500MG/VIAL	N008453	001		May	CAHN
	@		1GM/VIAL	N008453	004		May	CAHN

SULCONAZOLE NITRATE

CREAM; TOPICAL

EXELDERM

+	SUN PHARM INDS INC	1%	N018737	001	Feb 28, 1989	Aug	CAHN
---	--------------------	----	---------	-----	--------------	-----	------

SOLUTION; TOPICAL

EXELDERM

+	SUN PHARM INDS INC	1%	N018738	001	Aug 30, 1985	Aug	CAHN
---	--------------------	----	---------	-----	--------------	-----	------

SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

SULFACETAMIDE SODIUM

AT	SANDOZ INC	10%	A089560	001	Oct 18, 1988	Feb	CAHN
----	------------	-----	---------	-----	--------------	-----	------

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

BACTRIM

>D>	@	MUTUAL PHARM	80MG/ML; 16MG/ML	N018374	001		Sep	CRLD
>A>	+	@	80MG/ML; 16MG/ML	N018374	001		Sep	CRLD

SULFAMETHOXAZOLE AND TRIMETHOPRIM

AP	MYLAN LABS LTD	80MG/ML; 16MG/ML	A206607	001	Aug 30, 2017	Aug	NEWA	
AP	!	TEVA PHARMS USA	80MG/ML; 16MG/ML	A073303	001	Oct 31, 1991	Aug	CTEC

TABLET; ORAL

SEPTRA

AB	MONARCH PHARMS	400MG; 80MG	N017376	001		May	CAHN
	SEPTRA DS						

AB	MONARCH PHARMS	800MG; 160MG	N017376	002		May	CAHN
----	----------------	--------------	---------	-----	--	-----	------

SULFAMETHOXAZOLE AND TRIMETHOPRIM

AB	CHARTWELL MOLECULES	400MG; 80MG	A078060	002	Jan 25, 2007	Mar	CAHN
AB		800MG; 160MG	A078060	001	Jan 25, 2007	Mar	CAHN
AB	CHARTWELL PHARMS LLC	400MG; 80MG	A078060	002	Jan 25, 2007	Jan	CAHN
AB		800MG; 160MG	A078060	001	Jan 25, 2007	Jan	CAHN

SULFANILAMIDE

CREAM; VAGINAL

AVC

+	MYLAN SPECIALITY LP	15%	N006530	003	Jan 27, 1987	Mar	CAHN
---	---------------------	-----	---------	-----	--------------	-----	------

SUPPOSITORY; VAGINAL

AVC

@	MYLAN SPECIALITY LP	1.05GM	N006530	004	Jan 27, 1987	Mar	CAHN
---	---------------------	--------	---------	-----	--------------	-----	------

SULINDAC

TABLET; ORAL

SULINDAC

AB	EPIC PHARMA LLC	150MG	A073262	002	Sep 06, 1991	Aug	CAHN
AB		200MG	A073262	001	Sep 06, 1991	Aug	CAHN

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

SUMATRIPTAN SUCCINATE

	@	SANDOZ INC	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	A078067	002	Feb 06, 2009	Mar	CAHN
	@		EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A078067	001	Feb 06, 2009	Mar	CAHN
AP		WEST-WARD PHARMS INT	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A079123	001	Feb 06, 2009	Jan	CAHN

SYSTEM; IONTOPHORESIS  
ZECUITY

+ @	TEVA BRANDED PHARM	EQ 6.5MG BASE/4HR	N202278	001	Jan 17, 2013	Jan DISC
-----	--------------------	-------------------	---------	-----	--------------	----------

SUNITINIB MALATECAPSULE; ORAL  
SUTENT

+	CPPI CV	EQ 12.5MG BASE	N021938	001	Jan 26, 2006	Mar CTEC
+		EQ 25MG BASE	N021938	002	Jan 26, 2006	Mar CTEC
+		EQ 37.5MG BASE	N021938	004	Mar 31, 2009	Mar CTEC
+	!	EQ 50MG BASE	N021938	003	Jan 26, 2006	Mar CTEC

TACROLIMUSINJECTABLE; INJECTION  
PROGRAF

AP	+	!	ASTELLAS	EQ 5MG BASE/ML	N050709	001	Apr 08, 1994	Aug CFTG
AP			HOSPIRA INC	EQ 5MG BASE/ML	A203900	001	Aug 25, 2017	Aug NEWA

TALCPOWDER; INTRAPLEURAL  
STERITALC

+	NOVATECH SA	2GM/VIAL	N205555	001	May 01, 2017	Apr NEWA
+		3GM/VIAL	N205555	002	May 01, 2017	Apr NEWA
+	!	4GM/VIAL	N205555	003	May 01, 2017	Apr NEWA

TAMOXIFEN CITRATETABLET; ORAL  
TAMOXIFEN CITRATE

>A>	AB	!	MAYNE PHARMA	EQ 20MG BASE	A075797	002	Feb 20, 2003	Sep CMS1
-----	----	---	--------------	--------------	---------	-----	--------------	----------

TAMSULOSIN HYDROCHLORIDECAPSULE; ORAL  
TAMSULOSIN HYDROCHLORIDE

AB			MACLEODS PHARMS LTD	0.4MG	A204645	001	Jan 20, 2017	Jan NEWA
AB			ALKEM LABS LTD	0.4MG	A207405	001	Aug 11, 2017	Jul NEWA

TAZAROTENEAEROSOL, FOAM; TOPICAL  
FABIOR

+	!	MAYNE PHARMA	0.1%	N202428	001	May 11, 2012	Jan CAHN
---	---	--------------	------	---------	-----	--------------	----------

CREAM; TOPICAL  
AVAGE

AB	+	!	ALLERGAN	0.1%	N021184	003	Sep 30, 2002	Mar CFTG
AB			TARO	0.1%	A208258	001	Apr 03, 2017	Mar NEWA
AB	+	!	ALLERGAN	0.1%	N021184	002	Sep 29, 2000	Mar CFTG

TECHNETIUM TC-99M EXAMETAZIME KITPOWDER; INTRAVENOUS  
DRAX EXAMETAZIME

			JUBILANT DRAXIMAGE	N/A	N208870	001	Aug 17, 2017	Aug NEWA
--	--	--	--------------------	-----	---------	-----	--------------	----------

TECHNETIUM TC-99M MEDRONATE KITINJECTABLE; INJECTION  
MDP-BRACCO

AP			CARDINAL HEALTH 414	N/A	N018107	001		Apr CAHN
----	--	--	---------------------	-----	---------	-----	--	----------

TECHNETIUM TC-99M PENTETATE KITINJECTABLE; INJECTION  
AN-DTPA

		@	JUBILANT DRAXIMAGE	N/A	N017714	001		Aug DISC
			DTPA		N018511	001	Dec 29, 1989	Aug CTEC

TECHNETIUM TC-99M SESTAMIBI KITINJECTABLE; INJECTION  
TECHNETIUM TC 99M SESTAMIBI

>D>	AP	CARDINAL HEALTH 414	N/A	A078809	001	Apr 28, 2009	Sep	CAHN
>A>	AP		N/A	A078809	001	Apr 28, 2009	Sep	CAHN
	AP	JUBILANT DRAXIMAGE	N/A	A078806	001	Apr 29, 2009	Jun	CAHN

TECHNETIUM TC-99M TETROFOSMIN KITINJECTABLE; INJECTION  
MYOVIEV

	+ @	GE HEALTHCARE	N/A	N020372	001	Feb 09, 1996	Jul	DISC
		MYOVIEV 30ML						
	+!	GE HEALTHCARE	N/A	N020372	002	Jul 07, 2005	Aug	CMFD
	+ @		N/A	N020372	002	Jul 07, 2005	Jul	DISC

TECHNETIUM TC-99M TILMANOCEPTINJECTABLE; INJECTION  
LYMPHOSEEK KIT

>A>	+!	CARDINAL HEALTH 414	N/A	N202207	001	Mar 13, 2013	Sep	CAHN
>D>	+!	CARDINAL HLTH 414	N/A	N202207	001	Mar 13, 2013	Sep	CAHN
	+!		N/A	N202207	001	Mar 13, 2013	Mar	CAHN

TELAVANCIN HYDROCHLORIDEPOWDER; IV (INFUSION)  
VIBATIV

	+ @	THERAVANCE BIOPHARMA	EQ 250MG BASE/VIAL	N022110	001	Sep 11, 2009	Aug	DISC
	+		EQ 250MG BASE/VIAL	N022110	001	Sep 11, 2009	May	CAHN
	+!		EQ 750MG BASE/VIAL	N022110	002	Sep 11, 2009	May	CAHN

TELMISARTANTABLET; ORAL  
TELMISARTAN

	AB	CADILA PHARMS LTD	20MG	A208605	001	Jul 25, 2017	Jul	NEWA
	AB		40MG	A208605	002	Jul 25, 2017	Jul	NEWA
	AB		80MG	A208605	003	Jul 25, 2017	Jul	NEWA
	AB	GLENMARK PHARMS LTD	20MG	A090032	001	Jul 07, 2014	May	CAHN
	AB		40MG	A090032	002	Jul 07, 2014	May	CAHN
	AB		80MG	A090032	003	Jul 07, 2014	May	CAHN
>A>	AB	MICRO LABS	20MG	A207016	001	Oct 03, 2017	Sep	NEWA
>A>	AB		40MG	A207016	002	Oct 03, 2017	Sep	NEWA
>A>	AB		80MG	A207016	003	Oct 03, 2017	Sep	NEWA
	AB	PRINSTON INC	20MG	A207882	001	May 03, 2017	Apr	NEWA
	AB		40MG	A207882	002	May 03, 2017	Apr	NEWA
	AB		80MG	A207882	003	May 03, 2017	Apr	NEWA

TELOTTRISTAT ETIPRATETABLET; ORAL  
XERMELO

	+!	LEXICON PHARMS INC	EQ 250MG BASE	N208794	001	Feb 28, 2017	Feb	NEWA
--	----	--------------------	---------------	---------	-----	--------------	-----	------

TEMAZEPAMCAPSULE; ORAL  
TEMAZEPAM

	AB	ACTAVIS ELIZABETH	15MG	A071620	002	Aug 07, 1987	May	CMS1
	AB	PRINSTON INC	7.5MG	A201781	001	Jun 04, 2015	Feb	CAHN
	AB		15MG	A201781	002	Jun 04, 2015	Feb	CAHN
	AB		22.5MG	A201781	003	Jun 04, 2015	Feb	CAHN
	AB		30MG	A201781	004	Jun 04, 2015	Feb	CAHN

TEMOZOLOMIDECAPSULE; ORAL  
TEMOZOLOMIDE

	AB	ACCORD HLTHCARE	5MG	A201528	001	Feb 27, 2017	Feb	NEWA
	AB		20MG	A201528	002	Feb 27, 2017	Feb	NEWA
	AB		100MG	A201528	003	Feb 27, 2017	Feb	NEWA
	AB		140MG	A201528	004	Feb 27, 2017	Feb	NEWA
	AB		180MG	A201528	005	Feb 27, 2017	Feb	NEWA
	AB		250MG	A201528	006	Feb 27, 2017	Feb	NEWA
	AB	DEVA HOLDING AS	5MG	A207658	001	Apr 26, 2017	Apr	NEWA
	AB		20MG	A207658	002	Apr 26, 2017	Apr	NEWA
	AB		100MG	A207658	003	Apr 26, 2017	Apr	NEWA

CAPSULE;ORAL  
TEMOZOLOMIDE

AB		140MG	A207658	004	Apr 26, 2017	Apr	NEWA
AB		180MG	A207658	005	Apr 26, 2017	Apr	NEWA
AB		250MG	A207658	006	Apr 26, 2017	Apr	NEWA
AB	WATSON LABS TEVA	5MG	A203959	001	Apr 18, 2017	Apr	NEWA
AB		20MG	A203959	002	Apr 18, 2017	Apr	NEWA
AB		100MG	A203959	003	Apr 18, 2017	Apr	NEWA
AB		140MG	A203959	004	Apr 18, 2017	Apr	NEWA
AB		250MG	A203959	005	Apr 18, 2017	Apr	NEWA
AB	ZYDUS PHARMS USA INC	5MG	A206750	001	Jul 31, 2017	Jul	NEWA
AB		20MG	A206750	002	Jul 31, 2017	Jul	NEWA
AB		100MG	A206750	003	Jul 31, 2017	Jul	NEWA
AB		140MG	A206750	004	Jul 31, 2017	Jul	NEWA
AB		180MG	A206750	005	Jul 31, 2017	Jul	NEWA
AB		250MG	A206750	006	Jul 31, 2017	Jul	NEWA

TENIPOSIDEINJECTABLE;INJECTION  
VUMON

+ @	HQ SPECLT PHARMA	10MG/ML	N020119	001	Jul 14, 1992	Aug	DISC
-----	------------------	---------	---------	-----	--------------	-----	------

TERAZOSIN HYDROCHLORIDECAPSULE;ORAL  
TERAZOSIN HYDROCHLORIDE

AB	MYLAN PHARMS INC	EQ 1MG BASE	A075140	002	Feb 11, 2000	Mar	CAHN
AB		EQ 2MG BASE	A075140	003	Feb 11, 2000	Mar	CAHN
AB		EQ 5MG BASE	A075140	001	Feb 11, 2000	Mar	CAHN
AB		EQ 10MG BASE	A075140	004	Feb 11, 2000	Mar	CAHN

TERBINAFINE HYDROCHLORIDEGRANULE;ORAL  
LAMISIL

+ @	NOVARTIS	EQ 125MG BASE/PACKET	N022071	001	Sep 28, 2007	Aug	DISC
+ @		EQ 187.5MG BASE/PACKET	N022071	002	Sep 28, 2007	Aug	DISC

TABLET;ORAL  
TERBINAFINE HYDROCHLORIDE

@	MYLAN	EQ 250MG BASE	A077195	001	Jul 02, 2007	Aug	DISC
---	-------	---------------	---------	-----	--------------	-----	------

TERBUTALINE SULFATEINJECTABLE;INJECTION  
TERBUTALINE SULFATE

AP	! ATHENEX INC	1MG/ML	A076770	001	Apr 23, 2004	Mar	CAHN
----	---------------	--------	---------	-----	--------------	-----	------

TABLET;ORAL  
BRETHINE

+ @	ANI PHARMS INC	2.5MG	N017849	001		Feb	CAHN
+ @		5MG	N017849	002		Feb	CAHN

! LANNETT		5MG	A077152	002	Mar 25, 2005	Jan	CHRS
-----------	--	-----	---------	-----	--------------	-----	------

TESTOSTERONEGEL;TRANSDERMAL  
ANDROGEL

AB2	+ ABBVIE	1.62% (20.25MG/1.25GM PACKET)	N022309	002	Sep 07, 2012	Jun	CFTG
AB2	+!	1.62% (40.5MG/2.5GM PACKET)	N022309	003	Sep 07, 2012	Jun	CFTG

## TESTIM

AB2	+! AUXILIUM PHARMS LLC	50MG/5GM PACKET	N021454	001	Oct 31, 2002	May	CAHN
-----	------------------------	-----------------	---------	-----	--------------	-----	------

## TESTOSTERONE

>A>	AB2	ACTAVIS LABS UT INC	50MG/5GM PACKET	A091073	001	Sep 18, 2017	Sep	NEWA
	AB2	PERRIGO UK FINCO	1.62% (20.25MG/1.25GM PACKET)	A205781	001	Jul 12, 2017	Jun	NEWA
	AB2		1.62% (40.5MG/2.5GM PACKET)	A205781	002	Jul 12, 2017	Jun	NEWA

## VOGELXO

AB2	UPSHER-SMITH LABS	50MG/5GM PACKET	N204399	002	Jun 04, 2014	Jun	CAHN
-----	-------------------	-----------------	---------	-----	--------------	-----	------

GEL, METERED;TRANSDERMAL  
TESTOSTERONE

AB	ACTAVIS LABS UT INC	10MG/0.5GM ACTUATION	A204571	001	Aug 05, 2015	Mar	CAHN
----	---------------------	----------------------	---------	-----	--------------	-----	------

## VOGELXO

BX	UPSHER-SMITH LABS	12.5MG/1.25GM ACTUATION	N204399	003	Jun 04, 2014	Jun	CAHN
----	-------------------	-------------------------	---------	-----	--------------	-----	------

## SOLUTION, METERED;TRANSDERMAL

>D>		AXIRON						
>D>	AT	+! ELI LILLY AND CO	30MG/1.5ML ACTUATION	N022504	001	Nov 23, 2010	Sep	DISC
>A>		+ @	30MG/1.5ML ACTUATION	N022504	001	Nov 23, 2010	Sep	DISC

SOLUTION, METERED;TRANSDERMAL								
AXIRON								
AT	+		30MG/1.5ML ACTUATION		N022504	001	Nov 23, 2010	Feb CFTG
TESTOSTERONE								
AT		ACTAVIS LABS UT INC	30MG/1.5ML ACTUATION		A205328	001	Aug 07, 2017	Jul NEWA
>D>	AT	PERRIGO ISRAEL	30MG/1.5ML ACTUATION		A204255	001	Feb 28, 2017	Sep CHRS
>A>	AT	!	30MG/1.5ML ACTUATION		A204255	001	Feb 28, 2017	Sep CHRS
AT			30MG/1.5ML ACTUATION		A204255	001	Feb 28, 2017	Feb NEWA
TABLET, EXTENDED RELEASE;BUCCAL								
STRIANT								
	+	AUXILIUM PHARMS LLC	30MG		N021543	001	Jun 19, 2003	May CAHN
<u>TESTOSTERONE CYPIONATE</u>								
INJECTABLE;INJECTION								
TESTOSTERONE CYPIONATE								
AO		LUITPOLD PHARMS INC	200MG/ML		A207742	001	Jun 16, 2017	Jun NEWA
AO		SANDOZ INC	100MG/ML		A040615	001	Aug 10, 2006	Mar CAHN
AO			200MG/ML		A040615	002	Aug 10, 2006	Mar CAHN
AO		WATSON PHARMS INC	200MG/ML		A086030	001		Feb CAHN
AO		WEST-WARD PHARMS INT	100MG/ML		A090387	001	Jul 15, 2010	Jan CAHN
AO			200MG/ML		A090387	002	Jul 15, 2010	Jan CAHN
<u>TESTOSTERONE ENANTHATE</u>								
INJECTABLE;INJECTION								
TESTOSTERONE ENANTHATE								
AO		WATSON PHARMS INC	200MG/ML		A085598	001		Feb CAHN
<u>TETRABENAZINE</u>								
TABLET;ORAL								
TETRABENAZINE								
AB		ACTAVIS LABS FL INC	25MG		A206686	001	Jul 07, 2017	Jun NEWA
AB		APICORE US	12.5MG		A207682	001	Jan 31, 2017	Jan NEWA
AB			25MG		A207682	002	Jan 31, 2017	Jan NEWA
<u>TETRACYCLINE HYDROCHLORIDE</u>								
CAPSULE;ORAL								
ACHROMYCIN V								
AB	+	HERITAGE PHARMA	250MG		N050278	003		Jan CAHN
AB	+	!	500MG		N050278	001		Jan CAHN
TETRACYCLINE HYDROCHLORIDE								
AB		CHARTWELL TETRA	250MG		A062752	001	Aug 12, 1988	Apr CAHN
AB			500MG		A062752	002	Aug 12, 1988	Apr CAHN
		@ IMPAX LABS	100MG		A060469	002		Jul DISC
		@	250MG		A060469	001		Jul DISC
		@	500MG		A060469	003		Jul DISC
<u>THEOPHYLLINE</u>								
ELIXIR;ORAL								
THEOPHYLLINE								
		@ CHARTWELL RX	80MG/15ML		A085952	001		Apr CAHN
		@ PHARM ASSOC	80MG/15ML		A086720	001		May CAHN
TABLET, EXTENDED RELEASE;ORAL								
THEOCHRON								
AB		NOSTRUM PHARMS LLC	100MG		A088320	001	Feb 21, 1985	May CAHN
AB			200MG		A088321	001	Feb 21, 1985	May CAHN
		@	300MG		A087400	002	Jan 11, 1983	May CAHN
THEOPHYLLINE								
		!	ALEMBIC LTD	450MG	A090430	002	Oct 27, 2010	Apr CHRS
AB		!	ALEMBIC PHARMS LTD	300MG	A090430	001	Oct 27, 2010	May CAHN
		!		450MG	A090430	002	Oct 27, 2010	May CAHN
<u>THIAMINE HYDROCHLORIDE</u>								
INJECTABLE;INJECTION								
THIAMINE HYDROCHLORIDE								
		@ WEST-WARD PHARMS INT	100MG/ML		A080575	001		Jan CAHN



THIORIDAZINE HYDROCHLORIDE

## CONCENTRATE; ORAL

## THIORIDAZINE HYDROCHLORIDE

@ ANI PHARMS INC	30MG/ML	A 089602	001	Nov 09, 1987	Jan CAHN
@ PHARM ASSOC	30MG/ML	A 040187	001	Aug 28, 1997	May CAHN
@	100MG/ML	A 040213	001	May 29, 1998	May CAHN

## TABLET; ORAL

## THIORIDAZINE HYDROCHLORIDE

@ WATSON LABS TEVA	15MG	A 088477	001	Nov 08, 1983	May CAHN
@	25MG	A 088567	001	May 11, 1984	May CAHN
@	200MG	A 088872	001	Apr 26, 1985	May CAHN

THIOTEPA

## POWDER; IV (INFUSION)

## TEPADINA

+! ADIENNE SA	15MG/VIAL	N 208264	001	Jan 26, 2017	Jan NEWA
+!	100MG/VIAL	N 208264	002	Jan 26, 2017	Jan NEWA

TICAGRELOR

## TABLET; ORAL

## BRILINTA

+ ASTRAZENECA PHARMS	60MG	N 022433	002	Sep 03, 2015	Jan CAHN
+!	90MG	N 022433	001	Jul 20, 2011	Jan CAHN

TIGECYCLINE

## POWDER; IV (INFUSION)

## TIGECYCLINE

AP SANDOZ INC	50MG/VIAL	A 091620	001	May 27, 2015	Feb CDFR
AP +! PF PRISM CV	50MG/VIAL	N 021821	001	Jun 15, 2005	Feb CDFR

TIMOLOL MALEATE

## SOLUTION, GEL FORMING/DROPS; OPHTHALMIC

## TIMOLOL MALEATE

AB SANDOZ INC	EQ 0.25% BASE	N 020963	001	Oct 21, 1998	Feb CAHN
AB	EQ 0.5% BASE	N 020963	002	Oct 21, 1998	Feb CAHN

## SOLUTION/DROPS; OPHTHALMIC

## TIMOLOL MALEATE

AT ! ALCON RES LTD	EQ 0.25% BASE	A 074261	001	Apr 28, 1995	Jan CHRS
AT1 !	EQ 0.5% BASE	A 074262	001	Apr 28, 1995	Jan CHRS
AT ! SANDOZ INC	EQ 0.25% BASE	A 074261	001	Apr 28, 1995	Feb CAHN
AT1 !	EQ 0.5% BASE	A 074262	001	Apr 28, 1995	Feb CAHN

TINIDAZOLE

## TABLET; ORAL

## TINIDAZOLE

AB UNIQUE PHARM LABS	250MG	A 202489	001	Oct 09, 2013	Jan CTEC
AB	500MG	A 202489	002	Oct 09, 2013	Jan CTEC

TIZANIDINE HYDROCHLORIDE

## CAPSULE; ORAL

## TIZANIDINE HYDROCHLORIDE

AB JUBILANT GENERICS	EQ 2MG BASE	A 209605	001	Aug 04, 2017	Jul NEWA
AB	EQ 4MG BASE	A 209605	002	Aug 04, 2017	Jul NEWA
AB	EQ 6MG BASE	A 209605	003	Aug 04, 2017	Jul NEWA
AB PAR PHARM INC	EQ 2MG BASE	A 207199	001	Mar 14, 2017	Feb NEWA
AB	EQ 4MG BASE	A 207199	002	Mar 14, 2017	Feb NEWA
AB	EQ 6MG BASE	A 207199	003	Mar 14, 2017	Feb NEWA
AB ZYDUS PHARMS USA INC	EQ 2MG BASE	A 208622	001	Mar 03, 2017	Feb NEWA
AB	EQ 4MG BASE	A 208622	002	Mar 03, 2017	Feb NEWA
AB	EQ 6MG BASE	A 208622	003	Mar 03, 2017	Feb NEWA

## TABLET; ORAL

## TIZANIDINE HYDROCHLORIDE

AB EPIC PHARMA LLC	EQ 2MG BASE	A 076347	001	Oct 11, 2002	May CAHN
AB	EQ 4MG BASE	A 076347	002	Oct 11, 2002	May CAHN
AB PAR PHARM INC	EQ 2MG BASE	A 207170	001	Jan 26, 2017	Jan NEWA
AB	EQ 4MG BASE	A 207170	002	Jan 26, 2017	Jan NEWA

TOBRAMYCIN

SOLUTION; INHALATION

TOBRAMYCIN

AN	AMNEAL PHARMS	300MG/5ML	A205501	001	Jul 13, 2015	May	CAHN
AN	LUPIN ATLANTIS	300MG/5ML	A208964	001	Mar 22, 2017	Mar	NEWA

SOLUTION/DROPS; OPHTHALMIC

TOBRAMYCIN

AT	SOMERSET THERAPS LLC	0.3%	A207444	001	Jun 28, 2017	Jun	NEWA
AT	TOBREX						
AT	SANDOZ INC	0.3%	A062535	001	Dec 13, 1984	Feb	CAHN

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

TOBRAMYCIN SULFATE

AP	BAXTER HLTHCARE CORP	EQ 40MG BASE/ML	A206965	001	Jul 01, 2016	Aug	CAHN
----	----------------------	-----------------	---------	-----	--------------	-----	------

TOLMETIN SODIUM

TABLET; ORAL

TOLMETIN SODIUM

@	SUN PHARM INDS	EQ 200MG BASE	A073310	001	Nov 27, 1991	Apr	DISC
---	----------------	---------------	---------	-----	--------------	-----	------

TOPIRAMATE

CAPSULE, EXTENDED RELEASE; ORAL

QUDEXY XR

+	UPSHER-SMITH LABS	25MG	N205122	001	Mar 11, 2014	Jun	CAHN
+		50MG	N205122	002	Mar 11, 2014	Jun	CAHN
+		100MG	N205122	003	Mar 11, 2014	Jun	CAHN
+		150MG	N205122	004	Mar 11, 2014	Jun	CAHN
+		200MG	N205122	005	Mar 11, 2014	Jun	CAHN

TABLET; ORAL

TOPIRAMATE

@	MYLAN	25MG	A076314	001	Mar 27, 2009	May	DISC
@		50MG	A076314	002	Mar 27, 2009	May	DISC
@		100MG	A076314	003	Mar 27, 2009	May	DISC
@		200MG	A076314	004	Mar 27, 2009	May	DISC
AB	UPSHER-SMITH LABS	25MG	A078499	001	Jan 07, 2010	Jun	CAHN
AB		50MG	A078499	002	Jan 07, 2010	Jun	CAHN
AB		100MG	A078499	003	Jan 07, 2010	Jun	CAHN
AB		200MG	A078499	004	Jan 07, 2010	Jun	CAHN

TOPOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

TOPOTECAN HYDROCHLORIDE

>D>	AP	CHEM WERTH INC	EQ 4MG BASE/VIAL	A201166	001	Aug 08, 2012	Sep	CAHN
>A>	AP	HONG KONG	EQ 4MG BASE/VIAL	A201166	001	Aug 08, 2012	Sep	CAHN
>D>	AP	INGENUS PHARMS LLC	EQ 4MG BASE/VIAL	A206962	001	Nov 30, 2016	Sep	CAHN
>A>	AP	NOVAST LABS LTD	EQ 4MG BASE/VIAL	A206962	001	Nov 30, 2016	Sep	CAHN
>D>	AP	SUN PHARM INDS LTD	EQ 4MG BASE/VIAL	A202203	001	Aug 29, 2013	Sep	DISC
>A>		@	EQ 4MG BASE/VIAL	A202203	001	Aug 29, 2013	Sep	DISC

SOLUTION; INTRAVENOUS

TOPOTECAN HYDROCHLORIDE

AP	ACCORD HLTHCARE	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A204406	001	Jul 06, 2017	Jun	NEWA
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A204406	002	Jul 06, 2017	Jun	NEWA

TOREMIFENE CITRATE

TABLET; ORAL

FARESTON

+	KYOWA KIRIN	EQ 60MG BASE	N020497	001	May 29, 1997	Jan	CAHN
---	-------------	--------------	---------	-----	--------------	-----	------

TORSEMIDE

TABLET; ORAL

DEMADEX

AB	+	MYLAN SPECIALITY LP	5MG	N020136	001	Aug 23, 1993	Mar	CAHN
AB	+		10MG	N020136	002	Aug 23, 1993	Mar	CAHN
AB	+		20MG	N020136	003	Aug 23, 1993	Mar	CAHN
AB	+		100MG	N020136	004	Aug 23, 1993	Mar	CAHN

TORSEMIDE

>D>	AB	SUN PHARM INDS	5MG	A078478	001	Feb 26, 2008	Sep	DISC
>A>		@	5MG	A078478	001	Feb 26, 2008	Sep	DISC
>D>	AB		10MG	A078478	002	Feb 26, 2008	Sep	DISC
>A>		@	10MG	A078478	002	Feb 26, 2008	Sep	DISC

TABLET;ORAL  
TORSEMIDE

>D>	AB		20MG	A078478	003	Feb 26, 2008	Sep	DISC
>A>		@	20MG	A078478	003	Feb 26, 2008	Sep	DISC
>D>	AB		100MG	A078478	004	Feb 26, 2008	Sep	DISC
>A>		@	100MG	A078478	004	Feb 26, 2008	Sep	DISC

TRAMADOL HYDROCHLORIDE

TABLET;ORAL

TRAMADOL HYDROCHLORIDE

AB		ACCORD HLTHCARE	50MG	A202390	001	May 16, 2013	Mar	CAHN
AB		AMNEAL PHARMS	50MG	A076003	001	Jun 20, 2002	May	CAHN
		@ NORTHSTAR HLTHCARE	50MG	A078935	001	May 26, 2010	Aug	DISC

TABLET, EXTENDED RELEASE;ORAL

ULTRAM ER

+	@	VALEANT PHARMS	100MG	N021692	001	Sep 08, 2005	Mar	CRLD
+	@		200MG	N021692	002	Sep 08, 2005	Mar	CRLD
+	@		300MG	N021692	003	Sep 08, 2005	Mar	CRLD

TRAMETINIB DIMETHYL SULFOXIDE

TABLET;ORAL

MEKINIST

+	@	NOVARTIS PHARMS CORP	EQ 1MG	N204114	002	May 29, 2013	Jul	DISC
---	---	----------------------	--------	---------	-----	--------------	-----	------

TRANDOLAPRIL

TABLET;ORAL

TRANDOLAPRIL

		@ EPIC PHARMA LLC	1MG	A077256	001	Jun 12, 2007	May	CAHN
		@	2MG	A077256	002	Jun 12, 2007	May	CAHN
		@	4MG	A077256	003	Jun 12, 2007	May	CAHN
		@ INVAGEN PHARMS	1MG	A078320	001	Jun 12, 2007	Jun	DISC
BX		@	1MG	A078320	001	Jun 12, 2007	Apr	CTEC
		@	2MG	A078320	002	Jun 12, 2007	Jun	DISC
BX		@	2MG	A078320	002	Jun 12, 2007	Apr	CTEC
		@	4MG	A078320	003	Jun 12, 2007	Jun	DISC
BX		@	4MG	A078320	003	Jun 12, 2007	Apr	CTEC
		@ MYLAN	1MG	A078346	001	Apr 28, 2008	May	DISC
		@	2MG	A078346	002	Apr 28, 2008	May	DISC
		@	4MG	A078346	003	Apr 28, 2008	May	DISC

TRANEXAMIC ACID

INJECTABLE;INJECTION

TRANEXAMIC ACID

>A>	AP		AKORN	100MG/ML	A206594	001	Sep 28, 2017	Sep	NEWA
	AP		AMNEAL PHARMS CO	100MG/ML	A208840	001	Feb 28, 2017	Feb	NEWA
	AP		GLAND PHARMA LTD	100MG/ML	A207239	001	Feb 13, 2017	Jan	NEWA
>D>	AP		MICRO LABS	100MG/ML	A206713	001	Jun 27, 2017	Sep	CAHN
	AP			100MG/ML	A206713	001	Jun 27, 2017	Jun	NEWA
>D>	AP		NORTH CREEK PHARMS	100MG/ML	A202755	001	Feb 25, 2016	Sep	CAHN
>A>	AP		VIRTUS PHARMS	100MG/ML	A202755	001	Feb 25, 2016	Sep	CAHN
>A>	AP		VIVA HLTHCARE	100MG/ML	A206713	001	Jun 27, 2017	Sep	CAHN
	AP		ZYDUS PHARMS USA INC	100MG/ML	A205228	001	Jul 17, 2017	Jul	NEWA

TRAVOPROST

SOLUTION/DROPS;OPHTHALMIC

TRAVOPROST

AT		MYLAN PHARMS INC	0.004%	A205050	001	Jul 07, 2017	Jun	NEWA
----	--	------------------	--------	---------	-----	--------------	-----	------

TRAZODONE HYDROCHLORIDE

TABLET;ORAL

TRAZODONE HYDROCHLORIDE

AB		ACCORD HLTHCARE	50MG	A206923	001	Sep 08, 2017	Aug	NEWA	
AB			100MG	A206923	002	Sep 08, 2017	Aug	NEWA	
AB			150MG	A206923	003	Sep 08, 2017	Aug	NEWA	
AB			300MG	A206923	004	Sep 08, 2017	Aug	NEWA	
		@ MYLAN PHARMS INC	50MG	A090514	001	Jun 02, 2009	May	DISC	
		@	100MG	A090514	002	Jun 02, 2009	May	DISC	
		@	150MG	A090514	003	Jun 02, 2009	May	DISC	
		@	300MG	A090514	004	Jun 02, 2009	May	DISC	
>A>	AB		ZYDUS PHARMS USA INC	50MG	A205253	001	Oct 10, 2017	Sep	NEWA
>A>	AB			100MG	A205253	002	Oct 10, 2017	Sep	NEWA
>A>	AB			150MG	A205253	003	Oct 10, 2017	Sep	NEWA

	TABLET;ORAL							
	TRAZODONE HYDROCHLORIDE							
>A>	AB	300MG	A205253	004	Oct 10, 2017	Sep	NEWA	
	<u>TRETINOIN</u>							
	CAPSULE;ORAL							
	TRETINOIN							
AB	GLENMARK PHARMS LTD	10MG	A208279	001	Dec 23, 2016	Jun	CAHN	
	VESANOID							
	+ @ CHEFLAPHARM	10MG	N020438	001	Nov 22, 1995	May	CAHN	
	CREAM;TOPICAL							
	TRETINOIN							
AB2	ZO SKIN HEALTH	0.05%	A076498	001	Sep 15, 2005	Feb	CAHN	
	GEL;TOPICAL							
	TRETINOIN							
AB	MYLAN PHARMS INC	0.04%	A202567	001	Jul 17, 2013	Jun	CAHN	
AB		0.05%	A207955	001	Aug 13, 2015	Jun	CAHN	
AB		0.1%	A202026	001	Jul 17, 2013	Jun	CAHN	
	<u>TRIAMCINOLONE ACETONIDE</u>							
	CREAM;TOPICAL							
	TRIAMCINOLONE ACETONIDE							
AT	LUPIN ATLANTIS	0.025%	A208763	001	Feb 01, 2017	Jan	NEWA	
AT		0.1%	A208763	002	Feb 01, 2017	Jan	NEWA	
AT		0.5%	A208763	003	Feb 01, 2017	Jan	NEWA	
AT	+ MYLAN PHARMS INC	0.025%	N011601	003		Jan	CAHN	
AT	+ @ TARO	0.1%	N011601	006		Jan	CAHN	
		0.025%	A040038	001	Oct 26, 1994	Apr	CAHN	
AT		0.1%	A040039	001	Nov 26, 1997	Apr	CAHN	
AT		0.1%	A040039	001	Nov 26, 1997	Mar	CAHN	
>A>	AT	0.1%	A208848	001	Sep 18, 2017	Sep	NEWA	
	INJECTABLE;INJECTION							
	KENALOG-10							
	+ APOTHECON	10MG/ML	N012041	001		Jun	CRLD	
	TRIAMCINOLONE ACETONIDE							
	@ SANDOZ INC	10MG/ML	A090166	001	May 27, 2009	Apr	CAHN	
	@	40MG/ML	A090164	001	Jun 01, 2009	Apr	CAHN	
	OINTMENT;TOPICAL							
	KENALOG							
>D>	@ MYLAN PHARMS INC	0.025%	N011600	003		Sep	CRLD	
>A>	+ @	0.025%	N011600	003		Sep	CRLD	
	@	0.025%	N011600	003		Aug	DISC	
AT		0.025%	N011600	003		Jan	CAHN	
>D>	@	0.1%	N011600	001		Sep	CRLD	
>A>	+ @	0.1%	N011600	001		Sep	CRLD	
	@	0.1%	N011600	001		Aug	DISC	
AT		0.1%	N011600	001		Jan	CAHN	
	TRIAMCINOLONE ACETONIDE							
>A>	AT	0.5%	A208925	001	Oct 06, 2017	Sep	NEWA	
AT	G AND W LABS INC	0.1%	A208320	001	Aug 22, 2017	Aug	NEWA	
	@ TARO	0.025%	A040040	001	Sep 30, 1994	Apr	CAHN	
AT		0.1%	A040037	001	Sep 30, 1994	Apr	CAHN	
AT	TELIGENT PHARMA INC	0.5%	A208590	001	Mar 03, 2017	Feb	NEWA	
	TRIAMCINOLONE ACETONIDE IN ABSORBASE							
	! CMP PHARMA INC	0.05%	A089595	001	Mar 23, 1995	Apr	CAHN	
	PASTE;DENTAL							
	TRIAMCINOLONE ACETONIDE							
AT	G AND W LABS INC	0.1%	A205592	001	Jan 12, 2017	Jan	NEWA	
	SPRAY;TOPICAL							
	TRIAMCINOLONE ACETONIDE							
AT	RICONPHARMA LLC	0.147MG/GM	A206786	001	Sep 08, 2017	Aug	NEWA	
	SPRAY, METERED;NASAL							
	TRIAMCINOLONE ACETONIDE							
	@ PERRIGO ISRAEL	0.055MG/SPRAY	A078104	001	Jul 30, 2009	Jan	CAHN	
	<u>TRIAMCINOLONE DIACETATE</u>							
	INJECTABLE;INJECTION							
	ARISTOCORT							
	@ SANDOZ INC	25MG/ML	N011685	003		Jun	CAHN	
	+ @	40MG/ML	N012802	001		Jun	CAHN	

TRIAMCINOLONE HEXACETONIDEINJECTABLE; INJECTION  
ARISTOSPAN

+	!	SANDOZ INC	5MG/ML	N016466	001		Jun	CAHN
+	!		20MG/ML	N016466	002		Jun	CAHN

TRIFLURIDINESOLUTION/DROPS; OPHTHALMIC  
TRIFLURIDINE

AT		HI-TECH PHARMACAL	1%	A205438	001	Jul 28, 2017	Jul	NEWA	
AT		SANDOZ INC	1%	A074311	001	Oct 06, 1995	Feb	CAHN	
AT	+	!	MONARCH PHARMS	1%	N018299	001		Feb	CAHN

TRIHEXYPHENIDYL HYDROCHLORIDEELIXIR; ORAL  
TRIHEXYPHENIDYL HYDROCHLORIDE

AA	!	PHARM ASSOC	2MG/5ML	A040177	001	Apr 17, 1997	May	CAHN
AA		VINTAGE PHARMS LLC	2MG	A040254	001	Dec 24, 1998	Mar	CAHN
AA			5MG	A040254	002	Dec 24, 1998	Mar	CAHN

TRIMETHOBENZAMIDE HYDROCHLORIDECAPSULE; ORAL  
TIGAN

AB	+	!	KING PHARMS LLC	300MG	N017531	006	Dec 13, 2001	May	CAHN
----	---	---	-----------------	-------	---------	-----	--------------	-----	------

TRIMIPRAMINE MALEATECAPSULE; ORAL  
TRIMIPRAMINE MALEATE

AB		ELITE LABS INC	EQ 25MG BASE	A077361	001	Aug 02, 2006	May	CAHN
AB			EQ 50MG BASE	A077361	002	Aug 02, 2006	May	CAHN
AB			EQ 100MG BASE	A077361	003	Aug 02, 2006	May	CAHN

TRIPTORELIN PAMOATEFOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR  
TRIPTODUR KIT

+	!	ARBOR PHARMS LLC	EQ 22.5MG BASE/VIAL	N208956	001	Jun 29, 2017	Jun	NEWA
---	---	------------------	---------------------	---------	-----	--------------	-----	------

TROPICAMIDESOLUTION/DROPS; OPHTHALMIC  
MYDRIACYL

AT	!	SANDOZ INC	0.5%	A084305	001		Feb	CAHN
----	---	------------	------	---------	-----	--	-----	------

TROSPIMUM CHLORIDECAPSULE, EXTENDED RELEASE; ORAL  
TROSPIMUM CHLORIDE

@	UPSHER-SMITH LABS	60MG	A091635	001	Apr 29, 2015	Jun	CAHN
---	-------------------	------	---------	-----	--------------	-----	------

ULIPRISTAL ACETATETABLET; ORAL  
ELLA

AB	+	!	LAB HRA PHARMA	30MG	N022474	001	Aug 13, 2010	Jan	CFTG
AB			TEVA PHARMS USA	30MG	A207952	001	Feb 13, 2017	Jan	NEWA

URSODIOLCAPSULE; ORAL  
URSODIOL

@	IMPAX LABS INC	300MG	A077895	001	Jul 27, 2006	May	DISC
BX		300MG	A077895	001	Jul 27, 2006	Apr	CTEC
AB		300MG	A077895	001	Jul 27, 2006	Feb	CAHN

VALACYCLOVIR HYDROCHLORIDETABLET; ORAL  
VALACYCLOVIR HYDROCHLORIDE

@	MYLAN	EQ 500MG BASE	A078070	001	May 24, 2010	Jun	DISC
@		EQ 1GM BASE	A078070	002	May 24, 2010	Jun	DISC

VALBENAZINE TOSYLATECAPSULE;ORAL  
INGREZZA

+! NEUROCRINE 40MG N209241 001 Apr 11, 2017 Apr NEWA

VALPROATE SODIUMINJECTABLE;INJECTION  
VALPROATE SODIUM

AP ATHENEX INC EQ 100MG BASE/ML A076295 001 Nov 14, 2002 Mar CAHN

VALPROIC ACIDCAPSULE;ORAL  
VALPROIC ACID

@ USL PHARMA 250MG A070631 001 Jun 11, 1987 Jun CAHN

SYRUP;ORAL  
VALPROIC ACID

AA ECI PHARMS LLC 250MG/5ML A090517 001 May 28, 2010 Mar CAHN

AA PHARM ASSOC 250MG/5ML A075379 001 Dec 15, 2000 May CAHN

AA VISTAPHARM 250MG/5ML A075782 001 Dec 22, 2000 Feb CAHN

VALSARTANTABLET;ORAL  
VALSARTAN

AB AMNEAL PHARMS 40MG A204011 001 Jan 11, 2016 May CAHN

AB 80MG A204011 002 Jan 11, 2016 May CAHN

AB 160MG A204011 003 Jan 11, 2016 May CAHN

AB 320MG A204011 004 Jan 11, 2016 May CAHN

AB MYLAN PHARMS INC 40MG A090866 001 Jan 05, 2015 Feb CAHN

AB 80MG A090866 002 Jan 05, 2015 Feb CAHN

AB 160MG A090866 003 Jan 05, 2015 Feb CAHN

AB 320MG A090866 004 Jan 05, 2015 Feb CAHN

VANCOMYCIN HYDROCHLORIDEINJECTABLE;INJECTION  
VANCOMYCIN HYDROCHLORIDE

AP MUSTAFA NEVZAT ILAC EQ 500MG BASE/VIAL A065401 001 Jun 30, 2008 Aug CAHN

AP EQ 1GM BASE/VIAL A065401 002 Jun 30, 2008 Aug CAHN

VARDENAFIL HYDROCHLORIDETABLET;ORAL  
VARDENAFIL HYDROCHLORIDE

&gt;D&gt; AB TEVA PHARMS 2.5MG A091347 001 May 03, 2012 Sep DISC

&gt;A&gt; @ 2.5MG A091347 001 May 03, 2012 Sep DISC

&gt;D&gt; AB 5MG A091347 002 May 03, 2012 Sep DISC

&gt;A&gt; @ 5MG A091347 002 May 03, 2012 Sep DISC

&gt;D&gt; AB 10MG A091347 003 May 03, 2012 Sep DISC

&gt;A&gt; @ 10MG A091347 003 May 03, 2012 Sep DISC

&gt;D&gt; AB 20MG A091347 004 May 03, 2012 Sep DISC

&gt;A&gt; @ 20MG A091347 004 May 03, 2012 Sep DISC

TABLET, ORALLY DISINTEGRATING;ORAL  
STAXYN

+! BAYER HLTHCARE 10MG N200179 001 Jun 17, 2010 Jun CTEC

VASOPRESSINSOLUTION;IV (INFUSION)  
VASOSTRICT

+! PAR STERILE PRODUCTS 20UNITS/ML (20UNITS/ML) N204485 001 Apr 17, 2014 May CMFD

+ @ 20UNITS/ML (20UNITS/ML) N204485 001 Apr 17, 2014 Apr DISC

+! 20UNITS/ML (20UNITS/ML) N204485 002 Mar 18, 2016 Apr NEWA

+! 200UNITS/10ML (20UNITS/ML) N204485 002 Dec 17, 2016 May NEWA

VECURONIUM BROMIDEINJECTABLE;INJECTION  
VECURONIUM BROMIDE

AP @ WEST-WARD PHARMS INT 10MG/VIAL A075218 001 Aug 23, 1999 Mar CAHN

10MG/VIAL A075549 001 Jun 13, 2000 Jan CAHN

AP @ 20MG/VIAL A075218 002 Aug 23, 1999 Mar CAHN

20MG/VIAL A075549 002 Jun 13, 2000 Jan CAHN

VENLAFAXINE HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL  
VENLAFAXINE HYDROCHLORIDE

>A>	AB	MACLEODS PHARMS LTD	EQ 37.5MG BASE	A204889	001	Oct 05, 2017	Sep	NEWA
>A>	AB		EQ 75MG BASE	A204889	002	Oct 05, 2017	Sep	NEWA
>A>	AB		EQ 150MG BASE	A204889	003	Oct 05, 2017	Sep	NEWA
		@ MYLAN	EQ 37.5MG BASE	A078789	001	Jun 01, 2011	Aug	DISC
		@	EQ 75MG BASE	A078789	002	Jun 01, 2011	Aug	DISC
		@	EQ 150MG BASE	A078789	003	Jun 01, 2011	Aug	DISC

TABLET;ORAL

VENLAFAXINE HYDROCHLORIDE

AB		PRINSTON INC	EQ 25MG BASE	A090027	001	Aug 04, 2010	Feb	CAHN
AB			EQ 37.5MG BASE	A090027	002	Aug 04, 2010	Feb	CAHN
AB			EQ 50MG BASE	A090027	003	Aug 04, 2010	Feb	CAHN
AB			EQ 75MG BASE	A090027	004	Aug 04, 2010	Feb	CAHN
AB			EQ 100MG BASE	A090027	005	Aug 04, 2010	Feb	CAHN

TABLET, EXTENDED RELEASE;ORAL

VENLAFAXINE HYDROCHLORIDE

AB		NOSTRUM LABS INC	EQ 150MG BASE	A205468	002	Mar 24, 2017	Mar	NEWA
AB			EQ 225MG BASE	A205468	003	Mar 24, 2017	Mar	NEWA
AB	+	OSMOTICA PHARM	EQ 225MG BASE	N022104	004	May 20, 2008	Mar	CFTG

VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CALAN SR

		+ @ PFIZER	180MG	N019152	002	Dec 15, 1989	Jan	CRLD
		COVERA-HS						
		@ GD SEARLE LLC	180MG	N020552	001	Feb 26, 1996	Jan	DISC
		@	240MG	N020552	002	Feb 26, 1996	Jan	DISC

VERAPAMIL HYDROCHLORIDE

AB		CADILA PHARMS LTD	180MG	A206173	001	May 05, 2017	Apr	NEWA
AB			240MG	A206173	002	May 05, 2017	Apr	NEWA

VIGABATRIN

FOR SOLUTION;ORAL

SABRIL

AA	+	LUNDBECK PHARMS LLC	500MG/PACKET	N022006	001	Aug 21, 2009	Apr	CFTG
		+	500MG/PACKET	N022006	001	Aug 21, 2009	Jan	CAHN

VIGABATRIN

AA		PAR PHARM INC	500MG/PACKET	A208218	001	Apr 27, 2017	Apr	NEWA
----	--	---------------	--------------	---------	-----	--------------	-----	------

TABLET;ORAL

SABRIL

		+! LUNDBECK PHARMS LLC	500MG	N020427	001	Aug 21, 2009	Jan	CAHN
--	--	------------------------	-------	---------	-----	--------------	-----	------

VINORELBINE TARTRATE

INJECTABLE;INJECTION

VINORELBINE TARTRATE

AP		WEST-WARD PHARMS INT	EQ 10MG BASE/ML	A075992	001	Jun 10, 2003	Mar	CAHN
AP			EQ 10MG BASE/ML	A076461	001	Dec 11, 2003	Jan	CAHN

VORICONAZOLE

POWDER;IV (INFUSION)

VORICONAZOLE

XELLIA PHARMS APS 200MG/VIAL

N208562 001 Mar 09, 2017 Mar NEWA

VORTIOXETINE HYDROBROMIDE

TABLET;ORAL

TRINTELLIX

+ @ TAKEDA PHARMS USA EQ 15MG BASE

N204447 003 Sep 30, 2013 Mar DISC

WARFARIN SODIUM

TABLET;ORAL

JANTOVEN

AB		USL PHARMA	1MG	A040416	001	Oct 02, 2003	Jun	CAHN
AB			2MG	A040416	002	Oct 02, 2003	Jun	CAHN
AB			2.5MG	A040416	003	Oct 02, 2003	Jun	CAHN
AB			3MG	A040416	004	Oct 02, 2003	Jun	CAHN
AB			4MG	A040416	005	Oct 02, 2003	Jun	CAHN
AB			5MG	A040416	006	Oct 02, 2003	Jun	CAHN
AB			6MG	A040416	007	Oct 02, 2003	Jun	CAHN
AB			7.5MG	A040416	008	Oct 02, 2003	Jun	CAHN

## TABLET;ORAL

AB	JANTOVEN	10MG	A040416	009	Oct 02, 2003	Jun	CAHN
	WARFARIN SODIUM						
	@ MYLAN	1MG	A040415	001	Sep 27, 2004	Apr	DISC
	@	2MG	A040415	002	Sep 27, 2004	Apr	DISC
	@	2.5MG	A040415	003	Sep 29, 2004	Apr	DISC
	@	3MG	A040415	004	Sep 27, 2004	Apr	DISC
	@	4MG	A040415	005	Sep 27, 2004	Apr	DISC
	@	5MG	A040415	006	Sep 27, 2004	Apr	DISC
	@	6MG	A040415	007	Sep 27, 2004	Apr	DISC
	@	7.5MG	A040415	008	Sep 27, 2004	Apr	DISC
	@	10MG	A040415	009	Sep 27, 2004	Apr	DISC
AB	TARO PHARM	1MG	A040301	002	Jul 15, 1999	Mar	CAHN
AB		2MG	A040301	003	Jul 15, 1999	Mar	CAHN
AB		2.5MG	A040301	004	Jul 15, 1999	Mar	CAHN
AB		3MG	A040301	005	Jul 15, 1999	Mar	CAHN
AB		4MG	A040301	006	Jul 15, 1999	Mar	CAHN
AB		5MG	A040301	007	Jul 15, 1999	Mar	CAHN
AB		6MG	A040301	008	Jul 15, 1999	Mar	CAHN
AB		7.5MG	A040301	009	Jul 15, 1999	Mar	CAHN
AB		10MG	A040301	001	Jul 15, 1999	Mar	CAHN

ZALEPLON

## CAPSULE;ORAL

	ZALEPLON						
	@ MYLAN	5MG	A077238	001	Jun 06, 2008	Jul	DISC
	@	10MG	A077238	002	Jun 06, 2008	Jul	DISC
	@ UPSHER-SMITH LABS	5MG	A078095	001	Jun 06, 2008	Jun	CAHN
	@	10MG	A078095	002	Jun 06, 2008	Jun	CAHN

ZIDOVUDINE

## TABLET;ORAL

	ZIDOVUDINE						
	@ HEC PHARM USA INC	300MG	A202058	001	Oct 07, 2011	May	CAHN

ZILEUTON

## TABLET, EXTENDED RELEASE;ORAL

	ZILEUTON						
AB	PACK PHARMS LLC	600MG	A204929	001	Mar 17, 2017	Mar	NEWA
AB	RISING PHARMS INC	600MG	A204929	001	Mar 17, 2017	Mar	CAHN
	ZYFLO CR						
AB	+! CHIESI USA INC	600MG	N022052	001	May 30, 2007	Mar	CFTG

ZIPRASIDONE HYDROCHLORIDE

## CAPSULE;ORAL

	ZIPRASIDONE HYDROCHLORIDE						
AB	MACLEODS PHARMS LTD	EQ 20MG BASE	A204375	001	Feb 17, 2017	Feb	NEWA
AB		EQ 40MG BASE	A204375	002	Feb 17, 2017	Feb	NEWA
AB		EQ 60MG BASE	A204375	003	Feb 17, 2017	Feb	NEWA
AB		EQ 80MG BASE	A204375	004	Feb 17, 2017	Feb	NEWA
AB	ZYDUS PHARMS USA INC	EQ 20MG BASE	A208988	001	Aug 22, 2017	Aug	NEWA
AB		EQ 40MG BASE	A208988	002	Aug 22, 2017	Aug	NEWA
AB		EQ 60MG BASE	A208988	003	Aug 22, 2017	Aug	NEWA
AB		EQ 80MG BASE	A208988	004	Aug 22, 2017	Aug	NEWA

ZOLEDRONIC ACID

## INJECTABLE;IV (INFUSION)

	ZOLEDRONIC ACID						
>A>	AP BRECKENRIDGE PHARM	EQ 4MG BASE/5ML	A091170	001	Mar 04, 2013	Sep	CAHN
>A>	AP	EQ 4MG BASE/5ML	A202571	001	May 07, 2013	Sep	CAHN
>A>	AP	EQ 5MG BASE/100ML	A202163	001	Aug 05, 2013	Sep	CAHN
	AP MYLAN LABS LTD	EQ 5MG BASE/100ML	A203841	001	Feb 14, 2017	Jan	NEWA
>D>	AP PHARMACEUTICS	EQ 4MG BASE/5ML	A091170	001	Mar 04, 2013	Sep	CAHN
>D>	AP	EQ 5MG BASE/100ML	A202163	001	Aug 05, 2013	Sep	CAHN
>D>	AP PII	EQ 4MG BASE/5ML	A202571	001	May 07, 2013	Sep	CAHN
	AP	EQ 4MG BASE/5ML	A202571	001	May 07, 2013	May	CAHN



ZOLMITRIPTAN

## TABLET;ORAL

## ZOLMITRIPTAN

AB	APPCO PHARMA LLC	2.5MG	A206973	001	Jun 30, 2017	Jun	NEWA
AB		5MG	A206973	002	Jun 30, 2017	Jun	NEWA
AB	PLD ACQUISITIONS LLC	2.5MG	A207867	001	Feb 27, 2017	Feb	NEWA
AB		5MG	A207867	002	Feb 27, 2017	Feb	NEWA

ZOLPIDEM TARTRATE

## SPRAY, METERED;ORAL

## ZOLPIMIST

+!	MAGNA PHARMS	5MG/SPRAY	N022196	001	Dec 19, 2008	Aug	CAHN
----	--------------	-----------	---------	-----	--------------	-----	------

## TABLET;ORAL

## ZOLPIDEM TARTRATE

AB	ALLIED PHARMA INC	5MG	A077214	001	Apr 23, 2007	Mar	CAHN
AB		10MG	A077214	002	Apr 23, 2007	Mar	CAHN
	@ VIVIMED GLOBAL	5MG	A076062	001	Apr 23, 2007	Aug	CAHN
	@	10MG	A076062	002	Apr 23, 2007	Aug	CAHN

## TABLET;SUBLINGUAL

## EDLUAR

AB	+ MYLAN SPECIALITY LP	5MG	N021997	001	Mar 13, 2009	Mar	CAHN
AB	+!	10MG	N021997	002	Mar 13, 2009	Mar	CAHN

## ZOLPIDEM TARTRATE

AB	PAR PHARM INC	1.75MG	A204229	001	Sep 11, 2017	Aug	NEWA
AB		3.5MG	A204229	002	Sep 11, 2017	Aug	NEWA

## TABLET, EXTENDED RELEASE;ORAL

## ZOLPIDEM TARTRATE

AB	SUN PHARMA GLOBAL	6.25MG	A204170	001	Jan 24, 2017	Jan	NEWA
AB		12.5MG	A204170	002	Jan 24, 2017	Jan	NEWA
	@ SYNTHON PHARMS	6.25MG	A078483	001	Apr 12, 2011	Apr	DISC
	@	12.5MG	A078483	002	Jun 06, 2011	Apr	DISC

ZONISAMIDE

## CAPSULE;ORAL

## ZONISAMIDE

	@ EPIC PHARMA LLC	25MG	A077876	001	Feb 21, 2007	May	CAHN
	@	50MG	A077876	002	Feb 21, 2007	May	CAHN
	@	100MG	A077876	003	Feb 21, 2007	May	CAHN
	@ MYLAN PHARMS INC	25MG	A077647	001	Dec 22, 2005	Jun	DISC
	@	50MG	A077647	002	Dec 22, 2005	Jun	DISC
	@	100MG	A077647	003	Dec 22, 2005	Jun	DISC
	@ UPSHER-SMITH LABS	25MG	A077644	001	Dec 22, 2005	Jun	CAHN
	@	50MG	A077644	002	Dec 22, 2005	Jun	CAHN
	@	100MG	A077644	003	Dec 22, 2005	Jun	CAHN

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

	TABLET, CHEWABLE;ORAL						
>D>	FOAMCOAT						
>D>	GUARDIAN DRUG	80MG;20MG	A 071793	001	Sep 04, 1987	Sep	DISC
>A>	@	80MG;20MG	A 071793	001	Sep 04, 1987	Sep	DISC

AVOBENZONE; OCTINOXATE; OXYBENZONE

	LOTION;TOPICAL						
	SHADE UVAGUARD						
+	@ BAYER HEALTHCARE LLC	3%;7.5%;3%	N 020045	001	Dec 07, 1992	Jun	DISC

BUTOCONAZOLE NITRATE

	CREAM;VAGINAL						
	FEMSTAT 3						
+	@ BAYER	2%	N 020421	001	Dec 21, 1995	Aug	DISC

CETIRIZINE HYDROCHLORIDE

	CAPSULE;ORAL						
	CETIRIZINE HYDROCHLORIDE ALLERGY						
	STRIDES PHARMA	10MG	A 205291	001	Jul 21, 2017	Jul	NEWA
	SYRUP;ORAL						
	CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY						
	ALLIED PHARMA INC	5MG/5ML	A 091327	001	Oct 17, 2011	Apr	CAHN
	CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF						
	ALLIED PHARMA INC	5MG/5ML	A 091327	002	Oct 17, 2011	Apr	CAHN
	TABLET;ORAL						
	CETIRIZINE HYDROCHLORIDE ALLERGY						
	JUBILANT CADISTA	5MG	A 078933	001	Jun 15, 2010	Apr	CAHN
		10MG	A 078933	002	Jun 15, 2010	Apr	CAHN
	UNIQUE PHARM LABS	5MG	A 077829	001	Aug 26, 2009	Aug	CAHN
		10MG	A 077829	004	Aug 26, 2009	Aug	CAHN
	CETIRIZINE HYDROCHLORIDE HIVES						
	JUBILANT CADISTA	5MG	A 078933	003	Jun 15, 2010	Apr	CAHN
		10MG	A 078933	004	Jun 15, 2010	Apr	CAHN
	UNIQUE PHARM LABS	5MG	A 077829	003	Aug 26, 2009	Aug	CAHN
		10MG	A 077829	002	Aug 26, 2009	Aug	CAHN
	TABLET, ORALLY DISINTEGRATING;ORAL						
	CETIRIZINE HYDROCHLORIDE ALLERGY						
	PERRIGO R AND D	10MG	A 205490	001	Sep 02, 2015	Aug	CAHN

CHLORPHENIRAMINE MALEATE; IBUPROFEN; PHENYLEPHRINE HYDROCHLORIDE

	TABLET;ORAL						
	ADVIL MULTI-SYMPTOM COLD & FLU						
+	! PFIZER	4MG;200MG;10MG	N 022113	002	Apr 28, 2017	Apr	NEWA

CIMETIDINE

	TABLET;ORAL						
	CIMETIDINE						
	L PERRIGO CO	200MG	A 075285	001	Oct 29, 1998	Apr	CAHN
	@ SANDOZ INC	100MG	A 075122	001	Jun 19, 1998	Mar	CAHN
	@	200MG	A 075122	002	Jun 19, 1998	Mar	CAHN
	@ WATSON LABS TEVA	200MG	A 075425	001	Jul 29, 1999	May	CAHN

CLEMASTINE FUMARATE

	TABLET;ORAL						
	CLEMASTINE FUMARATE						
	L PERRIGO CO	1.34MG	A 074512	001	Nov 22, 1995	Apr	CAHN
	TAVIST-1						
+	! GLAXOSMITHKLINE CONS	1.34MG	N 020925	001	Aug 21, 1992	Apr	CAHN

CLOTRIMAZOLE

	CREAM;VAGINAL						
	CLOTRIMAZOLE						
!	ACTAVIS MID ATLANTIC	1%	A 074165	001	Jul 16, 1993	Jun	CHRS
	TARO	1%	A 072641	001	Dec 04, 1995	Apr	CAHN
	GYNE-LOTRIMIN						
+	@ BAYER HEALTHCARE LLC	1%	N 018052	002	Nov 30, 1990	Jun	DISC
	GYNE-LOTRIMIN 3						
+	@ BAYER HEALTHCARE LLC	2%	N 020574	001	Nov 24, 1998	Jun	DISC

CREAM, TABLET;TOPICAL, VAGINAL							
GYNE-LOTRIMIN 3 COMBINATION PACK							
+ @ BAYER HEALTHCARE LLC	1%,200MG	N020526	002	Jul 29, 1996	Jun	DISC	
GYNE-LOTRIMIN COMBINATION PACK							
+ @ BAYER HEALTHCARE LLC	1%,100MG	N020289	002	Apr 26, 1993	Jun	DISC	
TABLET;VAGINAL							
GYNE-LOTRIMIN							
+ @ BAYER HEALTHCARE LLC	100MG	N017717	002	Nov 30, 1990	Jun	DISC	
GYNE-LOTRIMIN 3							
+ @ BAYER HEALTHCARE LLC	200MG	N020525	001	Jul 29, 1996	Jun	DISC	
<u>DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN</u>							
TABLET, EXTENDED RELEASE;ORAL							
GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE							
ACTAVIS LABS FL	30MG;600MG	A091070	001	Aug 31, 2015	Mar	CAHN	
	60MG;1.2GM	A091070	002	Aug 31, 2015	Mar	CAHN	
AUROBINDO PHARMA LTD	30MG;600MG	A206941	001	Mar 17, 2017	Mar	NEWA	
	60MG;1.2GM	A206941	002	Mar 17, 2017	Mar	NEWA	
<u>DEXTROMETHORPHAN POLISTIREX</u>							
SUSPENSION, EXTENDED RELEASE;ORAL							
DEXTROMETHORPHAN POLISTIREX							
AMNEAL PHARMS LLC	EQ 30MG HBR/5ML	A203133	001	Jul 28, 2017	Jul	NEWA	
<u>ESOMEPRAZOLE MAGNESIUM</u>							
CAPSULE, DELAYED RELEASE;ORAL							
ESOMEPRAZOLE MAGNESIUM							
PERRIGO R AND D	EQ 20MG BASE	A207193	001	Aug 18, 2017	Aug	NEWA	
<u>FAMOTIDINE</u>							
TABLET;ORAL							
FAMOTIDINE							
PERRIGO R AND D	20MG	A077351	001	Sep 25, 2006	Apr	CAHN	
<u>FLUTICASONE FUROATE</u>							
SPRAY, METERED;NASAL							
FLONASE SENSIMIST ALLERGY RELIEF							
+! GLAXOSMITHKLINE CONS	0.0275MG/SPRAY	N022051	002	Aug 02, 2016	Jun	CAHN	
<u>GUAIFENESIN</u>							
TABLET, EXTENDED RELEASE;ORAL							
GUAIFENESIN							
ACTAVIS LABS FL	1.2GM	A091009	002	Sep 03, 2015	Mar	CAHN	
GUARDIAN PHARMS	600MG	A209215	001	Sep 06, 2017	Aug	NEWA	
	1.2GM	A209215	002	Sep 06, 2017	Aug	NEWA	
<u>GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE</u>							
TABLET, EXTENDED RELEASE;ORAL							
GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE							
ACTAVIS LABS FL	600MG;60MG	A091071	001	May 27, 2015	Mar	CAHN	
	1.2GM;120MG	A091071	002	May 27, 2015	Mar	CAHN	
<u>IBUPROFEN</u>							
CAPSULE;ORAL							
IBUPROFEN							
AMNEAL PHARMS	EQ 200MG FREE ACID AND POTASSIUM SALT	A202300	001	Dec 23, 2011	May	CAHN	
SUSPENSION;ORAL							
IBUPROFEN							
TARO	100MG/5ML	A209207	001	Jun 27, 2017	Jun	NEWA	
SUSPENSION/DROPS;ORAL							
IBUPROFEN							
L PERRIGO CO	40MG/ML	A075217	001	Dec 16, 1998	Apr	CAHN	
TABLET;ORAL							
IBUPROFEN							
AIPING PHARM INC	200MG	A207095	001	May 05, 2017	Apr	NEWA	
AMNEAL PHARMS	200MG	A079233	001	Mar 18, 2014	Apr	CAHN	
STRIDES PHARMA	200MG	A207052	001	May 30, 2017	Jun	CMS2	
	200MG	A207052	001	May 30, 2017	May	NEWA	
JUNIOR STRENGTH IBUPROFEN							
L PERRIGO CO	100MG	A075367	001	Apr 22, 1999	Apr	CAHN	

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL							
LANSOPRAZOLE							
>A>	KREMERS URBAN PHARMS	15MG	A207157	001	Sep 29, 2017	Sep	NEWA

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION;ORAL

XYZAL ALLERGY 24HR

+	SANOFI-AVENTIS US	2.5MG/5ML (0.5MG/ML)	N209090	001	Jan 31, 2017	Feb	CAHN
+	UCB INC	2.5MG/5ML (0.5MG/ML)	N209090	001	Jan 31, 2017	Jan	NEWA

TABLET;ORAL

XYZAL ALLERGY 24HR

+	SANOFI-AVENTIS US	5MG	N209089	001	Jan 31, 2017	Feb	CAHN
+	UCB INC	5MG	N209089	001	Jan 31, 2017	Jan	NEWA

LEVONORGESTREL

TABLET;ORAL

LEVONORGESTREL

	RECKITT BENCKISER	1.5MG	A202246	001	Jun 05, 2015	Apr	CAHN
--	-------------------	-------	---------	-----	--------------	-----	------

LOPERAMIDE HYDROCHLORIDE

SOLUTION;ORAL

LOPERAMIDE HYDROCHLORIDE

	ALLIED PHARMA INC	1MG/5ML	A073079	001	Apr 30, 1992	Mar	CAHN
--	-------------------	---------	---------	-----	--------------	-----	------

TABLET;ORAL

LOPERAMIDE HYDROCHLORIDE

	L PERRIGO CO	2MG	A075232	001	Jan 06, 2000	Apr	CAHN
--	--------------	-----	---------	-----	--------------	-----	------

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET, CHEWABLE;ORAL

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

!	PERRIGO	2MG;125MG	A076029	001	Aug 30, 2002	Jan	CHRS
---	---------	-----------	---------	-----	--------------	-----	------

LORATADINE

SYRUP;ORAL

LORATADINE

	TARO PHARM	1MG/ML	A201865	001	Jul 31, 2015	Mar	CAHN
--	------------	--------	---------	-----	--------------	-----	------

MICONAZOLE NITRATE

CREAM;VAGINAL

MICONAZOLE NITRATE

	TARO	2%	A074444	001	Jan 13, 1997	Apr	CAHN
--	------	----	---------	-----	--------------	-----	------

CREAM, SUPPOSITORY;TOPICAL, VAGINAL

M-ZOLE 3 COMBINATION PACK

	ACTAVIS MID ATLANTIC	2%,200MG	A074926	001	Apr 16, 1999	Jun	CAHN
--	----------------------	----------	---------	-----	--------------	-----	------

SUPPOSITORY;VAGINAL

MICONAZOLE NITRATE

	ACTAVIS PHARMA	100MG	A073507	001	Nov 19, 1993	May	CAHN
--	----------------	-------	---------	-----	--------------	-----	------

MINOXIDIL

AEROSOL, FOAM;TOPICAL

MINOXIDIL (FOR MEN)

	WATSON LABS INC	5%	A208092	001	Feb 17, 2017	Feb	NEWA
--	-----------------	----	---------	-----	--------------	-----	------

MINOXIDIL (FOR WOMEN)

	WATSON LABS INC	5%	A208092	002	Jul 27, 2017	Jul	NEWA
--	-----------------	----	---------	-----	--------------	-----	------

SOLUTION;TOPICAL

MINOXIDIL (FOR MEN)

	L PERRIGO CO	2%	A075357	001	Jul 30, 1999	Apr	CAHN
--	--------------	----	---------	-----	--------------	-----	------

MINOXIDIL (FOR WOMEN)

	L PERRIGO CO	2%	A075357	002	Jul 30, 1999	Apr	CAHN
--	--------------	----	---------	-----	--------------	-----	------

NAPROXEN SODIUM

TABLET;ORAL

NAPROXEN SODIUM

	LNK INTL INC	EQ 200MG BASE	A204872	001	Jan 23, 2017	Jan	NEWA
--	--------------	---------------	---------	-----	--------------	-----	------

NICOTINE

FILM, EXTENDED RELEASE;TRANSDERMAL  
HABITROL

+	DR REDDYS LABS SA	7MG/24HR	N020076	004	Nov 12, 1999	Jun	CAHN
+		14MG/24HR	N020076	005	Nov 12, 1999	Jun	CAHN
+	!	21MG/24HR	N020076	006	Nov 12, 1999	Jun	CAHN

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL  
NICOTINE POLACRILEX

	L PERRIGO CO	EQ 2MG BASE	A076775	001	Sep 16, 2004	Apr	CAHN
		EQ 2MG BASE	A076776	001	Sep 16, 2004	Apr	CAHN
		EQ 2MG BASE	A076777	001	Sep 16, 2004	Apr	CAHN
		EQ 4MG BASE	A076778	001	Sep 16, 2004	Apr	CAHN
		EQ 4MG BASE	A076779	001	Sep 16, 2004	Apr	CAHN
		EQ 4MG BASE	A076789	001	Sep 16, 2004	Apr	CAHN

OMEPRAZOLE

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL  
OMEPRAZOLE

+	DEXCEL PHARMA	20MG	N209400	001	Jul 05, 2017	Jul	NEWA
---	---------------	------	---------	-----	--------------	-----	------

OXYMETAZOLINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC  
OCUCLEAR

@	BAYER HEALTHCARE LLC	0.025%	N018471	001	May 30, 1986	May	DISC
---	----------------------	--------	---------	-----	--------------	-----	------

PERMETHRIN

LOTION;TOPICAL  
PERMETHRIN

	ACTAVIS MID ATLANTIC	1%	A075014	001	Mar 28, 2000	May	CAHN
--	----------------------	----	---------	-----	--------------	-----	------

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL  
POLYETHYLENE GLYCOL 3350

>A>	AILEX PHARMS LLC	17GM/SCOOPFUL	A202071	001	Dec 28, 2012	Sep	CAHN
>D>	RARITAN PHARMS INC	17GM/SCOOPFUL	A202071	001	Dec 28, 2012	Sep	CAHN

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL  
PSEUDOEPHEDRINE HYDROCHLORIDE

	AUROBINDO PHARMA LTD	120MG	A209008	001	Jun 09, 2017	May	NEWA
	L PERRIGO CO	120MG	A075153	001	Feb 26, 1999	Apr	CAHN

RANITIDINE HYDROCHLORIDE

TABLET;ORAL  
RANITIDINE HYDROCHLORIDE

	STRIDES PHARMA	EQ 150MG BASE	A200536	001	Jun 28, 2011	Jan	CAHN
	ZANTAC 150						
+	SANOFI US	EQ 150MG BASE	N021698	001	Aug 31, 2004	Mar	CAHN
+		EQ 150MG BASE	N021698	002	Mar 13, 2007	Mar	CAHN
	ZANTAC 75						
	SANOFI US	EQ 75MG BASE	N020520	001	Dec 19, 1995	Mar	CAHN

TERBINAFINE HYDROCHLORIDE

CREAM;TOPICAL  
LAMISIL

+	GLAXOSMITHKLINE	1%	N020980	001	Mar 09, 1999	Jul	CAHN
---	-----------------	----	---------	-----	--------------	-----	------

TIOCONAZOLE

OINTMENT;VAGINAL  
VAGISTAT-1

+	COMBE	6.5%	N020676	001	Feb 11, 1997	Jul	CAHN
---	-------	------	---------	-----	--------------	-----	------

TRIAMCINOLONE ACETONIDE

SPRAY, METERED;NASAL  
TRIAMCINOLONE ACETONIDE

	PERRIGO ISRAEL	0.055MG/SPRAY	A078104	002	Nov 14, 2014	Jan	CAHN
--	----------------	---------------	---------	-----	--------------	-----	------

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT  
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

**CUMULATIVE SUPPLEMENT NUMBER 09 SEPTEMBER 2017**

NO SEPTEMBER 2017 APPROVALS

## ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY  
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO SEPTEMBER 2017 ADDITIONS



PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE - ABACAVIR SULFATE</u>						
A 201107 001					>A> PC	Mar 14, 2018
<u>ABALOPARATIDE - TYMLOS</u>						
N 208743 001	7803770	Mar 26, 2028	U-2009		NCE	Apr 28, 2022
	8148333	Nov 08, 2027	DP			
	8748382	Oct 03, 2027	U-2009			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 001					>A> NCE	Sep 28, 2022
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 002					>A> NCE	Sep 28, 2022
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 003					>A> NCE	Sep 28, 2022
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 004					>A> NCE	Sep 28, 2022
<u>ABIRATERONE ACETATE - ZYTIGA</u>						
N 202379 002	8822438	Aug 24, 2027	U-1579			
	8822438	Aug 24, 2027	U-1580			
<u>ACETAMINOPHEN - OFIRMEV</u>						
N 022450 001	9610265	Nov 13, 2028	U-2000		M-196 PED	Jan 27, 2020 Jul 27, 2020
<u>ACETYLCYSTEINE - CETYLEV</u>						
N 207916 001	9561204	May 08, 2032	U-1373			
<u>ACETYLCYSTEINE - CETYLEV</u>						
N 207916 002	9561204	May 08, 2032	U-1373			
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N 202450 001	RE46417	Sep 05, 2020	DS DP U-1263			
<u>ADAPALENE; BENZOYL PEROXIDE - ADAPALENE AND BENZOYL PEROXIDE</u>						
A 203790 001					PC	Jan 23, 2018
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO FORTE</u>						
N 207917 001	8445543	Dec 23, 2022	U-1078			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 001	9539258	Nov 09, 2026	U-1950			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 002	9539258	Nov 09, 2026	U-1950			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 003	9539258	Nov 09, 2026	U-1950			
<u>ALBUTEROL SULFATE - PROAIR RESPICLICK</u>						
N 205636 001	9731087	May 18, 2031	DP			
<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - COMBIVENT RESPIMAT</u>						
N 021747 001	8733341	Oct 16, 2030	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALISKIREN HEMIFUMARATE - TEKTURNA</u>						
N 021985 001	>A> 5559111	Jul 21, 2018	DS DP U-3			
	>A> 5559111*PED	Jan 21, 2019				
	>A> 8617595	Feb 19, 2026	DP			
	>A> 8617595*PED	Aug 19, 2026				
<u>ALISKIREN HEMIFUMARATE - TEKTURNA</u>						
N 021985 002	>A> 5559111	Jul 21, 2018	DS DP U-3			
	>A> 5559111*PED	Jan 21, 2019				
	>A> 8617595	Feb 19, 2026	DP			
	>A> 8617595*PED	Aug 19, 2026				
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT</u>						
N 022107 001	>A> 5559111	Jul 21, 2018	DS DP U-3			
	>A> 5559111*PED	Jan 21, 2019				
	>A> 9023893	Mar 03, 2022	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT</u>						
N 022107 002	>A> 5559111	Jul 21, 2018	DS DP U-3			
	>A> 5559111*PED	Jan 21, 2019				
	>A> 9023893	Mar 03, 2022	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT</u>						
N 022107 003	>A> 5559111	Jul 21, 2018	DS DP U-3			
	>A> 5559111*PED	Jan 21, 2019				
	>A> 9023893	Mar 03, 2022	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT</u>						
N 022107 004	>A> 5559111	Jul 21, 2018	DS DP U-3			
	>A> 5559111*PED	Jan 21, 2019				
	>A> 9023893	Mar 03, 2022	DP			
<u>ALLOPURINOL; LESINURAD - DUZALLO</u>						
N 209203 001	>A> 8003681	Aug 25, 2025	DS			
	>A> 8084483	Aug 17, 2029			U-2104	
	>A> 8283369	Nov 26, 2028			U-2104	
	>A> 8357713	Nov 26, 2028	DP		U-2104	
	>A> 8546436	Feb 29, 2032	DS			
	>A> 8546437	Apr 29, 2029			U-2104	
	>A> 9216179	Aug 01, 2031			U-2104	
<u>ALLOPURINOL; LESINURAD - DUZALLO</u>						
N 209203 002	>A> 8003681	Aug 25, 2025	DS			
	>A> 8084483	Aug 17, 2029			U-2104	
	>A> 8283369	Nov 26, 2028			U-2104	
	>A> 8357713	Nov 26, 2028	DP		U-2104	
	>A> 8546436	Feb 29, 2032	DS			
	>A> 8546437	Apr 29, 2029			U-2104	
	>A> 9216179	Aug 01, 2031			U-2104	
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 001	8173663	Dec 02, 2025			U-1338	
	8697125	Jun 16, 2029	DP			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 002	8173663	Dec 02, 2025			U-1338	
	8697125	Jun 16, 2029	DP			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 003	8173663	Dec 02, 2025			U-1338	
	8697125	Jun 16, 2029	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 001	8288539	Jun 24, 2025	DS			
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 002	8288539	Jun 24, 2025	DS			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 005	6329404	Jun 19, 2021	DP U-1334			
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 001	>A> 8389578	Jan 22, 2028	U-2105		NP	Aug 24, 2020
	>A> 8741343	Dec 02, 2030	U-2106			
	>A> 8796337	Nov 23, 2025	U-2106			
	>A> 8889740	Nov 23, 2025	DP			
	>A> 8895614	Nov 23, 2025	DP			
	>A> 8895615	Nov 23, 2025	U-2106			
	>A> 8895616	Nov 23, 2025	U-2106			
	>A> 8895617	Nov 23, 2025	U-2106			
	>A> 8895618	Nov 23, 2025	DP			
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 002	>A> 8389578	Jan 22, 2028	U-2105		NP	Aug 24, 2020
	>A> 8741343	Dec 02, 2030	U-2106			
	>A> 8796337	Nov 23, 2025	U-2106			
	>A> 8889740	Nov 23, 2025	DP			
	>A> 8895614	Nov 23, 2025	DP			
	>A> 8895615	Nov 23, 2025	U-2106			
	>A> 8895616	Nov 23, 2025	U-2106			
	>A> 8895617	Nov 23, 2025	U-2106			
	>A> 8895618	Nov 23, 2025	DP			
<u>AMBRISENTAN - LETAIRIS</u>						
N 022081 001	9549926	Oct 14, 2031	U-1965			
<u>AMBRISENTAN - LETAIRIS</u>						
N 022081 002	9549926	Oct 14, 2031	U-1965			
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - GLEOLAN</u>						
N 208630 001					ODE	Jun 06, 2024
<u>AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA</u>						
N 205003 001					NP	Jan 21, 2018
<u>AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA</u>						
N 205003 002					NP	Jan 21, 2018
<u>AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA</u>						
N 205003 003					NP	Jan 21, 2018
<u>AMPHETAMINE - ADZENYS ER</u>						
N 204325 001	>A> 8709491	Jun 28, 2032	DP			
	>A> 9017731	Jun 28, 2032	DP			
	>A> 9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - DYANAVEL XR</u>						
N 208147 001	9675703	Mar 15, 2027	DP			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS</u>						
N 022063 001	6913768	May 24, 2023	DP U-2025		NP	Jun 20, 2020
	8846100	Aug 24, 2029	DP			
	9173857	May 12, 2026	U-2025			
	RE41148	Oct 21, 2018	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS</u>						
N 022063 001	RE42096	Oct 21, 2018	DP			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS</u>						
N 022063 002	6913768	May 24, 2023	DP U-2025		NP	Jun 20, 2020
	8846100	Aug 24, 2029	DP			
	9173857	May 12, 2026	U-2025			
	RE41148	Oct 21, 2018	DP			
	RE42096	Oct 21, 2018	DP			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS</u>						
N 022063 003	6913768	May 24, 2023	DP U-2025		NP	Jun 20, 2020
	8846100	Aug 24, 2029	DP			
	9173857	May 12, 2026	U-2025			
	RE41148	Oct 21, 2018	DP			
	RE42096	Oct 21, 2018	DP			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS</u>						
N 022063 004	6913768	May 24, 2023	DP U-2025		NP	Jun 20, 2020
	8846100	Aug 24, 2029	DP			
	9173857	May 12, 2026	U-2025			
	RE41148	Oct 21, 2018	DP			
	RE42096	Oct 21, 2018	DP			
<u>APIXABAN - ELIQUIS</u>						
N 202155 001	>A> 6967208	Nov 21, 2026	DS DP U-1167			
	>A> 6967208	Nov 21, 2026	DS DP U-1200			
	>A> 6967208	Nov 21, 2026	DS DP U-1301			
	>A> 6967208	Nov 21, 2026	DS DP U-1302			
	>A> 6967208	Nov 21, 2026	DS DP U-1323			
	>A> 6967208	Nov 21, 2026	DS DP U-1501			
	>A> 6967208	Nov 21, 2026	DS DP U-1502			
	>A> 6967208	Nov 21, 2026	DS DP U-1729			
	>A> 6967208	Nov 21, 2026	DS DP U-1730			
<u>APIXABAN - ELIQUIS</u>						
N 202155 002	>A> 6967208	Nov 21, 2026	DS DP U-1200			
	>A> 6967208	Nov 21, 2026	DS DP U-1301			
	>A> 6967208	Nov 21, 2026	DS DP U-1302			
	>A> 6967208	Nov 21, 2026	DS DP U-1323			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 001					I-746	Jul 27, 2020
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 002					I-746	Jul 27, 2020
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 003					I-746	Jul 27, 2020
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 004					I-746	Jul 27, 2020
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 001	9526726	Mar 19, 2035	DP			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 002	9526726	Mar 19, 2035	DP			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 003	9526726	Mar 19, 2035	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 004	8431576	Oct 26, 2030	DS		NCE	Oct 05, 2020
	8796276	Jun 24, 2030		U-543		
	9034867	Nov 07, 2032		DP U-543		
	9193685	Oct 24, 2033		DP U-543		
	9452131	Mar 19, 2035		U-543		
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 001	5763476	Jun 09, 2020		DP U-326	D-166	Jan 13, 2020
	5763476	Jun 09, 2020		DP U-1960	I-597	Jan 13, 2020
	5763476	Jun 09, 2020		DP U-1961		
	5763476	Jun 09, 2020		DP U-1962		
	5763476	Jun 09, 2020		DP U-1963		
	5763476*PED	Dec 09, 2020				
	7741358	Apr 06, 2026	DS DP	U-1064		
	7741358	Apr 06, 2026	DS DP	U-1960		
	7741358	Apr 06, 2026	DS DP	U-1961		
	7741358	Apr 06, 2026	DS DP	U-1962		
	7741358	Apr 06, 2026	DS DP	U-1963		
	7741358*PED	Oct 06, 2026				
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 002	5763476	Jun 09, 2020		DP U-326	D-166	Jan 13, 2020
	5763476	Jun 09, 2020		DP U-1960	I-597	Jan 13, 2020
	5763476	Jun 09, 2020		DP U-1961		
	5763476	Jun 09, 2020		DP U-1962		
	5763476	Jun 09, 2020		DP U-1963		
	5763476*PED	Dec 09, 2020				
	7741358	Apr 06, 2026	DS DP	U-1064		
	7741358	Apr 06, 2026	DS DP	U-1960		
	7741358	Apr 06, 2026	DS DP	U-1961		
	7741358	Apr 06, 2026	DS DP	U-1962		
	7741358	Apr 06, 2026	DS DP	U-1963		
	7741358*PED	Oct 06, 2026				
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 003	5763476	Jun 09, 2020		DP U-1893	D-166	Jan 13, 2020
	5763476	Jun 09, 2020		DP U-1966	I-597	Jan 13, 2020
	5763476*PED	Dec 09, 2020				
	7741358	Apr 06, 2026	DS DP	U-1893		
	7741358	Apr 06, 2026	DS DP	U-1966		
	7741358*PED	Oct 06, 2026				
<u>ASPIRIN; OMEPRAZOLE - YOSPRALA</u>						
N 205103 001	9539214	Mar 13, 2033		U-1902		
<u>ASPIRIN; OMEPRAZOLE - YOSPRALA</u>						
N 205103 002	9539214	Mar 13, 2033		U-1902		
<u>ATAZANAVIR SULFATE; COBICISTAT - EVOTAZ</u>						
N 206353 001					NCE	Aug 27, 2017
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
N 020702 001					M-204	Jun 23, 2020
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
N 020702 002					M-204	Jun 23, 2020
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494 001	9284314	Jun 15, 2032	DS			
	9695122	Jun 15, 2032	DS			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AXITINIB - INLYTA</u>						
N 202324 001	8791140	Dec 14, 2030	DS			
<u>AXITINIB - INLYTA</u>						
N 202324 002	8791140	Dec 14, 2030	DS			
<u>AZITHROMYCIN - AZITHROMYCIN</u>						
A 065488 001					>A> PC	Mar 26, 2018
<u>AZITHROMYCIN - AZITHROMYCIN</u>						
A 065488 002					>A> PC	Mar 26, 2018
<u>BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED - DUAVEE</u>						
N 022247 001	5998402	Apr 04, 2018	DS DP U-594		NCE	Oct 13, 2018
<u>BECLOMETHASONE DIPROPIONATE - OVAR REDIHALER</u>						
N 207921 001	6446627	Dec 18, 2017	DP			
	7637260	Aug 25, 2020	DP			
	8132712	Sep 07, 2028	DP			
	8931476	Jul 17, 2031	DP			
<u>BECLOMETHASONE DIPROPIONATE - OVAR REDIHALER</u>						
N 207921 002	6446627	Dec 18, 2017	DP			
	7637260	Aug 25, 2020	DP			
	8132712	Sep 07, 2028	DP			
	8931476	Jul 17, 2031	DP			
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384 001	7498343	Dec 01, 2026	DS DP U-1321			
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 001	9533955	Mar 26, 2029	DP U-1949			
	9533955	Mar 26, 2029	DP U-1952			
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 002	9533955	Mar 26, 2029	DP U-1949			
	9533955	Mar 26, 2029	DP U-1952			
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194 001	9572796	Jan 28, 2031	DP U-1971			
	9572796	Jan 28, 2031	DP U-1972			
	9572797	Jan 28, 2031	U-1971			
	9572797	Jan 28, 2031	U-1972			
	9572887	Mar 15, 2033	U-1971			
	9572887	Mar 15, 2033	U-1972			
	9579384	Mar 15, 2033	U-1971			
	9579384	Mar 15, 2033	U-1972			
	9597397	Mar 15, 2033	U-1971			
	9597397	Mar 15, 2033	U-1972			
	9597398	Mar 15, 2033	U-1971			
	9597399	Mar 15, 2033	U-1971			
	9597399	Mar 15, 2033	U-1972			
<u>BENZNIDAZOLE - BENZNIDAZOLE</u>						
N 209570 001					NCE	Aug 29, 2022
<u>BENZNIDAZOLE - BENZNIDAZOLE</u>						
N 209570 002					NCE	Aug 29, 2022
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ONEXTON</u>						
N 050819 002	9561208	Jun 03, 2029	DP U-916			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BETAMETHASONE DIPROPIONATE - SERNIVO</u>						
N 208079 001	9655907	Aug 31, 2030	DP U-1858			
<u>BETRIXABAN - BEVYXXA</u>						
N 208383 001	6376515	Sep 15, 2020	DS DP U-1167		NCE	Jun 23, 2022
	6376515	Sep 15, 2020	DS DP U-1502			
	6376515	Sep 15, 2020	DS DP U-2029			
	6376515	Sep 15, 2020	DS DP U-2030			
	6835739	Sep 15, 2020	DS DP			
	7598276	Nov 08, 2026	DS			
	8404724	Mar 29, 2031	DP U-2034			
	8518977	Sep 15, 2020	DS			
	8557852	Sep 08, 2028	U-1167			
	8557852	Sep 08, 2028	U-2030			
	8691847	Sep 15, 2020	DS DP U-2029			
	8691847	Sep 15, 2020	DS DP U-2035			
	8987463	Dec 28, 2030	DP			
	9555023	Nov 07, 2026	U-1502			
	9629831	Sep 15, 2020	U-1167			
	9629831	Sep 15, 2020	U-1502			
	9629831	Sep 15, 2020	U-2030			
	9629831	Sep 15, 2020	U-2035			
<u>BETRIXABAN - BEVYXXA</u>						
N 208383 002	6376515	Sep 15, 2020	DS DP U-1167		NCE	Jun 23, 2022
	6376515	Sep 15, 2020	DS DP U-1502			
	6376515	Sep 15, 2020	DS DP U-2029			
	6376515	Sep 15, 2020	DS DP U-2030			
	6835739	Sep 15, 2020	DS DP			
	7598276	Nov 08, 2026	DS			
	8404724	Mar 29, 2031	DP U-2034			
	8518977	Sep 15, 2020	DS			
	8557852	Sep 08, 2028	U-1167			
	8557852	Sep 08, 2028	U-2030			
	8691847	Sep 15, 2020	DS DP U-2029			
	8691847	Sep 15, 2020	DS DP U-2035			
	8987463	Dec 28, 2030	DP			
	9555023	Nov 07, 2026	U-1502			
	9629831	Sep 15, 2020	U-1167			
	9629831	Sep 15, 2020	U-1502			
	9629831	Sep 15, 2020	U-2030			
	9629831	Sep 15, 2020	U-2035			
<u>BIMATOPROST - LATISSE</u>						
N 022369 001	9579270	Jan 31, 2021	U-1975			
<u>BOSENTAN - TRACLEER</u>						
N 209279 001	>A> 7959945	Dec 28, 2027	DP			
	>A> 8309126	May 15, 2026	DP			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 001	9012462	Feb 06, 2031	DS		NCE	Apr 28, 2022
	9273077	May 21, 2029	U-1927		ODE	Apr 28, 2024
	9611283	Apr 10, 2034	U-1927			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 002	9012462	Feb 06, 2031	DS		NCE	Apr 28, 2022
	9273077	May 21, 2029	U-1927		ODE	Apr 28, 2024
	9611283	Apr 10, 2034	U-1927			
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N 021770 001	9687443	Jul 10, 2021	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BRIVARACETAM - BRIVIACT</u>						
N 205837 001	>A> 6784197	Feb 21, 2021	DS DP U-1815			
	>A> 6784197	Feb 21, 2021	DS DP U-2130			
	>A> 6911461	Feb 21, 2021	DS DP U-1815			
	>A> 6911461	Feb 21, 2021	DS DP U-2130			
	>A> 8492416	Feb 21, 2021	U-1815			
	>A> 8492416	Feb 21, 2021	U-2130			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205838 001	>A> 6784197	Feb 21, 2021	DS DP U-1815			
	>A> 6784197	Feb 21, 2021	DS DP U-2130			
	>A> 6911461	Feb 21, 2021	DS DP U-1815			
	>A> 6911461	Feb 21, 2021	DS DP U-2130			
	>A> 8492416	Feb 21, 2021	U-1815			
	>A> 8492416	Feb 21, 2021	U-2130			
<u>BROMFENAC SODIUM - PROLENSA</u>						
N 203168 001	9517220	Nov 11, 2033	U-1933			
	9561277	Jan 16, 2024	U-1933			
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	>A> 9352025	Jun 07, 2030	U-2111			
	>A> 9352025	Jun 07, 2030	U-2112			
	>A> 9352025	Jun 07, 2030	U-2113			
	>A> 9352025	Jun 07, 2030	U-2114			
	>A> 9352025	Jun 07, 2030	U-2115			
	>A> 9352025	Jun 07, 2030	U-2116			
	>A> 9352025	Jun 07, 2030	U-2117			
	>A> 9352025	Jun 07, 2030	U-2118			
	>A> 9352025	Jun 07, 2030	U-2119			
	9522117	Apr 30, 2032	DP U-976			
	9522117	Apr 30, 2032	DP U-1939			
<u>BUDESONIDE - UCERIS</u>						
N 203634 001	9532954	Jun 09, 2020	DP U-1325			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 001	6123924	Sep 26, 2017	DP		>A> M-210	Sep 11, 2020
	7367333	Nov 11, 2018	DP		NPP	Jan 27, 2020
	7367333*PED	May 11, 2019			PED	Jul 27, 2020
	7587988	Apr 10, 2026	DP			
	7587988*PED	Oct 10, 2026				
	>A> 7759328	Jan 29, 2023	DP U-2001			
	>A> 7759328	Jan 29, 2023	DP U-2002			
	>A> 7759328	Jan 29, 2023	DP U-2122			
	>A> 7759328*PED	Jul 29, 2023				
	7967011	Aug 11, 2021	DP			
	7967011*PED	Feb 11, 2022				
	>A> 8143239	Jan 29, 2023	DP U-2001			
	>A> 8143239	Jan 29, 2023	DP U-2002			
	>A> 8143239	Jan 29, 2023	DP U-2122			
	>A> 8143239*PED	Jul 29, 2023				
	8387615	Nov 10, 2024	DP			
	8387615*PED	May 10, 2025				
	8528545	Oct 16, 2028	DP			
	8528545*PED	Apr 16, 2029				
	>A> 8575137	Jan 29, 2023	DP U-2001			
	>A> 8575137	Jan 29, 2023	DP U-2002			
	>A> 8575137	Jan 29, 2023	DP U-2122			
	>A> 8575137*PED	Jul 29, 2023				
	8616196	Apr 07, 2029	DP			
	8616196*PED	Oct 07, 2029				
	8875699	Nov 10, 2024	DP			
	8875699*PED	May 10, 2025				



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 002	6123924	Sep 26, 2017	DP		>A> M-210	Sep 11, 2020
	7367333	Nov 11, 2018	DP			
	7367333*PED	May 11, 2019				
	7587988	Apr 10, 2026	DP			
	7587988*PED	Oct 10, 2026				
>A>	7759328	Jan 29, 2023	DP U-2001			
>A>	7759328	Jan 29, 2023	DP U-2002			
>A>	7759328	Jan 29, 2023	DP U-2122			
>A>	7759328*PED	Jul 29, 2023				
>A>	7897646	Sep 09, 2018	U-2002			
>A>	7897646	Sep 09, 2018	U-2122			
>A>	7897646*PED	Mar 09, 2019				
	7967011	Aug 11, 2021	DP			
	7967011*PED	Feb 11, 2022				
>A>	8143239	Jan 29, 2023	DP U-2001			
>A>	8143239	Jan 29, 2023	DP U-2002			
>A>	8143239	Jan 29, 2023	DP U-2122			
>A>	8143239*PED	Jul 29, 2023				
	8387615	Nov 10, 2024	DP			
	8387615*PED	May 10, 2025				
>A>	8461211	Sep 09, 2018	U-2002			
>A>	8461211	Sep 09, 2018	U-2122			
>A>	8461211*PED	Mar 09, 2019				
	8528545	Oct 16, 2028	DP			
	8528545*PED	Apr 16, 2029				
>A>	8575137	Jan 29, 2023	DP U-2001			
>A>	8575137	Jan 29, 2023	DP U-2002			
>A>	8575137	Jan 29, 2023	DP U-2122			
>A>	8575137*PED	Jul 29, 2023				
	8616196	Apr 07, 2029	DP			
	8616196*PED	Oct 07, 2029				
	8875699	Nov 10, 2024	DP			
	8875699*PED	May 10, 2025				
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 001	9585838	Dec 24, 2021	DP			
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 002	9585838	Dec 24, 2021	DP			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 001	9642850	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 002	9642850	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 003	9642850	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 004	9642850	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 005	9642850	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 001	9655843	Jul 23, 2027	DP U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 002	9655843	Jul 23, 2027	DP U-1556			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 003	9655843	Jul 23, 2027	DP U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 004	9655843	Jul 23, 2027	DP U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 005	9655843	Jul 23, 2027	DP U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 006	9655843	Jul 23, 2027	DP U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 007	9655843	Jul 23, 2027	DP U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 001	9687454	Aug 07, 2029	DP U-1464			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 002	9687454	Aug 07, 2029	DP U-1464			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 003	9687454	Aug 07, 2029	DP U-1464			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 004	9687454	Aug 07, 2029	DP U-1464			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637 001	9655843	Jul 23, 2027	DP U-2017			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637 002	9655843	Jul 23, 2027	DP U-2017			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637 003	9655843	Jul 23, 2027	DP U-2017			
<u>CABAZITAXEL - JEVTANA KIT</u>						
N 201023 001	5847170	Mar 26, 2021	DS DP		M-201	May 17, 2020
	5847170*PED	Sep 26, 2021			>A> M-209	Sep 14, 2020
	7241907	Dec 10, 2025	DS		PED	Nov 17, 2020
	7241907*PED	Jun 10, 2026				
	8927592	Oct 27, 2030	U-1630			
	8927592*PED	Apr 27, 2031				
<u>CABOZANTINIB S-MALATE - COMETRIO</u>						
N 203756 001	9717720	Feb 10, 2032	DP			
<u>CABOZANTINIB S-MALATE - COMETRIO</u>						
N 203756 002	9717720	Feb 10, 2032	DP			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 001	9724342	Jul 09, 2033	DP			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 002	9724342	Jul 09, 2033	DP			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 003	9724342	Jul 09, 2033	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042	001				M-197	Feb 01, 2020
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042	002				M-197	Feb 01, 2020
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353	001				M-197	Feb 01, 2020
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353	002				M-197	Feb 01, 2020
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353	003				M-197	Feb 01, 2020
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353	004				M-197	Feb 01, 2020
<u>CANGRELOR - KENGREAL</u>						
N 204958	001	9700575	Jul 10, 2035	DP		
<u>CARBAMAZEPINE - CARNEXIV</u>						
N 206030	001	9493582	Feb 27, 2033	DP		
		9629797	Nov 10, 2028	U-2004		
		9629797	Nov 10, 2028	U-2005		
		9629797	Nov 10, 2028	U-2006		
	>A>	9770407	Nov 10, 2028	DP		
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312	001	9533046	Dec 26, 2028	DP U-219		
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312	002	9533046	Dec 26, 2028	DP U-219		
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312	003	9533046	Dec 26, 2028	DP U-219		
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312	004	9533046	Dec 26, 2028	DP U-219		
<u>CARBINOXAMINE MALEATE - KARBINAL ER</u>						
N 022556	001	9522191	Jun 15, 2027	DP		
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714	001	9493582	Feb 27, 2033	DP		
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714	002	9493582	Feb 27, 2033	DP		
<u>CASPOFUNGIN ACETATE - CASPOFUNGIN ACETATE</u>						
N 206110	001	9636407	Dec 21, 2032	DP		
<u>CASPOFUNGIN ACETATE - CASPOFUNGIN ACETATE</u>						
N 206110	002	9636407	Dec 21, 2032	DP		
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327	001	9629861	Sep 21, 2030	DP		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 002	9629861	Sep 21, 2030	DP			
<u>CERTINIB - ZYKADIA</u>						
N 205755 001	8188276	Jan 31, 2023	DS DP		M-199	May 26, 2020
	8399450	Nov 20, 2027	DS DP		ODE	May 26, 2024
	8835430	Jan 31, 2023	DS DP			
	9018204	Jan 31, 2023	DS DP			
	9416112	Jan 31, 2023	DS DP			
<u>CETIRIZINE HYDROCHLORIDE - ZERVIAE</u>						
N 208694 001	8829005	Mar 15, 2030		U-1680	NDF	May 30, 2020
	8829005*PED	Sep 15, 2030			PED	Nov 30, 2020
	9254286	Jul 09, 2032	DP			
	9254286*PED	Jan 09, 2033				
	>A> 9750684	Mar 15, 2030	DP			
<u>CHLOROPROCAINE HYDROCHLORIDE - CLOROTEKAL</u>						
N 208791 001					>A> NP	Sep 26, 2020
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688 001					M-200	May 23, 2020
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688 002					M-200	May 23, 2020
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688 003					M-200	May 23, 2020
<u>CLOFARABINE - CLOFARABINE</u>						
A 204029 001					PC	Nov 05, 2017
<u>COBICISTAT - TYBOST</u>						
N 203094 001					NCE	Aug 27, 2017
<u>COBICISTAT; DARUNAVIR ETHANOLATE - PREZCOBIX</u>						
N 205395 001					NCE	Aug 27, 2017
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA</u>						
N 207561 001	7176220	Aug 27, 2026	DS DP U-257		NCE	Aug 27, 2017
					>A> NPP	Sep 25, 2020
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100 001	7176220	Aug 27, 2026	DS DP U-257		NCE	Aug 27, 2017
	>A> 9744181	Jan 13, 2024	DP U-257		NPP	Jan 27, 2020
<u>COLCHICINE - MITIGARE</u>						
N 204820 001	9555029	Aug 22, 2033		U-1020		
	9675613	Aug 22, 2033		U-1020		
<u>COPANLISIB DIHYDROCHLORIDE - ALIQOOPA</u>						
N 209936 001	>A> 7511041	May 13, 2024	DS DP		>A> NCE	Sep 14, 2022
	>A> 8466283	Oct 22, 2029	DS DP U-2124			
	>A> 9636344	Mar 29, 2032		U-2124		
<u>CRISABOROLE - EUCRISA</u>						
N 207695 001	8039451	Jun 11, 2026	DS DP		NCE	Dec 14, 2021
	8168614	Jan 20, 2030		U-1932		
	8501712	Feb 16, 2027		U-1932		
	9682092	Feb 16, 2027		U-1932		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CROFELEMER - FULYZAQ</u>						
N 202292 001	9585868	Oct 31, 2031	DS U-1319			
<u>CYCLOSPORINE - RESTASIS MULTIDOSE</u>						
N 050790 002	8292129	Feb 25, 2031	DP			
	8561859	Apr 16, 2032	DP			
	9669974	May 11, 2034	DP			
	9676525	Feb 07, 2034	DP			
<u>CYTARABINE; DAUNORUBICIN - VYXEOS</u>						
N 209401 001	7850990	Jan 23, 2027	DP U-2090		NP	Aug 03, 2020
	8022279	Sep 14, 2027	DP U-2090			
	8092828	Apr 01, 2029	U-2090			
	8431806	Apr 22, 2025	DP U-2090			
	8518437	Jun 07, 2026	DP			
	9271931	Jan 23, 2027	DP			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001	7994185	Jan 20, 2030	DS DP U-1406		I-745	Jun 22, 2020
	7994185	Jan 20, 2030	DS DP U-2031		ODE	Jun 22, 2024
	7994185	Jan 20, 2030	DS DP U-2032			
	8415345	Jan 20, 2030	DS DP U-1406			
	8415345	Jan 20, 2030	DS DP U-2031			
	8415345	Jan 20, 2030	DS DP U-2032			
	8835443	Sep 13, 2025	U-2026			
	8835443	Sep 13, 2025	U-2027			
	8952018	Oct 15, 2030	U-2027			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002	7994185	Jan 20, 2030	DS DP U-1406		I-745	Jun 22, 2020
	7994185	Jan 20, 2030	DS DP U-2031		ODE	Jun 22, 2024
	7994185	Jan 20, 2030	DS DP U-2032			
	8415345	Jan 20, 2030	DS DP U-1406			
	8415345	Jan 20, 2030	DS DP U-2031			
	8415345	Jan 20, 2030	DS DP U-2032			
	8835443	Sep 13, 2025	U-2026			
	8835443	Sep 13, 2025	U-2027			
	8952018	Oct 15, 2030	U-2027			
<u>DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 001	9616028	Nov 12, 2030	DP			
<u>DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 002	9616028	Nov 12, 2030	DP			
<u>DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 003	9616028	Nov 12, 2030	DP			
<u>DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 004	9616028	Nov 12, 2030	DP			
<u>DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 005	6414126	Oct 04, 2020	DS DP U-493		NCE	Jan 08, 2019
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	9198925	Oct 04, 2020	U-493			
	9616028	Nov 12, 2030	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN PROPANEDIOL; SAXAGLIPTIN HYDROCHLORIDE - QTERN</u>						
N 209091 001	6414126	Oct 04, 2020	DS DP U-1976		M-175	Apr 05, 2019
	6414126	Oct 04, 2020	DS DP U-1977		NC	Feb 27, 2020
	6515117	Oct 04, 2020	DS DP U-1976		NCE	Jan 08, 2019
	6515117	Oct 04, 2020	DS DP U-1977			
	6936590	Oct 04, 2020	U-1976			
	6936590	Oct 04, 2020	U-1977			
	7919598	Dec 16, 2029	DS			
	8221786	Mar 21, 2028	DP			
	8361972	Mar 21, 2028	U-1976			
	8361972	Mar 21, 2028	U-1977			
	8501698	Jun 20, 2027	DP U-1976			
	8501698	Jun 20, 2027	DP U-1977			
	8628799	Jul 13, 2025	DP			
	8716251	Mar 21, 2028	DP			
	9198925	Oct 04, 2020	U-1976			
	9198925	Oct 04, 2020	U-1977			
	RE44186	Jul 31, 2023	DS DP U-1976			
	RE44186	Jul 31, 2023	DS DP U-1977			
<u>DAPTOMYCIN - CUBICIN</u>						
N 021572 002					>A> M-211 NPP	Sep 01, 2020 Mar 29, 2020
<u>DAPTOMYCIN - CUBICIN RF</u>						
N 021572 003					>A> M-211 NPP	Sep 01, 2020 Mar 29, 2020
<u>DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA PAK (COPACKAGED)</u>						
N 206619 001	9629841	Oct 18, 2033	DP U-1753			
<u>DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA XR</u>						
N 208624 001	>A> 9744170	Jan 02, 2035	DP U-1889			
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968 001	6465504	Apr 05, 2019	DS DP			
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968 002	6465504	Apr 05, 2019	DS DP			
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968 003	6465504	Apr 05, 2019	DS DP			
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684 001					NCE ODE	Feb 09, 2022 Feb 09, 2024
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684 002					NCE ODE	Feb 09, 2022 Feb 09, 2024
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684 003					NCE ODE	Feb 09, 2022 Feb 09, 2024
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684 004					NCE ODE	Feb 09, 2022 Feb 09, 2024
<u>DEFLAZACORT - EMFLAZA</u>						
N 208685 001					NCE ODE	Feb 09, 2022 Feb 09, 2024

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEFLAZACORT - EMFLAZA</u>						
N 208685	001				NCE ODE	Feb 09, 2022 Feb 09, 2024
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201	001	9579359	Feb 10, 2029	U-1978		
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201	002	9579359	Feb 10, 2029	U-1978		
<u>DELAFLOXACIN MEGLUMINE - BAXDELA</u>						
N 208610	001	7728143	Nov 20, 2027	DS	NCE	Jun 19, 2022
		8252813	Oct 02, 2026	DP U-2028	GAIN	Jun 19, 2027
		8273892	Aug 06, 2026	DS		
		8497378	Dec 28, 2029	DS		
		8648093	Oct 07, 2025	DP U-2028		
		8871938	Sep 23, 2029	DS		
		8969569	Oct 07, 2025	DP U-2028		
		9539250	Oct 07, 2025	DS DP U-2028		
<u>DELAFLOXACIN MEGLUMINE - BAXDELA</u>						
N 208611	001	7728143	Nov 20, 2027	DS	NCE	Jun 19, 2022
		8252813	Oct 02, 2026	DP U-2028	GAIN	Jun 19, 2027
		8273892	Aug 06, 2026	DS		
		8497378	Dec 28, 2029	DS		
		8648093	Oct 07, 2025	DP U-2028		
		8871938	Sep 23, 2029	DS		
		9539250	Oct 07, 2025	DS DP U-2028		
<u>DEOXYCHOLIC ACID - KYBELLA</u>						
N 206333	001	9522155	Feb 21, 2028	DP U-1940		
		9636349	Feb 21, 2028	U-1940		
<u>DESMOPRESSIN ACETATE - NOCTIVA</u>						
N 201656	001	7405203	May 06, 2023	U-1980	NP	Mar 03, 2020
		7579321	May 06, 2023	U-1980		
		7799761	Sep 26, 2024	DP		
		9539302	Jun 15, 2030	DP		
<u>DESMOPRESSIN ACETATE - NOCTIVA</u>						
N 201656	002	7405203	May 06, 2023	U-1980	NP	Mar 03, 2020
		7579321	May 06, 2023	U-1980		
		7799761	Sep 26, 2024	DP		
		9539302	Jun 15, 2030	DP		
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204003	001				PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204003	002				PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204028	001				PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204028	002				PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204065	001				PC	Jan 25, 2017

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204065	002				PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204065	003				PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204082	001				PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204083	001				PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204095	001				PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204095	002				PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204172	001				PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204172	002				PC	Aug 28, 2017
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082	001	8524733	Mar 27, 2031	DS DP	I-751	Aug 30, 2020
		9233959	Sep 18, 2033	DP	NCE	Apr 03, 2022
		9296739	Sep 18, 2033	DP	ODE	Apr 03, 2024
	>A>	9550780	Sep 18, 2033	DS DP U-1846		
	>A>	9550780	Sep 18, 2033	DS DP U-1995		
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082	002	8524733	Mar 27, 2031	DS DP	I-751	Aug 30, 2020
		9233959	Sep 18, 2033	DP	NCE	Apr 03, 2022
		9296739	Sep 18, 2033	DP	ODE	Apr 03, 2024
	>A>	9550780	Sep 18, 2033	DS DP U-1846		
	>A>	9550780	Sep 18, 2033	DS DP U-1995		
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082	003	8524733	Mar 27, 2031	DS DP	I-751	Aug 30, 2020
		9233959	Sep 18, 2033	DP	NCE	Apr 03, 2022
		9296739	Sep 18, 2033	DP	ODE	Apr 03, 2024
	>A>	9550780	Sep 18, 2033	DS DP U-1846		
	>A>	9550780	Sep 18, 2033	DS DP U-1995		
<u>DEXAMETHASONE - OZURDEX</u>						
N 022315	001	9592242	Oct 20, 2020	U-1989		
		9592242	Oct 20, 2020	U-1990		
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038	002	9616049	Jan 04, 2032	DP		
		9616049*PED	Jul 04, 2032			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038	003	9616049	Jan 04, 2032	DP		
		9616049*PED	Jul 04, 2032			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038	004	9616049	Jan 04, 2032	DP		
		9616049*PED	Jul 04, 2032			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DICLOFENAC POTASSIUM - ZIPSOR</u>						
N 022202 001	9561200	Feb 24, 2029	U-1482			
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 204623 001	9539335	Oct 17, 2027	U-1614			
<u>DOXEPIIN HYDROCHLORIDE - SILENOR</u>						
N 022036 001	9532971	Jun 01, 2029	DP			
	9572814	Jul 20, 2027	U-620			
<u>DOXEPIIN HYDROCHLORIDE - SILENOR</u>						
N 022036 002	9532971	Jun 01, 2029	DP			
	9572814	Jul 20, 2027	U-620			
<u>DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE - BONJESTA</u>						
N 209661 001	7560122	Jan 25, 2019	DP			
	9089489	Feb 18, 2033	DP U-1382			
	9375404	Feb 18, 2033	DP U-1382			
	9526703	Feb 18, 2033	DP U-1382			
<u>DRONABINOL - SYNDROS</u>						
N 205525 001	8222292	Aug 06, 2028	DS DP			
	9345771	Aug 06, 2028	DS DP			
<u>EDARAVONE - RADICAVA</u>						
N 209176 001	6933310	Nov 13, 2020	U-2013		NCE ODE	May 05, 2022 May 05, 2024
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N 021937 001	8598185	Apr 28, 2029	DP			
	9545414	Jun 13, 2026	DP U-750			
	9545414	Jun 13, 2026	DP U-1170			
	>A> 9744181	Jan 13, 2024	DP U-257			
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567 001	9566272	Jan 03, 2028	U-1969			
	9662394	Oct 02, 2034	DP			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 207027 001	6280959	Oct 30, 2018	DS DP U-1736		ODE	Aug 26, 2021
	6280959*PED	Apr 30, 2019			PED	Feb 26, 2022
	7160870	Nov 20, 2022	DS DP U-1736			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-1736			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1736			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1736			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1736			
	7790704*PED	Nov 24, 2021				
	7795293	May 24, 2023	U-1736			
	7795293*PED	Nov 24, 2023				
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 001	8772325	Mar 14, 2025	U-1709			
	9675587	Mar 14, 2033	DP			
	9700542	Mar 14, 2025	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 002	8772325	Mar 14, 2025	U-1709			
	9675587	Mar 14, 2033	DP			
	9700542	Mar 14, 2025	DP			
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093 001	7176220	Aug 27, 2026	DS DP U-257		NCE	Aug 27, 2017
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093 002	7176220	Aug 27, 2026	DS DP U-257		NCE	Aug 27, 2017
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	>A> 8673927	May 04, 2027	U-1652			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	>A> 8673927	May 04, 2027	U-1652			
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE - ODEFSEY</u>						
N 208351 001					M-206 M-207	Aug 21, 2020 Aug 21, 2020
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - COMPLERA</u>						
N 202123 001	>A> 9744181	Jan 13, 2024	DP U-257			
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215 001					>A> NPP	Sep 25, 2020
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 001	>A> 9744181	Jan 13, 2024	DP U-257			
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 002	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			
	6642245	Nov 04, 2020	U-1170			
	6642245*PED	May 04, 2021				
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 003	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			
	6642245	Nov 04, 2020	U-1170			
	6642245*PED	May 04, 2021				
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 004	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			
	6642245	Nov 04, 2020	U-1170			
	6642245*PED	May 04, 2021				
<u>ENALAPRIL MALEATE - EPANED</u>						
N 208686 001	9669008	Mar 25, 2036	DP			
<u>ENASIDENIB MESYLATE - IDHIFA</u>						
N 209606 001	9512107	Jan 07, 2033	DS DP U-2087		NCE	Aug 01, 2022
	9732062	Sep 16, 2034	DS		ODE	Aug 01, 2024
	9738625	Aug 01, 2034	DS			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ENASIDENIB MESYLATE - IDHIFA</u>						
N 209606 002	9512107	Jan 07, 2033	DS DP U-2087		NCE	Aug 01, 2022
	9732062	Sep 16, 2034	DS		ODE	Aug 01, 2024
	9738625	Aug 01, 2034	DS			
<u>ENZALUTAMIDE - XTANDI</u>						
N 203415 001	8183274	Aug 24, 2026	U-1281			
	8183274	Aug 24, 2026	U-1588			
<u>EPINEPHRINE - EPIPEN</u>						
N 019430 001	9586010	Sep 11, 2025	DP			
<u>EPINEPHRINE - EPIPEN JR.</u>						
N 019430 002	9586010	Sep 11, 2025	DP			
<u>EPINEPHRINE - ADRENACLICK</u>						
N 020800 003	7905352	Apr 12, 2027	DP			
<u>EPINEPHRINE - ADRENACLICK</u>						
N 020800 004	7905352	Apr 12, 2027	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 001	9724471	May 23, 2027	DP U-2092			
	9737669	Nov 23, 2024	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 002	9724471	May 23, 2027	DP U-2092			
	9737669	Nov 23, 2024	DP			
<u>EPINEPHRINE - ADRENALIN</u>						
N 204200 001	9295657	Mar 13, 2035	U-1829			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 001	5753646	Jun 27, 2021	DS DP U-2041			
	9566244	Oct 23, 2028	DP			
	9643929	Apr 21, 2026	DP			
	>A> 9750747	Aug 24, 2032	U-2041			
	>A> 9750747	Aug 24, 2032	U-2121			
	>A> 9763954	Sep 13, 2028	U-2123			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 002	5753646	Jun 27, 2021	DS DP U-2041			
	9566244	Oct 23, 2028	DP			
	9643929	Apr 21, 2026	DP			
	>A> 9750747	Aug 24, 2032	U-2041			
	>A> 9750747	Aug 24, 2032	U-2121			
	>A> 9763954	Sep 13, 2028	U-2123			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 003	5753646	Jun 27, 2021	DS DP U-2041			
	9566244	Oct 23, 2028	DP			
	9643929	Apr 21, 2026	DP			
	>A> 9750747	Aug 24, 2032	U-2041			
	>A> 9750747	Aug 24, 2032	U-2121			
	>A> 9763954	Sep 13, 2028	U-2123			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 004	5753646	Jun 27, 2021	DS DP U-2041			
	9566244	Oct 23, 2028	DP			
	9643929	Apr 21, 2026	DP			
	>A> 9750747	Aug 24, 2032	U-2041			
	>A> 9750747	Aug 24, 2032	U-2121			
	>A> 9763954	Sep 13, 2028	U-2123			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 004	5753646	Jun 27, 2021	DS DP U-2041			
	9566244	Oct 23, 2028	DP			
	9643929	Apr 21, 2026	DP			
	>A> 9750747	Aug 24, 2032	U-2041			
	>A> 9750747	Aug 24, 2032	U-2121			
	>A> 9763954	Sep 13, 2028	U-2123			
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 001	9707181	May 31, 2022	DP		NPP	Jul 06, 2020
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 002	9707181	May 31, 2022	DP		NPP	Jul 06, 2020
<u>ESTRADIOL - ESTRADIOL</u>						
A 205256 001					PC	Apr 15, 2017
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 001	9730900	Jul 10, 2028	U-2086			
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 002	9730900	Jul 10, 2028	U-2086			
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 003	9730900	Jul 10, 2028	U-2086			
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 004	9730900	Jul 10, 2028	U-2086			
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 005	9724310	Jul 10, 2028	DS DP			
	9730900	Jul 10, 2028	DP U-2086			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 001	8377880	Jul 29, 2030	DS DP		NCE	Feb 07, 2022
	8999932	Jul 29, 2030	DS DP U-2014			
	9278995	Jul 29, 2030	DS			
	9701712	Jul 29, 2030	DS DP U-2014			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 002	8377880	Jul 29, 2030	DS DP		NCE	Feb 07, 2022
	8999932	Jul 29, 2030	DS DP U-2014			
	9278995	Jul 29, 2030	DS			
	9701712	Jul 29, 2030	DS DP U-2014			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 003	8377880	Jul 29, 2030	DS DP		NCE	Feb 07, 2022
	8999932	Jul 29, 2030	DS DP U-2014			
	9278995	Jul 29, 2030	DS			
	9701712	Jul 29, 2030	DS DP U-2014			
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 001	>A> 8486907	Jun 28, 2025	U-1904	Y		
	9243245	Oct 27, 2028	DS U-2097			
	9243245	Oct 27, 2028	DS U-2098			
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 002	>A> 8486907	Jun 28, 2025	U-1904	Y		
	9243245	Oct 27, 2028	DS U-2097			
	9243245	Oct 27, 2028	DS U-2098			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - FAYOSIM</u>						
A 205943	001				PC	Sep 30, 2017
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - MIBELAS 24 FE</u>						
A 206287	001				PC	Sep 11, 2017
<u>ETONOGESTREL - IMPLANON</u>						
N 021529	001 >A> 9757552	Jul 28, 2030	DP U-1			
<u>ETONOGESTREL - NEXPLANON</u>						
N 021529	002 >A> 9757552	Jul 28, 2030	DP U-1			
<u>EVEROLIMUS - ZORTRESS</u>						
N 021560	001 6239124	Jul 29, 2017	U-1049			
	6239124*PED	Jan 29, 2018				
<u>EVEROLIMUS - ZORTRESS</u>						
N 021560	002 6239124	Jul 29, 2017	U-1049			
	6239124*PED	Jan 29, 2018				
<u>EVEROLIMUS - ZORTRESS</u>						
N 021560	003 6239124	Jul 29, 2017	U-1049			
	6239124*PED	Jan 29, 2018				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334	001				ODE	Feb 26, 2023
<u>EVEROLIMUS - AFINITOR</u>						
N 022334	002				ODE	Feb 26, 2023
<u>EVEROLIMUS - AFINITOR</u>						
N 022334	003				ODE	Feb 26, 2023
<u>EVEROLIMUS - AFINITOR</u>						
N 022334	004				ODE	Feb 26, 2023
<u>FEBUXOSTAT - ULORIC</u>						
N 021856	001				M-205	Aug 15, 2020
<u>FEBUXOSTAT - ULORIC</u>						
N 021856	002				M-205	Aug 15, 2020
<u>FENTANYL - SUBSYS</u>						
N 202788	001 9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788	002 9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788	003 9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788	004 9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL - SUBSYS</u>						
N 202788 004	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 005	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 006	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 007	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 001	9597288	Jul 23, 2027	DP U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 002	9597288	Jul 23, 2027	DP U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 003	9597288	Jul 23, 2027	DP U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 004	9597288	Jul 23, 2027	DP U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 005	9597288	Jul 23, 2027	DP U-767			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 001 >A>	9731869	Jan 26, 2032	DP			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 002 >A>	9731869	Jan 26, 2032	DP			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 003 >A>	9731869	Jan 26, 2032	DP			
<u>FENTANYL HYDROCHLORIDE - IONSYS</u>						
N 021338 001 >A>	9731121	Oct 17, 2031	DP			
<u>FERRIC CITRATE - AURYXIA</u>						
N 205874 001 >A>	9757416	Feb 18, 2024	DS DP U-1577			
<u>FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%</u>						
N 207648 001					NCE	Jul 13, 2021
<u>FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%</u>						
N 207648 002					NCE	Jul 13, 2021
<u>FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%</u>						
N 207648 003					NCE	Jul 13, 2021

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUCICLOVINE F-18 - AXUMIN</u>						
N 208054 001	>A> 5808146	Nov 09, 2018	DS			
<u>FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - TRELEGY ELLIPTA</u>						
N 209482 001				>A> NCE		May 10, 2018
				>A> NCE		Dec 18, 2018
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001	>A> 7439393	May 21, 2025	DS DP U-1401		M-202	May 15, 2020
	>A> 7439393	May 21, 2025	DS DP U-1691		NCE	May 10, 2018
	>A> 7439393	May 21, 2025	DS DP U-2099			
	>A> 7439393	May 21, 2025	DS DP U-2100			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 002	>A> 7439393	May 21, 2025	DS DP U-1691		M-202	May 15, 2020
	>A> 7439393	May 21, 2025	DS DP U-2099		NCE	May 10, 2018
	>A> 7439393	May 21, 2025	DS DP U-2100			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 001	6446627	Dec 18, 2017	DP		NP	Jan 27, 2020
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 002	6446627	Dec 18, 2017	DP		NP	Jan 27, 2020
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 003	6446627	Dec 18, 2017	DP		NP	Jan 27, 2020
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 003	6446627	Dec 18, 2017	DP		NP	Jan 27, 2020
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
<u>FLUTICASONE PROPIONATE - XHANCE</u>						
N 209022 001					>A> NP	Sep 18, 2020
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 001	6446627	Dec 18, 2017	DP		NP	Jan 27, 2020
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9066957	Oct 06, 2034	DP U-645			
	9216260	Jun 28, 2031	DP			
	9415008	Oct 06, 2034	DP U-645			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 002	6446627	Dec 18, 2017	DP		NP	Jan 27, 2020
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9066957	Oct 06, 2034	DP U-645			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 003	6446627	Dec 18, 2017	DP		NP	Jan 27, 2020
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9066957	Oct 06, 2034	DP U-645			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 003	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
<u>FULVESTRANT - FASLODEX</u>						
N 021344 001					I-749	Aug 25, 2020
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781 001					NPP	Aug 25, 2020
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781 002					NPP	Aug 25, 2020
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781 003					NPP	Aug 25, 2020
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781 004					NPP	Aug 25, 2020
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781 005					NCE NPP	Mar 20, 2018 Aug 25, 2020
<u>GANCICLOVIR - GANCICLOVIR</u>						
N 209347 001	9486530	Sep 02, 2034	DP			
<u>GLECAPREVIR; PIBRENTASVIR - MAVYRET</u>						
N 209394 001					NCE	Aug 03, 2022
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284 001	9561197	Sep 22, 2030	U-1383		NPP	Apr 28, 2020
<u>GUAIFENESIN; HYDROCODONE BITARTRATE - OBREDON</u>						
N 205474 001	9549907	Nov 13, 2035	DS DP U-2023			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 001	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
	9713611	Sep 12, 2034	DP U-55			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 002	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
	9713611	Sep 12, 2034	DP U-55			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 003	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
	9713611	Sep 12, 2034	DP U-55			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 004	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
	9713611	Sep 12, 2034	DP U-55			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 005	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
	9713611	Sep 12, 2034	DP U-55			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 005	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
	9713611	Sep 12, 2034	DP U-55			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 006	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
	9713611	Sep 12, 2034	DP U-55			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 001	9023401	Oct 30, 2020	DP			
	9056052	Oct 30, 2020	DP			
	9060940	Oct 30, 2020	U-1556			
	9198863	Oct 30, 2020	DP			
	9205056	Oct 30, 2020	DP			
	9289391	Oct 30, 2020	DP			
	9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2020	DP			
	9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
	9675610	Jun 16, 2023	DP			
	9675611	Oct 30, 2020	U-1556			
	9682077	Oct 30, 2020	U-1556			
	>A> 9750703	Dec 21, 2031	DP			
	>A> 9763933	Aug 24, 2027	DP			
	>A> 9770416	Aug 24, 2027	DP			
	>A> 9775809	Aug 24, 2027	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 002	9023401	Oct 30, 2020	DP			
	9056052	Oct 30, 2020	DP			
	9060940	Oct 30, 2020	U-1556			
	9198863	Oct 30, 2020	DP			
	9205056	Oct 30, 2020	DP			
	9289391	Oct 30, 2020	DP			
	9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2020	DP			
	9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
	9675610	Jun 16, 2023	DP			
	9675611	Oct 30, 2020	U-1556			
	9682077	Oct 30, 2020	U-1556			
	>A> 9750703	Dec 21, 2031	DP			
	>A> 9763933	Aug 24, 2027	DP			
	>A> 9770416	Aug 24, 2027	DP			
	>A> 9775809	Aug 24, 2027	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 003	9023401	Oct 30, 2020	DP			
	9056052	Oct 30, 2020	DP			
	9060940	Oct 30, 2020	U-1556			
	9198863	Oct 30, 2020	DP			
	9205056	Oct 30, 2020	DP			
	9289391	Oct 30, 2020	DP			
	9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2020	DP			
	9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
	9675610	Jun 16, 2023	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 003	9675611	Oct 30, 2020	U-1556			
	9682077	Oct 30, 2020	U-1556			
	>A> 9750703	Dec 21, 2031	DP			
	>A> 9763933	Aug 24, 2027	DP			
	>A> 9770416	Aug 24, 2027	DP			
	>A> 9775809	Aug 24, 2027	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 004	9023401	Oct 30, 2020	DP			
	9056052	Oct 30, 2020	DP			
	9060940	Oct 30, 2020	U-1556			
	9198863	Oct 30, 2020	DP			
	9205056	Oct 30, 2020	DP			
	9289391	Oct 30, 2020	DP			
	9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2020	DP			
	9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
	9675610	Jun 16, 2023	DP			
	9675611	Oct 30, 2020	U-1556			
	9682077	Oct 30, 2020	U-1556			
	>A> 9750703	Dec 21, 2031	DP			
	>A> 9763933	Aug 24, 2027	DP			
	>A> 9770416	Aug 24, 2027	DP			
	>A> 9775809	Aug 24, 2027	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 005	9056052	Oct 30, 2020	DP			
	9060940	Oct 30, 2020	U-1556			
	9198863	Oct 30, 2020	DP			
	9205056	Oct 30, 2020	DP			
	9289391	Oct 30, 2020	DP			
	9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2020	DP			
	9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
	9675610	Jun 16, 2023	DP			
	9675611	Oct 30, 2020	U-1556			
	9682077	Oct 30, 2020	U-1556			
	>A> 9750703	Dec 21, 2031	DP			
	>A> 9763933	Aug 24, 2027	DP			
	>A> 9770416	Aug 24, 2027	DP			
	>A> 9775809	Aug 24, 2027	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 006	9056052	Oct 30, 2020	DP			
	9060940	Oct 30, 2020	U-1556			
	9198863	Oct 30, 2020	DP			
	9205056	Oct 30, 2020	DP			
	9289391	Oct 30, 2020	DP			
	9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2020	DP			
	9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
	9675610	Jun 16, 2023	DP			
	9675611	Oct 30, 2020	U-1556			
	9682077	Oct 30, 2020	U-1556			
	>A> 9750703	Dec 21, 2031	DP			
	>A> 9763933	Aug 24, 2027	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 006	>A> 9770416	Aug 24, 2027	DP			
	>A> 9775809	Aug 24, 2027	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 007	9056052	Oct 30, 2020	DP			
	9060940	Oct 30, 2020	DP	U-1556		
	9198863	Oct 30, 2020	DP			
	9205056	Oct 30, 2020	DP			
	9289391	Oct 30, 2020	DP			
	9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027	DP	U-1556		
	9572779	Dec 21, 2031	DP			
	9572804	Oct 30, 2021	DP			
	9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
	9675610	Jun 16, 2023	DP			
	9675611	Oct 30, 2020	DP	U-1556		
	9682077	Oct 30, 2020	DP	U-1556		
	>A> 9750703	Dec 21, 2031	DP			
	>A> 9763933	Aug 24, 2027	DP			
	>A> 9770416	Aug 24, 2027	DP			
	>A> 9775809	Aug 24, 2027	DP			
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975 001	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975 002	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975 003	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975 004	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975 005	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			
<u>HYDROXYPROGESTERONE CAPROATE - MAKENA PRESERVATIVE FREE</u>						
N 021945 002					ODE	Mar 03, 2018
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	8476284	Dec 28, 2026	U-1456		I-741	Jan 18, 2020
	8476284	Dec 28, 2026	U-1650		I-753	Aug 02, 2020
	8476284	Dec 28, 2026	U-1946		ODE	Jan 18, 2024
	8476284	Dec 28, 2026	U-1947		ODE	Aug 02, 2024
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	9540382	Aug 18, 2033	U-1456			
	9540382	Aug 18, 2033	U-1650			
	9540382	Aug 18, 2033	U-1684			
	9540382	Aug 18, 2033	U-1946			
	9540382	Aug 18, 2033	U-1947			
	9713617	Jun 03, 2033	DP			
	9725455	Jun 03, 2033	DS			
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 002	9649284	Sep 30, 2029	U-2018			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 002	8188146	Jan 27, 2020	DS DP		NCE	Jul 26, 2017
	8293727	Feb 09, 2030	U-1287			
	8293728	Feb 09, 2030	U-1287			
	8298554	Apr 29, 2030	DP			
	8314086	Feb 09, 2030	U-1287			
	8318715	Feb 09, 2030	U-1287			
	8357677	Feb 09, 2030	U-1287			
	8367652	Feb 09, 2030	U-1287			
	8377920	Feb 09, 2030	U-1287			
	8399446	Feb 09, 2030	U-1287			
	8415335	Feb 09, 2030	U-1287			
	8426399	Feb 09, 2030	U-1287			
	8440650	Feb 09, 2030	U-1287			
	8445003	Apr 29, 2030	U-1287			
	8445013	Apr 29, 2030	U-1287			
	8501225	Apr 29, 2030	U-1287			
	8518929	Apr 29, 2030	U-1287			
	8524698	Apr 29, 2030	U-1287			
	8546372	Apr 29, 2030	U-1287			
	8551521	Apr 29, 2030	U-1287			
	8563608	Apr 29, 2030	U-1287			
	8617593	Apr 29, 2030	U-1287			
	8617594	Apr 29, 2030	U-1287			
	8623406	Apr 29, 2030	U-1287			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH</u>						
N 020986 005	9687611	Feb 27, 2027	DP			
	RE46363	Aug 03, 2026	DP			
<u>INSULIN ASPART RECOMBINANT - FIASP</u>						
N 208751 001					>A> NP	Sep 29, 2020
<u>INSULIN ASPART RECOMBINANT - FIASP FLEXTOUCH</u>						
N 208751 002					>A> NP	Sep 29, 2020
<u>INSULIN ASPART; INSULIN DEGLUDEC - RYZODEG 70/30</u>						
N 203313 001	9687611	Feb 27, 2027	DP			
	RE46363	Aug 03, 2026	DP			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 001	9687611	Feb 27, 2027	DP			
	RE46363	Aug 03, 2026	DP			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 002	9687611	Feb 27, 2027	DP			
	RE46363	Aug 03, 2026	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN DEGLUDEC; LIRAGLUTIDE - XULTOPHY 100/3.6</u>						
N 208583 001	>A> 9687611	Feb 27, 2027	DP			
	RE46363	Aug 03, 2026	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH</u>						
N 021536 005	9687611	Feb 27, 2027	DP			
	RE46363	Aug 03, 2026	DP			
<u>INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR</u>						
N 021081 002	9561331	Aug 28, 2024	DP			
	9604008	Mar 02, 2024	DP			
	9604009	Aug 16, 2024	DP			
	9610409	Mar 02, 2024	DP			
	9623189	Aug 19, 2024	DP			
	>A> 9775954	Mar 02, 2024	DP			
<u>INSULIN GLARGINE RECOMBINANT - TOUJEO SOLOSTAR</u>						
N 206538 001	9561331	Aug 28, 2024	DP			
	9604008	Mar 02, 2024	DP			
	9604009	Aug 16, 2024	DP			
	9610409	Mar 02, 2024	DP			
	9623189	Aug 19, 2024	DP			
	>A> 9775954	Mar 02, 2024	DP			
<u>INSULIN GLARGINE; LIXISENATIDE - SOLIOUA 100/33</u>						
N 208673 001	9526764	Oct 09, 2029	DP			
	9561331	Aug 28, 2024	DP			
	9604008	Mar 02, 2024	DP			
	9604009	Aug 16, 2024	DP			
	9610409	Mar 02, 2024	DP			
	9623189	Aug 19, 2024	DP			
	9707176	Nov 11, 2030	DP			
	>A> 9775954	Mar 02, 2024	DP			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629 003	9561331	Aug 28, 2024	DP			
	9604008	Mar 02, 2024	DP			
	9610409	Mar 02, 2024	DP			
	9623189	Aug 19, 2024	DP			
	>A> 9775954	Mar 02, 2024	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 001	9597374	Oct 08, 2031	U-1987			
	9662461	Jun 12, 2029	DP U-2019			
	9717689	Sep 14, 2026	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 002	9597374	Oct 08, 2031	U-1987			
	9662461	Jun 12, 2029	DP U-2019			
	9717689	Sep 14, 2026	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 003	9597374	Oct 08, 2031	U-1987			
	9662461	Jun 12, 2029	DP U-2019			
	9717689	Sep 14, 2026	DP			
<u>IODIXANOL - VISIPAQUE 320</u>						
N 020351 002					I-752	Apr 05, 2020
<u>IODIXANOL - VISIPAQUE 320</u>						
N 020808 002					I-752	Apr 05, 2020

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IRINOTECAN HYDROCHLORIDE - ONIVYDE</u>						
N 207793 001	9717724	Jun 12, 2033	U-1848			
	9717724	Jun 12, 2033	U-2091			
	9724303	May 02, 2025	DS DP			
	9730891	May 02, 2025	U-1848			
<u>IVACAFTOR - KALYDECO</u>						
N 203188 001	9670163	Dec 28, 2026	DP U-1311			
<u>IVACAFTOR - KALYDECO</u>						
N 207925 001	9670163	Dec 28, 2026	DP U-1311			
<u>IVACAFTOR - KALYDECO</u>						
N 207925 002	9670163	Dec 28, 2026	DP U-1311			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	7973038	Nov 08, 2026	U-1973			
	9670163	Dec 28, 2026	DP U-1911			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 002	7973038	Nov 08, 2026	U-1973			
	9670163	Dec 28, 2026	DP U-1911			
<u>L-GLUTAMINE - ENDARI</u>						
N 208587 001					I-748 ODE	Jul 07, 2020 Jul 07, 2024
<u>LAMIVUDINE; RALTEGRAVIR POTASSIUM - DUTREBIS</u>						
N 206510 001	7169780	Oct 03, 2023	DS DP			
	7169780*PED	Apr 03, 2024				
	7217713	Oct 21, 2022	U-1663			
	7217713*PED	Apr 21, 2023				
	7435734	Oct 21, 2022	U-1663			
	7435734*PED	Apr 21, 2023				
	7754731	Mar 11, 2029	DS DP U-1663			
	7754731*PED	Sep 11, 2029				
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N 022074 001					>A> I-754	Sep 15, 2020
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N 022074 002					>A> I-754	Sep 15, 2020
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N 022074 003					>A> I-754	Sep 15, 2020
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 001					NPP ODE	Apr 07, 2020 Apr 07, 2024
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 001	5635517	Oct 04, 2019	DS		ODE	Feb 22, 2024
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 002	5635517	Oct 04, 2019	DS		ODE	Feb 22, 2024
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 003	5635517	Oct 04, 2019	DS		ODE	Feb 22, 2024

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 004	5635517	Oct 04, 2019	DS		ODE	Feb 22, 2024
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 005	5635517	Oct 04, 2019	DS		ODE	Feb 22, 2024
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 006	5635517	Oct 04, 2019	DS		ODE	Feb 22, 2024
<u>LETROZOLE; RIBOCICLIB SUCCINATE - KISOALI FEMARA CO-PACK (COPACKAGED)</u>						
N 209935 001	8324225	Jun 17, 2028	DS DP		NCE	Mar 13, 2022
	8415355	Feb 19, 2031	DS DP			
	8685980	May 25, 2030	DS DP			
	8962630	Dec 09, 2029		U-1981		
	9193732	Nov 09, 2031	DS DP			
	9416136	Aug 20, 2029		U-1981		
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021343 001	9254307	Oct 28, 2018	DS DP			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021379 001	8470359	Oct 15, 2023	DS DP U-621			
	8486455	Oct 28, 2018	DS DP			
	8840916	Nov 13, 2020	DP			
	9539333	Nov 13, 2020	DS DP U-621			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021488 001	8470359	Oct 15, 2023	DS DP U-621			
	8486455	Oct 28, 2018	DS DP			
	8840916	Nov 13, 2020	DP			
	9539333	Nov 13, 2020	DS DP U-621			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021731 001	8470359	Oct 15, 2023	DS DP U-621			
	8486455	Oct 28, 2018	DS DP			
	8840916	Nov 13, 2020	DP			
	9539333	Nov 13, 2020	DS DP U-621			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 001	9339489	Mar 14, 2034	DP U-1850			
	9669009	Mar 14, 2034	U-1850			
	9669009	Mar 14, 2034	U-2021			
	9669009	Mar 14, 2034	U-2022			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 002	9669009	Mar 14, 2034	U-1850			
	9669009	Mar 14, 2034	U-2021			
	9669009	Mar 14, 2034	U-2022			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 003	9669009	Mar 14, 2034	U-1850			
	9669009	Mar 14, 2034	U-2021			
	9669009	Mar 14, 2034	U-2022			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 004	9669009	Mar 14, 2034	U-1850			
	9669009	Mar 14, 2034	U-2021			
	9669009	Mar 14, 2034	U-2022			
<u>LEVOCETIRIZINE DIHYDROCHLORIDE - XYZAL ALLERGY 24HR</u>						
N 209090 001	8633194	Oct 16, 2027	DP			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVONORGESTREL - MIRENA</u>						
N 021225 001	9615965	Sep 16, 2029	DP U-2003			
	9668912	Apr 01, 2031	DP			
<u>LEVONORGESTREL - SKYLA</u>						
N 203159 001	9615965	Sep 16, 2029	DP U-2003			
	9668912	Apr 01, 2031	DP			
<u>LEVONORGESTREL - KYLEENA</u>						
N 208224 001	9615965	Sep 16, 2029	DP U-2003			
	9668912	Apr 01, 2031	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 001	9708371	Aug 16, 2033	DP U-1515			
	9708371	Aug 16, 2033	DP U-1516			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 002	9708371	Aug 16, 2033	DP U-1515			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 003	7304036	Aug 30, 2026	DS DP U-1516		NCE	Aug 30, 2017
	7371727	Jan 28, 2024	DS		NS	Jan 25, 2020
	7704947	Jan 28, 2024	DS DP			
	7745409	Jan 28, 2024	DS DP			
	8080526	Jan 28, 2024	DS DP			
	8110553	Jan 28, 2024			U-1516	
	8933030	Feb 17, 2031	DP U-1516			
	9708371	Aug 16, 2033	DP U-1516			
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	8846695	Jun 04, 2030	U-1503	Y		
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	8846695	Jun 04, 2030	U-1503			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	8846695	Jun 04, 2030	U-1503			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	8846695	Jun 04, 2030	U-1503	Y		
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 001	9555001	Mar 06, 2033	DP U-1967			
	9555001	Mar 06, 2033	DP U-1968			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 002	9555001	Mar 06, 2033	DP U-1967			
	9555001	Mar 06, 2033	DP U-1968			
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N 022341 001					I-750	Aug 25, 2020
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u>						
N 206321 001	9687611	Feb 27, 2027	DP			
	RE46363	Aug 03, 2026	DP			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 001	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 001	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023		U-727		
	7671030	Feb 24, 2023	DP	U-727		
	7671031	Feb 24, 2023		U-727		
	7674774	Feb 24, 2023	DP	U-727		
	7678770	Feb 24, 2023		U-727		
	7678771	Feb 24, 2023	DP	U-727		
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP	U-727		
	7713936	Feb 24, 2023		U-727		
	7718619	Feb 24, 2023	DP	U-727		
	7723305	Feb 24, 2023	DP	U-727		
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 002	7105486	Feb 24, 2023		U-727	I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP	U-727		
	7659254	Feb 24, 2023		U-727		
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023		U-727		
	7671030	Feb 24, 2023	DP	U-727		
	7671031	Feb 24, 2023		U-727		
	7674774	Feb 24, 2023	DP	U-727		
	7678770	Feb 24, 2023		U-727		
	7678771	Feb 24, 2023	DP	U-727		
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP	U-727		
	7713936	Feb 24, 2023		U-727		
	7718619	Feb 24, 2023	DP	U-727		
	7723305	Feb 24, 2023	DP	U-727		
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 003	7105486	Feb 24, 2023		U-727	I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP	U-727		
	7659254	Feb 24, 2023		U-727		
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023		U-727		
	7671030	Feb 24, 2023	DP	U-727		
	7671031	Feb 24, 2023		U-727		
	7674774	Feb 24, 2023	DP	U-727		
	7678770	Feb 24, 2023		U-727		
	7678771	Feb 24, 2023	DP	U-727		
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP	U-727		
	7713936	Feb 24, 2023		U-727		
	7718619	Feb 24, 2023	DP	U-727		
	7723305	Feb 24, 2023	DP	U-727		
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 004	7105486	Feb 24, 2023		U-727	I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP	U-727		
	7659254	Feb 24, 2023		U-727		
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023		U-727		
	7671030	Feb 24, 2023	DP	U-727		
	7671031	Feb 24, 2023		U-727		
	7674774	Feb 24, 2023	DP	U-727		
	7678770	Feb 24, 2023		U-727		
	7678771	Feb 24, 2023	DP	U-727		
	7687466	Feb 24, 2023	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 004	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 005	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 006	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
<u>LISINAPRIL - OBRELIS</u>						
N 208401 001	9616096	Nov 06, 2035	U-3			
	9616096	Nov 06, 2035	U-8			
	9616096	Nov 06, 2035	U-71			
	9616096	Nov 06, 2035	U-185			
	9616096	Nov 06, 2035	U-1723			
	9616096	Nov 06, 2035	U-1864			
	9616096	Nov 06, 2035	U-1991			
<u>LIXISENATIDE - ADLYXIN</u>						
N 208471 001	9707176	Nov 11, 2030	DP			
<u>LIXISENATIDE - ADLYXIN</u>						
N 208471 002	9707176	Nov 11, 2030	DP			
<u>LORCASERIN HYDROCHLORIDE - BELVIO</u>						
N 022529 001	>A> 9770455	Aug 31, 2031	U-2110			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LORCASERIN HYDROCHLORIDE - BELVIO XR</u>						
N 208524 001 >A>	9770455	Aug 31, 2031	U-2110			
<u>LOXAPINE - ADASUVE</u>						
N 022549 001	9687487	Oct 26, 2021	DS DP			
<u>LULICONAZOLE - LUZU</u>						
N 204153 001	5900488	Jan 18, 2020	DS DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001	9555027	May 26, 2026	DP U-543		M-195 NPP PED PED	Jan 27, 2020 Jan 27, 2020 Jul 27, 2020 Jul 27, 2020
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002	9555027	May 26, 2026	DP U-543		NPP PED	Jan 27, 2020 Jul 27, 2020
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003	9555027	May 26, 2026	DP U-543		M-195 NPP PED PED	Jan 27, 2020 Jan 27, 2020 Jul 27, 2020 Jul 27, 2020
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004	9555027	May 26, 2026	DP U-543			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005	9555027	May 26, 2026	DP U-543		M-195 NPP PED PED	Jan 27, 2020 Jan 27, 2020 Jul 27, 2020 Jul 27, 2020
<u>MARAVIROC - SELZENTRY</u>						
N 022128 001					NPP NS	Nov 04, 2019 Nov 04, 2019
<u>MARAVIROC - SELZENTRY</u>						
N 022128 002					NPP NS	Nov 04, 2019 Nov 04, 2019
<u>MARAVIROC - SELZENTRY</u>						
N 022128 003	6586430	Dec 01, 2019	DS DP U-824		NPP	Nov 04, 2019
	6667314	Aug 06, 2021	DS DP U-824		NS	Nov 04, 2019
	7368460	Nov 25, 2022	U-824			
	7576097	May 25, 2021	DS			
<u>MARAVIROC - SELZENTRY</u>						
N 022128 004	6586430	Dec 01, 2019	DS DP U-824		NPP	Nov 04, 2019
	6667314	Aug 06, 2021	DS DP U-824		NS	Nov 04, 2019
	7368460	Nov 25, 2022	U-824			
	7576097	May 25, 2021	DS			
<u>MARAVIROC - SELZENTRY</u>						
N 208984 001					NP	Nov 04, 2019
<u>MELOXICAM - VIVLODEX</u>						
N 207233 001	9649318	Mar 31, 2035	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MELOXICAM - VIVLODEX</u>						
N 207233 002	9649318	Mar 31, 2035	DP			
<u>MELPHALAN HYDROCHLORIDE - EVOMELA</u>						
N 207155 001	9493582	Feb 27, 2033	DP			
<u>MEROPENEM; VABORBACTAM - VABOMERE</u>						
N 209776 001	>A> 8680136	Aug 17, 2031	DS DP			
	>A> 9694025	Aug 08, 2031	U-2120			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 001					M-198	Feb 27, 2020
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 002	9339472	Jul 13, 2025	DP		M-198	Feb 27, 2020
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 003	9339472	Jul 13, 2025	DP		M-198	Feb 27, 2020
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 001	6303661	Apr 24, 2017	U-1996			
	6890898	Feb 02, 2019	U-1996			
	7078381	Feb 02, 2019	U-1996			
	7459428	Feb 02, 2019	U-1996			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 002	6303661	Apr 24, 2017	U-1996			
	6890898	Feb 02, 2019	U-1996			
	7078381	Feb 02, 2019	U-1996			
	7459428	Feb 02, 2019	U-1996			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 001	6303661	Apr 24, 2017	U-1996			
	6890898	Feb 02, 2019	U-1996			
	7078381	Feb 02, 2019	U-1996			
	7459428	Feb 02, 2019	U-1996			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 002	6303661	Apr 24, 2017	U-1996			
	6890898	Feb 02, 2019	U-1996			
	7078381	Feb 02, 2019	U-1996			
	7459428	Feb 02, 2019	U-1996			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 003	6303661	Apr 24, 2017	U-1996			
	6890898	Feb 02, 2019	U-1996			
	7078381	Feb 02, 2019	U-1996			
	7459428	Feb 02, 2019	U-1996			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 001	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 002	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 003	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHOTREXATE - OTREXUP</u>						
N 204824 004	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 005	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 006	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 007	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 008	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
<u>METHOTREXATE SODIUM - XATMEP</u>						
N 208400 001	9259427	Jan 02, 2033	DP		ODE	Apr 25, 2024
					ODE	Apr 25, 2024
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 001	9492445	Sep 30, 2029	DP U-1185			
	9669096	Apr 08, 2024	DP			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 002	9492445	Sep 30, 2029	DP U-1185			
	9669096	Apr 08, 2024	DP			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 003	9492445	Sep 30, 2029	DP U-1185			
	9669096	Apr 08, 2024	DP			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 208271 001	9492445	Sep 30, 2029	DP U-1185			
	9724343	Sep 30, 2029	DP U-1185			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 001	9668981	Oct 07, 2025	U-2024			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 002	9668981	Oct 07, 2025	U-2024			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 003	9668981	Oct 07, 2025	U-2024			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 004	9668981	Oct 07, 2025	U-2024			
<u>METHYLPHENIDATE - COTEMPLA XR-ODT</u>						
N 205489 001	8840924	Jun 05, 2026	DP		NP	Jun 19, 2020
	9072680	Jun 28, 2032	DP			
	9089496	Jun 28, 2032	DP			
<u>METHYLPHENIDATE - COTEMPLA XR-ODT</u>						
N 205489 002	8840924	Jun 05, 2026	DP		NP	Jun 19, 2020
	9072680	Jun 28, 2032	DP			
	9089496	Jun 28, 2032	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE - COTEMPLA XR-ODT</u>						
N 205489 002	8840924	Jun 05, 2026	DP		NP	Jun 19, 2020
	9072680	Jun 28, 2032	DP			
	9089496	Jun 28, 2032	DP			
<u>METHYLPHENIDATE - COTEMPLA XR-ODT</u>						
N 205489 003	8840924	Jun 05, 2026	DP		NP	Jun 19, 2020
	9072680	Jun 28, 2032	DP			
	9089496	Jun 28, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 001	9545399	Aug 14, 2033	DP U-1827			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 002	9545399	Aug 14, 2033	DP U-1827			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 003	9545399	Aug 14, 2033	DP U-1827			
<u>MIDOSTAURIN - RYDAPT</u>						
N 207997 001	7973031	Oct 17, 2024	U-2007		NCE	Apr 28, 2022
	8222244	Oct 29, 2022	U-2007		ODE	Apr 28, 2024
	8575146	Dec 02, 2030	U-2008		ODE	Apr 28, 2024
<u>MITOMYCIN - MITOSOL</u>						
N 022572 001	9539241	Jan 02, 2028	DS DP U-2095			
	9649428	May 21, 2029	U-2095			
<u>MORPHINE SULFATE - ARYMO ER</u>						
N 208603 001	9044402	Jul 01, 2033	DP U-1556			
	9549899	Jul 01, 2033	DP U-1556			
<u>MORPHINE SULFATE - ARYMO ER</u>						
N 208603 002	9044402	Jul 01, 2033	DP U-1556			
	9549899	Jul 01, 2033	DP U-1556			
<u>MORPHINE SULFATE - ARYMO ER</u>						
N 208603 003	9044402	Jul 01, 2033	DP U-1556			
	9549899	Jul 01, 2033	DP U-1556			
<u>NALDEMEDINE TOSYLATE - SYMPROIC</u>						
N 208854 001	9108975	Nov 11, 2031	DS DP		NCE	Mar 23, 2022
	RE46365	Jan 11, 2028	DS DP			
	RE46375	Oct 05, 2026	DS DP U-1185			
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787 001	9724471	May 23, 2027	DP U-2092			
	9737669	Nov 23, 2024	DP			
<u>NALOXONE HYDROCHLORIDE - NARCAN</u>						
N 208411 001	9211253	Mar 16, 2035	DP			
	9561177	Mar 16, 2035	DP U-1903			
	9629965	Mar 16, 2035	DP U-1903			
	>A> 9775838	Mar 16, 2035	U-1903			
<u>NALOXONE HYDROCHLORIDE - NARCAN</u>						
N 208411 002	9480644	Mar 16, 2035	DP U-1903			
	9707226	Mar 16, 2035	DP U-1903			
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 209862 001	9724471	May 23, 2027	DP U-2092			
	9737669	Nov 23, 2024	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 209862 001	9724471	May 23, 2027	DP U-2092			
	9737669	Nov 23, 2024	DP			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 001	9555000	Apr 04, 2023	DP U-1556			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 002	9555000	Apr 04, 2023	DP U-1556			
<u>NEPAFENAC - ILEVRO</u>						
N 203491 001	9662398	Dec 01, 2030	DP			
<u>NERATINIB MALEATE - NERLYNX</u>						
N 208051 001	6288082	Sep 24, 2019	DS DP U-2043		NCE	Jul 17, 2022
	7399865	Dec 29, 2025	DS DP			
	7982043	Oct 08, 2025	U-2043			
	8518446	Nov 20, 2030	DP U-2043			
	8790708	Nov 05, 2030	DP U-2043			
	9139558	Oct 15, 2028	U-2043			
	9211291	Mar 24, 2030	U-2043			
	9630946	Oct 15, 2028	U-2043			
<u>NIRAPARIB TOSYLATE - ZEJULA</u>						
N 208447 001	8071623	Mar 22, 2030	DS DP		NCE	Mar 27, 2022
	8436185	Apr 24, 2029	DS		ODE	Mar 27, 2024
<u>NUSINERSEN SODIUM - SPINRAZA</u>						
N 209531 001	6166197	Dec 26, 2017	DS		ODE	Dec 23, 2023
	6210892	Oct 07, 2018	U-1942			
	7101993	Sep 05, 2023	DS			
	7838657	Jul 11, 2027	DS			
	8110560	Dec 05, 2025	U-1942			
	8110560	Dec 05, 2025	U-1943			
	8110560	Dec 05, 2025	U-1944			
	8361977	May 27, 2030	DS DP			
	8980853	Nov 24, 2030	U-1941			
	9717750	Jun 17, 2030	U-1942			
	9717750	Jun 17, 2030	U-1943			
	9717750	Jun 17, 2030	U-2093			
	9717750	Jun 17, 2030	U-2094			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	>A> 7151102	Apr 29, 2022	DS DP		NCE	Dec 19, 2019
	>A> 7449464	Oct 11, 2024	DS DP		NP	Aug 17, 2020
	>A> 7981889	Oct 11, 2024	DS DP		ODE	Dec 19, 2021
	>A> 8143241	Aug 12, 2027	U-2101			
	>A> 8143241	Aug 12, 2027	U-2102			
	>A> 8143241	Aug 12, 2027	U-2103			
	>A> 8475842	Dec 31, 2029	DP			
	>A> 8859562	Aug 04, 2031	U-2101			
	>A> 8859562	Aug 04, 2031	U-2102			
	>A> 8912187	Mar 12, 2024	U-2101			
	>A> 8912187	Mar 12, 2024	U-2102			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	>A> 7151102	Apr 29, 2022	DS DP		NCE	Dec 19, 2019
	>A> 7449464	Oct 11, 2024	DS DP		NP	Aug 17, 2020
	>A> 7981889	Oct 11, 2024	DS DP		ODE	Dec 19, 2021
	>A> 8143241	Aug 12, 2027	U-2101			
	>A> 8143241	Aug 12, 2027	U-2102			
	>A> 8143241	Aug 12, 2027	U-2103			
	>A> 8475842	Dec 31, 2029	DP			
	>A> 8859562	Aug 04, 2031	U-2101			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	>A> 8859562	Aug 04, 2031	U-2102			
	>A> 8912187	Mar 12, 2024	U-2101			
	>A> 8912187	Mar 12, 2024	U-2102			
<u>OLODATEROL HYDROCHLORIDE - STRIVERDI RESPIMAT</u>						
N 203108 001	8733341	Oct 16, 2030	DP			
<u>OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT</u>						
N 206756 001	6149054	Dec 19, 2016	DP			
	6149054*PED	Jun 19, 2017				
	6846413	Aug 28, 2018	DP			
	6846413*PED	Feb 28, 2019				
	6977042	Aug 28, 2018	DP			
	6977042*PED	Feb 28, 2019				
	6988496	Feb 23, 2020	DP			
	6988496*PED	Aug 23, 2020				
	7284474	Aug 26, 2024	DP			
	7284474*PED	Feb 26, 2025				
	7396341	Oct 10, 2026	DP			
	7396341*PED	Apr 10, 2027				
	7802568	Feb 26, 2019	DP			
	7802568*PED	Aug 26, 2019				
	7837235	Mar 13, 2028	DP			
	7837235*PED	Sep 13, 2028				
	8733341	Oct 16, 2030	DP			
<u>OLOPATADINE HYDROCHLORIDE - OLOPATADINE HYDROCHLORIDE</u>						
A 090848 001					PC	Dec 05, 2017
<u>OLOPATADINE HYDROCHLORIDE - PAZEO</u>						
N 206276 001	9533053	May 19, 2032	DP			
<u>OMACETAXINE MEPESUCCINATE - SYNRIBO</u>						
N 203585 001	6987103	Oct 26, 2026	U-1300			
<u>OMBITASVIR; PARITAPREVR; RITONAVIR - TECHNIVIE</u>						
N 207931 001					I-743	Jul 24, 2018
<u>OMEGA-3-CARBOXYLIC ACIDS - EPANOVA</u>						
N 205060 001	5792795	May 13, 2018	DP			
	5948818	May 13, 2018	DP			
<u>ORITAVANCIN DIPHOSPHATE - ORBACTIV</u>						
N 206334 001	9649352	Jul 16, 2035	DP			
	9682061	Apr 26, 2030	U-1569			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 001	9732058	Jul 25, 2032	DS DP U-1777			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 002	9732058	Jul 25, 2032	DS DP U-1777			
<u>OSPEMIFENE - OSPHENA</u>						
N 203505 001	6245819	Jul 21, 2020	U-1370			
	9566252	Jul 21, 2020	U-1370			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 001	>A> 9248195	Jul 07, 2023	U-1556			
	9592200	Jul 07, 2023	DP			
	9682075	Dec 10, 2030	DP U-1556			
	9737530	Sep 02, 2036	DP U-1556			
	>A> 9763883	Jul 07, 2023	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 001	>A> 9248195	Jul 07, 2023	U-1556			
	9592200	Jul 07, 2023	DP			
	9682075	Dec 10, 2030	DP U-1556			
	9737530	Sep 02, 2036	DP U-1556			
	>A> 9763883	Jul 07, 2023	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 002	>A> 9248195	Jul 07, 2023	U-1556			
	9592200	Jul 07, 2023	DP			
	9682075	Dec 10, 2030	DP U-1556			
	9737530	Sep 02, 2036	DP U-1556			
	>A> 9763883	Jul 07, 2023	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 003	>A> 9248195	Jul 07, 2023	U-1556			
	9592200	Jul 07, 2023	DP			
	9682075	Dec 10, 2030	DP U-1556			
	9737530	Sep 02, 2036	DP U-1556			
	>A> 9763883	Jul 07, 2023	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 004	>A> 9248195	Jul 07, 2023	U-1556			
	9592200	Jul 07, 2023	DP			
	9682075	Dec 10, 2030	DP U-1556			
	9737530	Sep 02, 2036	DP U-1556			
	>A> 9763883	Jul 07, 2023	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 005	>A> 9248195	Jul 07, 2023	U-1556			
	9592200	Jul 07, 2023	DP			
	9682075	Dec 10, 2030	DP U-1556			
	9737530	Sep 02, 2036	DP U-1556			
	>A> 9763883	Jul 07, 2023	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 001	9675610	Jun 16, 2023	DP			
	>A> 9763933	Aug 24, 2027	DP			
	>A> 9770416	Aug 24, 2027	DP			
	>A> 9775808	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 002	9675610	Jun 16, 2023	DP			
	>A> 9763933	Aug 24, 2027	DP			
	>A> 9770416	Aug 24, 2027	DP			
	>A> 9775808	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 003	9675610	Jun 16, 2023	DP			
	>A> 9763933	Aug 24, 2027	DP			
	>A> 9770416	Aug 24, 2027	DP			
	>A> 9775808	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 004	9675610	Jun 16, 2023	DP			
	>A> 9763933	Aug 24, 2027	DP			
	>A> 9770416	Aug 24, 2027	DP			
	>A> 9775808	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005	9675610	Jun 16, 2023	DP			
	>A> 9763933	Aug 24, 2027	DP			
	>A> 9770416	Aug 24, 2027	DP			
	>A> 9775808	Aug 24, 2027	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005	9675610	Jun 16, 2023	DP			
	>A> 9763933	Aug 24, 2027	DP			
	>A> 9770416	Aug 24, 2027	DP			
	>A> 9775808	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 006	9675610	Jun 16, 2023	DP			
	>A> 9763933	Aug 24, 2027	DP			
	>A> 9770416	Aug 24, 2027	DP			
	>A> 9775808	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 007	9675610	Jun 16, 2023	DP			
	>A> 9763933	Aug 24, 2027	DP			
	>A> 9770416	Aug 24, 2027	DP			
	>A> 9775808	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXAYDO</u>						
N 202080 001	9492443	May 26, 2024	DP			
<u>OXYCODONE HYDROCHLORIDE - OXAYDO</u>						
N 202080 002	9492443	May 26, 2024	DP			
<u>OXYCODONE HYDROCHLORIDE - ROXYBOND</u>						
N 209777 001	7955619	Aug 12, 2028	DP			
<u>OXYCODONE HYDROCHLORIDE - ROXYBOND</u>						
N 209777 002	7955619	Aug 12, 2028	DP			
<u>OXYCODONE HYDROCHLORIDE - ROXYBOND</u>						
N 209777 003	7955619	Aug 12, 2028	DP			
<u>OXYMETAZOLINE HYDROCHLORIDE - RHOFAD</u>						
N 208552 001	7812049	May 02, 2028	U-1959		NP	Jan 18, 2020
	8420688	Aug 02, 2024	U-1959			
	8883838	Dec 01, 2031	DP			
<u>PACLITAXEL - ABRAXANE</u>						
N 021660 001	9393318	Mar 04, 2032	U-1290			
	9511046	Jan 12, 2034	U-1434			
	9597409	Mar 04, 2032	U-1290			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	7456168	Jan 16, 2023	U-1998			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002	7456168	Jan 16, 2023	U-1998			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 003	7456168	Jan 16, 2023	U-1998			
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 001	9439854	Jan 30, 2024	DP			
	9439854*PED	Jul 30, 2024				
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 002	9439854	Jan 30, 2024	DP			
	9439854*PED	Jul 30, 2024				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PERAMIVIR - RAPIVAB</u>						
N 206426 001					>A> NPP	Sep 20, 2020
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 001	6949571	Jun 08, 2021	DS DP U-106			
	6949571	Jun 08, 2021	DS DP U-2088			
	6949571	Jun 08, 2021	DS DP U-2089			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 002	6949571	Jun 08, 2021	DS DP U-106			
	6949571	Jun 08, 2021	DS DP U-2088			
	6949571	Jun 08, 2021	DS DP U-2089			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 003	6949571	Jun 08, 2021	DS DP U-106			
	6949571	Jun 08, 2021	DS DP U-2088			
	6949571	Jun 08, 2021	DS DP U-2089			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 004	6949571	Jun 08, 2021	DS DP U-106			
	6949571	Jun 08, 2021	DS DP U-2088			
	6949571	Jun 08, 2021	DS DP U-2089			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 005	6949571	Jun 08, 2021	DS DP U-106			
	6949571	Jun 08, 2021	DS DP U-2088			
	6949571	Jun 08, 2021	DS DP U-2089			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 006	6949571	Jun 08, 2021	DS DP U-106			
	6949571	Jun 08, 2021	DS DP U-2088			
	6949571	Jun 08, 2021	DS DP U-2089			
<u>PERAMPANEL - FYCOMPA</u>						
N 208277 001	6949571	Jun 08, 2021	DS DP U-106			
	6949571	Jun 08, 2021	DS DP U-2088			
	6949571	Jun 08, 2021	DS DP U-2089			
<u>PERFLUTREN - DEFINITY</u>						
N 021064 001	9545457	Jan 13, 2019	U-665			
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318 001	9566271	Jan 15, 2024	U-1974			
	>A> 9765053	Jul 27, 2022	U-1974			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 001	7566729	Apr 22, 2029	U-2077		NCE	Oct 16, 2019
	7566729	Apr 22, 2029	U-2078		ODE	Oct 15, 2021
	7635707	Apr 22, 2029	U-2072			
	7635707	Apr 22, 2029	U-2073			
	7635707	Apr 22, 2029	U-2074			
	7635707	Apr 22, 2029	U-2075			
	7635707	Apr 22, 2029	U-2076			
	7635707	Apr 22, 2029	U-2083			
	7767700	Dec 18, 2027	U-2080			
	7816383	Jan 08, 2030	U-2042			
	7816383	Jan 08, 2030	U-2050			
	7910610	Jan 08, 2030	U-2048			
	7910610	Jan 08, 2030	U-2049			
	8013002	Jan 08, 2030	U-2047			
	8013002	Jan 08, 2030	U-2082			
	8084475	Jan 08, 2030	U-2052			
	8084475	Jan 08, 2030	U-2054			
	8318780	Jan 08, 2030	U-2046			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 001	8318780	Jan 08, 2030	U-2081			
	8383150	Sep 22, 2026	DP U-1607			
	8420674	Dec 18, 2017	U-2079			
	8592462	Apr 22, 2029	U-2055			
	8592462	Apr 22, 2029	U-2056			
	8592462	Apr 22, 2029	U-2057			
	8592462	Apr 22, 2029	U-2058			
	8592462	Apr 22, 2029	U-2059			
	8592462	Apr 22, 2029	U-2060			
	8592462	Apr 22, 2029	U-2061			
	8592462	Apr 22, 2029	U-2062			
	8592462	Apr 22, 2029	U-2063			
	8609701	Apr 22, 2029	U-2064			
	8609701	Apr 22, 2029	U-2065			
	8609701	Apr 22, 2029	U-2066			
	8609701	Apr 22, 2029	U-2067			
	8609701	Apr 22, 2029	U-2068			
	8609701	Apr 22, 2029	U-2069			
	8609701	Apr 22, 2029	U-2070			
	8648098	Jan 08, 2030	U-2051			
	8648098	Jan 08, 2030	U-2052			
	8754109	Jan 08, 2030	U-2053			
	8778947	Aug 30, 2033	U-2044			
	8778947	Aug 30, 2033	U-2045			
	9561217	Jan 25, 2022	DP			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 002					NCE ODE	Oct 16, 2019 Oct 15, 2021
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 003	7566729	Apr 22, 2029	U-2077		NCE ODE	Oct 16, 2019 Oct 15, 2021
	7566729	Apr 22, 2029	U-2078			
	7635707	Apr 22, 2029	U-2072			
	7635707	Apr 22, 2029	U-2073			
	7635707	Apr 22, 2029	U-2074			
	7635707	Apr 22, 2029	U-2075			
	7635707	Apr 22, 2029	U-2076			
	7635707	Apr 22, 2029	U-2083			
	7767700	Dec 18, 2027	U-2080			
	7816383	Jan 08, 2030	U-2042			
	7816383	Jan 08, 2030	U-2050			
	7910610	Jan 08, 2030	U-2048			
	7910610	Jan 08, 2030	U-2049			
	8013002	Jan 08, 2030	U-2047			
	8013002	Jan 08, 2030	U-2082			
	8084475	Jan 08, 2030	U-2052			
	8084475	Jan 08, 2030	U-2054			
	8318780	Jan 08, 2030	U-2046			
	8318780	Jan 08, 2030	U-2081			
	8383150	Sep 22, 2026	DP U-1607			
	8420674	Dec 18, 2017	U-2079			
	8592462	Apr 22, 2029	U-2055			
	8592462	Apr 22, 2029	U-2056			
	8592462	Apr 22, 2029	U-2057			
	8592462	Apr 22, 2029	U-2058			
	8592462	Apr 22, 2029	U-2059			
	8592462	Apr 22, 2029	U-2060			
	8592462	Apr 22, 2029	U-2061			
	8592462	Apr 22, 2029	U-2062			
	8592462	Apr 22, 2029	U-2063			
	8609701	Apr 22, 2029	U-2064			
	8609701	Apr 22, 2029	U-2065			
	8609701	Apr 22, 2029	U-2066			
	8609701	Apr 22, 2029	U-2067			
	8609701	Apr 22, 2029	U-2068			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 003	8609701	Apr 22, 2029	U-2069			
	8609701	Apr 22, 2029	U-2070			
	8648098	Jan 08, 2030	U-2051			
	8648098	Jan 08, 2030	U-2052			
	8754109	Jan 08, 2030	U-2053			
	8778947	Aug 30, 2033	U-2044			
	8778947	Aug 30, 2033	U-2045			
	9561217	Jan 25, 2022	DP			
<u>PLECANATIDE - TRULANCE</u>						
N 208745 001	7041786	Mar 25, 2023	DS		NCE	Jan 19, 2022
	7799897	Jun 09, 2022	DS			
	8637451	Mar 28, 2022	U-1964			
	9610321	Sep 11, 2031	U-1999			
	9616097	Jul 02, 2032	DP			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 001	9493470	Dec 12, 2033	DS DP U-1700			
	9493470	Dec 12, 2033	DS DP U-1948			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 002	9493470	Dec 12, 2033	DS DP U-1700			
	9493470	Dec 12, 2033	DS DP U-1948			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 003	8114874	Dec 22, 2026	DS DP			
	9493470	Dec 12, 2033	DS DP U-1700			
	9493470	Dec 12, 2033	DS DP U-1948			
<u>PRASUGREL HYDROCHLORIDE - PRASUGREL</u>						
A 205927 001					PC	Feb 11, 2018
<u>PRASUGREL HYDROCHLORIDE - PRASUGREL</u>						
A 205927 002					PC	Feb 11, 2018
<u>PREDNISONE - RAYOS</u>						
N 202020 001	9504699	Aug 03, 2027	U-1362			
<u>PREDNISONE - RAYOS</u>						
N 202020 002	9504699	Aug 03, 2027	U-1362			
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 022145 001	7169780	Oct 03, 2023	DS DP		D-167	May 26, 2020
	7169780*PED	Apr 03, 2024			PED	Nov 26, 2020
	7217713	Oct 21, 2022	U-257			
	7217713*PED	Apr 21, 2023				
	7435734	Oct 21, 2022	U-257			
	7435734	Oct 21, 2022	U-900			
	7435734*PED	Apr 21, 2023				
	7754731	Mar 11, 2029	DS DP U-257			
	7754731*PED	Sep 11, 2029				
<u>RALTEGRAVIR POTASSIUM - ISENTRESS HD</u>						
N 022145 002	7169780	Oct 03, 2023	DS DP		NS	May 26, 2020
	7169780*PED	Apr 03, 2024			PED	Nov 26, 2020
	7217713	Oct 21, 2022	U-257			
	7217713*PED	Apr 21, 2023				
	7435734	Oct 21, 2022	U-257			
	7435734	Oct 21, 2022	U-900			
	7435734*PED	Apr 21, 2023				
	7754731	Mar 11, 2029	DS DP U-257			
	7754731*PED	Sep 11, 2029				
	9649311	Oct 21, 2030	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RALTEGRAVIR POTASSIUM - ISENTRESS HD</u>						
N 022145 002	9649311*PED	Apr 21, 2031				
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 203045 001	7169780	Oct 03, 2023	DS DP			
	7169780*PED	Apr 03, 2024				
	7217713	Oct 21, 2022		U-257		
	7217713*PED	Apr 21, 2023				
	7435734	Oct 21, 2022		U-257		
	7435734*PED	Apr 21, 2023				
	7754731	Mar 11, 2029	DS DP	U-257		
	7754731*PED	Sep 11, 2029				
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 203045 002	7169780	Oct 03, 2023	DS DP			
	7169780*PED	Apr 03, 2024				
	7217713	Oct 21, 2022		U-257		
	7217713*PED	Apr 21, 2023				
	7435734	Oct 21, 2022		U-257		
	7435734*PED	Apr 21, 2023				
	7754731	Mar 11, 2029	DS DP	U-257		
	7754731*PED	Sep 11, 2029				
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 205786 001	7169780	Oct 03, 2023	DS DP			
	7169780*PED	Apr 03, 2024				
	7217713	Oct 21, 2022		U-257		
	7217713*PED	Apr 21, 2023				
	7435734	Oct 21, 2022		U-257		
	7435734*PED	Apr 21, 2023				
	7754731	Mar 11, 2029	DS DP	U-257		
	7754731*PED	Sep 11, 2029				
<u>RASAGILINE MESYLATE - RASAGILINE MESYLATE</u>						
A 201823 001					PC	Jul 01, 2017
<u>RASAGILINE MESYLATE - RASAGILINE MESYLATE</u>						
A 201823 002					PC	Jul 01, 2017
<u>RASAGILINE MESYLATE - RASAGILINE MESYLATE</u>						
A 201950 001					PC	Jul 01, 2017
<u>RASAGILINE MESYLATE - RASAGILINE MESYLATE</u>						
A 201950 002					PC	Jul 01, 2017
<u>REGADENOSON - LEXISCAN</u>						
N 022161 001					M-194	Jan 17, 2020
<u>REGORAFENIB - STIVARGA</u>						
N 203085 001	7351834	Jun 28, 2022	DS		I-744 ODE	Apr 27, 2020 Apr 27, 2024
<u>RIBOCICLIB SUCCINATE - KISOALI</u>						
N 209092 001	8324225	Jun 17, 2028	DS DP		NCE	Mar 13, 2022
	8415355	Feb 19, 2031	DS DP			
	8685980	May 25, 2030	DS DP			
	8962630	Dec 09, 2029		U-1981		
	9193732	Nov 09, 2031	DS DP			
	9416136	Aug 20, 2029		U-1981		
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554 001	9629828	Jul 24, 2029		U-1994		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RIVAROXABAN - XARELTO</u>						
N 022406 001	9539218	Feb 17, 2034	U-1953			
	9539218	Feb 17, 2034	U-1954			
	9539218	Feb 17, 2034	U-1955			
	9539218	Feb 17, 2034	U-1956			
	9539218	Feb 17, 2034	U-1957			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 002	9539218	Feb 17, 2034	U-1953			
	9539218	Feb 17, 2034	U-1954			
	9539218	Feb 17, 2034	U-1955			
	9539218	Feb 17, 2034	U-1956			
	9539218	Feb 17, 2034	U-1957			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 003	9539218	Feb 17, 2034	U-1953			
	9539218	Feb 17, 2034	U-1954			
	9539218	Feb 17, 2034	U-1955			
	9539218	Feb 17, 2034	U-1957			
<u>ROFLUMILAST - DALIRESP</u>						
N 022522 001					M-208	Aug 31, 2020
<u>ROLAPITANT HYDROCHLORIDE - VARUBI</u>						
N 206500 001	8404702	Apr 04, 2027	U-1741			
<u>ROPINIROLE HYDROCHLORIDE - EQUIP XL</u>						
N 022008 001					M-203	Mar 23, 2020
<u>ROPINIROLE HYDROCHLORIDE - EQUIP XL</u>						
N 022008 002					M-203	Mar 23, 2020
<u>ROPINIROLE HYDROCHLORIDE - EQUIP XL</u>						
N 022008 003					M-203	Mar 23, 2020
<u>ROPINIROLE HYDROCHLORIDE - EQUIP XL</u>						
N 022008 004					M-203	Mar 23, 2020
<u>ROPINIROLE HYDROCHLORIDE - EQUIP XL</u>						
N 022008 005					M-203	Mar 23, 2020
<u>ROPINIROLE HYDROCHLORIDE - EQUIP XL</u>						
N 022008 006					M-203	Mar 23, 2020
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 001	7351701	Jul 23, 2024	U-2012		ODE	Dec 19, 2023
	7531530	Jul 23, 2024	U-2012			
	8071579	Aug 12, 2027	U-2012			
	8143241	Aug 12, 2027	U-2012			
	8859562	Aug 04, 2031	U-2012			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 002	7351701	Jul 23, 2024	U-2012		ODE	Dec 19, 2023
	7531530	Jul 23, 2024	U-2012			
	8071579	Aug 12, 2027	U-2012			
	8143241	Aug 12, 2027	U-2012			
	8859562	Aug 04, 2031	U-2012			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 003	6495541	Jan 10, 2020	DS DP			
	7351701	Jul 23, 2024	U-2012			
	7531530	Jul 23, 2024	U-2012			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 003	8071579	Aug 12, 2027	U-2012			
	8143241	Aug 12, 2027	U-2012			
	8754072	Feb 10, 2031	DS DP			
	8859562	Aug 04, 2031	U-2012			
	9045487	Feb 10, 2031	DS DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 001	9662335	Dec 12, 2026	DS			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 002	9662335	Dec 12, 2026	DS			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 003	9662335	Dec 12, 2026	DS			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 004	9662335	Dec 12, 2026	DS			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 005	9662335	Dec 12, 2026	DS			
<u>SACROSIDASE - SUCRAID</u>						
N 020772 001	9469847	Feb 07, 2034	DS DP			
<u>SAFINAMIDE MESYLATE - XADAGO</u>						
N 207145 001	8076515	Dec 10, 2028	DS DP U-1993		NCE	Mar 21, 2022
	8278485	Jun 08, 2027	DS U-1993			
	8283380	Sep 01, 2027	U-1993			
<u>SAFINAMIDE MESYLATE - XADAGO</u>						
N 207145 002	8076515	Dec 10, 2028	DS DP U-1993		NCE	Mar 21, 2022
	8278485	Jun 08, 2027	DS U-1993			
	8283380	Sep 01, 2027	U-1993			
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 001					M-198	Feb 27, 2020
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 002					M-198	Feb 27, 2020
<u>SECNIDAZOLE - SOLOSEC</u>						
N 209363 001					>A> NCE	Sep 15, 2022
					>A> GAIN	Sep 15, 2027
<u>SIMEPREVIR SODIUM - OLYSIO</u>						
N 205123 001	9623022	Jul 28, 2026	U-1467			
<u>SIMVASTATIN - SIMVASTATIN</u>						
N 206679 001	9597289	Feb 23, 2030	DP			
<u>SIMVASTATIN - SIMVASTATIN</u>						
N 206679 002	9597289	Feb 23, 2030	DP			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 001	6303661	Apr 24, 2017	U-1996			
	6890898	Feb 02, 2019	U-1997			
	7078381	Feb 02, 2019	U-1997			
	7459428	Feb 02, 2019	U-1945			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 002	6303661	Apr 24, 2017	U-1996			
	6890898	Feb 02, 2019	U-1997			
	7078381	Feb 02, 2019	U-1997			
	7459428	Feb 02, 2019	U-1945			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 003	6303661	Apr 24, 2017	U-1996			
	6890898	Feb 02, 2019	U-1997			
	7078381	Feb 02, 2019	U-1997			
	7459428	Feb 02, 2019	U-1945			
<u>SODIUM NITRITE; SODIUM THIOSULFATE - NITHIODOTE</u>						
N 201444 001	9345724	Mar 29, 2031	DS DP U-2015			
	9585912	Mar 29, 2031	DS DP			
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	9539330	Dec 22, 2019	DP			
<u>SODIUM THIOSULFATE - SODIUM THIOSULFATE</u>						
N 203923 001	9345724	Mar 29, 2031	DS DP U-2015			
	9585912	Mar 29, 2031	DS DP			
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671 001	9549941	Mar 26, 2029	U-1958		NPP ODE	Apr 07, 2020 Apr 07, 2024
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 208341 001	>A> 9757406	Jan 30, 2034	DP		NPP	Aug 01, 2020
<u>SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR - VOSEVI</u>						
N 209195 001	7964580	Mar 26, 2029	DS DP U-2039		NCE	Dec 06, 2018
	7964580	Mar 26, 2029	DS DP U-2040		NCE	Jun 28, 2021
	8334270	Mar 21, 2028	DS DP U-2039		NCE	Jul 18, 2022
	8334270	Mar 21, 2028	DS DP U-2040			
	8575135	Nov 05, 2033	DS DP U-2039			
	8575135	Nov 05, 2033	DS DP U-2040			
	8580765	Mar 21, 2028	DS DP U-2039			
	8580765	Mar 21, 2028	DS DP U-2040			
	8618076	Dec 11, 2030	DS DP U-2039			
	8618076	Dec 11, 2030	DS DP U-2040			
	8633309	Mar 26, 2029	DS DP U-2039			
	8633309	Mar 26, 2029	DS DP U-2040			
	8735372	Mar 21, 2028	DS DP U-2039			
	8735372	Mar 21, 2028	DS DP U-2040			
	8889159	Mar 26, 2029	DS DP U-2039			
	8889159	Mar 26, 2029	DS DP U-2040			
	8921341	Nov 16, 2032	DS DP U-2039			
	8921341	Nov 16, 2032	DS DP U-2040			
	8940718	Nov 16, 2032	DS DP U-2039			
	8940718	Nov 16, 2032	DS DP U-2040			
	9085573	Mar 21, 2028	DS DP U-2039			
	9085573	Mar 21, 2028	DS DP U-2040			
	9284342	Sep 13, 2030	DS DP U-2039			
	9284342	Sep 13, 2030	DS DP U-2040			
	9296782	Jul 17, 2034	DS DP			
	9585906	Mar 21, 2028	DS DP U-2039			
	9585906	Mar 21, 2028	DS DP U-2040			
<u>SOLIFENACIN SUCCINATE - VESICARE</u>						
N 021518 001	>A> 6017927	Nov 19, 2018	DS DP			
	>A> 6017927*PED	May 19, 2019				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOLIFENACIN SUCCINATE - VESICARE</u>						
N 021518 002	>A> 6017927	Nov 19, 2018	DS DP			
	>A> 6017927*PED	May 19, 2019				
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXP</u>						
N 021148 008	9687611	Feb 27, 2027	DP			
	RE46363	Aug 03, 2026	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXP</u>						
N 021148 009	9687611	Feb 27, 2027	DP			
	RE46363	Aug 03, 2026	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXP</u>						
N 021148 010	9687611	Feb 27, 2027	DP			
	RE46363	Aug 03, 2026	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXP</u>						
N 021148 011	9687611	Feb 27, 2027	DP			
	RE46363	Aug 03, 2026	DP			
<u>SORAFENIB TOSYLATE - NEXAVAR</u>						
N 021923 001	>A> 9737488	Sep 10, 2028	DP U-1480			
	>A> 9737488	Sep 10, 2028	DP U-1696			
	>A> 9737488	Sep 10, 2028	DP U-2107			
<u>SOTALOL HYDROCHLORIDE - SOTYLIZE</u>						
N 205108 001	9724297	Aug 31, 2035	DP U-2096			
<u>SPIRONOLACTONE - CAROSPIR</u>						
N 209478 001	>A> 9757394	Oct 28, 2036	DP U-2109			
<u>SUCROFERRIC OXYHYDROXIDE - VELPHORO</u>						
N 205109 001	9561251	Jan 23, 2030	DP U-1468			
<u>SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES - LUMASON</u>						
N 203684 001	>A> 5686060	Nov 11, 2019	DS DP			
<u>SUMATRIPTAN SUCCINATE - ONZETRA XSAIL</u>						
N 206099 001	9649456	Oct 21, 2030	DP U-1719			
	9649456	Oct 21, 2030	DP U-2010			
	9649456	Oct 21, 2030	DP U-2011			
<u>TACROLIMUS - ENVARUS XR</u>						
N 206406 001	9549918	May 30, 2028	DP			
<u>TACROLIMUS - ENVARUS XR</u>						
N 206406 002	9549918	May 30, 2028	DP			
<u>TACROLIMUS - ENVARUS XR</u>						
N 206406 003	9549918	May 30, 2028	DP			
<u>TALC - STERITALC</u>						
N 205555 001					ODE	May 01, 2024
<u>TALC - STERITALC</u>						
N 205555 002					ODE	May 01, 2024
<u>TALC - STERITALC</u>						
N 205555 003					ODE	May 01, 2024

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	9539234	Jan 25, 2033	U-1934			
	9549913	Jan 25, 2033	U-1486			
	9730910	May 17, 2034	U-2085			
<u>TAVABOROLE - KERYDIN</u>						
N 204427 001	7582621	May 26, 2027	U-2016			
	9549938	Feb 16, 2026	U-1951			
	9566289	Feb 16, 2026	DP			
	9566290	Feb 16, 2026	U-1970			
	9572823	Feb 16, 2026	U-1970			
<u>TEDUGLUTIDE RECOMBINANT - GATEX KIT</u>						
N 203441 001	9539310	Nov 01, 2025	U-1320			
	9545434	Nov 01, 2025	U-1320			
	9545435	Nov 01, 2025	U-1320			
	9555079	Nov 01, 2025	U-1320			
	9572867	Nov 01, 2025	U-1320			
	9592273	Nov 01, 2025	U-1320			
	9592274	Nov 01, 2025	U-1320			
<u>TELOTTRISTAT ETIPRATE - XERMELO</u>						
N 208794 001	7553840	Dec 11, 2027	DS		NCE	Feb 28, 2022
	7709493	Dec 11, 2027	DS	U-1979	ODE	Feb 28, 2024
	7968559	Dec 11, 2027		U-1979		
	8193204	Feb 27, 2031	DS			
	8653094	Dec 19, 2028		U-1979		
<u>TESTOSTERONE - VOGELXO</u>						
N 204399 002	9662340	Feb 11, 2034	DP U-1531			
<u>TESTOSTERONE - VOGELXO</u>						
N 204399 003	9662340	Feb 11, 2034	DP U-1531			
<u>THIOTEPA - TEPADINA</u>						
N 208264 001					I-747 ODE	Jan 26, 2020 Jan 26, 2024
<u>THIOTEPA - TEPADINA</u>						
N 208264 002					I-747 ODE	Jan 26, 2020 Jan 26, 2024
<u>TICAGRELOR - BRILINTA</u>						
N 022433 001	6525060	Dec 02, 2019	DS DP U-1171		Y	
	6525060	Dec 02, 2019	DS DP U-1860		Y	
	6525060	Dec 02, 2019	DS DP U-1862		Y	
	6525060	Dec 02, 2019	DS DP U-1863		Y	
	RE46276	Oct 30, 2024	DS DP U-1935			
	RE46276	Oct 30, 2024	DS DP U-1936			
	RE46276	Oct 30, 2024	DS DP U-1937			
	RE46276	Oct 30, 2024	DS DP U-1938			
<u>TICAGRELOR - BRILINTA</u>						
N 022433 002	6525060	Dec 02, 2019	DS DP U-1171		Y	
	6525060	Dec 02, 2019	DS DP U-1860		Y	
	6525060	Dec 02, 2019	DS DP U-1862		Y	
	6525060	Dec 02, 2019	DS DP U-1863		Y	
	RE46276	Oct 30, 2024	DS DP U-1935			
	RE46276	Oct 30, 2024	DS DP U-1936			
	RE46276	Oct 30, 2024	DS DP U-1937			
	RE46276	Oct 30, 2024	DS DP U-1938			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIGECYCLINE - TYGACIL</u>						
N 021821 001	9694078	Mar 13, 2026	DP			
<u>TIOTROPIUM BROMIDE - SPIRIVA</u>						
N 021395 001	6777423	Sep 24, 2021	DS DP			
	6777423*PED	Mar 24, 2022				
	6908928	Sep 24, 2021	DS DP U-566			
	6908928	Sep 24, 2021	DS DP U-762			
	6908928*PED	Mar 24, 2022				
	7070800	Jan 22, 2022	DP U-566			
	7070800*PED	Jul 22, 2022				
	7309707	Sep 24, 2021	DS DP			
	7309707*PED	Mar 24, 2022				
	7642268	Sep 24, 2021	DS DP			
	7642268*PED	Mar 24, 2022				
	7694676	Mar 12, 2027	DP			
	7694676*PED	Sep 12, 2027				
	8022082	Jan 19, 2026	DP U-1186			
	8022082*PED	Jul 19, 2026				
	9010323	Apr 19, 2030	DP			
	RE38912	Oct 11, 2021	DP			
	RE38912*PED	Apr 11, 2022				
	RE39820	Jan 30, 2018	DS DP U-566			
	RE39820*PED	Jul 30, 2018				
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 001	5964416	Oct 04, 2016	DP		NPP	Feb 15, 2020
	5964416*PED	Apr 04, 2017			PED	Aug 15, 2020
	6149054	Dec 16, 2016	DP			
	6149054*PED	Jun 16, 2017				
	6176442*PED	Dec 01, 2016				
	6453795	Dec 05, 2016	DP			
	6453795*PED	Jun 05, 2017				
	6726124	Oct 04, 2016	DP			
	6726124*PED	Apr 04, 2017				
	6846413	Aug 28, 2018	DP			
	6846413*PED	Feb 28, 2019				
	6977042	Aug 28, 2018	DP			
	6977042*PED	Feb 28, 2019				
	6988496	Feb 23, 2020	DP			
	6988496*PED	Aug 23, 2020				
	7104470	Oct 04, 2016	DP			
	7104470*PED	Apr 04, 2017				
	7246615*PED	Dec 01, 2016				
	7284474	Aug 26, 2024	DP			
	7284474*PED	Feb 26, 2025				
	7396341	Oct 10, 2026	DP			
	7396341*PED	Apr 10, 2027				
	7802568	Feb 26, 2019	DP			
	7802568*PED	Aug 26, 2019				
	7837235	Mar 13, 2028	DP			
	7837235*PED	Sep 13, 2028				
	7896264	May 26, 2025	DP			
	7896264*PED	Nov 26, 2025				
	7988001	Aug 04, 2021	DP			
	7988001*PED	Feb 04, 2022				
	8733341	Oct 16, 2030	DP			
	8733341*PED	Apr 16, 2031				
	RE39820	Jan 30, 2018	DS DP U-1593			
	RE39820*PED	Jul 30, 2018				
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 002	5964416	Oct 04, 2016	DP		NPP	Feb 15, 2020
	6149054	Dec 16, 2016	DP		PED	Aug 15, 2020
	6149054*PED	Jun 16, 2017				
	6453795	Dec 05, 2016	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 002	6726124	Oct 04, 2016	DP			
	6846413	Aug 28, 2018	DP			
	6846413*PED	Feb 28, 2019				
	6977042	Aug 28, 2018	DP			
	6977042*PED	Feb 28, 2019				
	6988496	Feb 23, 2020	DP			
	6988496*PED	Aug 23, 2020				
	7104470	Oct 04, 2016	DP			
	7284474	Aug 26, 2024	DP			
	7284474*PED	Feb 26, 2025				
	7396341	Oct 10, 2026	DP			
	7396341*PED	Apr 10, 2027				
	7802568	Feb 26, 2019	DP			
	7802568*PED	Aug 26, 2019				
	7837235	Mar 13, 2028	DP			
	7837235*PED	Sep 13, 2028				
	7896264	May 26, 2025	DP			
	7896264*PED	Nov 26, 2025				
	7988001	Aug 04, 2021	DP			
	7988001*PED	Feb 04, 2022				
	8733341	Oct 16, 2030	DP			
	8733341*PED	Apr 16, 2031				
	RE39820	Jan 30, 2018	DS DP			
	RE39820*PED	Jul 30, 2018				
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981 001	9527833	Jun 17, 2034	DS DP			
	RE46284	Dec 16, 2026			U-1751	
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981 002	9527833	Jun 17, 2034	DS DP			
	RE46284	Dec 16, 2026			U-1751	
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214 001	RE41783	Dec 08, 2025	DS			
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 001	RE41783	Dec 08, 2025	DS			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 001	8298576	Apr 04, 2028	DP U-106			
	8298576	Apr 04, 2028	DP U-1992			
	8298580	Nov 16, 2027	DP U-106			
	8298580	Nov 16, 2027	DP U-1992			
	8663683	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-1992			
	8877248	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-1992			
	8889191	Nov 16, 2027	U-106			
	8889191	Nov 16, 2027	U-1992			
	8992989	Nov 16, 2027	DP U-1675			
	8992989	Nov 16, 2027	DP U-1992			
	9549940	Nov 16, 2027	DP U-1675			
	9549940	Nov 16, 2027	DP U-1992			
	9555004	Nov 16, 2027	DP U-1675			
	9555004	Nov 16, 2027	DP U-1992			
	9622983	Nov 16, 2027	DP U-1675			
	9622983	Nov 16, 2027	DP U-1992			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 002	8298576	Apr 04, 2028	DP U-106			
	8298576	Apr 04, 2028	DP U-1992			
	8298580	Nov 16, 2027	DP U-106			
	8298580	Nov 16, 2027	DP U-1992			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 002	8663683	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-1992			
	8877248	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-1992			
	8889191	Nov 16, 2027	U-106			
	8889191	Nov 16, 2027	U-1992			
	8992989	Nov 16, 2027	DP U-1675			
	8992989	Nov 16, 2027	DP U-1992			
	9549940	Nov 16, 2027	DP U-1675			
	9549940	Nov 16, 2027	DP U-1992			
	9555004	Nov 16, 2027	DP U-1675			
	9555004	Nov 16, 2027	DP U-1992			
	9622983	Nov 16, 2027	DP U-1675			
	9622983	Nov 16, 2027	DP U-1992			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 003	8298576	Apr 04, 2028	DP U-106			
	8298576	Apr 04, 2028	DP U-1992			
	8298580	Nov 16, 2027	DP U-106			
	8298580	Nov 16, 2027	DP U-1992			
	8663683	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-1992			
	8877248	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-1992			
	8889191	Nov 16, 2027	U-106			
	8889191	Nov 16, 2027	U-1992			
	8992989	Nov 16, 2027	DP U-1675			
	8992989	Nov 16, 2027	DP U-1992			
	9549940	Nov 16, 2027	DP U-1675			
	9549940	Nov 16, 2027	DP U-1992			
	9555004	Nov 16, 2027	DP U-1675			
	9555004	Nov 16, 2027	DP U-1992			
	9622983	Nov 16, 2027	DP U-1675			
	9622983	Nov 16, 2027	DP U-1992			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 004	8298576	Apr 04, 2028	DP U-106			
	8298576	Apr 04, 2028	DP U-1992			
	8298580	Nov 16, 2027	DP U-106			
	8298580	Nov 16, 2027	DP U-1992			
	8663683	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-1992			
	8877248	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-1992			
	8889191	Nov 16, 2027	U-106			
	8889191	Nov 16, 2027	U-1992			
	8992989	Nov 16, 2027	DP U-1675			
	8992989	Nov 16, 2027	DP U-1992			
	9549940	Nov 16, 2027	DP U-1675			
	9549940	Nov 16, 2027	DP U-1992			
	9555004	Nov 16, 2027	DP U-1675			
	9555004	Nov 16, 2027	DP U-1992			
	9622983	Nov 16, 2027	DP U-1675			
	9622983	Nov 16, 2027	DP U-1992			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 001	9555005	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 002	9555005	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 003	9555005	Mar 19, 2033	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 004	9555005	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 005	9555005	Mar 19, 2033	DP			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001	8703781	Oct 15, 2030	DS DP U-1712		I-745	Jun 22, 2020
	8703781	Oct 15, 2030	DS DP U-2033		ODE	Jun 22, 2024
	8835443	Sep 13, 2025	U-1581			
	8835443	Sep 13, 2025	U-1582			
	8835443	Sep 13, 2025	U-2020			
	8835443	Sep 13, 2025	U-2037			
	8952018	Oct 15, 2030	U-2020			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002	8703781	Oct 15, 2030	DS DP U-1712		I-745	Jun 22, 2020
	8703781	Oct 15, 2030	DS DP U-2033		ODE	Jun 22, 2024
	8835443	Sep 13, 2025	U-1581			
	8835443	Sep 13, 2025	U-1582			
	8835443	Sep 13, 2025	U-2020			
	8835443	Sep 13, 2025	U-2037			
	8952018	Oct 15, 2030	U-2020			
	9155706	Jan 28, 2032	DP			
	9271941	Jan 28, 2032	DP			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	8703781	Oct 15, 2030	DS DP U-1712		I-745	Jun 22, 2020
	8703781	Oct 15, 2030	DS DP U-2033		ODE	Jun 22, 2024
	8835443	Sep 13, 2025	U-1581			
	8835443	Sep 13, 2025	U-1582			
	8835443	Sep 13, 2025	U-2020			
	8835443	Sep 13, 2025	U-2037			
	8952018	Oct 15, 2030	U-2020			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 001	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
	9713599	Dec 16, 2024	U-2036			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 002	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
	9713599	Dec 16, 2024	U-2036			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 003	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
	9713599	Dec 16, 2024	U-2036			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 004	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
	9713599	Dec 16, 2024	U-2036			
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 001	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 005	6765117	Oct 24, 2017	DS		D-156	Jan 28, 2019
	7417070	Jul 30, 2026	DS		D-157	Jan 28, 2019
	7544713	Jul 14, 2024		U-1475		
	8252839	May 24, 2024	DP			
	8349892	Jan 22, 2031	DP			
	8410169	Feb 13, 2030	DP			
	8497393	Dec 15, 2028	DS			
	8747897	Oct 08, 2029	DP			
	9050311	May 24, 2024	DS DP			
	9278901	May 24, 2024		U-1475		
	9393203	Apr 27, 2026	DP	U-1877		
	9422223	May 24, 2024	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TRIPTORELIN PAMOATE - TRIPTODUR KIT</u>						
N 208956 001					NP ODE	Jun 29, 2020 Jun 29, 2024
<u>UMECLIDINIUM BROMIDE - INCRUSE ELLIPTA</u>						
N 205382 001	>A> 7488827	Dec 18, 2027	DS DP		NCE	Dec 18, 2018
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975 001	>A> 7439393	May 21, 2025	DS DP	U-1476	NCE	May 10, 2018
	>A> 7488827	Dec 18, 2027	DS DP		NCE	Dec 18, 2018
	>A> 9750726	Nov 29, 2030	DP			
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241 001	8039627	Oct 06, 2029	DS DP		NCE	Apr 11, 2022
	8357697	Nov 08, 2027		U-1995		
<u>VALGANCICLOVIR HYDROCHLORIDE - VALCYTE</u>						
N 022257 001	9642911	Dec 11, 2027	DP			
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 001	9687526	Jan 30, 2035		U-1857		
	9744209	Jan 30, 2035		U-1857		
	9744239	Jan 30, 2035		U-1857		
	9750785	Jan 30, 2035	DP			
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 002	9375478	Jan 30, 2035		U-1857		
	9687526	Jan 30, 2035		U-1857		
	9744209	Jan 30, 2035		U-1857		
	9744239	Jan 30, 2035		U-1857		
	9750785	Jan 30, 2035	DP			
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 001	9707270	Oct 01, 2024		U-2084		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 002	9707270	Oct 01, 2024	U-2084			
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 003	9707270	Oct 01, 2024	U-2084			
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 004	9707270	Oct 01, 2024	U-2084			
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997 001	9265720	Feb 25, 2031	U-674			
	9597281	Apr 06, 2027	U-674			
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997 002	9265720	Feb 25, 2031	U-674			
	9597281	Apr 06, 2027	U-674			

## Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

## PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 37<sup>th</sup> Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at [http://www.accessdata.fda.gov/scripts/cder/ob/results\\_patent.cfm](http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm)

The current complete list of exclusivity terms is available at [http://www.accessdata.fda.gov/scripts/cder/ob/results\\_exclusivity.cfm](http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm)